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Introduction
1.1 An introduction to light
1.1.1 History
The ancient Egyptians were the first to recognize the beneficial effect of sunlight 
on humans. In the earliest study on the physics of light, reported in 1671, Newton 
investigated the refraction of light based on the observation that a prism decomposes 
white light into the many colors, which form the visible spectrum. The visible spectrum 
is the part of light that is visible to the human eye. The existence of invisible rays 
in sunlight was not known until the beginning of the nineteenth century. In 1800, 
Herschell demonstrated the existence of irradiation beyond the red end of the visible 
spectrum, now known as infrared (IR) radiation. Only one year later, Ritter discovered 
the ultraviolet (UV) region of the solar spectrum. The law of quantum physic, which 
states that irradiation is emitted in discrete bundles of energy, known in photobiology 
as photons, was formulated by Planck in 1901.12
1.1.2 Solar spectrum
Light represents only a small part of the electromagnetic spectrum. The classification 
of electromagnetic light is based on wavelength. The light spectrum consists of UV 
(100-400nm), visible (400-760nm) and IR (beyond 760nm) portions (figure 1).
X-rays
760 W avelength (nm)
Figure 1: The light spectrum is classified in different forms of light according to wavelength. The 
visible spectrum is visible to the human eye, which responds to wavelengths from 400nm to 
760nm.
The visible spectrum is the portion of electromagnetic radiation visible to the human 
eye, which responds to wavelengths from 400 to 760nm. Newton divided the spectrum 
into seven named colors: red (625-760nm), orange (590-625nm), yellow (565-590nm), 
green (495-565nm), blue (450-495nm), indigo (420-450nm), and violet (400-420nm).2 
Ultraviolet means “beyond violet”, as violet being the color of the shortest wavelength 
in visible light. Thus, ultraviolet radiation (UVR) has shorter wavelengths as compared 
to violet light. In the UV spectrum of light, the biological effects vary enormously and 
therefore the UV-spectrum is subdivided in three regions. UVA comprises approximately 
95% of the UV spectrum. UVA radiation (315-400nm) is further subdivided into UVA-1 
(340-400nm) and UVA-2 (315-340nm). Although only 5% of the UV spectrum is UVB 
(280-315nm), it is responsible for 80% of the harmful effects associated with sun
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exposure. UVA contributes only the remaining 20%. UVB is responsible for sunburn, 
pigmentation, vitamin D production, skin ageing and carcinogenesis. UVA is mainly 
responsible for photodermatoses, while it is also capable of producing the effects 
seen after UVB exposition, although at least 1000 times higher irradiation dosages 
are needed. The longer wavelength of UVA penetrates deeper into the skin than UVB. 
Cytotoxic UVC (100-280nm) has the shortest wavelength in the solar spectrum and 
thus the highest energy part of UV radiation. Its wavelengths are absorbed in the 
atmosphere and therefore do not reach the earth's surface.34
1.2 General aspects of light and the skin
1.2.1 Photons
The photobiological action spectrum of light on the skin is dependent on the available 
photoactive substances, the amount of energy conveyed by the light and the 
penetration depth. Light exhibits properties of both waves and particles (photons). 
For some descriptions it is adequate to treat light as a electromagnetic wave (Hertz, 
1888), while for the description of other properties light is best described a sequence of 
particles (Planck, 1901). This is referred to as the wave-particle duality. The energy of 
a photon E has a fixed relation with the frequency of light v (waves per second), which 
is described in the Planck's equation.
Ephoton = h.v (h = Planck's constant)
This means that with a longer wavelength, a photon contains less energy.
1.2.2 Photochemical reactions in the skin
Whenever light reaches tissue, it can be transmitted, scattered, reflected, or absorbed, 
depending on the type of tissue and the wavelength of light. Decreased penetration 
of light into the skin is a limiting factor of lower wavelengths, whereas at higher 
wavelengths the energy of photons is lower (Planck's equation). Light absorption must 
take place for any biological effects. The absorption characteristics of the skin depend 
on specific components of the skin. The main absorbing components (chromophores 
or photosensitizers) of tissue are hemoglobin in blood, melanin in skin and hair and 
water in all tissue. The terms “chromophore” or “photosensitizer” refer to a region in a 
molecule with a very characteristic radiation absorption spectrum. All chromophores 
have a specific absorption spectrum depending on wavelength. Accumulation of 
chromophores can also be induced by administrating exogenous photosensitizing 
drugs, like psoralens in PUVA therapy and aminolevulinic acid cream in photodynamic 
therapy (PDT). The main chromophores in the skin (water, melanin and hemoglobin) 
absorb less light in the wavelength range from 600-1300nm. Light from this range 
deeply penetrates the human body. Considering the absorption spectra of these 
chromophores, this 'optical window' for the skin gives a natural protection against the
14
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toxic effects of UVR. However, this limits the use of short wavelengths in the treatment 
of deeper skin lesions.
The transmitted energy of the photon after absorption of light in the skin induces 
chemical reactions (a) directly within itself as a target molecule (e.g. deoxyribonucleic 
acid (DNA)), resulting in a subsequent chemical reaction or (b) indirectly with 
photosensitizing molecules in the immediate environment (e.g. porphyrins), causing 
indirect photosensitized damage to adjacent molecules (e.g. strand breaks in DNA).15
1.2.3 Photosensitization
After a photon reaches the chromophore in the skin, it excites an electron to a higher 
energy level, from its ground state into an excited singlet state. This unstable singlet 
state can return to the ground state by photon emission, resulting in the emission of 
light in the form of fluorescence (radiative process). Instead of returning to the ground 
state, the unstable singlet state may convert all the excitation energy into heat. This 
second reaction is called internal conversion (IC), which is a radiationless process. A 
third reaction is also a non-radiative process called intersystem crossing (ISC), which 
is the transition into a longer lived state with higher spin multiplicity. Once intersystem 
crossing has taken place, the molecule undergoes the usual internal conversion into 
a more stable triplet state. Triplet states contain more energy than singlet states. 
Transition of the triplet state into the ground state is called phosphorescence (figure 
2). Deactivation of an excited state of a photosensitizer varies per molecule and is 
strongly dependent on the environment.5
1 p s **
IC
excitation 'PS*
ISC
3PS*
fluorescence phosphorescence
IC IC
SP0
Figure 2: Jablonski diagram illustrates the electronic state and transportation of energy of PS 
(photosenzitizer). 0PS represents the ground state, which is transferred to 1PS* and 1PS**, 
unstable singlet states. 1PS* can undergo intersystem crossing (ISC) and reach 3PS* , the more 
stable triplet state. IC refers to internal conversion.
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1.2.4 Photo-oxidative reactions
Cellular damage via an excited photosensitizer may occur by two types of photo­
oxidative reactions. The type I pathway involves electron or hydrogen atom transfer 
from the triplet state of the sensitizer to a substrate. This results in producing radical 
forms of the substrate, which in turn may react with surrounding molecules (substrates) 
causing immediate tissue damage. These free radicals may also react with oxygen 
molecules to form reactive oxygen species (ROS), including peroxides, superoxide 
ions and hydroxyl radicals. In the type II reaction, the activated sensitizer directly 
reacts with ground state oxygen, leading to the formation of singlet oxygen. This highly 
reactive singlet oxygen results in a very effective method of oxidation of biological 
substrates. Both reactions occur simultaneously and in competition. Competition 
between the substrate and oxygen for the triplet state of the sensitizer determines the 
predominant reaction type.25
1.3 Photobiological effects of light
UVR reaching the skin, is either reflected or absorbed by structures of the skin, 
depending on the wavelength. Unlike UVB, penetrating at the most into the papillary 
dermis, longer wavelengths in the UVA region (315-400nm) have the capacity to reach 
the subcutis as well. Therefore UVB radiation mainly affects epidermal keratinocytes 
and Langerhans cells (LCs). As UVA radiation can penetrate more deeply into the 
skin, it affects epidermal keratinocytes and LCs, but also dendritic cells, endothelial 
cells, inflammatory T cells, mast cells and granulocytes in the dermis. UVA has been 
divided into UVA-1 (340-400nm) and UVA-2 (315-340nm). UVA-2 induces biological 
effects similar to UVB. Theoretically, visible light could induce photobiological effects 
comparable with UVA-1, because wavelengths of visible light are closely related to the 
UVA spectrum. Several studies have shown that near-UVA irradiation results in UVA- 
like effects.6-8
UVB and UVA may have very similar immunosuppressive and anti-inflammatory 
effects, at least under in vitro conditions. UVB irradiation has been proven to have 
combined local and systemic immunological effects on the skin.910 In case of UVB, the 
most important light absorbing molecules are DNA, urocanic acid and melanin. The 
interaction of UV with chromophores can lead to a multitude of effects as the induction 
of oxidative stress, activation of transcription factors, damage to the cell membrane 
and DNA damage, initiating immunosuppression.
The stratum corneum and epidermis provide an optical barrier primarily by absorption 
of radiation. Hyperplasia and melanogenesis induce an endogenous photoprotective 
system. Melanin is photo-inducible and has variable concentrations and distributions. 
UVA causes immediate pigment darkening as well as persistent darkening of the skin 
within hours after exposure. In contrast, UVB induces a slower, but more stable type
16
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of pigmentation, called delayed tanning, which requires an increased synthesis of 
melanin.11 In addition to an increased melanogenesis in the skin, UV exposure to the 
skin causes epidermal hyperplasia.12
1.3.1 Urocanic acid
Trans-urocanic acid, a histidine product present in the stratum corneum, acting as UV- 
chromophore (absorption peak 268nm), absorbs UVR and isomerizes to cis-urocanic 
acid. Cis-urocanic acid is thus induced by UVB therapy and has been implicated as one 
of the mediators of UVB-induced immunosuppression since it can mimic many of the 
effects of UV irradiation on the immune system. Cis-urocanic acid is likely an important 
mediator of UV-induced immunosuppression, as it has been shown to modulate the 
induction of contact type hypersensitivity and delayed type hypersensitivity, allograft 
rejection, and the functions of monocytes and T-lymphocytes as well as natural killer 
cells.13-16
1.3.2 DNA
The absorption of visible light or UVR by chromophores in the skin is the main event 
in commencing biological effects of light on the skin. Endogenous chromophores can 
be target molecules and cause direct damage or induce indirect damage to adjacent 
molecules. UVR can cause direct damage or indirect damage to DNA, proteins and 
lipids.117 UVR is able to induce mutagenic photoproducts or lesions in DNA and is 
believed to play an important role in initiating skin cancer. In skin, nucleic acids are the 
most critical chromophores, as DNA has a maximum absorption spectrum at 260nm 
in the UVC region with a significant absorption of UVB radiation. It also has minimal 
absorbing properties in the UVA region. The effects of UVB on the skin are mediated 
predominantly by direct DNA damage, while the effects of UVA on DNA are dominated 
by indirect damage caused by ROS, such as singlet oxygen.17
1.3.3 Photodamage
Photodamage can be divided in photo-carcinogenesis and photo-ageing. Melanin and 
the stratum corneum act as filters by absorbing and scattering UVB, UVA, as well as 
visible and IR radiation. It preserves DNA from photoproduct formation. Absorption 
of UVR in DNA leads to formation of dimeric photoproducts, like cyclobutane dimers 
(CPDs), between adjacent thymine (T) and cytosine (C) residues, and pyrimidine 
photoproducts, which are generated in keratinocytes and LCs. These UV-induced 
mutations are characterized by transition of C to T and CC to TT. The cutaneous effects 
of UVB are mainly mediated by direct DNA damage as a result of UVR absorption, 
whereas UVA causes indirect damage via the production of ROS.115 
Every cell contains several DNA repair systems in order to remove DNA damage after 
growth arrest to protect the cell from the effects of DNA damage. Once activated, 
p53 regulates the cell cycle and functions as tumor suppressor gene ('guardian of
17
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the genome'). It induces growth arrest by holding the cell cycle, activates DNA repair 
mechanisms and induces apoptosis.18 Most of the DNA damage is repaired. If not 
repaired, UV-induced lesions can lead to mutations in DNA-sequences. Apoptotic 
pathways are activated to eliminate damaged cells and to maintain the genomic 
stability. Normally, p53 is up-regulated in case of UV-induced DNA damage, but sun 
exposure results in loss or mutation of p53, facilitating carcinogenesis. Mutations in p53 
are seen at a high frequency in non-melanoma skin cancers (NMSC). Photoproducts 
are repaired much faster than CPDs.19 CPD, as the main form of UV-induced DNA 
damage, is the main site for p53 gene mutations. In case such mutations occur in p53, 
the ability to undergo restoration or apoptosis will decrease.120 
UVB radiation reduces the amount of LCs, which leads to an impaired antigen presenting 
capacity and reduces local immunity, inducing immunosuppression by an impaired 
ability of LCs to stimulate the induction of T helper 1 (Th1) lymphocytes.21 Consequently, 
UVB irradiation results in promotion of T helper 2 (Th2) responses with anergy of 
Th1 responses. This results in natural killer (NK) cell activity, lymphoproliferation and 
cytokine responses (IL-10). Thus, UVB irradiations leads to CPDs in LCs, resulting in 
an impairment of their antigen presenting capacity. This immunosuppressive effect 
persists several days. UV irradiation results in failure of the skin immunosurveillance 
mechanism. Immunosurveillance is a monitoring process of the immune system, which 
normally detects and destroys neoplastic cells.14;18;21
In conclusion, carcinogenesis of the skin is a result of DNA damage and 
immunosuppressive effects.
1.4 Photo(chemo)therapy and photodiagnostics
1.4.1 Photochemotherapy
Several skin disorders can be treated with phototherapy (UVB) or photochemotherapy 
(PUVA). Phototherapy using UVR has been part of treatment in dermatology for many 
years, being used for a variety of skin disorders. Before modern phototherapy was 
developed, the physiological effects of natural sunlight (heliotherapy) on the human 
body have been used for many years. Hindus with vitiligo were given certain plant 
extracts and then exposed to the sun. The Greek physician, Herodotus, emphasized 
the importance of sun exposure for restoration of health. Phototherapy describes 
the use of UVR in the treatment of disease, while photochemotherapy involves a 
combination of the administration of a photosensitizer followed by the action of light. 
The first observations with the combination of photosensitizing drugs and consecutive 
irradiation were reported by Abn Mohamed Abdullah Ben Ahmed (1200 a.c.). Psoralens 
are photosensitizing agents found in some plants. These photosensitizers allow 
a lower dose of UVA to be used. They can be administered systemically or applied 
directly on the skin. The combination of psoralens (8-MOP) with exposure to UVA
18
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is called PUVA. A major disadvantage of PUVA is its highly increased risk of skin 
cancer compared to UVB phototherapy.22-24 8-MOP forms unstable complexes in the 
DNA molecule. Subsequent irradiation with UVA results in cross links in DNA, which 
interfere with DNA synthesis. This cross linking is highly mutagenic, but PUVA also 
leads to immunosuppression and inhibition of immunosurveillance.25
1.4.2 Phototherapy
Phototherapy was discovered later in history. In 1893, Finsen was the first physician 
to investigate the therapeutic effects of sunlight scientifically. In 1901, he published 
the results of treatment of lupus vulgaris with filtered UVR from a carbon arc lamp 
(Finsen lamp). The real interest in the use of UV irradiation in the treatment of 
various skin diseases as an alternative for heliotherapy started in the 19th century 
when Finsen received the Nobel Prize (1903) for his work on phototherapy. In 1923, 
Alderson recommended using a mercury quartz lamp to treat psoriasis.26 Goeckerman 
demonstrated in 1925 the beneficial effects of natural sunlight in combination with coal 
tar for psoriasis. In 1953, the Ingram regime was introduced for psoriasis, involving UVB 
and the application of anthraline paste. Phototherapy as a monotherapy for psoriasis 
was introduced not until 1978, when Wiskemann suggested an irradiation cabin with 
broad-band UVB tubes for the treatment of psoriasis.2728 However, broad-band UVB 
therapy was less effective for treating psoriasis than PUVA. In addition, broad-band 
UVB phototherapy contains wavelengths (280-315nm) most closely to the absorption 
spectrum of DNA (maximum absorption peak of 260nm). Therefore, in theory UVB is 
more carcinogenic than UVA.24 In practice, UVA in combination with psoralens (PUVA) 
demonstrated to be highly carcinogenic as compared to UVB. Parrish and Jaenicke 
defined in 1976 the action spectrum for psoriasis with a peak at 311-313nm. In 1988, 
the more effective narrow-band UVB phototherapy was introduced for the treatment of 
psoriasis by van Weelden et al. and Green et al.. Since then, it has proven to be more 
effective than broad-band UVB in various skin disorders with less side effects and so 
far studies have demonstrated no significant association between narrow-band UVB 
phototherapy and skin cancer. The use of PUVA has declined with the emergence of 
narrow-band UVB.24;26;29;30
1.4.3 Photodynamic therapy in dermatology
PDT is a treatment modality, which requires the combination of a photosensitizer, 
tissue oxygen and light of the appropriate wavelength to activate the photosensitizer 
(see chapter 1.2). The activated photosensitizer reacts with oxygen to form ROS, 
that are cytotoxic resulting in tissue destruction. Essential is an optimal therapeutic 
concentration of the photosensitizer in the target tissue. It is understood that the 
photosensitizer is especially taken up by rapidly proliferating cells.
Amplifying the effect of light with different dyes in order to kill malaria-causing protozoa 
was first reported by Raab, a medical student, and von Tappeiner, professor of the
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department of Experimental Pharmacology in Munich in 1897. The toxicity on protozoa 
increased at the same dye concentration in the presence of light. Together with Jesionek, 
von Tappeiner started the first experiments in man. As skin is an easily accessible 
organ, skin diseases, like pityriasis versicolor, psoriasis, molluscum contagiosum, skin 
cancer, lupus vulgaris and secondary syphilis, were first studied with an injection of 
eosin followed by irradiation with light. In 1904, von Tappeiner described these oxygen 
consuming reactions induced by photosensitization as 'photodynamic action'. In 1911, 
Hausmann published the first results on the use of a photosensitizer, derived from 
the heme synthesis, hematoporphyrin (Hp). Silver described in 1937 the successful 
treatment of psoriasis after Hp injections and subsequent irradiations of UV light. 
Despite these encouraging results, little was done with PDT until the early 1960's. In 
1966, Lipson treated an ulcerated, recurrent breast carcinoma with systemic PDT. This 
resulted in a marked therapeutic effect. In 1978, Dougherty reported the first series of 
patients with skin cancers successfully treated with PDT, using Hp and a xenon arc 
lamp. It was not until 1990 that Kennedy reported the use of a new topical porphyrin 
precursor, 5-aminolevulinic acid (ALA).5;31;32
Figure 3: Penetration depth of visible light in the skin.
The topical application of photosensitizers reduces long-lasting photosensitization as 
well as systemic immunosuppressive effects. ALA is a precursor of a photosensitizing 
protoporphyrin IX (PpIX). Topical application of ALA induces the accumulation of PpIX. 
PpIX has a maximum absorption peak at 408nm (Soret band) and as a result blue light 
is more effective than red light in activating PpIX. The visible spectra of porphyrins 
also show weaker absorption peaks at longer wavelengths (Q-bands) (figure 5). For
20
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optimal activation of PpIX not only the maximal absorption spectrum of PpIX but also 
the absorption characteristics of the skin have to be considered. Therefore, red light is 
preferred in PDT because of deeper light penetration in the skin (figure 3). In general, 
all PpIX accumulating skin disorders can be a potential target for PDT.5;32 
Accumulation of PpIX in the target tissue is essential for good therapeutic effects. It is 
important to provide sufficient ALA for maximum uptake and conversion to PpIX. A longer 
application time of ALA results in more PpIX accumulation. For ALA, maximum PpIX 
accumulation is seen after 6 hours of incubation.33 34 However, preferential accumulation 
of PpIX in the target tissue is dependent of penetration of the photosensitizer and 
the metabolic conversion into porphyrins. ALA is an endogenous precursor of PpIX, 
which is a compound of the endogenous heme-biosynthetic pathway, taking place 
in every metabolic active cell. Bypassing the endogenous rate-limiting steps of the 
heme pathway by excessive administration of exogenous ALA, induces an increase 
of endogenous PpIX (figure 4).32 An increase in ALA-uptake with enhanced PpIX 
production is seen predominantly in terminally differentiated cells without differences 
between various skin diseases.35 36
Figure 4: Heme biosynthetic pathway.
Not only metabolic conversion into porphyrins, but also penetration of ALA into the 
skin is essential for PpIX accumulation. The stratum corneum, as the main skin 
barrier, is a very important limiting factor in penetration of ALA. Pretreatments, such as 
tape-stripping, curettage or keratolytics, aimed at removing the hyperkeratosis of the
21
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stratum corneum, improve the amount of PpIX in the skin.333437 Also, an altered stratum 
corneum of the skin overlaying tumors and psoriasis plaques probably contributes to 
the tumor-selectivity. Since underlying skin tumors disrupt epidermal structures and 
inflammatory dermatoses disturb keratinization and differentiation, ALA may diffuse 
more easily through the disruptions in the stratum corneum.34 ALA-PDT is limited by 
the fact that ALA is a hydrophilic molecule and its capabilities to penetrate lipophilic 
barriers, such as cell membranes and the stratum corneum, are limited after topical 
application. Ester derivatives are more lipophilic and are de-esterified into ALA by 
intracellular enzymes. ALA-derivatives, especially methyl aminolevulinic acid (MAL), 
have been reported to induce a more selective distribution of PpIX than ALA. These 
effects are contributed to the fact that ALA is transported to distant sites through local 
circulation. On the contrary, ALA produces higher PpIX concentrations in the skin than 
MAL, especially at short incubation times. This phenomenon can be explained by the 
fact that ALA-derivatives first have to be converted (de-esterified) into ALA before they 
can interact in the heme-biosynthetic pathway.38-41
PDT has proven to be clinically effective in treatment of superficial skin (pre)malignancies 
including actinic keratosis (AK), Bowen's disease and superficial basal cell carcinoma 
(BCC), but no studies have compared the treatment effect of ALA-PDT and MAL-PDT 
for these most widely used indications. PDT can also be recommended for thin nodular 
BCC lesions. PDT may also prevent the development of certain non-melanoma skin 
cancers (NMSC) in immunosuppressed patients.42 However, no differences in clinical 
efficacy between ALA and MAL were demonstrated after PDT in nodular BCC and 
inflammatory acne, indicating that both ALA and MAL can be equally recommended as 
topical photosensitizers.4344
In most clinical studies 16% MAL and 20% ALA are used. At this moment, only the 
commercial form of MAL (Metvix®, Galderma, Paris, France) is approved in most 
European countries for the treatment of AKs, Bowens' disease, superficial BCC 
and small nodular BCC. Before Metvix® became widely available in Europe, most 
clinical studies were performed using a non-standardized treatment protocol. A main 
drawback to studies with ALA-PDT is the lack of a standardized treatment protocol. The 
concentration of ALA used, the formulation of the vehicle, the methods of preparation 
and conservation of the final compound, the time of application, as well as many 
specific parameters of the light used (such as exact wavelength, duration and intensity 
of the various light sources) varied widely in different studies.
1.4.4 Fluorescence d iagnosis in dermatology
As PpIX has characteristic fluorescence properties, its preferential accumulation in 
certain cell types can also be used as a cellular marker. In 1948, Figge was the first to 
report on the detection of tumors by the red fluorescence of PpIX. In 1960, Lipson and 
Baldes performed tissue localization experiments with intravenous Hp derivatives in 
neoplastic tissue.5
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Figure 5: Fluorescence diagnosis with aminolevulinic acid induced porphyrins, which have a 
maximum absorption peak at 408nm. After illumination with blue light, PpIX accumulating cells 
can be visualized by emission of red fluorescence (633nm).
Due to the high absorption of porphyrins at 408nm (Soret-band) and the good distinction 
of red fluorescence generated, usually blue light is used for fluorescence diagnosis 
with ALA-induced porphyrins (FDAP) after incubation with ALA. As PpIX shows red 
fluorescence when excited by blue light, PpIX accumulating cells can be visualized 
(figure 5).37 To avoid the photodynamic effect of PDT, the intensity of the excitation 
light is much lower for fluorescence diagnosis than for PDT. A Wood's lamp (Wood, 
1903) is a diagnostic tool used in dermatology by which UV light (370-405nm) is used 
onto the skin of the patient with a subsequent perceptible pink to red fluorescence. 
Low fluorescence intensity and unspecific background fluorescence resulted in the 
development of special digital detection systems with the ability to record fluorescence 
images in order to perform fluorescence analysis afterwards. In this thesis, fluorescence 
intensity on the skin is recorded using a digital fluorescence imaging system (Dyaderm, 
Biocam GmbH, Regensburg, Germany) (figure 6). The Dyaderm digital imaging 
system consists of a flash light (Xenon light source with a custom band pass filter (370­
440nm)) and a 12-bit Sony CCD camera combined in one adjustable arm coupled to a 
Pentium IV computer equipped with custom made image capturing software (Dyaderm 
Pro v1.4, Biocam GmbH, Regensburg, Germany). The flash light emits 7 light pulses 
per second to the skin which are recorded by the CCD camera (exposure time 100 
psec) equipped with a special Schott GG 455 long pass filter to filter out the excitation 
light. As PpIX fluorescence emission consists of light in the red spectrum, the red
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pixels of the CCD camera can be used to generate a fluorescence image. In this way 
a normal colored image and a fluorescence image can be processed in real-time. 
Photobleaching is defined as the light-induced loss of absorption or emission intensity. 
During light exposure, PpIX is degraded due to photobleaching. Because of the short 
exposition time to the excitation light, photobleaching of PpIX is minimalized in this 
way. To correct for different lighting environments between pictures, a fluorescence 
reference standard (Maccal 8044, 738-00, Multifoil, Utrecht; the Netherlands) is 
included on every image.
In a clinical setting, FDAP can provide additional information on detection and 
demarcation of (pre)malignant skin lesions in a non-invasive setting and on the efficacy 
of PDT by visualizing the amount of PpIX in the skin during PDT.5 Since the exact 
mechanism of PpIX accumulation in the skin are poorly understood, interpretation of 
fluorescence data is still problematic.
1.5 Actinic keratoses and squamous cell carcinoma
1.5.1 History
'Keratosis actinica', also called AK or solar keratosis, refers to the hyperkeratotic 
growth of the skin, which is caused by sun damage. AK was first identified as 'keratosis 
seniles' by Dubreuilh in 1896. In 1926, Freudenthal described the histopathological 
features of keratosis seniles. Both Sutton (1938) and Lever (1949) stated that these
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lesions are not precancerous, but in fact are superficial squamous cell carcinoma 
(SCC). In 1958, Pinkus was the first person renaming keratosis seniles as 'solar 
or actinic keratosis' in the context of hyperkeratotic lesions caused by chronic 
exposure to sunlight. Historically, AKs have been described as 'pre-malignant' or 'pre­
cancerous'.45146
1.5.2 Epidem iology and clinical features
Skin cancer is the most common cancer in the Western world with a continuous 
increasing incidence. The majority of skin cancer is formed by NMSC. The most 
common forms of NMSC are BCC and SCC, accounting for more than 95% of all 
NMSC. BCC arise de novo and seldom cause metastasis, but can be locally invasive 
if left untreated. On the contrary, SCC can be life threatening. AKs and squamous 
cell carcinoma in situ (Morbus Bowen or Bowen's disease) are generally regarded as 
cutaneous epithelial premalignancies that are able to progress to invasive SCC.4748 
Recognition of AKs is important, because if left untreated, there is a risk of evolving in 
SCC. AKs have the potential to clear spontaneously, persist or progress into invasive 
SCC. Probably 15-25% of AKs show spontaneous regression. Generally, 6-16% will 
develop into SCC over a 10 year period.49'53 It is not known which AK will progress to 
SCC. Therefore, it is essential to treat all AK lesions.
AKs are characterized by scaly, keratotic, sometimes pigmented, papules and plaques 
with an erythematous base predominantly occurring on sun-exposed skin, such as 
the face, forearms and dorsa of hands (figure 7a). They are very common lesions, 
especially on the sun-exposed skin of fair skinned Caucasians, with an increase in 
prevalence with advancing age. Usually, other signs of chronic sun damage, such as 
freckled pigmentation and elastosis of surrounding skin, can be seen. Besides the 
individual susceptibility, cumulative UVR exposure is the other major factor determining 
the risk of developing AKs. AKs can progress into thickened or hypertrophic lesions. 
Risk factors for the development of new AKs are the same for developing SCC. The 
highest risk factor is the presence of AKs. However, there are relatively more AKs on 
dorsa of hands and forearms than there are SCCs. SCC frequently develop on the 
scalp, face and neck. Risk of metastases increases rapidly with localization on lip, ear, 
nose or scar and with the use of immunosuppressive medication.5455
1.5.3 Histopathology
The diagnosis of AK is usually made based on the clinical characteristics. However, 
a biopsy is necessary to exclude deeper involvement in order to distinguish AK from 
SCC. Histologically, AKs are characterized by the presence of atypical keratinocytes in 
the epidermis. Advanced lesions may extend into the whole epidermis. Keratinocytes 
vary in size and shape, cellular atypia is present and mitotic figures are present (figure 
7b). This presentation may resemble SCC. The distinction is a matter of histological 
extension of the lesion rather than differences in individual cells. The main feature
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that distinguishes invasive SCC from Bowen’s disease and AKs is invasion of 
atypical keratinocytes through the basement membrane and into the dermis (figure 
8). Keratinization results in the production of squamous eddies or keratin pearls. 
The neoplastic cells may demonstrate varying degrees of squamous differentiation 
and atypia. The degree of differentiation has prognostic implications, whereas poorly 
differentiated tumors have been associated with a higher risk of metastasis. The 
defective maturation of keratinocytes in the epidermis results in hyperkeratosis with 
parakeratosis. In general, hair follicles, sebaceous glands, and apocrine and eccrine 
ducts are not involved. Almost always a dense inflammatory infiltrate and solar elastosis 
are seen in the dermis.56 57
Figure 7: Clinical appearance (A) and histopathology (B) of AK.
Figure 8: Clinical appearance (A) and histopathology (B) of SCC.
1.5.4 Pathogenesis
The most important factor for developing AKs and SCC is cumulative exposure to 
UVR. Both UVA and UVB can contribute to skin cancer by directly inducing DNA 
damage (UVB dependent p53 mutations) or indirectly by UVA induced oxidative stress
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generating genomic instability (see also chapter 1.3.3).58 Especially UVB radiation is 
involved in skin carcinogenesis by inducing thymine dimer formation in DNA of the 
p53 gene. This mutation, in which cytosine is changed into thymine, is an unique UVB 
induced mutagenic effect on DNA. Mutation of the cancer gene p53 alone is not enough 
to cause skin cancer. Repeated exposure to UVR leads to the repeated assault of 
DNA, inducing mutations that cause the cell cycle to lose control. After continuous 
promotion of initiated cells, the premalignant lesion may convert to a malignant lesion. 
In conclusion, UVR is not only the initiator, but also the promoter of skin cancer. 
Mutations of p53 are found in more than 90% of SCC and in most AKs. On a genetic 
base, AK is an early condition of SCC.59
1.5.5 Classification system s and prognostic factors
Fundamentally, there is no difference between AK and SCC. Historically, AKs have 
been characterized as 'premalignant' and 'pre-cancerous'. This was based on the 
fact that AKs are confined to the epidermis and do not possess metastatic potential. 
However, a significant number of AKs eventually progress, extend into the dermis and 
potentially metastasize. Clinically and histologically, it is not predictable which AK will 
progress into SCC, but this probably depends on the number of risk factors present. 
There are no standard, widely accepted grading criteria. Various classification 
systems have been proposed and discussed for AKs, reflecting the controversy in 
literature about the nature of AKs. Since AK represents a proliferation of keratinocytes 
confined to the epidermis, the term 'keratinocytic intraepidermal neoplasia' (KIN) is 
proposed by Cockerell.57 The KIN classification system has been criticized several 
times in the literature and is not widely accepted.60 Neoplastic lesions confined to the 
epidermis are divided into three categories based on clinical and histological features. 
This classification system is analogous to CIN and VIN grading system for cervical 
and vulvar cancers.61 Based on the clinical and histological correlation, clinicians 
and pathologists have to work together. The earliest, usually subclinical, lesion is 
KIN I. These KIN I lesions exhibit flat, pink macules or patches on sun damaged 
skin without roughness or hyperkeratosis. Histologically, focal atypia of the basal 
keratinocytes of the lower one third of the epidermis is seen. The next stage is KIN II, 
which represents pink to red papules or plaques with rough, hyperkeratotic surfaces 
and induration. Microscopically, focal atypia of keratinocytes is demonstrated in the 
lower two thirds of the epidermis. Orthokeratosis alternates hyperkeratosis with 
sparing of hair follicles, sebaceous glands, and apocrine and eccrine ducts. The 
most advanced form of AK is KIN III. These red, scaly and indurated plaques on 
severe sun damaged skin are representing histologically the proliferation of atypical 
keratinocytes with involvement of the full thickness of the epidermis including the 
adnexal structures. Bowen's disease and SCC in situ are forms of KIN III.57 61 62 It is 
suggested that there is not a continuum from KIN I to invasive SCC and that KIN I and 
KIN II lesions also have the possibility to convert directly into invasive SCC, thereby
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omitting the logical gradual step of KIN III. In 2007, Stockfleth proposed a modified 
version of the grading system of Cockerell, by using the term 'in situ SCC type AK1 
instead of AK. Other, less detailed grading systems, suggested that proliferative AKs 
(Goldberg, 1994) or inflamed AKs (Berhane, 2002) are associated with an increased 
risk of developing SCC.46 53
It is unpredictable whether a SCC will metastasize, but the prognosis of SCC depends 
on several factors, influencing the metastatic potential. The incidence of metastasis 
from SCC varies from 0.5-25%. SCCs arising in injured or chronically diseased skin are 
even associated with a risk of metastasis that approaches 40%. Patients with metastatic 
SCC have a poor prognosis with a 10 year survival rate of less than 20%.63-65 Therefore 
it is important to define high risk tumors in order to treat these tumors efficiently. The 
International Union against Cancer (UICC) has established a clinical classification 
system for SCC, using the TNM system. The TNM staging system for all solid tumors 
was devised by Denoix between 1943 and 1952, using the size and extension of the 
primary tumor (T), its lymphatic involvement (N) and the presence of metastases (M) 
to classify the progression of cancer.66 Recording of the clinical tumor size (T) has 
the disadvantage that it is not reliable for the assessment of the metastatic potential 
of SCC. Clinical experience demonstrates that even small SCC can metastasize and 
recur. Diameter of more than two centimeters, depth of tumor invasion of more than 
four millimeters (according to Breslow) and location on the lip or ear are correlated 
with a higher risk of recurrence and metastasis of SCC. Tumors arising in patients who 
are immunosuppressed have a poorer prognosis. As mentioned before, the degree 
of differentiation has prognostic implications, whereas poorly differentiated tumors 
have been associated with a higher risk of metastasis. A classification system for 
the histological differentiation of SCC was introduced by Broders in 1921. The tumor 
grade was established according to the degree of keratinization and cell differentiation. 
The grading system is divided into four categories, based on the extent to which the 
neoplasm resembles normal squamous epithelium. The greater the proportion of 
tissue resembling the tissue of origin, the greater the degree of differentiation (grade 
1, well differentiated; grade 2, moderately differentiated; grade 3, poorly differentiated; 
grade 4, tumors cells have no tendency towards differentiation). Not only clinical and 
histological features, but also previous treatments influence the risk of local recurrence 
and risk of metastasis.67-69
1.5.6 Fluorescence d iagnosis
Currently, the diagnosis of AKs is based on clinical grounds with, in case of doubt, 
routine histopathology as a gold standard. Since a majority of patients with AKs suffer 
from field cancerization (areas with multiple or confluent lesions), multiple biopsies 
need to be taken in order to determine the extent of differentiation. If potentially invasive 
AKs are treated at an early stage, cure rate will increase, morbidity and mortality will 
decrease and costs of treatment will be minimized. In addition, in order to completely
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remove SCC with surgical therapy, clinical margins of the tumor must be identified. 
Until now, the gold standard for identification of the tumor margins is also histological 
assessment. The current diagnostic modalities are invasive and cause a significant 
burden on patients. Determination of the localization and extension of (pre)malignant 
tissue is still a major problem in oncology.
FDAP offers the opportunity to study differences between normal tissue and actinically 
damaged tissue. After administration of ALA, PpIX accumulates predominantly in (pre) 
malignant cells.70 Under irradiation with blue light, red fluorescent areas become visible. 
This specific fluorescence can distinguish normal tissue from the target tissue and this 
specific accumulation of PpIX in certain tissue types can be used as a diagnostic 
tool. Lack of selectivity and great variation between and within various skin diseases 
is seen after incubation with ALA. The exact cause for differences in affinity for PpIX 
is not known. Autofluorescence properties, differences in permeability of the stratum 
corneum and differences in the heme biosynthetic pathway are possible explanations. 
This procedure has been widely studied, but because of different procedures that have 
been used, the results are difficult to compare.3771 For more information on this topic 
the reader is referred to chapter 2 and 3 of this thesis.
1.5.7 Treatment options
Treatment of AKs is strongly motivated, because if left untreated, there is a risk of 
evolving in SCCs. 49-52 As it is not known which AK will resolve or will progress to SCC, 
it is essential to treat all AK lesions. The clinical appearance of AKs varies strongly, 
which has implications in the choice of the treatment modality.
Topical therapies
Therapy for AKs begins with prevention, which starts with sun avoidance and physical 
protection. Photoprotection must always be recommended, since avoidance of 
excessive sun exposure is the best prevention.72 Sun blocks have photoprotective 
effects, but also act as emollients. Mild actinic damage of the skin can be managed by 
emollients or only a sun block. Salicylic acid ointment, like emollients, does not reverse 
the biological process of AKs, but improves the clinical manifestations and additionally 
can be used as a pretreatment for other therapies.5273
5-Fluorouracil cream (5-FU, Efudix®) inhibits thymidylate synthetase, interfering DNA 
synthesis. It is very effective for more wide spread lesions in field cancerization, when 
used twice daily for several consecutive weeks. The cure rate is highly dependent on 
the compliance of patients. Erosions of the treated lesions are necessary for successful 
treatment, but are frequently associated with pain, discomfort and inflammation. As 
these factors decrease patient compliance and 5-FU cream is used for severe and 
extensive cases, recurrence rates of 5-FU cream are high.72-76 
Imiquimod cream is a topical immune response modifier, stimulating the cellular immune 
system through the release and up-regulation of cytokines. Imiquimod is very effecting
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in treatment of large areas and is applied three times weekly for four consecutive 
weeks. Treatment is stopped for at least four weeks and if necessary imiquimod cream 
is restarted for another period of four consecutive weeks. It is more expensive than 
5-FU with comparable local side effects, but also systemic effects, like headache, 
fever, nausea, may occur.7273 Several studies demonstrate high response rates of 45­
84% with lower recurrence rates as compared to 5-FU and cryosurgery.7576 
Recently, diclofenac 3% gel is approved for the treatment of AKs, as the only anti­
inflammatory agent. It is a topical non-steroidal anti-inflammatory drug, which inhibits 
cyclo-oxygenase. Its specific mode of action in the treatment of AKs remains to be 
discovered. Diclofenac 3% gel needs to be applied twice daily for at least twelve 
weeks. It is effective in mild to moderate, multiple and diffuse, non-hyperkeratotic AKs 
with few side effects.72;73
Topical and systemic retinoids
Tretinoin (all-trans-retinoic acid) is a retinol (vitamin A) derivative which has been 
evaluated as a topical treatment for the symptoms of photodamaged skin. Topical 
retinoic acid inhibits the proliferation of neoplastic keratinocytes and stimulates the 
proliferation of normal epidermal cells. Retinoic acid, therefore, has an inhibitory effect 
on epithelial neoplasias, particularly in combination with 5-FU. Retinoid dermatitis is a 
common side effect of topical tretinoin, which can be minimized through incremental 
dosage regimens.
Oral retinoids, such as acitretin, have an anti-tumor effect, as a result of reducing the 
number of AKs and an apparent prophylactic effect against skin cancer. Use of systemic 
retinoids may be justified in high-risk patients, such as organ transplant patients, with 
hyperkeratotic AKs, when there is a presumed increased risk of progression from AK
to SCC.72;73;77
Destructive therapies
Currently, cryotherapy with liquid nitrogen (-196 °C) is the most commonly used method 
of destructing few isolated, well-demarcated AKs. Curettage of hyperkeratotic AKs 
prior to cryotherapy increases the cure rate. The procedure is quick, simple and cost- 
effective. Major disadvantages of this therapy include discomfort during cryotherapy 
with blistering, scarring and changes in pigmentation afterwards. Cryotherapy is not 
the most appropriate treatment option for multiple AKs occurring in field cancerization. 
Dermabrasion, laser, chemical peels and electrodessication are other effective, 
destructive methods for treatment of AKs, but are less commonly used.72-74
Surgical excision
Surgery is not a treatment option for AKs, because AKs are superficially located lesions 
and there are different topical treatments with high efficacy for AKs. However, surgical 
excision is the treatment of choice for the majority of SCCs. Histological examination
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gives information about margins of the excised tissue and the differentiation grade of the 
tumor. With an appropriately chosen excision margin, local metastasis extending beyond 
the primary tumor should be included in the excised tissue in most cases. In high risk 
SCC (more than 2 centimeters in diameter, clinically ill-defined tumor extension, poor 
differentiation grade, tumors extending into subcutaneous fat tissue, high risk locations 
with potential functional impairment) Mohs' micrographic surgery might be considered. 
It is established that incomplete surgery is associated with a worse prognosis. In 
cases of contra-indications for surgery, incomplete excision of the tumor, cosmetically 
sensitive areas and the need to reduce the risk of functional impairment, radiotherapy 
is considered to be an alternative or addendum to surgical therapy.
Work-up and follow-up
All patients treated for cutaneous SCC need surveillance for the early recognition 
and management of treatment-related complications, local or regional recurrences, 
metastasis and the development of new skin cancers. Determining the extent of 
disease is critical to maximize the likelihood of long-term control. The initial evaluation 
of all patients should also include physical examination of locoregional lymph nodes. 
Patients with high-risk SCCs may require echographic or radiographic imaging 
(computed tomography (CT) or magnetic resonance imaging (MRI)), fine needle 
aspiration, or lymph node biopsy.67
1.5.8 PDT in actinic keratoses and Bowen's disease
Therapies for AKs are not always successful, demand patient's utmost compliance 
and have important side-effects (pain, scarring, loss of pigmentation). Since AKs often 
appear as field cancerization in cosmetically sensitive areas, PDT, which can be used 
over large surface areas with good clinical outcome, may have significant advantages 
over the standard treatment options.73
The use of topical application of 5-ALA in PDT for non-melanoma skin cancers was 
introduced by Kennedy and Pottier in 1990. They were the first who reported successful 
treatment of AKs with ALA in combination with blue light.5 PDT with topical ALA or MAL 
has proven to be effective and well-tolerated in treatment of NMSC. Currently, in Europe 
MAL-PDT is approved for use in AKs and Bowen's disease. After removal of superficial 
hyperkeratosis, MAL is applied for three hours under occlusion. The incubation time 
of ALA and MAL is related to the time point of the highest ratio of PpIX fluorescence 
to tumor depth. Two cycles of PDT induce cure rates ranging from 69% to 91% after 
three months. Thinner lesions respond better than thicker AKs. In the treatment of AKs, 
the results of PDT are at least as effective as the other treatment options mentioned 
before.7879 Immunosuppressive patients have an increased risk of developing AKs with 
an increased transformation rate into SCC. PDT is also effective in prevention of actinic 
damage in immunosuppressed patients. In case of a partial response or relapse, PDT 
can be repeated several times, because no cumulative toxicity has been reported yet.
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A major disadvantage of PDT is pain during irradiation. A neural mechanism has been 
discussed, since ALA is taken up by receptors for Y-aminobutyric acid (GABA) in the 
peripheral nerve endings.8081 MAL-PDT may be less painful, probably because it has 
no neurogenic uptake and the induction of porphyrins in normal skin is much lower 
compared to ALA.82 Probably, other factors, such as the penetration depth of light 
(wavelength) and the severity of actinically damaged skin, which is treated with PDT, 
are contributing factors to the experienced pain.83
As mentioned before, the choice of the light source depends on the absorption 
spectrum of the photosensitizer and the penetration depth of the light (see chapter 
1.4.3). Topical ALA induces an accumulation of PpIX, which has a maximum absorption 
peak at 408nm (Soret band) and as a result blue light is more effective than red light in 
activating PpIX. The visible spectra of porphyrins also show weaker absorption peaks 
at longer wavelengths (Q-bands). At first, blue rather than red light was investigated, 
because of the superficial localization of AKs. ALA with blue light has been effective in 
the treatment of diffuse superficial photodamage. PDT in conjunction with red light has 
also proven to be a very effective treatment option for AKs. The application of a 20% 
ALA hydrochloride solution (Levulan®, Kerastick™, DUSA pharmaceuticals, Wilmington, 
USA) followed within 14-18 hours by irradiation with blue (407nm) lamps has been 
approved for the treatment of AKs in the USA, while in Europe MAL-PDT in combination 
with red light is registered for the treatment of AKs and Bowen's disease. As SCC are 
potentially life threatening, PDT is not recommended for the treatment of SCC. 5;32;42;84;85 
For more information on this topic the reader is referred to chapter 2 of this thesis.
1.6 Psoriasis
1.6.1 History
Psoriasis is originally derived from the Greek word 'psora', which means itch. 
Hippocrates (460-377 BC) first described a skin disease with dry, scaly eruptions, 
which was grouped together with leprosy. In 1809, Robert Willan gave the first 
accurate description of psoriasis, as an independent disease entity, distinguishing the 
disorder from leprosy. It was not until 1841 that the condition was finally given the 
name psoriasis by Hebra.86;87
1.6.2 Epidemiology
Psoriasis is a very common, chronic disease with a prevalence of approximately 
1-3% of the population worldwide. Males and females are equally affected. A bimodal 
distribution of age of onset is seen with a larger, early peak between 16-22 years and 
a later, smaller peak at 57-60 years. An earlier onset in females is reported, but not 
universally observed.8889 It is a multifactorial and heterogenetically inherited disease. 
The clinical course is characterized by remissions and exacerbations, influenced
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by various exacerbating environmental factors, particularly infections (streptococcal 
infection of the upper respiratory tract) and several types of medications (beta-blockers, 
lithium).86;88;90;91 Psoriasis is characterized by eliciting a psoriatic lesion after local 
trauma of the skin, named the Koebner phenomenon.92 Moderate to severe psoriasis 
is associated with smoking, obesity, hypertension, dyslipidemia and insulin resistance, 
which are all components of the metabolic syndrome. This metabolic syndrome is 
associated with a relative risk of cardiovascular disease, however the pathogenic link 
with psoriasis is still unknown.93-96 Psoriasis can produce a significant decrease in 
quality of life by feelings of stigmatization and major changes in lifestyle.97
1.6.3 Clinical features
The most common type of psoriasis is psoriasis vulgaris (90%) with symmetrically 
distributed, sharply demarcated chronic erythematous plaques covered with silvery 
white scaling (figure 9a). Characteristic adherence of scales can be seen as if 
one scratches on a wax candle. This is called the candle wax sign. After scaling is 
completely removed, characteristic pinpoint bleedings may occur. This is called the 
Auspitz sign, which occurs because the capillaries run very close to the surface of the 
skin under a psoriasis lesion, and removing the scale pulls the tops off the capillaries, 
causing bleeding.
Predilection sites are the extensor sites of elbows and knees, scalp and lumbosacral 
region and umbilicus.8798 Psoriatic lesions can sometimes itch and may be painful, but 
generally the cosmetic aspects of the disease are responsible for most of the disease 
burden. Involvement of the skin folds in psoriasis is very common. These areas include 
the axillary, inframammary, genital, abdominal, retroauricular, intergluteal and perianal 
skin, where scaling is minimal. This form is called intertriginous psoriasis or psoriasis 
inversa.99 Guttate psoriasis is frequently the result of a preceding streptococcal infection 
two weeks before the skin lesions appear. The word guttate is from the Latin word meaning 
“drop.” It is characterized by small droplet-like erythematosquamous papules, mainly on 
the trunk. Its appearance is acute, typically occurring in children or young adults as the 
initial manifestation of the disease.100 Pustular psoriasis is not common and is classified 
into localized and generalized forms. Sterile pustules can also appear on hand palms 
and foot soles (psoriasis pustulosa palmoplantaris, M. Andrews-Barber) or localized at 
the distal ends of fingers and toes with involvement of the nails (acrodermatitis continua 
of Hallopeau). Generalized pustular psoriasis (von Zumbusch) is the most severe form 
in which small pustules develop in painful inflamed skin in combination with fever and 
malaise.87101 Another severe and unstable form of psoriasis is erythroderma, in which the 
whole body surface is affected. It is potential life threatening as hypo- or hyperthermia, 
loss of proteins and an imbalance of electrolytes can occur. Psoriatic erythroderma is 
not substantially different from erythroderma by other causes.95 
Associated features of psoriasis occur at the nails and joints. About 20-50% of patients 
with psoriasis have nail changes distinctive to the skin disease (pitting, onycholysis, oil
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spots and dystrophy). Nail psoriasis (psoriasis unguium) is most common in patients 
with psoriatic arthritis, which is defined as an inflammatory arthritis occurring during the 
course of psoriasis and is characterized by negative rheumatoid factor in the blood. 
The joints are affected in 10-20% of patients with psoriasis.8795
Figure 9: Clinical appearance (A) and histopathology (B) of psoriasis.
1.6.4 Histopathology
The histological hallmarks of psoriatic plaques are epidermal hyperproliferation, 
abnormal differentiation (keratinization) and inflammation. The epidermal changes are 
characterized by hyperkeratosis with focal parakeratosis, acanthosis, elongation of 
the rete ridges, thinning of the suprapapillary plate and loss of the granular cell layer. 
Characteristic is the presence of micropustules of Kogoj and microabcesses of Munro, 
containing neutrophils. In addition, increased vascularization in the upper dermis and 
inflammatory infiltrates in the dermis are seen (figure 9b).
Proliferation and differentiation
In psoriasis, proliferation of basal keratinocytes is increased. In normal skin the ratio 
of proliferating to nonproliferating keratinocytes, is around 60% whereas in psoriasis 
it is almost 100%.102 This hyperproliferation in psoriasis can be demonstrated with 
an immunohistochemical staining with antibody MIB-1, directed against recombinant 
parts of Ki67.103 Ki67-antigen is cell cycle associated and is expressed in all parts of 
the cell cycle, except in G0 and early G1, thus representing the epidermal proliferative 
compartment.104
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As a result of the hyperproliferation, immature keratinocytes appear throughout the 
epidermis. Keratin 10 (K10) is a marker for terminal differentiation, that is one of the 
predominant keratins in suprabasal keratinocytes of which expression is generally 
decreased in psoriasis.105 Another structural marker for differentiation is filaggrin. 
Filaggrin is involved in the formation of keratohyalin granules. In normal skin filaggrin is 
present in the stratum corneum and the stratum granulosum and supports cutaneous 
hydratation. In general, active psoriasis is known for its absent or discontinuous 
filaggrin expression.106-108
Inflammation
Immunohistochemical staining with cluster of differentiation antigens (CD-markers) 
enables the identification and investigation of specific cell surface molecules, present 
on all leukocytes. CD3 is the most specific T cell antibody, which is present on all T cells. 
Almost all T cells have either the CD4 (T helper cell) or CD8 (cytotoxic T cell) marker 
on their surface. Psoriasis is characterized by an inflammatory infiltrate comprised 
of CD4+ and CD8+ T lymphocytes. Both are found in the dermis, but CD8+ T cells 
dominate in the epidermis while in the upper dermis CD4+ T cells are predominantly 
present.109 T cells in the infiltrate of a psoriatic plaque are predominantly of CD45RO+ 
(memory effector) subtype rather than CD45RA+ (naïve) subtype. The naïve T cells 
have not yet been activated yet, while the memory effector T cells are activated in the 
lymph nodes to perform specific immunological actions.
Stratum corneum
The stratum corneum acts as a physical barrier function. As the epidermis is mainly 
responsible for the production of the stratum corneum cells, changes in the epidermal 
differentiation and proliferation, as in psoriasis, lead to a disturbed skin barrier.110111 
The rapid keratinocyte proliferations causes parakeratosis and thus the formation 
of a poorly adherent stratum corneum, which results in the characteristic white 
scaling. Epidermal keratinocytes are activated as a result of an abnormal skin barrier, 
resulting in production of different inflammatory cytokines, like TNF-a and IFN-y. On 
the contrary, the loss of epidermal barrier function in psoriasis does not lead to an 
increased susceptibility to invasion of micro-organisms compared to normal skin, 
probably because activation of the immune system and antimicrobial proteins, like
beta-defensins.112;113
1.6.5 Pathogenesis
The cause of psoriasis remains unknown. The pathogenesis of psoriasis is very 
complex. The mechanism of this disease is still not known, but genetic susceptibility, 
abnormal function of keratinocytes, or immunological disturbance, especially in T 
cells, are postulated. Psoriasis is generally regarded as an immunologically mediated 
disorder characterized by abnormal keratinocyte proliferation and differentiation, local
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vascular changes and a mixed inflammatory infiltrate in the epidermis and dermis. 
The role of various cell types involved in the innate immunity (T cells, neutrophils 
and keratinocytes) has been well documented. Psoriasis is fundamentally an 
inflammatory skin condition with reactive abnormal epidermal differentiation and 
hyperproliferation. The inflammatory mechanisms are immune based and most 
likely initiated and maintained by T cells in the dermis. For many years, psoriasis 
was thought to be a primary proliferation and keratinization disorder of the skin with 
cutaneous inflammation as a secondary feature. This is probably because the most 
pronouncing feature of psoriasis is the prominent increased proliferation of epidermal 
keratinocytes. As a consequence, the first therapeutic strategies, like arsenic and 
methotrexate, were aimed at reducing the hyperproliferation. In 1979, a major shift 
took place after the successful use of T cell suppressive agents, like cyclosporine, 
as a therapy for psoriasis. This immunologically based hypothesis indicates specific 
antigen recognition by T cells of a yet unknown antigen, that results in inducing several 
cytokines, causing inflammation and keratinocyte proliferation. Several cytokines (e.g. 
TNF-a) and many T cell subsets have been studied, resulting in the development of 
many novel therapeutic approaches.
Some supposed loci for genetic susceptibility, in which PSORS1 is considered most 
important, have been associated with psoriasis.114 Several other studies have reported 
psoriasis loci on other chromosomes and identified genes involving the cutaneous 
immune response and the skin barrier function.113;115;116 The general opinion nowadays 
is that psoriasis is a polygenetic disease affecting both genes involved in the immune 
function and genes involved in the keratinocyte biology.86;87;117
1.6.6 Treatment options
1.6.6.1 Topical treatments
Topical therapies are the mainstay in treatment of psoriasis. Patients with limited 
disease principally use topical anti-psoriatic therapies, while patients with extended 
psoriasis use topical therapies as an addendum to systemic treatments in order to 
reduce dose and duration of treatment.
Emollients and keratolytics
Emollients and keratolytics in psoriasis are used in combination with other therapies. 
Salicylic acid reduces the amount of hyperkeratosis in order to enhance the penetration 
of topically applied medication and, in case of photo(chemo)therapy, the penetration 
of light. Emollients do not contain pharmacologically active substances, but increases 
hydration and reduces desquamation by normalization of proliferation and differentiation 
in psoriasis. Consequently, the amount of scaling and itch are reduced. Subsequently, 
the integrity of the stratum corneum is maintained reducing the induction of Koebner 
phenomenon.118
36
Introduction
Corticosteroids
Topical corticosteroids remain an essential treatment option for psoriasis, because 
of their anti-inflammatory, anti-proliferative, immunosuppressive, and vasoconstrictive 
effects. In the Netherlands, corticosteroids are divided into four potency groups (class 
I-IV). Potent and very potent topical corticosteroids are more successful in psoriasis 
than the corticosteroids with a mild and moderate potency.119 Limitation in the use of 
topical corticosteroids is the loss of efficacy with ongoing therapy (tachyphylaxis) and 
the rapid atypical recurrence of psoriasis upon discontinuation of treatment (rebound).120 
Local side effects, like skin atrophy, teleangiectasia, striae distensiae and purpura, and 
systemic side effects, like adrenal insufficiency (after application on large body areas), 
may occur. These side effects are mostly dose dependent. In order to reduce the 
risk of side effects mild to moderate potent corticosteroids for intertriginous areas and 
intermittent usage in combination with other therapies, like vitamin D3 derivatives, are 
recommended.119
Vitamin D3 derivatives
After the observation of improvement of psoriasis in patients with osteoporosis treated 
with systemic vitamin D, vitamin D analogues, such as calcitriol and calcipotriol, were 
investigated as novel treatment options. Both calcitriol and calcipotriol can be used as 
monotherapy or in combination. They inhibit the proliferation, stimulate the terminal 
differentiation of keratinocytes in psoriatic lesions, and decrease inflammation.121 
Local side effects, like pruritus, burning, oedema, peeling, and erythema, are reduced 
with ongoing treatment. The initial clinical responses are slower compared to topical 
corticosteroids, but maintenance therapy with vitamin D derivates has a higher 
safety on the long run. A benefit of vitamin D analogues is their value in combination 
therapy, with topical corticosteroids, photo(chemo)therapy and systemic treatments 
for psoriasis, resulting in a reduction of dose and duration of the other anti-psoriatic 
agents.119 It is a relative safe therapy, provided that patients do not use more than 
the recommended dose of 100 grams per week in adults for calcipotriol and 210 
grams a week for calcitriol. Vitamin D derivatives have a limited effect on the calcium 
homeostasis, however clinically relevant hypercalcaemia is rarely seen.120
Calcineurin inhibitors
Topical calcineurin inhibitors, such as tacrolimus and pimecrolimus, were initially 
developed for the treatment of atopic dermatitis, inhibiting T cell activation and 
consequently suppressing the local inflammatory reactions. These calcineurin inhibitors 
are a useful alternative to topical corticosteroids as they do not cause skin atrophy or 
tachyphylaxis. Their effects on psoriasis is limited, unless applied under occlusion. 
However, positive clinical effects are demonstrated on sites of the body susceptible 
to the side effects of the topical corticosteroids, like the intertriginous areas and the 
face.120;122
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Dithranol
Dithranol, also known as cignolin or anthralin, is a synthetic analogue of chrysarobin. 
It was first synthesized in 1916. After oxidation dithranol directly affects DNA, probably 
in mitochondria, which induces apoptosis and consequently reduces proliferation and 
inflammation in psoriasis.123 It is a highly effective and safe therapy. Dithranol has 
a slower mode of action compared to topical corticosteroids, but without the risk of 
rebound or tachyphylaxis and no long term side effects. Application of dithranol in 
an out-patient setting used to be difficult, because of its substantial side effects, like 
skin irritation and staining of skin, hair, nails and clothes.120 Since the development of 
short contact dithranol therapy, which consists of a regimen in which dithranol in an 
ascending concentration is applied for minutes to an hour, treatment with dithranol at 
home or in a day care setting was possible.124
Coal tar
Coal tar is one of the oldest treatments for psoriasis and eczema. Its exact mode of 
action is still unknown, but coal tar has anti-inflammatory, antibacterial, antipruritic and 
antimitotic effects. Although coal tar is an effective therapy, its use in daily practice is 
limited by discoloration of clothing, odour, skin irritation, phototoxicity and folliculitis.125 
In occupational settings and in animal studies, coal tar has proven to be carcinogenic. 
However, carcinogenicity following coal tar applications in psoriasis and atopic 
dermatitis remains unconfirmed.120
1.6.6.2 Photo(chemo)therapy
Of all systemic treatments for psoriasis, phototherapy is preferred based on efficacy, 
safety and patient burden. Phototherapy is an important treatment option in extensive 
psoriasis and/or when topical application of anti-psoriatic agents fail. UVB phototherapy 
is preferred above PUVA, because its efficacy is comparable, systemic administration 
of psoralens has significant side effects and PUVA has demonstrated cumulative 
toxicity.
UVB phototherapy
Broad-band UVB was used by Goeckermann in combination with coal tar and later 
by Ingram in combination with dithranol paste. In 1978, UVB phototherapy proved to 
be effective in psoriasis as a monotherapy. However, broad-band UVB phototherapy 
(290-320nm) was less successful for treating psoriasis than PUVA.2728 UV wavelengths 
(“mercury lines”) longer than 313nm are not effective in resolving psoriasis, whereas 
wavelengths shorter than 300nm produce only UV burns without clearing psoriasis. 
In 1984, the most effective wavelength of UVR for psoriasis was determined to be 
311-313nm.126 Narrow-band UVB phototherapy has significant advantages over broad­
band UVB therapy, including faster resolution of skin lesions, a higher percentage 
of patients attaining clearing of disease, and the ability to achieve these results with
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an easy to administer, suberythematogenic dosing schedule. For achieving complete 
remission or a significant improvement of psoriasis, an average of 25-30 treatments 
with a frequency of three times weekly is necessary.127;128
The optimum dosage regimen for narrow-band UVB irradiation in psoriasis still has to 
be determined. Adequate equipment and treatment protocols are essential for good 
therapeutic results and (cost-)effectiveness with minimal unwanted negative side 
effects. There is a strong relation between UVB-induced sunburns, high cumulative 
UV exposure and the development of skin cancer. Cumulative dosages for narrow­
band UVB are generally higher compared to doses with broad-band UVB.129 However, 
narrow-band and broad-band UVB phototherapy induce similar effects on inflammation 
and photo-ageing in comparable erythematogenic dosages.130 No increased risk of 
NMSC is found in association with narrow-band UVB phototherapy.30 On the contrary, 
maintenance therapy in order to extend the period of remission is discouraged, 
because of the increased risk of photo-ageing of the skin and development of non­
melanoma skin cancers (NMSC).131 In order to reduce cumulative dosage and to 
enhance clearance of psoriasis, combination therapies with dithranol (Ingram), coal 
tar (Goeckerman) and systemic retinoids have been established. However, caution 
must be used when combining phototherapy with other agents, because unwanted 
results of combination treatments may include increased photosensitivity and burning 
or shortened duration of remission.29124
The sensitivity of the skin to sunburn is dependent of the skin type. The classification of 
skin type, according to Fitzpatrick, depends on the amount of melanin in the skin.132 In 
using UVB phototherapy, the minimal erythema dose (MED) is determined per patient 
before starting treatment to standardize the risk to sunburn. MED is the minimum 
amount of UVB that produces redness 24 hours after exposure and determines the 
starting dose of UVB phototherapy. An erythematogenic schedule starts with 70% of 
the MED, while a suberythematogenic regimen begins with 35% of MED.133 The last 
few years, both erythematogenic and suberythematogenic irradiation schemes are 
under investigation with regard to effectiveness and safety. For more information on 
this subject the reader is referred to chapter 3 of this thesis.
PUVA phototherapy
In 1974, photochemotherapy was introduced as a highly effective treatment option 
for psoriasis with potential for long remissions. This combination treatment of UVA 
phototherapy with photosensitizing psoralens (8-MOP) can be administered topically 
or systemically. In order to achieve complete or substantial remission of psoriasis, an 
average of 20-30 treatments is given with a frequency of two to three times weekly. In 
PUVA, the minimal phototoxicity dose (MPD) is determined for defining the start dose. 
The most common side effect of 8-MOP is nausea. Acute side effects of PUVA are 
erythema, phototoxicity and pruritus of the skin, while on the long-term it is established 
that PUVA therapy has photo-ageing and carcinogenic side-effects. The combination
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of 8-MOP and UVA induces indirect DNA damage by induction of singlet oxygen. 
Normally, genomic stability is maintained by DNA repair mechanisms and apoptosis.22 
Because of a dose-dependent risk for melanoma and non-melanoma skin cancer, a 
maximum cumulative dose and a maximum number of treatments are maintained for 
PUVA treatment. For UVB no maximum dose has been established yet, because the 
role of UVB phototherapy in developing skin cancer is less clear.134 In order to minimize 
the cumulative dosage, combination therapy with retinoids has been established. 
Faster clearing is also seen after combining PUVA with topical steroids. However, a 
shorter remission time is demonstrated after the application of topical corticosteroids 
during phototherapy.135;136
1.6.6.3 Systemic treatments
When topical therapies or photo(chemo)therapy are not effective, fail to induce long­
term remission or are contra-indicated, systemic treatments can be used for patients 
with moderate to severe psoriasis. Systemic therapies are particular beneficial for 
patients with psoriatic arthritis or nail psoriasis.
Methotrexate
In 1958, Edmundson described the effectiveness of a folic acid antagonist on psoriasis. 
Since 1971, methotrexate is an approved therapy for severe psoriasis.137 This folic acid 
antagonist inhibits dihydrofolate reductase, an enzyme necessary for DNA synthesis 
and thereby inhibiting cell proliferation. In addition, it also has important effects on 
pyrimidine and purine metabolism, resulting in anti-inflammatory effects.138 Doses of
7.5 mg to 22.5 mg per week are clinically effective. To reduce toxicity, methotrexate 
administration is recommended in oral doses with 12 hour intervals for a total of three 
doses at weekly intervals.139 Combining methotrexate with oral folic acid does not 
affect its effectiveness, but prevents stomatitis and gastrointestinal symptoms.140 Long­
term use of methotrexate is associated with liver fibrosis and cirrhosis. A liver biopsy, 
as a periodical evaluation of liver toxicity, is currently under discussion as several 
non-invasive diagnostic tests are emerging. In order to reduce cumulative toxicity, the 
lowest effective dose of methotrexate should be sought by tapering the dose slowly 
after reaching stability or clearance.119;141
Retinoids
Oral retinoids, also known as vitamin A derivates, bind and/or activate nuclear retinoid 
receptors. Retinoids modulate keratinocyte proliferation and differentiation to normal. 
The second generation retinoids, etretinate and its metabolite acitretin, are only 
effective as a systemic treatment. Today, acitretin is the only preferred systemic retinoid 
in the treatment of psoriasis.142 Retinoids can be effective for pustular psoriasis and 
erythrodermic psoriasis. As a monotherapy, the start dose of acitretin is 0.3-0.4 mg/ 
kg/day for the first three to four weeks. Hereafter, dose adjustments are made based
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on response and side effects.134 In combination with PUVA or UVB phototherapy, the 
clinical response is increased and the cumulative UV dosage is lowered. The most 
common side effects are mucocutaneous reactions, like cheilitis, conjunctivitis, hair 
loss and dry skin. Other side effects include hyperlipidaemia, ligamentous calcifications 
and skeletal abnormalities. As acitretin is highly teratogenic, systemic retinoids should 
be used with extreme caution in women of child-bearing potential.119;141
Ciclosporin
Within T cells, ciclosporin inhibits the activity of calcineurin phosphatase, which is 
responsible for the dephosphorylation of nuclear factor of activated T cells. Therefore, 
ciclosporin is an immunosuppressive agent. In 1979, Mueller and Hermann demonstrated 
for the first time improvement of psoriasis after treatment with ciclosporin.143 The 
recommended initial dose of ciclosporin is 3 mg/kg/day. The effect on psoriasis is dose 
dependent. Dose adjustments up to 5 mg/kg/day are based on clinical efficacy and 
side effects. Because of an increased risk of nephrotoxicity and hypertension careful 
monitoring is required and therapy should be restricted to short intermittent courses of 
several weeks. Considering the long-term cumulative toxicity, ciclosporin is no option 
for the long-term management of psoriasis. Therefore, ciclosporin is highly effective 
treatment option in inducing a rapid remission of psoriasis.119;134;137;141
Fumaric acid esters
In 1959, fumaric acid esters were used for the first time in Germany as a therapy for 
psoriasis. Fumaderm® has been registered as a systemic treatment option for psoriasis 
followed since 1994, only in Germany. Fumarates are naturally occurring molecules, 
which are part of the citric acid cycle. The anti-psoriatic effects are mainly due to 
inhibition of NFkB and T cell apoptosis. The produced tablets are available in low- 
strength (Fumaderm initial) and high-strength (Fumaderm) forms to allow a therapy 
with increasing doses. A daily dosage of six high-strength tablets of Fumaderm is 
the maximum dose. Dosage adjustments are made, based on clinical efficacy and 
side effects. The most common side effects are gastro-intestinal problems, flushing, 
headache and fatigue. These effects are seen more with high doses.119;134;144
Biologics
The implication of certain immunological pathways leading to psoriasis, has led to the 
development of new agents, targeting these specific immunological steps. Biological 
agents, also known as biologics or biologicals, are recombinant molecules. These 
proteins all have an inhibitory effect on the inflammatory process of psoriasis.
Since TNF-a production is also involved in the pathogenesis of psoriasis, the use of anti- 
TNF-a therapy has shown promising results in treatment of therapy resistant psoriasis. 
Etanercept is a recombinant human receptor body fusion protein that combines the Fc 
portion of human immunoglobulin G with two soluble TNF receptors. Consequently,
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binding of circulating soluble TNF-a prevents interaction of TNF-a with cell-bound 
receptors and the pro-inflammatory cascade is interrupted.145 146 Adalimumab is a fully 
human monoclonal antibody, which has a high specificity and affinity to both soluble 
and membrane-bound TNF-a and therefore neutralizes the biological activities of TNF-
a.146 Infliximab has a clinical efficacy comparable with adalimumab, but is a chimeric 
anti-TNF-a monoclonal antibody. Disadvantages of infliximab are the intravenous drug 
delivery and the potential of developing human anti-chimeric antibodies, decreasing 
the clinical efficacy of the therapy.
The second group of biologicals are directed specifically against T cells or antigen 
presenting cells. Both alefacept and efalizumab bind to CD2 on memory effector T 
cells. Alefacept induces a apoptosis of CD45RO-positive T cells, while efalizumab 
inhibits adhesion of T cells to other cells, which prevents circulating T cells from 
entering the skin. In the Netherlands, alefacept in not registered and efalizumab was 
recently taken from the market after a few reports on serious side effects.119;134;147 
Recent studies on psoriasis pathogenesis were focused on the activation of T cells 
with a recently described phenotype Th17 and consequent expression of IL-12 and 
IL-23. IL-12 and IL-23 have a common p40 subunit that is a target of a new therapeutic 
class of biologic agents. Anti-IL-12 and IL-23, fully human monoclonal antibodies 
(ustekinumab and ABT-874), show significant promise for the treatment of moderate to 
severe psoriasis.148 149 However, as new agents in medicine, more evidence is required 
regarding long-term safety.
1.6.6.4 PDT in psoriasis
PDT has been proven to be clinically effective in non-melanoma skin cancer including 
AKs, Bowen's disease and (superficial) BCC. Since PpIX highly accumulating skin 
disorders in general may be a potential target for photodynamic treatment, other (non- 
oncological) indications have also been studied or are currently under evaluation. 
There is a permanent need for new treatment modalities in the treatment of psoriasis 
as topical therapies aren't always successful and demand patient's utmost compliance, 
and many systemic and photo(chemo)therapies are limited by cumulative toxicity and 
carcinogenicity in the long run. Although the long-term safety of PDT remains to be 
established, current data do not point in the direction of PDT having carcinogenic 
potential.5
The use of PDT in psoriasis was first reported in 1937, when Silver reported 
improvement of psoriasis in therapeutic trial with systemic Hp and UV light. In 1994, 
Boehncke et al. demonstrated selective PpIX localization in psoriasis after PDT with 
a topical application of a photosensitizer, with immunomodulatory effects on psoriasis 
comparable to PUVA therapy.150
Psoriasis has been shown to highly accumulate PpIX selectively and its susceptibility 
to PDT has been previously studied by various authors.150-154 In these studies clinical 
efficacy varied largely but results are difficult to compare because of the different
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treatment parameters that have been used. Considering the discomfort of this treatment 
and variable clinical efficacy, several authors therefore concluded PDT to be unsuitable 
for the treatment of psoriasis.153;155;156 Taking these factors into account, when efficacy 
could be increased by optimizing the treatment protocol, the photodynamic treatment 
of psoriasis would be of additional value in the current treatment arsenal.
As psoriasis has been reported to accumulate PpIX strongly, lower concentrations of 
ALA than used for dermato-oncological indications may be sufficient to exert a beneficial 
clinical effect. In addition, the primary goal of the photodynamic treatment of psoriasis 
is not likely to be the cytotoxic effect, for which a few higher photodynamic doses are 
required, but rather the immunomodulatory effect in which exposure to multiple lower 
photodynamic doses over a longer period of time are thought to be required.150 
Clinical efficacy of PDT in psoriasis might be improved by using multiple treatments.152153 
However, the predominant factor limiting the efficacy of topical ALA-PDT is the 
penetration depth of ALA and light. The penetration depth of ALA and ALA-induced 
porphyrins is dependent on the incubation time and skin type. The presence of high 
intra-lesional porphyrin levels is important for effective ALA-PDT. The maximum levels 
of porphyrins have been detected in psoriasis six hours after application of topical ALA. 
PpIX selectively accumulates in psoriasis plaques, but with variations in porphyrin 
levels between plaques of the same patients as well as between different patients.154 
The amount of hyperkeratosis may be one of the reasons for variable penetration of 
ALA, which presents as heterogeneous fluorescence after application and incubation 
of ALA in psoriasis. Pretreatment with a topical keratolytic agent seems to be of utmost 
importance, in order to optimize penetration of ALA and light.34156 
However, not only exogenous application of ALA leads to elevation of porphyrins in 
the psoriatic skin. In the absence of exogenous applied photosensitizers, illumination 
of psoriasis plaques with visible light induced fluorescence, which is referred to as 
'autofluorescence'. This autofluorescence in psoriasis has an emission peak of 
635nm, corresponding with the excitation peak of PpIX, which is demonstrated to be 
present in the stratum corneum. Therefore, it might be possible that visible light could 
improve psoriasis in the presence of these endogenous porphyrins in the stratum 
corneum of psoriasis plaques.157 However, repeated exposures to blue light without 
the administration of exogenous photosensitizers did not induce clinical improvement 
of psoriasis.158 For more information on this topic the reader is referred to chapter 3 of 
this thesis.
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1.7 Aims of the thesis
In the present thesis several aspects of photo(dynamic)therapy and fluorescence 
diagnosis with aminolevulinic acid induced porphyrins in psoriasis, actinic keratosis 
and cutaneous squamous cell carcinoma have been studied. The following aims were 
formulated.
Main aim: To study diagnostic and therapeutic innovations in 
photo-dermatology in psoriasis and (pre)malignancies of the skin
Aim I: To study fluorescence diagnosis and photodynamic therapy for non­
melanoma skin cancer (chapter 2)
As different tissue types have distinct capabilities to accumulate PpIX, FDAP could be 
used to discriminate between different tissue types.
Ia To evaluate the value of FDAP as a diagnostic tool to discriminate between different 
stages of KIN or proliferative status.
Considering the high fluorescence observed in SCC, it might be interesting whether 
FDAP can be useful to discriminate between KIN and invasive carcinoma.
Ib To investigate the possibility to discriminate between AKs and cutaneous SCC with 
FDAP.
Since AKs often appear in areas with field cancerization, PDT may have significant 
advantages over the standard treatment options.
Ic To study the clinical efficacy of PDT with topical methyl aminolevulinate (MAL-PDT) 
in field cancerization with respect to the number of AKs and skin rejuvenation.
Aim II: Optimization of UVB phototherapy and evaluation of innovations in 
phototherapy for psoriasis (chapter 3)
UVB phototherapy is an established treatment option for psoriasis. The optimum 
dosage regimen for narrow-band UVB irradiation in psoriasis still has to be determined. 
Both erythematogenic and suberythematogenic irradiation schemes have been 
under investigation with regard to effectiveness and safety in body-half comparisons. 
However, the shortcoming in left-right comparison is the omission of the systemic effect 
of UVB treatment.
IIa To study the time to clearance in patients with psoriasis in a randomized, controlled 
trial, in which patients are treated with narrow-band UVB phototherapy in either a high­
dose or a low-dose regimen.
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There is a high individual variability in the number of UVB treatment sessions patients 
need for clearance. Several clinical and treatment-related factors have been identified 
as predictors of the time to clearance. The role of itching and related scratching 
behavior has been frequently neglected in psoriasis in general and their role for 
possible treatment efficacy of UVB treatment specifically.
IIb To assess predictors for the time to clearance of psoriasis with narrow-band UVB 
phototherapy.
Non-adherence is a common problem in patients with chronic dermatological conditions, 
including psoriasis. The role of non-adherence on the outcome of dermatological 
treatments, including the long-term effectiveness of UVB therapy in psoriasis, is not 
well understood.
IIc To establish whether treatment adherence is a predictor of long-term treatment 
response in patients with psoriasis who had been successfully treated with UVB 
phototherapy.
There is a permanent need for new treatment modalities in the treatment of psoriasis. 
Psoriasis has been shown to highly accumulate PpIX. The clinical efficacy of PDT on 
psoriasis varies largely. Knowledge on the histological effects of PDT in psoriasis is 
crucial to better understand the mechanism responsible for the variable clinical effects 
of PDT in psoriasis.
IId To study the clinical effectiveness and immunohistochemical changes of ALA-PDT 
in patients with psoriasis.
A variable distribution of PpIX within plaques after FDAP is seen. It is unknown what 
causes this heterogeneity of fluorescence in psoriatic skin. Variations in fluorescence 
might explain the variable and mostly partial clinical response of psoriasis seen after 
PDT.
IIe To study the morphological and immunohistochemical differences in inhomogeneous 
PpIX-induced fluorescence in stable plaque psoriasis.
Inhomogeneous distribution of PpIX may result from variations in the amount of 
hyperkeratosis, leading to a variable penetration of ALA and light.
IIf To study the effects of different keratolytic pretreatments in FDAP and during PDT.
Over the last few years phototherapy with visible light has gained interest in 
dermatological practice as a safe treatment modality. Nevertheless, the effects of 
visible light on the skin are only partly known. Theoretically, blue light could induce 
biological effects comparable to UVA radiation.
IIg To study the clinical and histological effects of blue light on normal skin.
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Psoriasis has been shown to accumulate PpIX after application of ALA and its 
susceptibility to PDT with red light has been previously studied. PpIX is also present 
in psoriatic skin without the preceding application of its precursor. Consequently, the 
interaction of high-dose visible light and endogenous photosensitizers, like PpIX, 
in psoriasis may represent a new principle for photodynamic treatment of psoriasis 
without the application of an exogenous photosensitizer.
IIh To study the effects of blue and red light in stable plaque psoriasis in a randomized 
blinded study.
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Chapter 2
Fluorescence diagnosis and photodynamic 
therapy for non-melanoma skin cancer
This chapter is based on the following publications:
Fluorescence diagnosis in keratinocytic intraepidermal neoplasias
T. Smits, M.M. Kleinpenning, W.A.M. Blokx, P.C.M. van de Kerkhof, P.E.J. van Erp, 
M.J.P. Gerritsen
J. Am. Acad. Derm atol., 2007; 57(5): 824-831
Fluorescence diagnosis in actinic keratosis and squamous cell carcinoma
M.M. Kleinpenning, E.W. Wolberink, T. Smits, W.A.M. Blokx, P.C.M. van de Kerkhof, 
M.J.P. Gerritsen
Accepted, Photoderm atol. Photoim m unol. Photomed.
The clinical efficacy of topical methyl-aminolevulinate photodynamic therapy in 
moderate to severe actinic keratoses of the face and scalp
M.M. Kleinpenning, P.C.M. van de Kerkhof, M.J.P. Gerritsen 
J. Derm. Treatment, 2010 Jul; 21(4): 252-257
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Fluorescence diagnosis and PDT for non-melanoma skin cancer
---------------------------- 1----------------------------
Fluorescence diagnosis in keratinocytic 
intraepidermal neoplasias
Tim  Sm its, MD,a M arloes M. K lein p en nin g , M D,a W illeke A. M. B lokx, MD, PhD ,b Peter C. M. van  de  
Kerkhof, MD, PhD ,a Piet E. J. van  Erp, PhD ,a and M arie-Jeanne P. G erritsen, MD, PhD a 
Nijmegen, The Netherlands
Background: As different tissue types have distinct capabilities to accumulate protoporphyrin-IX, 
fluorescence diagnosis with aminolevulinic acid—induced porphyrin (FDAP) could be used to discriminate 
between different tissue types.
Objective: Protoporphyrin-IX accumulation and proliferation were studied in cutaneous squamous 
(pre)malignancies to see whether FDAP could be used to discriminate between different stages of 
keratinocytic intraepidermal neoplasia or proliferative status.
Methods: FDAP was performed in 14 patients (86 lesions) and biopsy specimens were taken, on which 
(immuno)histochemistry was performed for histopathologic classification and assessment of Ki67-antigen 
expression. Stratum corneum thickness was also measured.
Results: The fluorescence ratio (lesional:nonlesional skin) showed neither significant differences between 
the different keratinocytic intraepidermal neoplasia stages, nor between different levels of Ki67-antigen 
expression. Macroscopic fluorescence intensity and stratum corneum thickness were negatively correlated.
Limitations: Relatively few malignancies were biopsied.
Conclusions: With FDAP we were not able to discriminate between keratinocytic intraepidermal neoplasia 
lesions or proliferative activity. However, hyperkeratosis appeared to be an important determinant in 
variations in macroscopic fluorescence intensity. (J Am Acad Dermatol 2007;57:824-31.)
Photodynamic therapy (PDT) with 5-amino­levulinic acid (ALA) or its methylester as a topical photosensitizer is now a widespread 
treatment modality in actinic keratosis (AK), Bowen’s 
disease (BD), and (superficial) basal cell carcinoma 
in an increasing number of dermatologic centers. In 
this treatment the preferential accumulation of en­
dogenous porphyrins, in particular protoporphyrin
IX (PpIX), in lesional skin after incubation with
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Abbreviations used:
AK: actin ic  keratosis
ALA: am in o lev u lin ic  acid
BD: B o w e n ’s d isease
CCD: c h a rg e d  c o u p le d  dev ice
FDAP: flu o re sc e n c e  d iag n o sis  w ith
am in o lev u lin ic  ac id —in d u ce d  p o rp h y rin s
KIN: kera tin o cy tic  in traep id e rm a l n eo p las ia
PDT: p h o to d y n am ic  th e ra p y
PpIX: p ro to p o rp h y rin -IX
SC: s tra tu m  co rn eu m
SCC: sq u a m o u s  cell carc in o m a
TIFF: tag g e d  im ag e  file fo rm a t
ALA/methylester is used to treat various skin dis- 
eases.1,2 As PpIX has characteristic fluorescence 
properties, its preferential accumulation in certain 
tissue types can also be used as a diagnostic tool. In 
fluorescence diagnosis with ALA-induced porphyrin 
(FDAP), lesional and nonlesional skin is irradiated 
with blue (408 nm) light after incubation of the skin 
with ALA. As PpIX shows red fluorescence when 
excited by blue light, PpIX accumulating cells can be 
visualized after irradiation with blue light. In cases
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where demarcation of lesional skin is clinically 
problematic, in dermatologie screening of field- 
cancerized skin, and to study PpIX accumulation 
during PDT, FDAP may provide additional informa­
tion. Interpretation of these data is still problematic 
because of the low reproducibility of the procedure 
as a result of the numerous factors influencing 
fluorescence detection and poor understanding of 
the mechanisms involved in PpIX tumor selectivity. 
Macroscopic fluorescence intensity after incubation 
with ALA has been shown to differ in various skin 
diseases. In a previous study we have shown PpIX 
accumulation to be higher in psoriasis compared 
with AK and macroscopic fluorescence on the skin to 
be a good predictor of PpIX content in the skin.3 
However, the exact cause of these different affinities 
for PpIX accumulation in different tissue types is 
unknown. Alterations in permeability properties of 
the stratum corneum (SC) and/or differences in the 
heme biosynthetic pathway are believed to play a 
role, although systematic in vivo studies are lacking.
For the application of FDAP in daily practice it 
is of utmost importance to know the relationship 
between the fluorescence data and histopathology 
and to know which factors can influence/disturb this 
relationship. Because of the increasing incidence of 
nonmelanoma skin cancer in the Western world field 
cancerization is an increasing problem, in which 
there are multiple (pre)malignant lesions diffusely 
spread over ultraviolet-exposed skin in particular. To 
treat these patients adequately, the physician often 
needs to take multiple biopsy specimens of the 
clinically highly suggestive lesions, which can be a 
significant burden for the patient. A noninvasive 
technique would, therefore, be of great value. Most 
studies on FDAP have mainly focused on basal cell 
carcinoma.4-8 Data on FDAP in squamous (pre)ma- 
lignancies, however, are relatively scarce.9,10
Because epidermal squamous (pre)malignancies 
comprise a spectrum from the premalignant AK and 
BD to invasive carcinoma, Yantsos et al11 have 
suggested a classification system, to emphasize this 
progressive nature, in which the amount of epider­
mal atypical keratinocytes combined with a clinical 
evaluation is graded into 3 categories of keratinocytic 
intraepidermal neoplasia (KIN). According to them a 
typical KIN-I lesion comprises a clinical flat lesion 
with focal atypia of the lower third of keratinocytes 
in the epidermis, whereas a typical KIN-II lesion 
appears clinically as a (hyperkeratotic) papule with 
focal atypia of the lower two thirds of the epidermis. 
Diffuse atypia involving the full thickness of the 
epidermis in a clinically indurated plaque is regarded 
a typical KIN-III lesion, formerly classified as bowe- 
noid AK, BD, or squamous cell carcinoma (SCC)
in situ. Similar grading systems have been developed 
in other epithelial neoplasias such as prostate, cer­
vical, and vulvar cancer.
In this study macroscopic fluorescence intensity 
is studied in cutaneous squamous (pre)malignancies 
with respect to histopathologic KIN classification 
and conventional histologic diagnosis. Other factors 
influencing macroscopic fluorescence intensity are 
also assessed including the thickness of SC, which 
has been demonstrated to account for heteroge­
neous fluorescence within psoriatic plaques as 
reported earlier by our group12 and proliferative 
activity, which could theoretically be of influence on 
PpIX accumulation.
METHODS 
Patient characteristics
This study was approved by the local medical 
ethics committee. Fourteen patients with a medical 
history of nonmelanoma skin cancer and field 
cancerization were included in this study after giving 
written informed consent. Additional patient charac­
teristics are depicted in Table I.
Fluorescence diagnosis and biopsy procedure
Before the day FDAP took place, the skin areas 
under study were pretreated with 5% or 10% salicylic 
acid in petrolatum for 1 or 2 weeks, depending on the 
clinical picture, to get rid of excess scales and hyper­
keratosis until clinically satisfactory results were 
achieved. On the day of the FDAP procedure, 20% 
ALA cream (Medac GmbH, Wedel, Germany) was 
applied under an occlusive dressing to these skin 
areas. After 3 hours of incubation, fluorescence 
intensity on the skin was recorded using a digital 
fluorescence imaging system (DyaDerm, Biocam 
GmbH, Regensburg, Germany). This system consists 
of a flash light (xenon light source with a custom band 
pass filter [370-440 nm]) and a 12-bit charged coupled 
device (CCD) camera combined in one adjustable 
arm coupled to a computer system equipped with 
custom image capturing software (Dyaderm Pro v1.4, 
Biocam GmbH). The flash light emits 7 light pulses/s 
to the skin, which are recorded by the CCD camera 
(exposure time 100 microseconds) equipped with a 
special long pass filter (Schott GG 455, Schott BV, 
Tiel, The Netherlands) to filter out the excitation light. 
As PpIX fluorescence emission consists of light in the 
red spectrum, the red pixels of the CCD camera were 
used to generate a fluorescence image. In this way a 
normal-colored image and a fluorescence image 
were processed in real time. Because of the short 
exposure time to the excitation light, photobleaching 
of PpIX was minimized. To correct for different
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Table I. Patient characteristics
No. Sex Age, y Immune suppressive drugs Lesions Body site R (P) Remarks
1 M 78 - 2 X  KIN II, 2 X  KIN III, 1 X  NS ue -0 .3 0  (.70)
2 F 42 AZA 1 X  KIN II, 6 X  VH, 1 X  NS ue, le -
3 F 68 - 1 X  KIN I, 4  X  KIN II, 1 X  KIN III, 3 X  NS le -0 .8 8  (.12)
4 F 52 - 6 X  KIN III, 2 X  NS ue, le -0 .8 7  (.05)
5 F 80 - 4  X  KIN I, 3 X  KIN II, 6 X  KIN III le -0 .1 4  (.67)
6 M 40 - 3 X  KIN II, 3 X  SCC ue -0 .8 0  (.10) ACT
7 F 59 - 2 X  KIN II, 1 X  KIN III le - 1 .0  ( \ .0 1 )
8 F 62 - 3 X  KIN I, 2 X  KIN II, 1 X  KIN III le -0 .9 4  (.21) ACT
9 F 57 - 1 X  KIN I, 1 X  KIN II le - 1 .0  (0.10) ACT
10 F 84 - 2 X  KIN I, 4  X  KIN II c -0 .8 7  (.03)
11 F 42 TA, PR, AZA 4 X  KIN I, 3 X  NS c -0 .5 8  (.41) RTR
12 M 73 - 4  X  KIN II c -0 .1 9  (0.80)
13 F 76 - 3 X  KIN I, 1 X  KIN II ue - 1 .0  (.10)
14 M 71 - 5 X  KIN II c -0 .3 3  (.78)
ACT, Acitretin; AZA, azathioprine; c, chest; F, female; KIN, keratinocytic intraepidermal neoplasia; le, lower extremities; M, male; NS, normal- 
appearing skin (no KIN); PR, prednisone; RTR, renal transplant recipient; SCC, squamous cell carcinoma; TA, tacrolimus; ue, upper extremities; 
VH, verrucous hyperkeratosis.
R (P) denotes Pearson's R and its P value from the correlation between fluorescence intensity and stratum corneum thickness in each patient.
lighting environments between pictures, a fluores­
cence reference standard (Maccal 8044, 738-00, 
Multifoil, Utrecht, The Netherlands) was included 
on every image. Images were recorded in 16-bit gray­
scale tagged image file format (TIFF) format.
After FDAP, 4-mm punch biopsy specimens were 
taken from selected lesions/skin areas of interest 
under local anesthesia with 1% lidocaine-adrenalin.
Analysis of fluorescence images
The 16-bit gray-scale TIFF fluorescence images 
were imported in software (ImageJ, National Insti­
tutes of Health, Bethesda, Maryland). Because the 
xenon light source used for excitation had the 
highest intensity in the center of the illuminated 
area, shading correction was performed by means of 
the following algorithm:
S =  I/C with C =  B/BImax
where B = blank image (image from a white homo­
geneous background recorded with the Dyaderm 
system), BImax = highest intensity of blank image, I = 
(uncorrected) image, C = normalized shading image, 
and S = shading corrected image.
Histopathology and immunohistochemistry
The 6-jUm slices were fixed on a glass slide, 
deparaffinized, hydrated, and washed in phosphate- 
buffered saline subsequently. For Ki67-antigen stain­
ing the sections were first pretreated in citrate buffer 
(pH 6.0) using the microwave antigen-retrieval 
method. Afterward, immunohistochemical analysis 
was performed after blocking for endogenous
peroxidase using a staining system (Powervision, 
Immunologic, Duiven, The Netherlands) with diami- 
nobenzidine as chromogen. The sections were incu­
bated for 1 hour with the primary MIB-1 antibody 
(Dako, Heverlee, Belgium) (1:100) directed against 
the cell-cycle associated antigen Ki67. For counter- 
staining, Mayer's hematoxylin was used.
Hematoxylin-eosin staining was also performed 
on every slide for assessment of the histopathologic 
diagnosis and KIN classification. All slides were 
assessed by one and the same pathologist (W. A. 
M. B.) for uniformity.
Immunohistochemical and digital 
image analysis
Immunoreactivity for the Ki67 antigen was scored 
semiquantitatively in the following manner accord­
ing to Keating et al13: 0 = only basal layer positivity,
1 = positivity confined to basal third of the epidermis,
2 = positivity confined to basal two thirds of the 
epidermis, 3 = transepidermal positive staining.
Analysis of digital microscopic images was done 
using digital image analysis software (ImageJ, 
National Institutes of Health). Digital photographs 
of the hematoxylin and eosin sections were made at
X 50 magnification. To determine the thickness of the 
SC, the average thickness was calculated as total SC 
surface including hyperkeratosis per millimeter 
length of the SC in different biopsy sections.
Statistical analysis
To analyze Ki67 expression and KIN grade in 
relation to fluorescence intensity, 1-way analysis of
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Fig 1. Fluorescence ratio and histopathology. Fluores­
cence in lesional skin was higher than in normal-appear­
ing surrounding skin but between different keratinocytic 
intraepidermal neoplasia (KIN) stages no significant dif­
ferences were found. Values are depicted by standard box 
plots in which horizontal line, gray box, and error bars 
represent median value, first to third quartile, and highest 
and lowest values, respectively. SCC, Squamous cell car­
cinoma. *P <.05,**P< .001.
variance was used. For analysis between groups, 
Duncan's post hoc test was performed. Analysis of 
fluorescence intensity in AK and BD, Ki67 expres­
sion, and SC thickness among the 4 diagnostic 
categories was performed using an unpaired 
Student t test. Correlation analysis of macroscopic 
fluorescence and SC thickness was performed using 
Pearson's R. All statistical calculations were per­
formed using software (Statistica, Statsoft Inc, and 
Excel 2000, Microsoft BV, Schiphol-Rijk, The 
Netherlands). A P value less than .05 was considered 
statistically significant.
RESULTS
Fluorescence diagnosis and histopathology
From the 86 lesions that were biopsied, 67 
appeared to be KIN with the majority (32/67) being 
KIN II and with comparable amounts of KIN-I 
(18/67) and KIN-III (17/67) lesions. Three lesions 
showed microinvasion and were classified as micro- 
invasive SCC accordingly. Ten lesions did not show 
nuclear atypia or other epidermal abnormalities and 
were classified as normal-appearing skin. From these
10 lesions 5 showed dermal elastosis and were 
subclassified as actinically damaged skin. In one 
patient verrucous epidermal abnormalities (papillo­
matosis, acanthosis) were seen without evident
Actinic keratosis Bowen's disease
Fig 2. A, Fluorescence ratio in keratinocytic intraepider­
mal neoplasia (KIN). Mean fluorescence ratio (lesional 
skin:nonlesional skin) was assessed in different KIN stages, 
but no significant differences were found. B, Fluorescence 
ratio in actinic keratoses and Bowen’s disease. Fluores­
cence ratio (lesional skin:nonlesional skin) was assessed 
using conventional histologic classification, but no signif­
icant differences were found. Errorbars, SEM.
nuclear atypia; these lesions were classified as 
verrucous hyperkeratosis consequently.
Nearly all lesions showed higher fluorescence com­
pared with nonlesional skin except for some of the 
verrucous hyperkeratoses and some hyperkeratotic 
KIN lesions (Figs 1 to 3). Macroscopic fluorescence 
between the different KIN lesions, however, did 
not show statistically significant differences (P  = .07) 
(Fig 2, A). When the lesions were classified according 
to the conventional nomenclature, AK and BD did not 
show significant differences (P = .16) (Fig 2, B). In 
SCC the highest fluorescence ratios were found but 
the low number and the fact that these came from a 
single patient did not allow reliable statistical com­
parisons to be made.
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Fig 3. Images acquired with fluorescence diagnosis imaging system. Color (A), fluorescence 
(B), and pseudocolor (C) images from two lesions classified as Bowen’s disease. Note that 
fluorescence corresponds well with clinical picture. Color (D), fluorescence (E), and pseudo­
color (F) images from verrucous hyperkeratosis with no atypia. Lesional fluorescence is lower 
than surrounding normal-appearing skin fluorescence.
Fluorescence diagnosis and proliferation
Analysis of proliferative activity as assessed by 
immunoreactivity for the Ki67 antigen did not reveal 
any significant differences in fluorescence ratios 
among the 3 levels of Ki67 expression (P = .46) 
(Fig 4). Ki67 is a cell cycle—associated antigen ex­
pressed in all parts of the cell cycle except G0, rep­
resenting the epidermal proliferative compartment.14
When the lesions were divided into 4 diagnostic 
categories (true/false positives/negatives), with a 
fluorescence ratio of 1.0 taken as a cut-off value 
and KIN lesions/SCC and verrucous hyperkerato­
ses/normal-appearing skin classified as (pre)malig- 
nant and benign lesions, respectively, lesions with a 
fluorescence intensity lower than surrounding skin 
(fluorescence ratio <  1.0; true and false negatives) 
had a significantly lower number of Ki671 cells than 
lesions with a fluorescence ratio greater than 1.0 
(true and false positives) (P <  .05) (Table II). 
However, when Ki67 immunoreactivity from all 4 
diagnostic categories was mutually compared only 
a significant difference between the false-positive 
and true-positive lesions (P <  .01) and true-positive 
and true-negative lesions (P <  .01) was found.
Fluorescence and thickness of SC
Assessment of the thickness of the SC in relation to 
the fluorescence intensity revealed a negative
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Fig 4. Fluorescence ratio and Ki67 expression.
correlation, which suggests SC to have a negative 
effect on fluorescence intensity measured with FDAP 
(Fig 5). This correlation was also assessed within 
every patient if possible. Interestingly, in every 
patient a negative correlation was seen, as reflected 
by negative correlation coefficients (R) in Table I. In 
addition, no association was found between the type 
of keratin (orthokeratosis vs parakeratosis) and flu­
orescence intensity. However, the amount of
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Table II. Stratum corneum thickness, Ki67 immunoreactivity, and number of samples classified according to 
fluorescence intensity and histopathology
KIN/SCC Normal-appearing skin/verrucous hyperkeratoses
No. SC thickness, mm Ki67+ cells/mm BM No. SC thickness, mm Ki67+ cells/mm BM
Fluorescence d iagnosis
H igh fluorescence 64 0.089 (±0 .010) 32.59 (±2 .92 ) 11 0.069 (±0 .016) 18.76 (±2 .61 )
L o w  fluorescence 7 0.281 (±0 .078) 20.75 (±4 .85 ) 4  0.336 (±0 .126) 19.13 (±2 .34 )
SC thickness, Ki67 immunoreactivity, and number of lesions were classified into 4 diagnostic categories based on histopathology and 
fluorescence intensity using a fluorescence ratio of 1.0 as a cut-off value with KIN lesions/SCC and normal-appearing skin/verrucous 
hyperkeratoses classified as benign and (pre)malignant skin lesions, respectively. (Pre)-malignant lesions with high and low fluorescence 
representthetrue positives and false negatives, respectively. Benign lesionswith high and lowfluorescence representthefalse positives and 
true negatives, respectively. SC thickness and Ki67 positivity are expressed as mean values (±SEM).
BM, Basement membrane; KIN, keratinocytic intraepidermal neoplasia; SC, stratum corneum; SCC, squamous cell carcinoma.
0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7
Thickness Stratum Corneum (mm)
Fig 5. Normalized fluorescence and thickness of stratum 
corneum. R = -0.45. Dotted lines indicate 95% confidence 
intervals.
samples with a solely orthokeratotic (nonparakera- 
totic) SC was relatively small compared with the 
samples with parakeratosis and, regarding the large 
statistical variation of the fluorescence data, possible 
differences in fluorescence intensity between the 
parakeratotic and nonparakeratotic samples might 
not be measurable at all.
When the lesions were divided into 4 diagnostic 
categories, as described earlier, lesions with a fluo­
rescence intensity lower than surrounding skin (flu­
orescence ratio <  1.0; true and false negatives) had a 
significantly thicker SC than lesions with a fluores­
cence ratio greater than 1.0 (true and false positives) 
(P = .01) (Table II). Moreover, in the true-positive 
lesions the mean SC thickness was significantly 
lower (P <  .05) compared with the false-negative 
lesions. Also, in the false-positive lesions a signifi­
cantly lower SC thickness was found compared with 
the false-negative lesions (P <  .05). However, among 
the other 4 diagnostic categories, no significant 
differences in SC thickness were found.
DISCUSSION
In this study no differences were seen in the 
different stages of KIN in their ability to accumulate 
PpIX, although KIN-III lesions tended to have higher 
fluorescence ratios than KIN- I/-II lesions. However, 
fluorescence intensity in lesional skin was almost 
always higher than nonlesional (surrounding) skin 
but there were also a few skin lesions histologically 
classified as normal-appearing skin that showed high 
(false-positive) fluorescence (8 lesions) and lesions 
with histologic atypia that showed low (false-nega­
tive) fluorescence (7 lesions) compared with normal- 
appearing surrounding skin. Possible explanations 
for this could be differences in SC thickness12 or 
pigmentation in lesional skin compared with nonle- 
sional skin but this could not be assessed because no 
biopsy specimens were taken from nonlesional 
(surrounding) skin. The lesions classified as verru­
cous hyperkeratosis, however, tended to have a 
thicker SC than the other diagnoses, although this 
was not statistically significant. In one patient with 
numerous verrucous hyperkeratoses without atypia 
lesional fluorescence was always lower than normal- 
appearing surrounding skin fluorescence (Fig 3, D to 
F) but also compared with the KIN lesions (Fig 1). 
Three samples were classified as SCC and showed 
high macroscopic fluorescence. Unfortunately, be­
cause there were only 3 lesions that also came from a 
single patient, reliable statistical comparisons were 
not possible. However, it would be interesting in the 
clinical setting to know whether FDAP can be used to 
discriminate between intraepithelial squamous pre­
malignancies and invasive SCC. Further studies on 
this are needed.
As penetration of the hydrophilic ALA through the 
lipophilic SC is a prerequisite for PpIX formation, 
which is predominantly synthesized by the epider­
mal keratinocytes, SC thickness and integrity can 
influence macroscopic fluorescence in vivo.12 In our 
samples a negative correlation was found between
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the thickness of the SC and fluorescence intensity, 
indicating hyperkeratosis to be an important factor 
in intrapatient and interpatient differences in fluo­
rescence intensity (Fig 5 and Table I). This is in 
accordance with a significant thicker SC found in all 
true and false negatives compared with the true and 
false positives (P <  .01). The fact that a significantly 
thinner SC was found in true-positive lesions com­
pared with the false-negative lesions also empha­
sizes the important role of the SC in fluorescence 
intensity. In addition, a significant thicker SC was 
found in the false-negative lesions compared with 
false-positive lesions, but no significant differences 
were found between the false-positive and true- 
negative lesions. The latter can possibly be explained 
by the relatively low number of true-negative lesions 
and high variation (high SEM).
Differences in SC thickness are probably not an 
explanation for the preferential accumulation of 
PpIX in lesional skin compared with nonlesional 
skin, because hyperkeratosis is very common in 
hyperproliferative skin disorders that highly accu­
mulate PpIX. Disruptions in SC integrity overlying 
a pathologic epidermis15 and/or alterations of the 
heme biosynthetic pathway16,17 are thought to be 
responsible for this. In a previous study of our group, 
AK was found to accumulate significantly more PpIX 
than surrounding nonlesional skin.3 However, when 
correcting PpIX content for the number of epidermal 
cells, differences in PpIX content between AK and 
nonlesional surrounding skin disappeared, indicat­
ing the PpIX content per cell to be comparable in AK 
versus nonlesional surrounding skin. Higher lesional 
fluorescence in AK can, therefore, be explained by 
an increased number of cells in lesional skin, leading 
to a higher PpIX quantum yield. In conclusion, SC 
thickness seems to play an important role in varia­
tions in fluorescence intensity. This should be con­
sidered when performing FDAP or PDT, for example 
by curettage or adequate keratolytic treatments be­
fore the procedure. In our study 5% to 10% salicylic 
acid in petrolatum was applied for 1 or 2 weeks 
depending on the clinical picture, until clinically 
adequate desquamation was achieved (as assessed 
by the investigating physician). This would theoret­
ically increase fluorescence intensity by facilitating 
penetration of ALA through the SC.18 As both lesional 
and nonlesional (surrounding) skin were pretreated 
with salicylic acid, the effects of different keratolytic 
regimes on the fluorescence ratio (lesional:nonle- 
sional skin) are assumed to be minimal.
Regulation of the enzymes in the heme synthesis 
(metabolism) might be expected to be related to 
proliferative activity as PpIX accumulation is in­
creased in many hyperproliferative (skin) disorders,
including psoriasis. Consequently, expression of the 
cell cycle-associated Ki67 antigen was assessed to 
study its relation with respect to macroscopic fluo­
rescence intensity. However, no significant differ­
ences were found in the macroscopic fluorescence 
ratios within various degrees of Ki67 expression, 
although, in lesions with low fluorescence ratios 
(<1.0, true and false negatives), significantly lower 
Ki67 expression was seen compared with high fluo­
rescing lesions (fluorescence ratio >  1.0, true and 
false positives), most likely a result of the relatively 
high number of true positives that are mostly hyper­
proliferative lesions. The significantly higher number 
of Ki67 cells in the true positives compared with 
the false positives and true negatives can also be 
explained by this. However, no differences in Ki67 
expression were found between the true negatives 
compared with the false positives and true positives 
compared with the false negatives. Therefore, 
differences in Ki67 expression cannot explain vari­
ations in fluorescence intensity. FDAP, therefore, 
cannot be used to discriminate between lesions 
based on differences in proliferative activity. Moan 
et al19 studied the relationship between PpIX accu­
mulation and cell-cycle phase and found cells in 
G21M  phase to have increased PpIX concentrations 
compared with the G1 phase but this was only 
related to the increased cell size during G21M . 
Fukuda et al20 found no obvious cell-cycle depen­
dency after incubation of cultured mammalian epi­
thelial cells with ALA. They attributed the slight 
differences in the PpIX concentrations, found in 
different cell phases, to extracellular PpIX loss during 
ALA incubation. Thus, proliferation does not seem 
a determinant of PpIX accumulation but rather a 
confounder.
In conclusion, in this study no significant differ­
ences were found in the macroscopic fluorescence 
ratios between various stages of cutaneous squa­
mous (pre)malignancies, although a slight tendency 
toward higher fluorescence ratios was seen in BD 
compared with AK. Proliferative activity assessed by 
expression of the Ki67 antigen also did not show 
significant differences in the different KIN stages. 
Thus, FDAP does not seem useful in the histopath­
ologic discrimination between these lesions nor can 
it be used to assess proliferative activity, although it 
might be interesting to further investigate the poten­
tial applicability of FDAP in the discrimination be­
tween premalignant squamous cutaneous lesions 
and SCC based on the higher fluorescence intensity 
observed in SCC compared with KIN lesions in this 
study. However, SC thickness and macroscopic 
fluorescence intensity appear negatively correlated 
among patients but also within patients, indicating
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hyperkeratosis to be an important determinant in 
variations in macroscopic fluorescence intensity. 
More knowledge on the mechanisms of the prefer­
ential accumulation of PpIX in various tissue types 
and the factors influencing this is needed to better 
understand false-positive and false-negative out­
comes in FDAP, which also may help us to understand 
the variable treatment efficacy observed in PDT.
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Background  A s d iffe ren t t issu e  ty p es  h av e  d istin c t cap ab ilities  to  accum ulate  
p ro to p o rp h y rin  IX  (P p iX ), f lu o rescen ce  d iagnosis  (F D A P ) cou ld  b e  u se d  to 
d iscrim in ate  b e tw een  differena tissu e  types. P rev io u s resu lts  d em o n stra ted  
h ig h er f luo rescence  ra tio s  in  sq uam ous cell ca rc in o m a  (S C C ) co m p ared  to 
actin ic  k e ra to sis  (AK ).
O bjectives T he les io n  a l:n o n -les io n al f lu o rescen ce  ratio  o f  A K s w as co m p ared  
■with the  ra tio  o f  SCC. O ther fac to rs  in fluencing  m acro sco p ic  f lu o rescen ce  w era  
a lso  a ssessed , includ ing  s tra tu m c a rn e u m th ic k n ess , w h ish  h as  b een  d em o n stra ted  
to  a cco u n i fo r  he te ro g en eo u s f luo rescence  in  p so ria s is  an d  in  A K s.
M ethods  A fte r  o n t  w eek  aU kera to ly tic  p r e (reatm ent, F D A P  w as p e rfo rm ed  in
13 p a tien ts  w ith  ( 6  lestona su sp ic ious fo r  A K  or S C C . B io p sie s  w ere  oaken for 
h isto p a th o lo g ica l d iag n o sis  and  m e a s u re m e n to f  s tra tu m  c o rn eu m  thicknees. 
Results  N o  s ig n ifican t d iffe ren ces  w ere  fo u n d  in  the  f lu o rescen ce  ratio  
(le s io n a l :non-lesional sic id) b e tw een  A K : and  SC C s, ilth o u g h  m tn ro sco p ic  
f lu o rescen ce  w as s ign ifican tly  h ig h er in  B o w e n ’s d isease  and  m icro -in v asiv e  
flCCs.
Conclusions  T h ere  cou ld  be  a p o ten tia l ap p licab ility  o f  F D A P  to  d iffe ren tia te  
p rrm a lig n a n t lesions w ith  a ten d en cy  to  p ro g ress  in to  SC C  and  sq u tm o u t 
cu taneoua lesions a lready  p ro g re s tin g  in to  early  invasive  can cer f ro m  other 
squam o u s cu tan e  o ur (pr e )m alig n an ci ten. T h e a m o u n t  o f  hy p erk era to sis, 
in v asiv en ess  und deu ree  o f  d iffe ren tia tio n  seem  to  b e  re sp o n sib le  fo r  v a ria tio n s  
in  fluorencence intensity .
A clin ic  k e ra to ses  (A K s) a re  gen e ra lly  reg a rd ed  as cu taneous 
ep ithe lia l p rem a lig n an c ies  th a t are  ab le  to  p ro g ress  to 
in v a s iv :  squam o u s c t i i  ca rc in o m a (S C C ).1'2 R eco g n itio n  o f  
A K s is im portan t, b ecau se  i f  le f t u n trea ted , th ere  is a low  risk  
o f  evo lv in g  in to  SCC. G enerally , 1-10%  w ill d eve lop  into 
SC C o v er a 10 y e a r  period , w ith  an  annual tran sfo rm atio n  
ra te  o f  less th an  one  in  th o u san d  A K s p e r  y ea r.3-6 H ow ever, 
it is n o t k n o w n  w h ic h  A K  w ill p ro g ress  to  SCC.
W orld w id e , th e  in creasin g  in c id en ce  o f  p a tie n ts  w ith  
n o n -m e lan o m a  sk in  c an ce r (N M S C ) an d  th e  p re se n c e  o f  
f i t id  c a a c t r iz a tio n  l a s  b t c o m t  a m a jo r  I t a i t l  p ro b itm . 
In  f i t id  c a n c tr iz a tio n , m u it ip i t  (p rt)m a iiu n a n t its io n s  
a re  d iffu se ly  sp read  o v e r c h ro n ic a lly  su n  e x p o sed  areas 
o f  th e  skin. In  o rd er to  d ec rease  th e  m o rb id ity  and 
m o rta lity  o f  SC C , b e n ig n  p re -c a n c e ro u s  les io n s  h a v e  to  be 
d istin g u ish e d  f ro m  m a lig n an t lesions. B e c a u se  A K s have 
n o n -sp tc if ic  c iin ica i f t a tu r t s  an d  d tm a rc a tio n  o f  i ts io n a l  
sk in  can  b e  c lin ica lly  p ro b lem atic , a d iag n o s is  o ften  is 
b a sed  o n  h is to lo g ic a l in v estig a tio n . T he k e ra t in o c y t^
in lrao p ieo rm a l n e o p la s ia  (K IN ) g rad e  h as  b e e n  u se d  as 
a l is to io u ic a i  c ia ss if ica tio n  sy s ttm , in  o r d t r  to  g u id t  
c lin ic ian s  in  d iag n o s is  an d  tre a tm e n t o f  A K s evo lv in g  
in  SCC. T l t  p r o u r t s s iv t  s p tc t ru m  o f  A K  an d  B o A tn ’s 
d isease  to  SC C  is g rad e d  in to  3 ca teg o rie s . G rad e  depends 
on  th e  a m o u n t o f  e p id e rm a l a ty p ic a l k e ra tin o c y te s  is 
c o m b in ed  w ith  a c lin ica l e v a lu a tio n . T yp ical K IN  I lesions 
c o m p ro m is t  c iin ica i fla t i ts io n s  A i t l  fo ca i a ty p ia  o f  t l t  
b asa l th ird  o f  k e ra tin o c y te s  in  th e  ep id e rm is , w h ereas  
ty p ic a l K IN  II les io n s  a p p e ar c lin ica lly  as (ay p o reo ra lo lic )  
p ap u les  w ith  fo ca l a ty p ia  o f  th e  lo w er tw o  th ird s  o f  the 
tp id t rm is .  D if fu s t  a ty p ia  in v o iv in g  t l t  fu ii  t l i c k n ts s  o f  
t l t  tp id t rm is  in  a c iin ica iiy  in d u ra ttd  p ia q u t  is r tu a r d td  a 
ty p ic a i K IN  III  i ts io n ,  a iso  c ia s s if i td  as B o A tn ’s d i s t a s t . 7 
A s sk in  b io p s i ts  can  b t  a s ig n ifican t b u r d tn  fo r  p a ti tn ts ,  
t s p tc ia i ie  A l t n  in  a r ta s  o f  f i t id  c a n c tr iz a tio n  m u it ip i t  
b io p s i ts  l a v t  to  b t  ta k tn ,  a n o n - in v a s iv t  t t c l n i q u t  fo r 
d e te c tio n  an d  d e m a rc a tio n  o f  sk in  (p re )m a lig n an c ies  
w o u ld  b e  o f  g re a t  v alue.
67
C
h
a
p
te
r
 
2
Chapter 2
Photodynamic therapy (PDT) with 5-aminolevulinic acid 
(ALA) or its methyl ester (MAL) as a topical photosensitizer 
has proven to be clinically effective in AKs, Bowen’s disease 
and superficial basal cell carcinoma(BCC). Topical application 
o f ALA or MAL leads to formation o f protoporphyrin IX 
(PpIX) in the skin. Preferential accumulation o f PpIX  in 
lesional skin is used to treat various skin diseases. As PpIX 
has characteristic fluorescence properties, its preferential 
accumulation in certain cell types can also be used as a 
cellular marker. In fluorescence diagnosis with ALA-induced 
porphyrins (FDAP), lesional and non-lesional areas are 
irradiated with blue light (408 nm ) after incubation o f  the 
skin with M AL or ALA. As PpIX  shows red fluorescence 
when excited by blue light, PpIX  accumulating cells can 
be visualised.8 In cases were demarcation o f lesional skin 
is clinically problematic, in dermatological screening of 
field-cancerized skin and to study PpIX accumulation 
during PDT, FDAP may provide additional information. 
Interpretation o f  these data is still problematic, because o f the 
low reproducibility o f the procedure due to numerous factors 
influencing fluorescence detection and poor understanding 
o f the mechanisms involved in PpIX tumor selectivity. M ost 
studies on FDAP have mainly focused on BCC or AKs. 
Our group has demonstrated that FDAP cannot be used as a 
non-invasive diagnostic procedure to discriminate between 
different stages o f AKs, because no significant differences 
in fluorescence between the various stages o f AKs were 
found. Although the fluorescence ratio in Bowen’s disease 
tended to be higher as compared to KIN I and KIN  II lesions. 
The highest fluorescence ratios were found in SCCs, but the 
low number o f SCCs tested (3 out o f 86 lesions, that were 
biopsied, were classified as SCC) and the fact that these 
came from a single patient did not allow reliable statistical 
comparison to be made.9
In the present study, the potential applicability o f FDAP 
in discriminating AKs from  SCC is further investigated. 
The lesional:non-lesional fluorescence ratio o f  AKs 
w ere compared w ith the ratios o f  SCCs. O ther factors, 
besides histological diagnosis, influencing macroscopic 
fluorescence w ere also assessed, such as stratum corneum 
thickness, which has been demonstrated to account for 
heterogeneous fluorescence in psoriasis.10
Methods
Subjects
The local medical ethics committee has approved this 
study. Thirteen patients w ith lesions highly suspicious for 
SCC and AKs were invited to participate in this study. 
A ll subjects were included in this study after given their 
written informed consent. Patients were not allowed to 
use immunosuppressive medication. Exclusion criteria 
included topical treatm ent (liquid nitrogen, imiquimod,
5-fluorouracil, PDT) 4 weeks prior to the study. Topical 
treatm ent during the study was restricted to 10%  salicylic 
acid in petrolatum.
Study protocol
One week before FDAP would take place, the skin areas 
under study were pretreated with 10%  salicylic acid in 
petrolatum once daily, in order to remove excessive scaling 
potentially interfering the penetration o f the M AL cream or 
the irradiation w ith visible light. On the day o f the FDAP 
procedure, MAL cream was applied under an occlusive 
dressing (Tegaderm, 3M  Pharmaceuticals, Zoeterwoude, 
the Netherlands) to enhance M AL penetration in these skin 
areas. The occlusive dressing was covered by aluminium foil 
to avoid premature photobleaching effects. After three hours 
o f incubation11 the ointment and foils were removed and the 
skin surface was cleaned using 80% denaturated alcohol v/v.
Fluorescence diagnosis
A fter 3 hours o f  incubation with M AL ointment, 
fluorescence intensity on the skin was recorded using a 
digital fluorescence imaging system (Dyaderm, Biocam 
GmbH, Regensburg, Germany). The D yaderm  digital 
imaging system consists o f  a flash light (Xenon light 
source w ith a custom band pass filter (370-440 nm )) and a 
12-bit Sony CCD camera com bined in one adjustable arm 
coupled to a Pentium  IV com puter equipped w ith custom 
made image capturing software (Dyaderm Pro v1.4, Biocam 
GmbH, Regensburg, Germany). The flash light emits 7 
light pulses per second to the skin w hich are recorded by 
the CCD camera (exposure tim e 100 ^sec) equipped with 
a special Schott GG 455 long pass filter to filter out the 
excitation light. As PpIX  fluorescence emission consists o f 
light in the red spectrum, the red pixels o f the CCD camera 
w ere used to  generate a fluorescence image. In this way 
a normal coloured image and a fluorescence image were 
processed in real-time. Because o f the short exposition 
tim e to the excitation light, photobleaching o f  PpIX  was 
m inim alised in this way. To correct for different lighting 
environments between pictures, a fluorescence reference 
standard (M accal 8044, 738-00, M ultifoil, U trecht; the 
N etherlands) was included on every image. Images were 
recorded in 16-bit grayscale TIFF format.
Analysis o f fluorescence images
16-bit grayscale TIFF fluorescence images were imported in 
NIH ImageJ software (http://rsb.info.nih.gov/ij/). Because 
the X enon light source used for excitation has the highest 
intensity in the centre o f  the illumunated area, shading 
correction was performed by means o f the following 
algorithm:
S = I / C with C = B /  B i max 
B = blank image (image from a w hite homogeneous 
background recorded with the D yaderm  system), BImax =
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highest intensity o f  blank image, I = (uncorrected) image, C 
= normalised shading image, S = shading corrected image.
Biopsy procedure, histopathology and 
immunohistochemistry
A fter FDAP, 4 mm punch biopsies were taken from  selected 
lesions / skin areas o f  interest under local anaesthesia 
w ith 1% xylocain/adrenalin. From the skin samples 4 
^m  sections w ere fixed on a glass slide, deparaffinised, 
hydrated and washed in phosphate buffered saline (PBS, 
Invitrogen, M erelbeke; Belgium). H aem atoxylin-eosin 
staining was performed on every slide for assessm ent o f 
the histopathological diagnosis and KIN-classification. 
A ll slides were assessed by one and the same pathologist 
(W.A.M. Blokx) for uniformity.
Im m unohistochem ical and digital image analysis
Analysis o f digital m icroscopic images was done using the 
image processing program  ImageJ 1.37 (National Institutes 
o f  Health, M aryland; U.S.A.). A ll digital photographs were 
made at a 50x quantification. To determine the thickness of 
the stratum corneum, the average thickness was calculated 
as total stratum corneum surface including hyperkeratosis 
per millimeter length o f  stratum corneum in different 
biopsy sections.
Statistical analysis
To compare fluorescence intensity in AKs and SCCs 
and stratum corneum thickness between the diagnostic 
categories, a two-tailed Student’s t-test was used. Correlation 
analysis of macroscopic fluorescence and stratum corneum 
thickness was performed using a Pearson’s R. A  p-value 
<0.05 was regarded statistically significant. M icrosoft Excel 
2007 and SPSS 16.0 were used for statistical calculations.
Results
Fluorescence diagnosis and histopathology
In total, 13 patients with a total of 36 suspicious lesions were 
included (50-83 years w ith a mean o f  66.4 years ± 11.8 SD; 
7 men, 6 women). From the 36 lesions that were biopsied,
7 appeared to be SCC and 17 appeared to be AKs w ith an 
equal distribution between the different KIN  gradations; 
K IN  I (5/17), KIN  II (6/17) and K IN  III (6/17). Three 
lesions were classified as basal cell carcinoma (BCC). Nine 
biopsies did not show nuclear atypia and w ere classified as 
normal skin, benign (verrucous) hyperkeratosis or prurigo 
nodularis.
Nearly all lesions showed higher fluorescence compared 
with non-lesional skin, except for three KIN lesions and 
one BCC lesion. M acroscopic fluorescence of KIN  I and
II lesions did not show statistically significant differences 
(p=0.56). K IN  III lesions dem onstrated a significant higher
il
All SCC miSCC KIN III KIN II KIN I 
Fig. 1 Fluorescence ratio of non4esional versus lesional skin in the 
different histopathological diagnosis. M ean fluorescence ratio was 
assessed and significant differences were found between miSCC/ 
KIN III and SCC/KIN I. * p=0.05; ** p<0.05 (au ., arbitrary 
units; miSCC, microinvasive squamous cell carcinoma; KIN, 
keratinocytic epidermal neoplasia).
fluorescence compared to K IN  I lesions (p<0.05). It was 
not possible to differentiate between K IN  II and KIN  III 
lesions based on differences of the fluorescence intensity 
(p=0.31). W hen the lesions were classified according to the 
conventional classifying system, the highest fluorescence 
ratios were found in Bow en’s disease. These fluorescence 
ratios tended to be significantly higher compared to SCCs 
(p=0.05). However, the highest fluorescence ratios o f  all 
SCC were micro-invasive SCC. These values showed a 
significant higher fluorescence com pared to the moderately 
and w ell differentiated SCCs (p=0.03) and were comparable 
with the fluorescence intensity of Bow ens’ disease (p=0.84) 
(Figure 1).
Fluorescence diagnosis and stratum corneum thickness
No significant differences in stratum corneum thickness 
between the different histological diagnoses could be 
demonstrated. Assessment o f  the stratum corneum thickness 
in relation to the fluorescence intensity revealed a negative 
correlation (R=-0.35), which suggests stratum corneum to 
have a negative effect on fluorescence intensity measured 
with FDAP. Because this correlation was less evident 
than in earlier studies9,10, we also assessed the epidermal 
thickness o f  each biopsy. There was no correlation between 
the fluorescence ratio and the epidermal thickness.
Discussion
In this study, the lesional:non-lesional fluorescence ratios 
of AKs were com pared with the ratio of SCC. Fluorescence 
intensity in lesional skin was almost always higher than 
in (surrounding) non-lesional skin, except for three AKs 
and one BCC despite adequate keratolytic pretreatment. 
No differences were seen between the various stages o f 
K IN  in their ability to accumulate PpIX. These results 
were in concordance w ith the earlier results o f  Smits et al.,
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concluding that it is not possible with FDAP to differentiate 
between the different K IN  grades.9 Although, the 
fluorescence ratio in B ow en’s disease tended to be higher 
than in low-grade AKs and this observation was verified 
in this study. However, our fluorescence ratios o f  B ow en’s 
disease w ere also higher than in SCCs. This is in contrast 
w ith the results o f  Smits et al., because in their study the 
highest fluorescence ratios w ere found in SCCs, accidentally. 
Reliable statistical comparisons were not possible, because 
the low number and the fact that all three SCCs came from 
a single patient. The conclusion was that FDAP is not 
useful in the histopathological discrimination between the 
different stages o f  KIN, although there could be a potential 
applicability o f  FDAP to discriminate premalignant 
squamous cutaneous lesions from  SCC. In the present study, 
the potential applicability o f  FDAP in discriminating AKs 
from  SCC was further investigated, based on the previous 
dem onstrated higher fluorescence ratio in SCC. On the 
contrary, our results show a low fluorescence intensity of 
SCC com parable with K IN  II lesions. A fter subdividing 
SCCs into degrees o f  differentiation, we assessed the 
highest fluorescence ratios to be from  three micro-invasive 
SCC. The other (m oderately and well differentiated) SCCs 
had fluorescence ratios even lower than K IN  I lesions. The 
fluorescence ratio o f m icro-invasive SCC was identically 
high to the fluorescence ratio o f  B ow en’s disease. The term 
micro-invasive carcinoma defines cases o f  early invasive 
cancer, describing it as a lesion invading the papillary dermis 
only. The micro-invasive SCCs are clinically less apparent 
com pared to other, m ore invasive, SCCs and consequently 
m ore difficult to differentiate from  prem alignant squamous 
cutaneous lesions. Therefore, FDAP could be a potentially 
diagnostic tool to discriminate w hich prem alignant lesions 
have the tendency to progress into SCC or which squamous 
cutaneous lesion already progressed into an early invasive 
cancer as both Bow en’s disease and m icro-invasive SCC 
have com parable high fluorescence ratios.
Interpretation o f FDAP results in different tissue types is 
still problematic, as a result o f  numerous factors influencing 
fluorescence detection and poor understanding o f  the 
mechanism s involved in PpIX  selectivity. The exact cause 
o f  different affinities for PpIX  accumulation in different 
skin diseases is unknow n. D isruptions in  stratum corneum 
integrity and/or alterations in the hem e biosynthetic pathway 
are thought to be responsible for this.12-14 As penetration 
o f  the precursor o f  PpIX  through the stratum corneum 
is a prerequisite for PpIX  form ation in the skin, stratum 
corneum thickness and integrity can influence macroscopic 
fluorescence in vivo.10 Comparable to previous results9;10;15, 
a negative correlation between stratum corneum thickness 
and fluorescence intensity was demonstrated. However, 
the correlation between the am ount o f hyperkeratosis 
and fluorescence intensity was less pronounced, whereas 
pretreatm ent w ith salicylic acid in petrolatum  m inimized
the am ount o f hyperkeratosis substantially, indicating that 
there are other factors influencing PpIX  accumulation.
In a previous study o f our group, it was dem onstrated that 
AKs accumulate significantly more PpIX  than surrounding 
non-lesional skin. However, when correcting for the number 
o f epidermal cells, differences in PpIX  content between AK 
and non-lesional surrounding skin disappeared, indicating 
PpIX  content per cell to be com parable in both lesional 
and non-lesional skin.16 SCCs are m ore extensive tumors 
in both epidermis and dermis with large capacity o f  cells 
able to accumulate PpIX. Therefore, we hypothesized 
these tum ors to have the highest lesional:non-lesional 
fluorescence ratio. However, our results demonstrate 
that B ow en’s disease and m icro-invasive SCC, the more 
superficial and less hyperkeratotic squamous lesions with 
abnorm al proliferation are able to accumulate m ost PpIX. 
As SCCs are characterized by hyperkeratosis and invasion 
o f atypical keratinocytes in the dermis w ith a dense 
inflammatory infiltrate, it is likely that penetration o f  the 
precursor o f  PpIX  and/or light are the limiting factors for 
FDAP in SCCs. As both M AL and ALA, precursors of 
PpIX, are able to penetrate over the whole dermal layer 
in normal mouse skin17, it is possible that the am ount of 
invasiveness and degree o f differentiation in squamous 
(pre)malignancies o f the skin are, partially, responsible for 
variations in fluorescence intensity.
The results o f the present study w ere com pared with 
previous studies o f  our group. It needs to be m entioned that 
the previous fluorescence results were obtained w ith ALA 
as PpIX-precursor. It is known that MAL, w hich is used in 
this study, is m ore selective than ALA with respect to PpIX 
accumulation in vivo. Consequently, M AL has significantly 
higher lesional:non-lesional fluorescence ratios.14;18 The 
fluorescence ratios o f this study are indeed higher, but the 
size o f these ratios between the different histopathological 
diagnosis did not change. Therefore, the fluorescence ratios 
o f previous studies are com parable w ith our results.
In conclusion, in this study significant high fluorescence 
ratios w ere dem onstrated in B ow en’s disease and micro- 
invasive SCCs, although no significant differences 
were found in macroscopic fluorescence between AKs 
and (moderately and w ell differentiated) SCCs. Thus, 
FDAP is not useful in discriminating SCCs from AKs 
or in differentiating between the different K IN  stages. 
A lthough there could be a potential applicability o f FDAP 
to differentiate prem alignant lesions w ith a tendency 
to progress into SCC and squamous cutaneous lesions 
already progressing into an early invasive cancer from 
other squamous cutaneous (pre)m alignancies, as both 
Bow en’s disease and micro-invasive SCC have comparable 
fluorescence ratios. A t this very moment, FDAP is not 
sensitive enough to state w ith certainty that a lesion is AK 
or SCC. The am ount o f  hyperkeratosis rem ains an im portant 
factor in variations o f macroscopic fluorescence. Probably,
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the am ount o f  invasiveness and degree o f differentiation 
in squamous (pre)malignancies o f  the skin are responsible 
for variations in fluorescence intensity. M ore knowledge 
on the mechanism s o f the preferential accumulation o f 
PpIX  in various tissue types and the factors influencing 
PpIX  accumulation is needed to better understand the 
variable outcomes in FDAP, despite clinically adequate 
desquam ation prior to  fluorescence detection.
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The clinical efficacy of topical methyl-aminolevulinate photodynamic 
therapy in moderate to severe actinic keratoses of the face and scalp
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A b strac t
Introduction: Since actinic keratoses (AKs) often appear in areas with field cancerization, photodynamic therapy (PDT) 
may have significant advantages over the standard treatm ent options. Objectives: Clinical efficacy o f P D T  with topical 
methyl aminolevulinate (M AL-PDT) in field cancerization was evaluated with respect to the num ber of AKs and photo­
damage. M eéods: A total of 14 patients with 223 AKs on the face or scalp were treated with M AL-PDT. Two treatments with 
a 3-monthly interval were given. At baseline, before tlie second taeatment and 3 months after the end o f therapa, the: 
num ber of AKs were counted and photodamage was assassed with respect to skin touahness, hyperpigmenlation, hypo­
pigmentation, searring, atrophy, telangieclasia and wrinkling. Rarults: Complete clearance was reached in patiems with a 
moderate degree o t actinic damage, whereas a seaere degree op field canceriaation dem onstrated only partial cleyrance. 
Tlie global score for photodamage improved significently. After thee follow-up period, none o f the patients reaching 
ylearance had developed relypsing or new AKs. Concfusions: M AL-PD T induces a high clearance rate o f AKs, dependent 
an  the degree of field cancerization, with a good improvement in photodamage add preaention o f developing new AKs. 
Thus, more P D T  sessions are needed in patients with e severe degree o t field cancerization.
K ey  w o rd s : A ctin ic keratrnis, field, cancerization, methyl aninolevulinata ( M A L ) t photodamage, photodynamic thecapy
In troduction
Actinic keeetüsis (AK) end squena>us cell cefcidüme in 
situ (Maebus Bawen ar Bowen’s piseese) ere generally 
regarded es cuteneaus epithelial premelignancies thut 
ore eble ta propreu to idvasieesquamüus cell carcinome 
(SCC) (1,2). Inabout20% aA AKs spodtadeous regres­
sion is passible. Geneeenv, l —s0% will develop into S C C 
avee e l O-yeeepeeiop, with en eddual tradsfofmatiod rate 
atless one in a thousand elK s^]l ee veee (3—(S) .It is not 
known which AK will progress to SCC. Therefore, it i- 
esswdV to teeet ell AK lesions.
i'(fultilile treatment modalities eee cuerentlv usece 
incluping cevatheeepv, topfel 5-fluoeoueet:il ae imi- 
quimod. These topical theeepies eee not elwevs suc­
cessful, thev pemedp a patient’s utmost compliance 
und have important side effects (pain, scaring, lass
of pigmentecian). Since AKs often eppeae with mul­
tiple ae confluent lesions (field cancerization) in cas- 
metice1ly sedsitive eaees, ph(rtodydemic theeapv 
(PDT), which can be used ovee leege SAefece eeees 
with good clinical auScame, mev have signincant 
edvenfeges ovee the standaed treatment options (7). 
PD T wlth topical aminolevulinic acid (ALA) ae its 
methaiestef deeivetive (mathvlemidalevulete, MAAL) 
are effective end wcll-talcratep in the treatment of 
non-melanoma okin cancue (NMSC). Cueeentlv, in 
Europe, MAL-PDT is appromed foe use m AKs, 
Bowen’I disepse, superficial end law-risk dapuief 
basal cell carcinoma (BCC). Exogenous application 
of ALA ae MAL leads ta accumulation of protopoe- 
phvein IX (PpIX), an endogenous photosensitizee, 
peefeeentiellv in lesional skin. Iffadiation with 
v<risible lig^ tet iddu^cies cctive tion of PpIX endsubsequent
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formation of oxygen radicals results in selective tissue 
destruction (8). Accumulation of high intralesional 
porphyrin levels is essential for effective PDT. Owing 
tothe hydrophilic properties ofALA, ALA-PDT can be 
limited by impaired uptake of ALA by the target cells 
and/or its penetration through tissue. As ALA-esters 
penetrate deeper into lesions and have a higher lesion 
selectivity, MAL-PDT might be more efficient in the 
treatment of areas with multiple, thicker AKs (9-11).
The aim of the present study was to evaluate the 
clinical efficacy of MAL-PDT in field cancerization 
and the improvement of cosmesis of photodamaged 
skin. Cosmetic improvement was related to the 
degree of skin changes due to photoaging, including 
skin roughness, hyperpigmentation, hypopigmenta­
tion, scarring, atrophy, telangiectasia and wrinkling.
Methods
Subjects
Over a 1-year period, 20 patients with multiple AKs 
and sun-damaged skin of the face and scalp were 
invited to participate in this observational study. 
Finally, 18 patients were included in the study after 
giving their written informed consent (age: 53-86 years, 
mean 72.6 years ± 9.9 SD; 17 men, one woman). 
Patients were not allowed to use immunosuppres­
sive medication. Other exclusion criteria were pre­
vious photodynamic treatment on the face or scalp, 
presence of potential invasive AKs or squamous 
cell carcinoma or skin types V or VI. Topical treat­
ment before and during the study was restricted 
to 10% salicylic acid in petrolatum and a topical 
antibacterial agent. Other topical treatments were 
not permitted for at least 4 weeks before the 
study Table I).
Table I. Inclusion and exclusion criteria.
Inclusion criteria Exclusion criteria
Actinic keratoses on scalp Use of immunosuppressive
or face medication
N o signs of potential Previous photodynamic
invasive actinic keratoses treatment of the target area
or squamous cell carcinoma
Written informed consent Skin type V or VI
is given
N o other skin diseases Topical treatment (liquid
in the target area nitrogen, imiquimod,
5-fluorouracil, PDT)
4  weeks prior to the study
PD T  = photodynamic therapy.
Study protocol
One week before baseline, an area with field can- 
cerization of 50 cm2 with AKs of the scalp or the 
face was pretreated with 5% or 10% salicylic acid in 
petrolatum once daily in order to remove excessive 
scaling potentially interfering with the penetration 
of the MAL cream or the irradiation with visible 
light. Keratolytic pretreatment was necessary in 
10 patients (10/14 = 71%). A topical erythromycin 
solution was also part of the pretreatment for all 
included patients to avoid bacterial overgrowth 
interfering with the porphyrin accumulation.
Before applying alayer of Metvix® cream (Galderma, 
Alby Sur Cheran, France), persisting excessive scaling 
and crusting were gently removed with a small derma- 
tological curette, avoiding bleeding. Metvix cream was 
applied under an occlusive dressing (Tegaderm; 3M 
Pharmaceuticals, Zoeterwoude, The Netherlands) to 
enhance MAL penetration. The occlusive dressingwas 
covered by aluminium foil to avoid premature photo- 
bleaching effects. After 3 hours the ointment and foils 
were removed and the skin surface was cleaned using 
80% denaturated alcohol v/v. Subsequently, the skin 
was illuminated with the red light of a light-emitting 
diode (LED, 630 nm) with a light fraction of 37 J/cm2 
(Aktilite128, PhotoCure; ASA, Oslo, Norway). To 
reduce discomfort, cooling ofthe treatment area during 
illumination with a cold airstream was administered or 
treatment was discontinued for several minutes. If 
necessary, a second treatment was delivered after 3 
months. In case of a second treatment session, again
1 week prior to treatment, 5% or 10% salicylic acid in 
petrolatum once daily was prescribed.
Assessment
At baseline (t = 0), before the second treatment (t = 1) 
and 3 months after the end of the therapy (t = 2) 
the number of AKs were assessed and clinical 
photographs were taken. In case of disseminated 
actinic damage in the target area, in which an accurate 
calculation was hardly possible, the maximum num­
ber of 30 AKs was used. Clearance was defined 
when no AKs were present. Treatment was stopped 
after one or two treatments when clearance was 
reached or in case of treatment failure (partial 
clearance -  no clearance after the maximum number 
of two treatments of MAL-PDT -  or relapse in the 
follow-up period of 3 months).
To evaluate the cosmetic outcome, photodamage 
was measured using a four-point scale. In this 
score skin surface (roughness, dryness, scaling), 
hyperpigmentation, hypopigmentation, scarring,
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atrophy, telangiectasia and wrinkling were each 
scored as: 0, absent; 1, mild; 2, moderate; 3, severe. 
A global score (range 0-21) was defined as the sum of 
all scores together, reflecting the degree of photo­
damage. Finally, patients were asked to score the 
intensity of pain during treatment using a 10-cm 
visual analogue scale (VAS, 0 = no pain, 
10 = unbearable pain).
Statistical analysis
To compare the differences in number of AKs and 
photodamage between time points, a one-way analysis 
of variance (ANOVA) for repeated measures was 
used. When significant changes were found, a two­
tailed Student’s t-test was performed for analysis 
between time points. To compare mean VAS scores 
between the two treatment sessions a two-tailed 
Student’s t-test was used. A p-value < 0.05 was 
regarded as statistically significant. Microsoft Excel 
2007 and SPSS 16.0 were used for statistical 
calculations.
Results
Subjects
In total, 18 patients with a total of 295 AKs on the 
face (n = 8) or the scalp (n = 10) were included after 
giving their written informed consent. A mean of 
16.4 AKs/patient (6-30, SD ± 7.2) indicates a mod­
erate to severe degree of field cancerization.
Unfortunately, four patients dropped out early 
because of severe pain during the first PD T session. 
These patients were withdrawn from the study 
because they preferred another treatment modality 
for the remaining AKs, such as 5-fluorouracil cream 
or imiquimod. These drop-outs accounted for 
72 AKs in total with a mean of 18.0 AKs/patient 
(range 10-30, SD ± 8.5). Data for the drop-outs 
were excluded from further evaluation as these 
patients were lost in follow-up.
The average lesion count reduced from 223 to 
101 lesions after the first treatment and then to 
85 lesions. Therefore, the total amount of AKs of 
the remaining 14 patients at baseline decreased 
with 54.7% (223/101) after only one PD T session 
(p < 0.01). After a second treatment, the number of 
AKs was reduced by 61.9% (223/85) (p < 0.01) 
(Table II). Finally, six patients with a mean of
11.3 AKs/patient (range 6-18, SD ± 4.3) reached 
complete clearance (6/14 = 42.9%). Of these 
six patients only two patients needed a second treat­
ment. After a follow-up period of 3 months, none of
the patients reaching clearance had developed relaps­
ing or new AKs. All these patients were invited for an 
extra follow-up visit after 6 months. The first relapses 
presented 6 months after cessation of PDT. Partial 
clearance was seen in eight patients because two 
treatments of MAL-PDT were insufficient to clear 
all present AKs, despite a significant decrease in 
AKs (p < 0.05). The mean number of AKs at baseline 
was statistically significantly higher in patients failing 
MAL-PDT compared with the patients reaching 
clearance after two treatments with MAL-PDT 
(sum 155 AKs, mean 19.4 ± 7.0 (range 11-30) 
versus sum 68 AKs, mean 11.3 ± 4.3 (range 6-18); 
p < 0.05) (Table II).
Hyperkeratosis
Keratolytic pretreatment was necessary in 10 patients. 
Of the patients reaching clearance, four patients (4/6, 
66.7%) needed 5% or 10% salicylic acid in petrolatum, 
whereas six patients (6/8,75%) of the treatment failures 
used a keratolytic ointment.
Photodamage
The global score for photodamage improved signifi­
cantly (p < 0.05). This was due to the group of 
patients reaching clearance (p < 0.05). No significant 
differences in photoaging were seen in the group of 
partial clearance. None of the variables of photodam­
age showed significant differences between clearance 
and treatment failure or between the different time 
points (Table II).
Table II. Clinical results.
Baseline 
(t = 0)
t = 1 t = 2
AKs (total number) 223 101* 85*
Clearance 68 24* 0*
Treatment failure 155** 77* 85*, **
AKs per patient 
(mean)
15.9 ± 7.1 7.2 ± 6.6* 6.1 ± 8.5*
Clearance 11.3 ± 4.3 4.0 ± 6.3* 0*
Treatment failure 19.4 ± 7.0** 9.6 ± 6.0* 10.6 ± 6.9*,**
Photodamage 
(global score)
7.3 ± 3.2 6.6 ± 3.7 5.9 ± 3.7*
Clearance 6.8 ± 2.3 5.2 ± 3.6 4.7 ± 3.4*
Treatment failure 7.6 ± 3.9 7.6 ± 3.6 6.9 ±  3.9
*p < 0.05 clinical results at t\ or t2 versus baseline; **p < 0.05 
clinical outcome of the complete group or treatment failures versus 
clearance.
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Pain
All patients experienced moderate to severe pain. 
No differences in pain between patients reaching 
clearance and the treatment failures occurred after 
the first treatment (VAS 7 ± 2.1 versus VAS 7.8 ± 1.0). 
The second treatment caused significantly less pain 
in patients reaching clearance (p < 0.05). The VAS 
score of the two patients who needed a second PDT 
session for reaching clearance decreased from mod­
erate pain (VAS 7) during the first treatment session 
to mild pain (VAS 2.5) during the second PDT 
session, whereas the number of AKs did not change 
(13 AKs at baseline and 14 AKs after the first treat­
ment) until the last treatment had taken place 
(0 AKs). In patients failing MAL-PDT, no significant 
change in experiencing pain was seen between the 
treatment sessions. No significant difference in pain 
sensation could be demonstrated for the four patients 
dropping out because of intolerable pain during treat­
ment. Their mean VAS score was 8.1 ± 1.7.
Discussion
The present study demonstrates that MAL-PDT of 
the scalp and face induces a high partial to complete 
clearance rate of AKs with a good improvement in 
photodamage and prevention of the development of 
new AKs. Complete clearance was reached in patients 
with a moderate degree of actinic damage. On the 
contrary, patients with a severe degree of field can- 
cerization demonstrated a significant improvement in 
the number of AKs, leading to partial clearance. 
Therefore, the clearance rate seems to be dependent 
on the degree of field cancerization.
Our results are partially comparable with previous 
results. Zane et al. demonstrated in a comparable 
study a high clearance rate of AKs with an excellent 
cosmesis and the improvement of a few of the clinical 
manifestations of chronic photodamage (12). How­
ever, they assessed a clearance rate of 88.3% after two 
treatments with a monthly interval and a follow-up 
period of 2 months, while our clearance rate was 
considerably lower (61.9%). Second, all of their 
20 subjects completed the study and experienced 
mild to moderate pain (VAS 2-6), while four patients 
in our study had to stop early because of intolerable 
pain during the first photodynamic treatment. Our 
remaining 14 subjects all experienced moderate to 
severe pain (range VAS 6-9). The better clearance 
rate and lower pain score in the study of Zane et al. 
can be explained by a lower degree of field canceriza- 
tion. The mean number of AKs in their subjects at 
baseline was 6.85 AKs/patient (137/20), while in our
present study, 15.93 AKs/patient (223/14) were trea­
ted with a resulting lower clearance rate overall. 
Our drop-outs accounted for a mean of 18.0 AKs/ 
patient. The number of AKs in patients who reached 
complete clearance were closely in accordance with 
the results of the subjects in the study of Zane et al. 
(11.33 AKs/patient (68/6) versus 6.85 AKs/patient, 
respectively). In conclusion, MAL-PDT, in the pro­
tocol used, is an effective treatment for multiple 
AKs, but only for mild to moderate cases.
Treatment of facial lesions or lesions on the scalp 
result in more pain during treatment. The amount of 
pain is also influenced by the size of the treated area and 
the degree ofskin damage. There are reports that PDT 
with topically applied methyl aminolevulinate, pene­
trating more selectively into the damaged skin, induces 
less pain than ALA-PDT. ALA is more effective in 
penetrating the epidermal barrier because an intense 
PpIX-induced fluorescence is seen after local applica­
tion of ALA in both lesional and surrounding skin, 
while MAL preferentially accumulates in the damaged 
skin of AKs. Both MAL-PDT and ALA-PDT are 
efficacious in treatment of AKs (11,13,14). An expla­
nation for the high levels of pain during photodynamic 
treatment in our present study could be a maximal 
absorption of MAL cream into the skin due to the 
keratolytic pretreatments. Other studies only used 
superficial curettage prior to applying the methyl ami- 
nolevulinate cream, while our patients used salicylic 
acid in petrolatum and topical erythromycin lotion in 
order to remove excessive scaling and bacterial over­
growth potentially interfering with the photodynamic 
effects. Pain during PD T is dependent on PpIX fluo­
rescence, which is related to the amount of PpIX 
accumulated in the target skin (15). Despite the fact 
that our subjects experienced more pain, we strongly 
recommend adequate keratolytic pretreatment prior to 
PD T in order to accomplish high amounts of PpIX in 
the skin and therefore to achieve the most favourable 
results in moderate to severely photodamaged skin 
(16,17). Since pain during treatment is a frequent 
side effect of PDT, new methods of alleviating pain 
are of great interest. Recently, several studies on alle­
viating pain duringPD T have beenpublished. The use 
of unilateral peripheral nerve blocks effectively 
reduces pain in facial and scalp AKs treated with 
PD T  without affecting the clinical outcome. Also, 
subcutaneous infiltration anaesthesia is significantly 
more effective in diminishing pain during PD T than 
oral analgesics (18-20).
Both MAL-PDT and ALA-PDT are clinically effec­
tive in the treatment of AKs. In studies of various 
authors, clinical efficacy varied largely, but results are 
difficult to compare because ofthe different treatment 
parameters that have been used (21-25). Adequate
75
C
h
a
p
te
r
 
2
Chapter 2
moderate degree of field cancerization. Despite our 
relatively short follow-up period of a maximum of
6 months, none of the patients reaching clearance 
had developed relapsing or new AKs after 3 months. 
After just 6 months, the first relapses were seen. 
Therefore, the patient burden in the clearance group 
was significantly decreased because these patients 
did not need any treatment for their chronically 
photodamaged skin for a long period of 6 months. 
However, more studies are needed for optimizing 
the treatment protocol of MAL-PDT in patients 
with larger numbers of AKs (i.e. a severe degree of 
field cancerization) and for managing the high levels 
of pain experienced during treatment.
Acknowledgements
The authors would like to thank Galderma, 
Gorinchem, The Netherlands for providing Metvix® 
cream and Lotte K. Engels for her assistance with 
this project.
Figure 1. Patient at baseline (A), before the second treatment (B) 
and after 3 months of follow-up (C).
treatment protocols are essential for good therapeutic 
results with minimal unwanted negative side effects.
The optimum treatment regimen for PD T in AKs 
still has to be determined. When treating thin and 
few AKs, it seems that one treatment is sufficient 
using MAL-PDT, although two treatment sessions 
are recommended for more hyperkeratotic lesions 
(26). It is possible that skin areas with severe actinic 
damage on the face or scalp need more MAL-PDT 
sessions to achieve complete clearance. Our results 
demonstrate that two treatments with MAL-PDT 
give excellent cosmetic results with good clinical 
results in patients with multiple AKs with a maximum 11. 
of 10-12 AK lesions per patient, namely a
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Optimization of UVB phototherapy in psoriasis
This part of the chapter is based on the following publications:
Narrow-band ultraviolet B therapy in psoriasis: Randomized double-blind 
comparison of high-dose and low-dose irradiation regimens
M.M. Kleinpenning, T Smits, J. Boezeman, P.C.M. van de Kerkhof, A.W.M. Evers, 
M.J.P. Gerritsen
Br. J. Dermatol., 2009; 161: 1351-1356
Itch and scratching as predictors of time to clearance of psoriasis with narrow­
band ultraviolet B therapy
A.W.M. Evers, M.M. Kleinpenning, T. Smits, J. Boezeman, P.C.M. van de Kerkhof, F.W.
Kraaimaat, M.J.P. Gerritsen
Br. J. Dermatol., 2009; 161(3): 542-546
Treatment nonadherence and long-term effects of narrow-band UVB therapy in 
patients with psoriasis
A.W.M. Evers, M.M. Kleinpenning, T. Smits, J. Boezeman, P.C.M. van de Kerkhof, F.W. 
Kraaijmaat and M.J.P. Gerritsen 
Arch. Derm., 2010; 146(2): 198-199
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Narrowband ultraviolet B therapy in psoriasis: randomized 
double-blind comparison of high-dose and low-dose 
irradiation regimens
M.M. Kleinpenning,* T. Smits,* J. Boezeman,* P.C.M. van de Kerkhof,* A.W.M. Evers*f and M.J.P. Gerritsen*
^Departments of Dermatology and fMedical Psychology, Radboud University Nijmegen Medical Centre, PO Box 9101, 6500 HB Nijmegen, the Netherlands
Summary
Background Ultraviolet (UV) B photo therapy is an established treatm ent option for 
psoriasis. The op tim um  dosage regim en still has to  be determ ined. W ithin- 
subject com parisons do not take into account the systemic effects o f  UVB pho to­
therapy. The area o f  the body treated w ith  low -dose UVB may benefit from  the 
systemic effects o f  the site treated w ith  a higher UVB dose.
Objectives To study the tim e to clearance in patients w ith  psoriasis in  a random ized 
controlled trial, in  w hich  patients w ere treated w ith  narrow band UVB in either a 
high-dose or a low -dose regim en.
Methods O ne hundred  and nine patients w ere random ized to a high-dose regim en 
(group 1) or to  a low -dose regim en (group 2). Patients o f  group 1 and 2 w ere 
irradiated w ith  40% and w ith  20% increm ental doses, respectively, three times 
weekly. Psoriasis Area and Severity Index (PASI) was m easured at baseline and 
at every 4-w eek control visit. Treatm ent was stopped in  cases o f  clearance 
(90%  reduction o f  baseline PASI).
Results No significant differences w ere found in  the num ber o f  patients achieving 
clearance. The high-dosage schem e resulted in  four few er treatm ents w ith  no sig­
nificant differences in  cum ulative UV dose, although m ore pro tocol adjustments 
w ere required  in the beginning o f  the study because o f  erythem a. After 3 months 
a significantly better clinical outcom e was seen after high-dose UVB therapy. 
Conclusions H igh-dose UVB therapy results in  few er treatm ents w ith  better long­
term  efficacy, w ith  cost-effective benefits for hospital and patients. Therefore 
UVB photo therapy in a high-dose regim en for psoriasis is recom m ended. H ow ­
ever, a protocol adjustm ent in  the second w eek w ith  a high-dose regim en is 
desirable to prevent erythema.
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Ultraviolet (UV) B phototherapy is an established treatment 
option for psoriasis. Therapeutic efficacy depends on both 
dose and frequency of the treatm ent. How ever, the radiation 
spectrum used is also an im portant parameter. Narrowband 
UVB phototherapy (311  nm ) has proven to be superior to 
broadband UVB.1-3 Adequate equipm ent and treatm ent p ro to ­
cols are essential for good therapeutic results and (cost-)effec- 
tiveness w ith  m inim al unw anted negative side-effects.
The optim um  dosage regim en for narrow band UVB irradia­
tion in  psoriasis still has to be determined. In 1998 both 
W ainw right et al.4 and Hofer et al.5 observed in a body-half 
com parison study that high-dose UVB therapy was equally 
effective as low-dose treatm ent, but required fewer treatm ent 
sessions w ith  a higher cumulative UV dose. During the last 
few years, however, different studies suggested that lower
UVB doses are equally effective or have fewer negative side- 
effects compared w ith  high UVB doses.
Narrowband UVB therapy has been demonstrated to be 
superior to broadband UVB in reversing psoriasis at low doses 
given three times weekly.2 In a retrospective study by Boztepe 
et al.,6 147 patients w ith  psoriasis w ere treated w ith  narrow ­
band UVB phototherapy in a 20%  incremental regim en com ­
pared w ith  44 patients receiving a regim en w ith  5% or 10% 
increases. Occurrence o f  erythema as well as the cumulative 
dose were higher w ith  the 20%  regim en, whereas the 
response rate and num ber o f  irradiations did n o t differ signifi- 
cantly.6 O ther studies in body-half com parison settings dem ­
onstrated that three times weekly treatm ent is superior to 
twice weekly or five times weekly UVB irradiations.3,7,8 Limi­
tations o f  almost all the above-m entioned studies are the
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retrospective study design, lim ited patient num bers and/or 
the left-right body half comparison o f random ized treatment 
regimens.
The shortcoming in left-right comparison is the omission 
o f  the systemic effect o f  UVB treatment. UVB irradiation has 
been proven to have local and systemic immunological 
effects on  the skin. In 2002 Dawe et al.9 stated that UVB 
phototherapy clears psoriasis through local effects. During 
UVB treatment individuals' plaques were covered. These cov­
ered plaques demonstrated a clinical im provement o f  42% 
compared w ith a m axim um  response o f  the UVB-treated 
plaques. The subsequent com m ent o f Gibbs10 in 2003 on 
this study was that only a systemic effect o f  UVB photo­
therapy could explain this great im provement o f  the covered 
plaques during UVB phototherapy. The significantly greater 
response in UVB-treated plaques suggests that the combined 
effect o f  local and systemic effects is greater than systemic 
effects alone in the covered plaques. Thus, a left-right com ­
parison study m ight not be an ideal study design to evaluate 
the effects o f  UVB irradiation as advantageous results o f 
low-dose regimens m ay be due to systemic effects o f  UVB 
irradiation.
In the present study the prim ary objective was to compare 
the tim e to clearance in patients w ith psoriasis treated w ith 
narrow band UVB in either a high-dose or a low-dose regi­
m en. All patients w ith psoriasis w ho w ere referred for UVB 
treatm ent w ere random ized, i f  eligible, for w hole-body irradi­
ation w ith  a high-dose or a low-dose regim en. To the best o f 
our knowledge, this is the first prospective, randomized, 
double-blind study on  tw o narrow band UVB protocols not in 
a left-right body-half comparison setting in order to prevent 
potential systemic effects o f  UVB phototherapy.
Patients and methods
Subjects
The local medical ethics comm ittee approved this study. 
From January 2003 until May 2006 all patients with 
psoriasis referred for UVB phototherapy w ere invited to par­
ticipate in this study. Power calculations were based on 
previous studies, showing overall m oderate effect sizes 
(d = 0 '45 ).2,5,11 For a two-way analysis o f  variance (testing 
m ain effects o f  the two treatm ents), 52 cases per cell had to 
be included w ith an alpha o f  0 05. Main effects w ith an 
effect size (d) o f  0 45 yielded a pow er o f  0 88. In summary, 
104  patients were required. Finally 10 9  patients were 
included after giving their written informed consent. Patients 
were not allowed to use any systemic psoriatic treatment for 
at least 2 m onths before starting phototherapy. Topical treat­
m ent before and during the study was restricted to 10% sali­
cylic acid in petrolatum  and emollients. O ther topical 
treatments were not perm itted for at least 2 weeks before 
the study. M edication know n to have the potential to aggra­
vate psoriatic lesions, such as beta-blockers, was also not 
allowed (Table 1).
Table 1 Inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
Mild to moderate psoriasis Topical treatment for psoriasis
as defined by PASI £ 12 > 2 weeks before starting UVB
Stable plaque psoriasis for Systemic treatment for psoriasis
more than 6  months > 2 months before starting UVB
Written informed consent Medication potentially
is given aggravating psoriasis
(beta-blocker, lithium,
prednisone)
Subject age > 18 years History of skin cancer or
cutaneous premalignancies
No other skin diseases Planned exposure to sun, UVA or
UVB affecting psoriasis during
study period
PASI, Psoriasis Area and Severity Index; UV, ultraviolet.
Randomization
Patients were random ized (block size o f  4, random ization 
num ber placed in sealed envelopes by one research nurse) for 
either narrow band UVB irradiation w ith a low-dose regim en 
or to UVB treatm ent w ith a high-dose regim en. After random ­
ization only nursing personnel o f  the phototherapy depart­
m ent were informed o f the assigned treatm ent protocol. 
Clinical efficacy was evaluated in a blinded m anner every
4 weeks by a dermatologist. Two blinded observers were 
involved in  this study. Irradiation regimens were adjusted by a 
third dermatologist in cases o f erythema or a prolonged per­
iod o f  nonirradiation according to the study protocol.
Phototesting and treatment
For irradiation a W aldm ann UV 7001K light cabin (Wald­
m ann Medizinische Technik, Villingen-Schwenningen, Ger­
m any) w ith Philips TL-01 lamps (Philips, Eindhoven, the 
Netherlands) (311 nm ) was used. Minimal erythema dose 
(MED) was determ ined on  the low er back following standard 
procedures 1 day before starting phototherapy. For patients 
with Fitzpatrick skin phototype I and II the administered doses 
were 0 20, 0 40, 0 60, 0 80, 100  and 1 20 J cm -2 . For skin 
phototype III and IV patients the doses 0 50, 0 70, 0 90, 110 , 
130  and 150 J cm 2 were administered. The MED was 
recorded as the lowest dose to produce perceptible ery­
thema. The initial dose for the high-dose regim en (group 1) 
was 70% o f  MED and for the low-dose regim en (group 2) 
was 35% o f MED. At each irradiation the radiation dose was 
increased by 40% for the high-dose regim en and by 20% for 
the low-dose regim en (Fig. 1). Patients were treated three 
times weekly. All m ale patients wore genital protection, and 
facial protection was administered to all w hen no  facial psoria­
sis was present.
The increase o f the irradiation dose was dependent on ery­
them a response 48 h  after the last treatment. Increments given 
at each visit were based on  a percentage o f the previous dose
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Fig 1. Treatment regimen. UV, ultraviolet; 
MED, minimal erythema dose.
Table 2 Protocol adjustments
Erythema response 48 h after last treatment Group 1 -  high dose Group 2  -  low dose
0 -  none No erythema 40% increment 20% increment
1 -  mild Barely perceptible, Repeat previous dose followed by an Repeat previous dose followed by an
asymptomatic erythema increase with 40% every subsequent visit increase with 20% every subsequent visit
2  -  moderate Well-defined, asymptomatic Postpone one treatment, followed by Postpone one treatment, followed by
erythema previous dose and increase with previous dose and increase with
40% (or 20% in cases of repeated 20% (or 10% in cases of repeated
erythema) every subsequent visit erythema) every subsequent visit
3  -  severe Painful erythema, repeated No treatment until recovery, restart No treatment until recovery, restart
symptomatic erythema with adjusted dose, 20% increment with adjusted dose, 10% increment
and /or bullae (or 10% in cases of repeated erythema) (or 5% in cases of repeated erythema)
every visit every visit
Table 3 Dosage adjustments after a few days without phototherapy Table 4 Definitions of outcome measures
Number of days without
phototherapy treatment Dosage adjustment
4 0% increment
5-6 75% of previous dosage
6-7 50% of previous dosage
> 8 Dropout
Outcome measure Definition
Clearance 90% reduction of baseline PASI
Treatment failure > 30 treatments without 90%
reduction of baseline PASI
Relapse Affected area in follow-up
period > 50% baseline area
PASI, Psoriasis Area and Severity Index.
and erythema response. Depending on  the grade o f  the ery­
them a the irradiation dose was adjusted according to the study 
protocol (Table 2). Protocol adjustments were needed not 
only because o f  erythem a, but also because o f  other reasons 
(holidays, m inor medical discomfort such as a cold or a head­
ache, etc.) resulting in m ore than 3 days w ithout phototherapy 
treatm ent (Table 3).
Assessment
At baseline and during the following 4-weekly control visits 
the Psoriasis Area and Severity Index (PASI) was calculated. 
The PASI comprises the average redness, thickness and desqua­
m ation o f  the lesions (each graded on  a 0 -4  scale), weighted 
by the area o f  involvem ent.12 Clearance was defined as a 90% 
reduction o f  baseline PASI. Treatment was stopped w hen
clearance was reached, in cases o f  treatm ent failure (> 30 
treatments w ithout reaching clearance, persisting erythema or 
worsening o f  psoriasis) or if  patients did n o t complete the 
study because o f other reasons (initiation o f  medication 
potentially aggravating psoriasis, hospital admission or medical 
intervention for another medical condition, poor compliance).
In the follow-up period, 3 m onths after cessation o f  UVB 
therapy, PASI was calculated and relapse was evaluated. W hen 
the affected area in the follow-up period reached 50% o f the 
baseline area, this was defined as relapse (Table 4).
Statistical analysis
Student's t-test was used to determ ine statistical differences 
between the high-dose regim en and the low-dose regim en for 
subjects reaching clearance and also for dropout patients.
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Analysis o f  random ization was perform ed w ith  one-way analy­
sis o f  variance. To determ ine w hether the differences between 
both studied irradiation protocols w ere independent o f  poten­
tially confounding or m ediating pathways, multivariate analy­
ses w ere perform ed adjusting for gender, age, educational 
level, alcohol consum ption, sm oking, pretreatm ent PASI, skin 
phototype, MED, cumulative irradiation dose and num ber o f  
protocol adjustments (total adjustments, adjustments because 
o f  erythema and because o f other reasons). Differences 
betw een both studied groups w ere determined by analysis o f  
covariance. P < 0 05 was regarded as statistically significant. 
Statistical Package for the Social Sciences 14 (SPSS, Chicago, 
IL, U.S.A.) was used for statistical calculations.
Results
Patient characteristics
In total, 135 patients w ith  psoriasis w ere referred for UVB 
phototherapy. O f these patients, 109 (80'7% ) m et the inclu­
sion criteria and agreed to participate. The m ean ±  SD PASI 
score was 9'2 ±  5'3 (range 3 '3 -3 7 '6 ) , indicating m ild to 
m oderate psoriasis. Sexes w ere equally divided: 54 m en 
(49'5% ) and 55 w om en (50'5% ) w ere included. The 
m ean ± SD age was 46 3 ±  161 years (range 18' 1—87'4). 
Patients w ere predom inantly o f skin type II or III (88'6%) 
according to the Fitzpatrick classification. After random ization, 
group 1 contained 55 patients and 54 patients w ere included 
in group 2 (Fig. 2). Pretreatment analysis revealed no  signifi­
cant differences for gender, age, educational level, alcohol 
consumption, smoking, PASI, skin phototype and MED 
between both random ized groups.
Dropouts
There w ere no  significant differences in the num ber o f  drop­
outs betw een both random ization schemes. In total, 32
patients (29'4% ) did not complete the study. Group 1 con­
tained 14 dropouts (14 o f  55, 25%): eight patients stopped 
because o f  treatment failure and six patients for other reasons. 
Eighteen patients (18 o f 54, 33%) dropped out o f  group 2: 
nine because o f treatm ent failure and nine for other reasons 
(Fig. 2). The cumulative dose for all dropouts was found to 
be significantly higher compared w ith  patients w ho achieved 
clearance (64 6 vs. 39'7 J cm -2 , P < 0 01).
The treatm ent protocol was adjusted in  cases o f  erythema 
or because o f  other reasons, for instance m ore than 3 days 
w ithout irradiation. Depending on  the grade o f  the erythema 
and the num ber o f nonirradiation days, the dose was adjusted 
according to the study protocol. The num ber o f  protocol 
adjustments for all dropouts was significantly higher (8 '37 
vs. 6 '38, P = 0 '05), because o f other reasons (3 '79 vs. 2'75, 
P < 0 '05) but not because o f  erythema (5 00 vs. 4 '24 , P = 
0 '14) (Table 5).
Clearance
No significant difference betw een the two regimens was 
found in the num ber o f  patients achieving clearance. In total, 
77 patients (77 o f  109, 70'6%) achieved clearance: 41 
patients (41 o f  55, 75%) treated according to the high-dose 
regim en and 36 patients (36 o f  54, 67%) irradiated w ith  the 
low-dose regim en.
In addition, the cumulative dose for group 1, the high-dose 
regim en (42'5 ±  30 8 J cm 2) did not differ significantly 
from  that for group 2, the low-dose regim en (36 '7  ± 
25'9 J cm -2).
W ith regard to the num ber o f irradiations, group 1 needed 
significantly fewer irradiations (20'6 ±  6 '9) to reach clearance 
in comparison w ith  group 2 (24'1 ±  6 1 )  (P < 0 '0 5 ) .  This 
effect rem ained significant after controlling for all possible 
covariates (gender, age, educational level, alcohol consum p­
tion, smoking, PASI, skin phototype, MED, cumulative irradi­
ation dose and num ber o f  protocol adjustments).
Screened 
psoriasis 
patients (a = 135)
Included 
patients (a = 109) \
Excluded 
patients (a = 26)
High-dose 
regimen 
Group 1 (a = 55)
Low-dose 
regimen 
Group 2 (a = 54)
Clearance 
(a = 41)
Dropouts 
(a = 14)
Clearance 
(a = 36)
Dropouts 
(a = 18)
Treatment 
failure (a = 8)
Other reasons
(a = 6)
a 30 treatments
(a = 7)
Erythema
(a = 0)
Worsening of 
psoriasis (a = 1)
ä 30 treatments
(a = 8)
Treatment 
failure (a = 9)
Erythema
(a = 0)
\Other reasons
(a = 9)
Worsening of 
psoriasis (a = 1)
Fig 2. CONSORT flo w  chart.
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Table 5 Dropout results of all dropout patients or only treatment 
failures vs. all patients who reached clearance
Total
dropouts
Treatment
failures
Clearance 
(group 1 and 2)
PASI score 3'1 31 2
Cumulative dose, J cm 2: 64'6*** 80Æ5*** 397
Protocol adjustments 84* 9'6* 6'4
(all)
Protocol adjustments 5'0 59 42
(erythema)
Protocol adjustments 3Æ8** 4Æ2** 2 8
(other reasons)
PASI, Psoriasis Area and Severity Index. *P = 0-05, **P < 0-05, 
***P < 0-01.
Table 6 Clearance results of high and low dose
Group 1 Group 2
(high dose) (low dose) P-value
PASI score 2 9 2*8 0*30
Cumulative dose, J cm)2 42 ' 5 367 0*38
Protocol adjustments (all) 7 9 47 < 0'01
Protocol adjustments (erythema) 4 9 34 < 0'01
Protocol adjustments (other) 3 0 24 022
Number of treatments 20' 6 24 1 0*02
PASI, Psoriasis Area and Severity Index.
There were significantly m ore protocol adjustments per 
patient in group 1 (P < 0 0 1 ) , mainly because o f  erythema 
(P < 0 01) and not because o f  other reasons (P = 0 22). 
The protocol o f  the high-dose regim en was adjusted
7 92 ± 3 '86 times: 4 '87 ±  2 '40 times because o f  erythema 
and 2Æ97 ± 1Æ97 times because o f other reasons (Table 6). 
Most protocol adjustments in group 1 w ere perform ed after 
four treatments. The protocol o f  the low-dose regim en was 
adjusted 4 66 ± 1 9 8  times: 3 38 ±  1 '68 times because o f ery­
thema and 2Æ44 ± 1 Æ50 times because o f other reasons. In 
group 2 m ost protocol adjustments were m ade after 10 irradi­
ations. This was statistically significant later on as compared 
w ith  the high-dose treatment protocol (P < 0 01).
Follow up
Comparing both treatment protocols in the follow-up period,
3 m onths after cessation o f the UVB treatm ent, no  differ­
ences were found in the num ber o f  relapses. In both studied 
groups three patients relapsed. The decrease in the PASI 
score o f the high-dose regim en group after 3 m onths was 
5Æ93 ± 4Æ1 compared w ith baseline. There was also a pro­
longed im provement in group 2 (4 '14  ±  2 96). However, a 
significantly low er PASI in the follow-up period was 
m easured in group 1, indicating better long-term  effects on 
psoriasis after high-dose irradiations (P < 0 05). This effect
rem ained significant after controlling for the num ber o f 
irradiations, skin type, protocol adjustments, cumulative dose, 
MED, pretreatment PASI, alcohol consumption, smoking, age 
and gender.
Discussion
In the present study a high-dose irradiation regim en was 
superior to a low-dose protocol, regardless o f  the psoriasis 
severity. The num ber o f patients achieving clearance and drop­
outs because o f treatment failure in both irradiation protocols 
w ere comparable. High-dose irradiations resulted in four 
fewer treatments (20%) w ith a better long-term  efficacy, 
although m ore protocol adjustments w ere required in the 
beginning o f the study because o f  erythema.
Most studies determining optimal therapeutic and safety 
regimens for narrow band phototherapy o f  psoriasis have used 
body-half comparisons. The shortcoming in left-right com ­
parison is the omission o f the systemic effect o f  UVB treat­
ment. UVB irradiation has been proven to have local and 
systemic immunological effects on the skin. Langerhans cells 
(LCs) are very im portant dendritic antigen-presenting cells 
present in the epidermis, w hich offer a first line o f  im m uno­
logical defence. UVB therapy reduces the am ount o f  LCs, 
w hich leads to an impaired antigen-presenting capacity and 
local immunity. Because LCs migrate to draining lymph 
nodes after taking up foreign antigens, treatm ent w ith UVB 
irradiation also affects the systemic immunity. Several reports 
have shown that UVB irradiation results in prom otion o f 
T helper (Th) 2 responses w ith anergy o f  Th1 responses. 
This results in natural killer cell activity, lymphoproliferation 
and cytokine responses, indicating a systemic immunological 
response induced by UVB irradiation. Also cis-urocanic acid is 
induced by UVB therapy and has been implicated as one o f 
the mediators o f  UVB-induced imm unosuppression as it can 
m im ic many o f  the effects o f  UV irradiation on the imm une 
system.11 To the best o f  our knowledge, this is the first 
prospective, random ized, double-blind study on two narrow ­
band UVB protocols no t in a left-right body-half comparison 
setting in order to prevent potential systemic effects o f UVB 
phototherapy.
A high-dose irradiation regim en for patients w ith  psoriasis 
resulted in an average o f four fewer treatments (=  20%) 
compared w ith the low-dose treatment regim en, w ithout dif­
ferences in clearance. In 2002, Hartman et al.13 concluded 
that the overall costs (medical and nonmedical) o f  UVB 
treatment for psoriasis are €43 38 per patient per session 
(€1258 for a m ean o f  29 irradiations). By using the high­
dose regim en an average saving o f  €173Æ52 per UVB treat­
m ent course per patient w ith  psoriasis can be achieved. The 
limitations o f  this calculation should be mentioned. O ur cost 
figures w ere taken from  a m ulticentre study where UVB 
treatments were m ixed narrow band as well as broadband 
UVB phototherapy. Secondly, the cost calculation o f  Hartman 
et al. is about 10 years old. However, the general opinion 
nowadays is that narrow band UVB phototherapy is m ore
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effective than broadband UVB.2,14 The current costs will be 
higher now  than 10 years ago, w ith  the result that the 
savings will be higher and at the same tim e the benefits of 
narrow band UVB will be higher. Also the num ber of visits 
to the phototherapy departm ent will be reduced, resulting in 
m ore convenience for the patient. In  addition, longer remis­
sion periods and low er relapse levels m ight be achieved 
using the high-dose treatm ent protocol. Hence, UVB treat­
m ent w ith  a high-dose irradiation regim en is m ore cost- 
effective compared w ith  a low-dose treatment.
Sunburn but also chronic sun exposure are w ell-known 
risk factors for developing nonm elanom a skin cancer. Both 
UVA and UVB radiation induce m utagenic and im m uno­
suppressive effects. It is established that psoralen plus UVA 
(PUVA) therapy has carcinogenic side-effects. Because of a 
dose-dependent risk for m elanoma and nonm elanom a skin 
cancer, a m axim um  cumulative dose o f  2000 J cm 2 is set 
for PUVA treatment. For UVB n o  m axim um  dose has been 
established yet, because the role of UVB phototherapy in 
developing skin cancer is less clear.15 Recently, Hearn et al.16 
demonstrated no  significant association betw een narrow band 
UVB phototherapy and (non-)m elanom a skin cancer. In  the 
present study the cumulative dose was not significantly dif­
ferent betw een the two irradiation protocols studied. How­
ever, m ore protocol changes because of erythema were 
observed in  the high-dose regim en. O n the one hand fewer 
visits are probably m ore patient friendly, but on the other 
hand frequent burning causes patient discomfort. It is desir­
able to adjust the standard increment of 40%  of high-dose 
irradiation protocol after four to five treatments to reduce 
the frequency of burning and patient discomfort. More stud­
ies are needed on refining the optim um  high-dose regimen. 
To date there are n o  studies that demonstrate an enhanced 
risk of skin cancer in  patients treated w ith  UVB phototherapy. 
In 2004 W eischer et al.17 could not retrospectively dem on­
strate an increased skin cancer risk in patients w ith psoriasis 
treated w ith  broadband or narrow band UVB phototherapy. 
In addition, Tjioe et al.3 preferred narrow band UVB therapy 
because of higher efficacy w ith  comparable parameters of 
inflammation and photodam age after narrow band and broad­
band UVB phototherapy. In general, the risk o f  no n ­
melanoma skin cancer has been show n to be considerably 
higher in patients treated w ith  PUVA compared w ith  UVB 
phototherapy.17 19
The goal of UVB phototherapy has to be achieving maxi­
m um  effect w ith  m inimal side-effects. In accordance w ith  our 
study, the long-term  effects are m ore favourable after high­
dose irradiation compared w ith a low-dose regim en. Intensive 
personal guidance o f the patient w ith  psoriasis during UVB 
therapy is required to avoid burning and to achieve optimal 
results during and after UVB phototherapy.
In conclusion, high-dose UVB therapy results in fewer treat­
ments w ith  better long-term  efficacy, w ith  cost-effective bene­
fits for hospital and patients. UVB phototherapy in a high-dose 
regim en for psoriasis is preferred w ith  a protocol adjustment 
after four irradiations to prevent erythema.
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Itch and scratching as predictors of time to clearance of 
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Background N arrow -band ultraviolet (UV) B phototherapy is an effective treatm ent 
for psoriasis. However, there is considerable variability in  the num ber o f  treat­
m ent sessions needed to achieve psoriasis clearance. W hile several clinical and 
treatm ent-related factors predict tim e to clearance, the effect o f  itching and 
scratching on  the num ber o f  irradiation sessions is insufficiently understood. 
Objective Predictors o f  the tim e to clearance w ere assessed in  patients w ith  psoriasis 
w ho w ere referred for UVB treatm ent in  a random ized double-blind com parison 
o f  irradiation regim ens for UVB phototherapy.
Methods After random ization to either UVB irradiation w ith  a suberythem atogenic 
or an erythem atogenic regim en, patients w ere irradiated w ith  20% and 40% 
increm ental doses, respectively, three times weekly. The Psoriasis Area and Sever­
ity Index (PASI) score was m easured at baseline and every 4 weeks, and itching 
and habitual scratching w ere m easured at baseline.
Results Among the 77 patients w ho  achieved psoriasis clearance (90% reduction of 
PASI), itching and scratching w ere correlated w ith  the num ber o f  irradiation 
sessions needed to achieve clearance, w ith  h igher levels o f  itch and scratching 
predicting m ore sessions. These effects rem ained significant after controlling for 
the initial PASI score, irradiation schemes, m inim al erythem a dose (MED), skin 
type, cum ulative dose, protocol adjustments and lifestyle factors (smoking habits 
and alcohol consum ption).
Conclusions Patients w ith  higher levels o f  itch and scratching need m ore irradiation 
sessions to achieve clearance o f  psoriasis w ith  UVB phototherapy. Systematic assess­
m ent o f  the severity o f  itch and scratching, followed by short-term  itch-coping p ro ­
gram m es fo r patients at risk, m ight be a cost-effective, adjunct to UVB therapy.
Ultraviolet (UV) B phototherapy, particularly narrow -band 
UVB phototherapy, is an effective treatm ent for psoriasis, w ith 
therapeutic efficacy depending on  the dose and the frequency 
o f  irradiation.1-3 The optim um  dosage regim en for UVB 
irradiation in  psoriasis still has to be determ ined, although 
suberythematogenic doses have been suggested to be as effec­
tive as, and to have fewer negative side-effects than, erythe- 
m atogenic doses.4-6 However, the frequently used left-right 
body comparisons to investigate different erythema regimens 
neglect the systemic effects o f  UVB treatment. For example, 
UVB therapy reduces the num ber o f Langerhans cells and p ro ­
m otes T helper (Th) 2 responses, w ith  anergy in Th1 cells.7
Independent o f  the dosage schedule, there is considerable 
variability in the num ber o f treatm ent sessions required to 
achieve psoriasis clearance. Several clinical and treatm ent-
related factors have been identified as predictors o f  the tim e to 
clearance. For example, the initial Psoriasis Area and Severity 
Index (PASI) score, skin type, m inimal erythema dose (MED), 
cumulative dose and the num ber o f  protocol adjustments are 
predictors o f  the effects and frequency o f  UVB treatm ent.1-6 
In addition, it has been proposed that lifestyle factors, such 
as smoking and alcohol consum ption, dim inish the effect 
o f  dermatological treatments in psoriasis, including UVB 
treatm ent.8,9
The role o f  itch and scratching in  psoriasis has received 
m uch less attention, and especially w ith  regard to the efficacy 
o f  UVB treatm ent, even though 7 0 -8 0 %  o f patients w ith psori­
asis experience relatively persistent itching and scratching.10-13 
There is some evidence that itching and scratching are as 
relevant as predictors in  psoriasis as they are in  other chronic
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inflammatory skin diseases.13 16 UVB treatm ent can elicit itch­
ing (and hence scratching) as a result o f  causing erythema 
and from  irradiation, and thus the initial benefit o f  UVB 
phototherapy m ay be counteracted by severe itch and habitual 
scratching. However, itching and scratching have not yet been 
assessed as predictors o f  the duration o f  UVB treatm ent for 
psoriasis and their role in regular dermatological treatments is 
insufficiently understood.
In the present prospective study, predictors o f  time to clear­
ance w ere assessed in patients w ith psoriasis referred for UVB 
treatm ent as part o f  a random ized, controlled trial o f  irradia­
tion given in an erythematogenic or a suberythematogenic 
reg im en.17 Specifically, the effect o f  itching and habitual 
scratching on  the num ber o f  irradiation sessions was studied 
after controlling for clinical and treatm ent variables (baseline 
PASI, skin type, erythematogenic and suberythematogenic 
regim en, MED, cumulative dose, protocol adjustments) and 
lifestyle variables (smoking habits, alcohol consumption).
Methods
Subjects and procedure
Over a 3-year period, all patients w ith  psoriasis referred for 
UVB phototherapy at the Department o f  Dermatology o f  the 
Radboud University Nijmegen Medical Centre, w ere invited to 
participate in this study. One hundred and nine patients were 
included after giving their w ritten  inform ed consent. Patients 
were not allowed to use any systemic psoriatic treatm ent for 
at least 2  m onths before starting phototherapy. Topical treat­
m ent before and during the study was restricted to 10%  sali­
cylic acid in  petrolatum  and emollients. O ther topical 
treatments w ere not perm itted for at least 2  weeks before the 
study, or medications know n potentially to aggravate psoriatic 
lesions, such as beta-blockers.
Patients w ere random ized to UVB irradiation w ith  either a 
suberythematogenic regim en or an erythematogenic regim en. 
After random ization, only nursing personnel o f  the photother­
apy departm ent knew  the treatm ent assigned. In  all the 
patients, the Fitzpatrick skin type was assessed at the start of 
treatm ent. The Fitzpatrick skin type is a simple and useful 
m ethod for categorizing cutaneous sensitivities to UV radia­
tion. The result is a classification o f  six different skin types: 
type I (very fair skin that always burns and never tans), type II 
(fair skin that always burns easily and tans m inimally), type III 
(m edium  skin that sometimes burns and always tans), type
IV (light brow n skin that rarely burns and always tans), type
V (dark brow n skin that never burns and tans profusely), and 
type VI (dark brow n or black skin that never burns and is 
deeply pigm ented). The clinical efficacy o f  treatm ent, deter­
m ined as the change in  PASI score, was evaluated, blinded, 
every 4 weeks by a dermatologist. Irradiation regim ens were 
adjusted according to the study protocol by another derm atol­
ogist in the event o f  erythema or a prolonged period  o f  n o n ­
irradiation. Potential predictors o f  itch and habitual scratching 
and lifestyle factors (average alcohol consum ption and smok­
ing habits) were assessed by validated questionnaires. MED, 
cumulative adjusted dosage and protocol adjustments were 
registered by nursing personnel during treatment.
Phototesting and treatment
A W aldm ann UV 700 1  K light cabin (Medizinische Technik, 
Villingen-Schwenningen, Germany) w ith  Philips TL-01 lamps 
(311 n m ; Philips, Eindhoven, the Netherlands) was used for 
irradiation. The MED, the lowest dose causing erythema, was 
determ ined on  the lower back according to standard proced­
ures 1  day before the start o f  phototherapy. For patients w ith 
Fitzpatrick skin phototypes I and II, doses o f  0*20, 0*40, 0*60, 
0 ‘80, 1 *00 and 1 *20 J cm 2 w ere administered; for patients 
w ith  skin phototypes III and IV, the doses w ere 0*50, 0*70, 
0*90, 1*10, 1*30 and 1*50 J cm -2 . The initial dose was 70% 
o f  MED for the erythematogenic regim en (group 1) and 35% 
o f  MED for the suberythematogenic regim en (group 2). The 
dose was increased at each irradiation session by 40% for the 
erythematogenic regim en and by 20% for the suberythemato- 
genic regim en, depending on  the erythema response 48 h 
after the last treatm ent. Patients w ere treated three times 
weekly. All male patients w ore genital protection, and facial 
protection was provided for those patients w ithout facial pso­
riasis. Depending on  the severity o f erythema and the num ber 
o f  nonirradiation days (>  5), the dose was adjusted according 
to the study protocol. Treatment was stopped w hen  psoriasis 
clearance was achieved, defined as a 90% reduction in  the 
PASI score at baseline, or if  treatm ent was deemed to have 
failed (m ore than 40 treatments w ithout achieving clearance 
or if  persistent erythema was present).
Assessment
Time to clearance was defined as the num ber o f  irradiation 
sessions needed to achieve psoriasis clearance.
Clin ica l and treatm ent variables
The PASI score was calculated at baseline and every 4 weeks 
by a derm atologist blinded for the random ization scheme. The 
PASI comprises the average redness, thickness and desquama­
tion  o f  the lesions (each graded on a 0 -4  scale), weighted by 
the area o f  involvem ent.18 In addition, the skin phototype 
according to the Fitzpatrick classification and MED were 
assessed at intake. Protocol adjustments (adjustments because 
o f  erythema and because o f  other reasons) and the cumulative 
dosage w ere registered during treatment.
Itch and scratch ing
Itch and scratching at study entry were assessed w ith  the 
Impact o f Skin Disease on Daily Life (ISDL) questionnaire, a 
health status questionnaire for chronic skin diseases that has 
been validated for patients w ith  psoriasis.12,16 Itching was 
assessed w ith  a four-item  scale assessing the severity and
9 0
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frequency o f  the itching. The scale includes the following 
items w ith  response categories on  a four-point Likert scale: 
‘My skin disease has been accompanied by itching during the 
past 4 w eeks', ‘I have had itching attacks during the past 
4 w eeks' and ‘I suffered continuously from  itching during the 
past 4 weeks'. The fourth item, m ean level o f  itching over the 
past 4 weeks, was m easured on  a visual analogue scale (VAS, 
0 -1 0  cm) w here 0 = no  itching and 10 = worst itching ever 
experienced. The total itching score was calculated by adding 
up the scores on  all four items, after conversion o f  the VAS 
score to a four-point scale. Scratching was assessed w ith a 
three-item  scale investigating the am ount o f  habitual scratch­
ing during the previous 4 weeks on a four-point Likert scale 
w ith  the following items: ‘I scratched during the past
4 w eeks', ‘I scratched w ith  m y nails during the past 4 weeks' 
(ranging from  ‘rarely ' to ‘almost always') and ‘The longest 
tim e I spent continuously scratching' ( ‘less than half a m inute ' 
to ‘m ore than 5 m in '). The total scratching score was calcu­
lated by adding up the scores on  all three items.
Lifestyle  variables
Self-administered questionnaires assessed the average alcohol 
consum ption (1 = less than one glass o f alcohol per week to
7 = m ore than 10 glasses per day) and smoking habits 
(1 = no  smoking at all to 7 = m ore than 20 cigarettes per 
day) during the past 6 m onths.8
Statistical analysis
The data for all variables w ere checked for a norm al distribu­
tion. Differences betw een patients w ho achieved clearance or 
stopped treatm ent and betw een the two protocols for patients 
w ho achieved clearance were calculated w ith  the Student's 
t-test or the V  test as appropriate. Predictor analyses for the 
outcom e variable tim e to clearance (num ber o f  irradiation ses­
sions) w ere conducted w ith  the following variables: clinical 
and treatm ent variables (baseline PASI, skin type, erythemato- 
genic and suberythematogenic regim en, MED, cumulative 
dose, protocol adjustments), lifestyle variables (smoking hab­
its, alcohol consum ption), and itch-scratching variables (itch 
and scratching intensity). Predictors that significantly corre­
lated w ith time to clearance w ere entered in consecutive steps 
in sequential regression analyses, to examine the independent 
contribution o f  the different predictors. The standardized beta 
was used as an indicator for the relative contribution o f  indi­
vidual predictors. P <  0*05 was regarded as being statistically 
significant. SPSS 14 (SPSS Inc., Chicago, IL, U.S.A.) was used 
for the statistical analyses.
Results
Patient characteristics at study entry
Out o f  135 patients w ith psoriasis referred for UVB photo ther­
apy, 109 (80*7%; m ean age 46 years, SD 16*1, range ± 16*1
Table 1 Study characteristics of patients with psoriasis who were 
referred for ultraviolet B therapy
Variable
Age (years), mean (SD) 46-3 (16-1)
Sex (female), % 50-5
Marital status (married or living together), % 68
Age at onset of psoriasis (years), mean (SD) 29*2 (16*4)
Clinical severity of psoriasis PASI, mean (SD) 9*2 (5*3)
Skin phototype (%) 
I 5*2
II 51*5
III 37*1
IV 6*2
Itching score, mean (SD) 9*44 (3*73)
Scratching score, mean (SD) 6*69 (2*80)
PASI, Psoriasis Area and Severity Index.
years; 49*5% m en) m et the inclusion criteria and agreed to 
participate (for patient characteristics, also see Table 1). The 
m ean PASI score was 9*2 (range 3*3-37*6, SD ± 5*3), indicat­
ing m ild to m oderate psoriasis. Most o f  the patients had skin 
type II or III (88*6%) from  a total range o f  skin types, I-IV 
(Table 1). Fifty-five patients w ere random ized to the erythe- 
m atogenic regim en and 54 to the suberythematogenic regi­
m en. There w ere no  significant differences in demographic 
and lifestyle variables (sex, age and educational level, alcohol 
and smoking habits), clinical and treatm ent-related variables 
(the baseline PASI score, MED or skin phototype) and itch - 
scratching variables (itching and scratching intensity) between 
the tw o groups.
Clearance
Seventy-seven patients (70*6%) achieved clearance. Seventeen 
patients stopped treatm ent because o f  treatm ent failure and 15 
patients stopped treatm ent for other reasons (use o f co-m edi­
cation, holidays). There w ere no  significant differences in life­
style variables, clinical variables or itch-scratching variables 
betw een the patients w ho achieved clearance and those w ho 
stopped treatm ent. However, the cumulative irradiation dosage 
was significantly higher in those patients w ho stopped treat­
m ent than in those w ho achieved psoriasis clearance (80*5 vs. 
39*7 J cm 2, P <  0*01). There w ere also no  significant differ­
ences in the num ber o f  patients w ho achieved clearance 
betw een both random ization schemes (74*5% vs. 66*7%).17
Predictors of time to clearance
The m ean num ber o f  irradiation sessions for the 77 patients 
w ho achieved clearance was 22*2 (±  6*76). The patients 
receiving the erythematogenic regim en needed significantly 
fewer irradiation sessions to achieve clearance than did 
the patients receiving the suberythematogenic regim en 
(P <  0*05), as previously reported .17 In addition, a lower 
MED, higher cumulative dose and m ore protocol adjustments
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Table 2 Correlates and regression analyses for significant predictors of 
the time to clearance (number of irradiations) for ultraviolet B 
treatment in patients with psoriasis
were significantly associated w ith  m ore irradiation sessions 
(Table 2). Lastly, higher levels o f  itching and scratching at 
study entry w ere significantly associated w ith m ore irradiation 
sessions before achieving clearance (Table 2). No significant 
correlations were found for the initial PASI score, skin type or 
the lifestyle variables o f  smoking habits and alcohol use. W hen 
the predictors that significantly correlated w ith  tim e to clear­
ance w ere entered in  a sequential regression analysis, higher 
levels o f  itch and scratching at baseline still significantly pre­
dicted m ore irradiation sessions until clearance was achieved, 
w ith significant standardized beta values for both itch 
(t = 2 -3 8 , P < 0 -0 5 )  and scratching (t = 2 -5 3 , P < 0 -0 5 ) 
(Table 2). These effects rem ained significant after taking into 
account all o ther predictors.
Discussion
In the present study, predictors o f  the time to clearance of 
psoriasis w ith narrow -band UVB therapy w ere studied. Both 
the levels o f  itching and scratching predicted the time to clear­
ance, independently o f  the initial PASI score or skin photo­
type, and in addition to treatm ent-related factors, such as the 
irradiation regim en (erythem atogenic or suberythematogenic 
doses), cumulative dose and protocol adjustments. Results 
showed that the num ber o f irradiation sessions required to 
achieve psoriasis clearance depended on  several clinical and 
treatm ent-related factors, w ith  the independent role o f  itching 
and scratching being identified for the first time.
W hile the role o f  itching and scratching in  psoriasis and their 
possible predictive function in UVB treatm ent efficacy is often 
neglected in  clinical practice, m ost patients w ith psoriasis suffer
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from  relatively persistent itching and scratching.10 15 More­
over, UVB treatm ent itself can cause or aggravate itching and 
scratching by eliciting erythema and by the irradiation. Conse­
quently, high levels o f  itching and scratching m ight worsen 
plaques o f psoriasis, w hich in turn  m ight decrease the possible 
initial beneficial effects o f  UVB treatm ent, resulting in  the need 
for m ore irradiation sessions to achieve disease clearance and 
consequently a reduced cost-effectiveness o f  UVB treatment.
Independent o f  the role o f  itch and scratching, an erythe- 
m atogenic irradiation regim en appeared to be superior to a 
suberythematogenic protocol regardless o f  psoriasis severity 
and required fewer treatm ent sessions.16 In line w ith  previous 
studies, other treatm ent-related factors, such as cumulative 
dosage, protocol adjustments and a low er MED also predicted 
a longer time to clearance.1 6 In contrast, pretreatm ent clinical 
factors, such as the initial PASI score or skin phototype, or the 
frequently assumed effects o f  lifestyle, such as smoking habits 
and alcohol consum ption,8,9 w ere not found to be predictive 
o f UVB therapy effectiveness.
The results o f  our prospective study m ight have direct im pli­
cations for clinical practice and m ight increase the effectiveness 
o f UVB therapy in  psoriasis. Similar predictors o f  itch and 
scratching have been show n to be relevant in various chronic 
inflammatory skin diseases, including psoriasis,11 15 and com ­
parable itch-coping treatments for chronic skin disease w ith  a 
high prevalence o f  itching seem to be effective in psoriasis.14,16 
In addition, there is evidence that specific forms o f  relaxation 
therapy in com bination w ith  phototherapy are m ore effective 
than phototherapy alone in psoriasis.19 As relaxation therapy is 
a com ponent o f  itch-coping program mes and effectively 
reduces itching and scratching in chronic skin diseases,17,20 its 
beneficial effect m ight be due to the indirect effect o f  reducing 
itching and scratching. Consequently, the habitual problem s of 
itching and related scratching behaviour m ight be a relatively 
generic problem  in chronic skin diseases w ith  h igh itch com ­
plaints and aversively affect various outcomes o f  the regular 
dermatological treatments. Identification o f  patients w ho expe­
rience itching and scratching, followed by their participation 
in short-term  itch-coping program m es, m ight be a cost-effec­
tive adjunct to UVB therapy for these patients. For example, 
itching and scratching habits can be assessed through validated 
questionnaires before their consultation w ith  the derm atolo­
gist, together w ith advice for possible additional care options,
L i, - 12,16,19-21such as itch-coping programmes.
Several lim itations o f  the study should be m entioned. As 
the patients w ere from  one university hospital, some selection 
bias cannot be excluded. However, all patients w ho visited the 
outpatient clinic w ith in  the given time period and w ho ful­
filled the inclusion criteria agreed to participate in the study. 
In addition, other factors not measured in  the present study 
m ight have had an effect on  the outcom e o f  UVB therapy. For 
example, high levels o f worrying and psychological distress 
have previously been found to predict the outcom e o f  UVB 
therapy in  psoriasis and the effects o f  itching and scratch­
ing m ight also be a consequence or cause o f psychological 
distress.9 Moreover, itch and scratching did not affect the
r R2
Standardized
beta
Clinical parameters
PASI score 0-10
Skin type -0-05
MED -0-30** 0-13** -0-40***
Treatment parameters
Erythematogenic/ 0-26* 0-11** 0-45***
suberythematogenic dose
Cumulative dosage 0-59*** 0-39*** 0-54***
Protocol adjustments 0-27* 0-09*** 0-32***
Lifestyle parameters
Smoking habits -0-04
Alcohol use -0-06
Itch-scratch parameters
Itch 0-34** 0-03* 0-16*
Scratching 0-27* 0-03* 0-17*
r, Pearson’s correlation coefficients; R2, explained variance in 
regression analyses; PASI, Psoriasis Area and Severity Index; 
MED, minimal erythema dose. *P < 0-05; **P < 0-01; 
***P < 0-001.
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num ber o f  patients w ho achieved psoriasis clearance, which 
suggests that other factors are responsible for treatm ent failure. 
Lastly, longer-term  follow-up results are needed to determine 
if  itching and scratching also affect the rem ission period and 
relapse rates over time.
In conclusion, the levels o f  itching and scratching are p re­
dictors o f  the tim e to psoriasis clearance w ith  UVB photo ther­
apy, independently o f other clinical and treatment-related 
factors. Systematic assessment o f patients at risk o f  suffering 
from  itching and scratching, followed by short-term  itch- 
coping program mes for these patients, m ight be a cost- 
effective adjunct to UVB therapy for psoriasis.
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Chapter 3
RESEARCH LETTERS
Treatment Nonadherence and Long-term 
Effects of Narrowband UV-B Therapy 
in Patients With Psoriasis
Nonadherence to a treatm en t reg im en  is a com ­m on  problem  in  patients w ith  derm atologie con­d itions, in clu d ing  psoriasis. F rom  30% to 80% 
of patients report being nonadheren t a t som e stage of their 
derm ato log ic  treatm en t, and  p articu la rly  h igh  n o n ad ­
herence  has b een  rep o rted  for topical treatm en ts .1,2 Pa­
tien ts’ adherence to the in stru c tio n s and  advice g iven by 
derm ato log ists , in c lu d in g  se lf-m anag em ent of topical 
treatm en ts  and  m ed ication  in take  for system atic treat­
m en ts, can  in fluence the effectiveness of therap ies such
as UV-B treatm ent. Particularly  d u ring  fo llow -up  treat­
m en t, p atien ts m ay fail to  com ply  w ith  in stru c tio n s to 
regularly  app ly  topical m ed ications. N on adh eren ce  to 
tre a tm e n t reg im en s m igh t be a p red ic to r of the  lo ng ­
term  effectiveness and  m ain tenance  of resu lts  after suc­
cessful UV-B therapy.
In  the p resen t p rospective study , w e investigate the 
predictive value of nonadherence w ith  derm atologic treat­
m en t on psoriasis outcom e (Psoriasis and  A rea Severity 
Index  [PASI]) a t fo llow -up  assessm ents 3 and  6 m on ths 
after p soriasis clearance. In  our analysis, w e con tro lled  
for clinical and  treatm ent variables (PASI a t the sta rt and 
end  of treatm ent, sk in  type, irrad ia tion  reg im en, m in i­
m al ery them a dose [MED], cum ulative  dose, and  p ro to ­
col ad ju stm en ts) and  lifestyle variables (sm ok ing  hab its 
and  a lcohol con su m p tion ).
M ethods. T he p artic ipan ts w ere  p atien ts w ith  psoriasis 
referred  for UV-B treatm ent as part of a random ized , con-
Tab le . C orre la tions and Regression A na lyses fo r P redictors o f the PASI at 3- and 6-M onth  Fo llow -up  Assessm ents A lte r F in ish ing  
UV-B T reatm ent in Pa tien ts  W ith  P soriasis
3 Months 6 Months
C haracteris tic1 ^  R2c ^  R~c p^"1
.03
NA
NA
.24
NA
NA
.02
.11
.07
NA
NA
.10
NA
NA
Sex
Age
Educational level 
Clinical parameters 
PASI at start of UV-B treatment 
PASI at end of UV-B treatment 
Skin type 
MED
Treatment parameters 
Erythema o r suberythema dose 
Cumulative dose 
Protocol adjustments 
Lifestyle parameters 
Smoking habits 
Alcohol use 
Adherence to dermatologic treatment regimen 
Total R2 variance
.45e .18e .40e
.47e .14e .33s
.17 NA NA
.18 NA NA
.23 NA NA
.13 NA NA
.06 NA NA
-.09 NA NA
.02 NA NA
-.5 0 e .10f - .3 6 f
NA .4 5 f NA
.32s .07 .21
.53f .15f .32'
.27 NA NA
.08 NA NA
.16 NA NA
.15 NA NA
-.03 NA NA
.04 NA NA
.08 NA NA
-.5 9 g .17e -.47
NA .4 6 f NA
Abbrevi ati ons: MED, mi ni mal erythema dose; NA, not appli cable; PASI, Psori asi s Area and Severity Index.
aScores and/or ranges of all characteristics: sex: male, 0; female, 1; age range, 18 to  75 years; educational level, 1 to 7; PASI, 0 to  38; skin type, I to V;
MED, 0.00 to 1.50; irradiation doses: suberythema, 1; erythema, 2; cumulative dose, 5.64 to 407.20 J/cm 2; protocol adjustments, 0 to 19; smoking habits, 1 to 7: 
alcohol use, 1 to 7; adherence, 1 to 4.
b Pearson correlati on coeffici ents: the signifi cant correlati on ( r ) indi cates that male sex, a higher PASI score at the start and end of treatment, and weaker 
adherence to dermatologic treatment are related to  a higher PASI score at the follow-up assessments.
Percentages of the explained variance in regression analyses fo r predictors that significantly correlated w ith the PASI at 3- and 6-month follow-up 
assessments.
d Standardized beta (and ttests) in regression analyses fo r predictors that significantly correlated w ith the PASI at 3- and 6-mo fo llow-up assessments.
e P c .0 1 .
f P < .0 5 .
s P < .001 .
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tro lled  trial of irrad ia tion  given in  an  ery them atogenic 
or suberythem atogenic regim en.3 O f the 77 patien ts  w ho 
achieved clearance, data of 69 (90%) and 47  (61% ) pa­
tien ts  w ere available for the 3 - and  6 -m onth  follow -up 
assessm ents, respectively. Analyses on both  follow-up data 
sets as w ell as analyses for the 47 com pleters revealed the 
sam e resu lts  overall, and  so the analyses for the 47 com ­
p le ters  are repo rted  herein.
C lin ica l severity  w as assessed  w ith  the PASI score 
a t baseline, every 4 w eeks, a t the tim e of clearance, and 
a t b o th  th e  3- a n d  6 -m o n th  fo llo w -u p  assessm en ts . 
Variables of UV-B treatm en t w ere assessed by a derm a­
tologist and  n u rs ing  personnel and  inc luded  sk in  p ho ­
totype (F itzpatrick  classification of 6 skin types), MED, 
reg is tra tio n  of p ro to c o l a d ju stm en ts , an d  cum ulative  
dose.
N onadherence  w as assessed at baseline via the n o n ­
adherence scale of the Im pac t of Skin D isease on  Daily 
Life questionnaire .4 Specifically, patien ts  w ere asked “In 
general, do you  attend  to the trea tm en t in stru c tio n s  and  
advice given by the derm atologist?” A nsw ersw ere scored 
on  a 4 -p o in t L ikertsca le  (1, n o t a t all; 2, a little  bit; 3, to 
a relatively large extent; and  4, com pletely).
L ifes ty le  v a r ia b le s  w e re  assesse d  by  s e lf -a d m in ­
istered  questionnaires  ask ing  ab o u t the average alcohol 
c o n s u m p tio n  an d  sm o k in g  h ab its  d u r in g  the  p as t 6 
m onths.
R esults. E ight p ercen t of the s tudy  patien ts  w ere largely 
nonadheren t to recom m ended treatm ent instructions and 
advice; 63% w ere som etim es nonadheren t; and  29% w ere 
largely adherent. A higher level of nonadherence w as sig­
n ificantly  re la ted  to a h ighe r PASI score a t the 3- and
6 -m on th  fo llow -up assessm ents ( r  = -0 .5 0  [P <  .01] and 
r = -0 .5 9  [P <  .001], respectively) (T a b le ) . In  addition , 
a h igher PASI score at bo th  the s ta rt and  end  of trea t­
m en t w as related  to PASI scores a t 3 and  6 m onths. F i­
nally , m ale sex w as significantly  associated w ith  higher 
PASI at the 6 -m onth , b u t n o t at the 3 -m on th , follow -up 
assessm ent. W hen  the p red ic to rs tha t significantly  co r­
re la ted  w ith  PASI scores at fo llow -up assessm ents w ere 
en tered  in to  a sequential regression  analysis (PASI score 
a t the s ta rt and  end  of treatm ent, m ale sex), h igher lev­
els of nonadherence  still significantly  pred ic ted  a higher 
PASI score at 3- and  6-m onth  follow-up assessm ents, w ith  
significant standard ized  beta values for b o th  assessm ent 
p o in t s ( t= -2 .6 0  [P < .0 5 ]  a n d t = -3 .3 8  [P < .0 1 ],respec- 
tively) (Table).
C om m ent. O ur resu lts  ind ica te  tha t non ad h e ren ce  to 
derm atologic treatm ent instruc tions and advice is a pre­
d ic tor of longer-term  outcom es after psoriasis clearance 
w ith  UV-B therapy. A h igher level of nonadherence  at 
the  s ta rt of the  s tudy  significantly  p red ic ted  a poorer 
PASI score at bo th  follow-up assessm ents. These effects 
rem ained significant after we contro lled  for PASI scores 
a t the s ta rt and  end  of treatm en t, irrad ia tion  schem es, 
MED, sk in  type, cum ulative dose, pro tocol ad justm ents, 
and  lifestyle factors (sm oking  hab its  and  a lcohol con ­
sum ption). A cost-effective ad junct to UV-B therapy to 
im prove adherence w ould  include (1) short, systematic 
assessm ents of barriers to  and facilitators of adherence;
(2) identification of subgroups of patients w ho are m ore 
likely  to be n o n a d h e re n t by m eans of q u es tio n n a ire  
assessm ents before patien t consultation  w ith  the derm a­
to logist; an d  (3) ad m in is tra tio n  of 1 or 2  sh o rt- te rm  
p s y c h o e d u c a tio n a l o r s e lf-m a n a g e m e n t, co g n itiv e - 
b ehav io ra l p ro g ram s w h en  the  d isease  is in  an  early  
stage.5
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Evaluation of innovations for phototherapy for 
psoriasis
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A placebo-controlled randomized study on the clinical 
effectiveness, immunohistochemical changes and proto­
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Background Topical 5-am inolaevulinic acid (ALA)-photodynamic therapy (PDT) for 
the treatm ent o f  psoriasis has been evaluated in a few studies. In these studies 
different treatm ent param eters w ere used, there was a variable clinical response, 
and a nonhom ogeneous fluorescence was seen after irradiation w ith  W o o d ’s 
light.
Objectives To study the clinical effectiveness, im m unohistochem ical changes and 
p ro toporphyrin  IX accum ulation in ALA-PDT in patients w ith  psoriasis.
Methods Eight patients w ith  stable plaque psoriasis w ith  symmetrical involvement 
w ere included in  the study. Two symmetrical plaques w ere random ly allocated 
to PDT either w ith  10% ALA o r w ith  placebo. Irradiation consisted o f  2 and
8 J cm -2 w ith  a dark interval o f  2 h  (W aldm ann PDT 1200 L, 600 -7 5 0  nm, 
40 m W  cm 2) once weekly for 4  weeks. Before, during and after irradiation, 
fluorescence diagnosis was perform ed. Biopsies w ere taken at baseline, w eek 1 
and week 6 for im m unohistochem ical assessment. Psoriatic plaques w ere clinic­
ally assessed using the plaque severity (sum) score. Fluorescence diagnosis was 
perform ed and expression o f  im m unohistochem ical markers for proliferation, 
differentiation and T-cell infiltration [Ki67, keratin 10 (K10), CD4, CD8 and 
CD45RO] was assessed.
Results From w eek 1 up to w eek 6, ALA-PDT gave a significant reduction in the 
num ber o f  K i67+ nuclei, w hile the K10 expression increased. After 6 weeks sig­
nificant im provem ent was observed for CD8 and CD45RO. These changes w ere 
absent in  the placebo-treated lesions. The sum  scores w ere also significantly 
low er in the ALA-treated plaques. H eterogeneity o f  macroscopic fluorescence was 
observed during treatm ent despite keratolytic treatm ent.
Conclusions The present study shows that clinical im provem ent during fractionated 
ALA-PDT in psoriasis parallels histological im provem ent as seen in  norm alization 
o f  epiderm al proliferation, differentiation and infiltration o f  relevant T-cell sub­
sets. Optim izing the current treatm ent protocol may increase clinical efficacy fur­
ther.
Over the last few years photodynam ic therapy (PDT) with 
topical 5-aminolaevulinic acid (ALA) has been gaining interest 
in  m ore and m ore dermatological centres and its clinical effic­
acy has convinced m any dermatologists to im plem ent this 
therapy in their daily practice. Although m ore random ized 
controlled studies are still needed and 5-year follow-up data 
are m ostly lacking, PDT has been proven to be clinically 
effective in nonm elanom a skin cancer including actinic kerato­
sis, Bowen’s disease and (superficial) basal cell carcinoma. As 
protoporphyrin IX (PpIX)-accumulating skin disorders in gen­
eral m ay be a potential target for PDT, other (nononcological) 
indications have also been studied or are currently under eval­
uation. Psoriasis has been shown to accumulate PpIX selec­
tively and its susceptibility to PDT has been previously studied 
by various authors.1 5 In these studies clinical efficacy varied 
largely but results are difficult to compare because o f  the
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different treatm ent parameters that were used. Various m echa­
nisms have been proposed for the clinical effect o f  ALA-PDT 
in psoriasis. Boehncke et al.5 reported topical ALA-PDT to have 
inhibitory effects on  tum our necrosis factor-a, interleukin 
(IL)-1 and IL-6 secretion in a dose-dependent m anner, which 
has also been reported in psoralen +  ultraviolet A therapy, 
whereas Bissonette et al.6 found PDT w ith  systemic ALA to 
induce apoptosis in CD3+ cells. Pain during irradiation is one 
o f  the m ain drawbacks in PDT, and this was the case in  sev­
eral reports on PDT o f  psoriasis. Considering the discomfort 
o f  this treatm ent and the variable clinical efficacy, several 
authors therefore concluded PDT to be unsuitable for the 
treatm ent o f  psoriasis.7,8 On the other hand, there is a perm a­
nent need for new treatm ent modalities in  the treatm ent of 
psoriasis as topical therapies are not always successful and 
dem and the patient's utmost compliance; m oreover, cumula­
tive toxicity and carcinogenicity o f  many systemic and 
photo(chem o)therapies are lim itations in the long run. 
Although the long-term  safety o f  PDT rem ains to be estab­
lished, current data do not point in the direction o f  PDT hav­
ing carcinogenic potential. Taking these factors into account, 
if  efficacy could be increased by optim izing the treatm ent p ro ­
tocol, PDT o f psoriasis w ould be o f  additional value in the 
current treatm ent arsenal.
W hile previous studies on  PDT in psoriasis have focused 
m ainly on  the clinical efficacy, knowledge on  the histological 
effects o f  PDT in  psoriasis is crucial, better to understand the 
m echanism  responsible for the clinical im provem ent in PDT 
o f  psoriasis. These data may also be used to optim ize the 
treatm ent protocol further. Therefore, the aim o f  the present 
study was to evaluate the clinical and histological effects o f 
PDT in psoriasis w ith respect to the histological hallmarks o f 
psoriatic plaques, these being epidermal hyperproliferation, 
abnormal keratinization and T-cell infiltration. For this pu r­
pose, several im m unohistochem ical markers w ere chosen 
including Ki67 (epiderm al proliferation), keratin 10 (K10; 
epidermal keratinization), CD4 (helper T cells), CD8 (cyto­
toxic T-cells) and CD45RO (mem ory T-cells). As light frac­
tionation has been proposed as a possible way to improve 
clinical efficacy,9 a twofold fractionated protocol w ith a dark 
interval o f  2 h  was used. As lowering o f  the fluence rate has 
also been reported to enhance the clinical response,10,11 
40 m W  cm 2 was chosen as a standard fluence rate during 
the irradiation process. To study PpIX form ation and photo- 
bleaching in the treated areas, w hich can also be informative 
in understanding the photodynam ic effects in psoriasis, fluor­
escence intensity on  the skin was assessed using a digital 
fluorescence imaging system.
Patients and methods
Patients
This study was approved by the local medical ethics com m it­
tee. The recruitm ent period lasted from  August until Septem­
ber 2004 and the treatm ent period from  September until
December 2004. Eight patients selected out o f  our research 
database (age range 3 9 -6 4  years; five m en and three wom en) 
w ith  stable plaque psoriasis w ith  symmetrical involvement 
w ere included in  this study after giving their w ritten informed 
consent. All the lesions w ere located on  the legs. Lesions were 
treated w ith  10% salicylic acid in petrolatum  for 1 week prior 
to the baseline visit to rem ove excess scales that could poten­
tially interfere w ith  ALA and light penetration. Patients were 
not allowed to use any systemic psoriatic treatments or topical 
m edication on these lesions for at least 4 weeks. Medication 
know n potentially to aggravate psoriatic lesions, such as 
ß-blockers, was also not allowed. Patients w ere requested to 
refrain from  sun exposure during the treatm ent period.
Photodynamic therapy
At the baseline visit tw o contralateral psoriatic lesions were 
random ized by means o f  a special com puter algorithm  to 
either PDT w ith  10% ALA ointm ent (Medac GmbH, Wedel, 
Germany) or the vehicle (Medac GmbH). Before the ALA oint­
m ent or vehicle was applied lesions w ere photographed. Sub­
sequently, according to the random ization outcom e, ALA 
ointm ent and vehicle w ere applied under an occlusive dressing 
(Tegaderm; 3M Pharmaceuticals, Zoeterwoude, the Nether­
lands) to enhance ALA penetration. The occlusive dressing was 
covered by alum inium  foil to avoid prem ature photobleaching 
effects. After 4 h  the ointm ents and foils w ere rem oved and 
the skin surface was cleaned using 80% denaturated alcohol 
v /v . Thereafter the first light fraction o f 2 J cm 2 was deliv­
ered [W aldmann PDT 1200 L (W aldmann Medische Techniek 
BV, Tiel, the Netherlands), 600-750  nm , 40 m W  cm -2]. 
Lesions w ere covered again w ith  the occlusive dressing and 
alum inium  foil for 2 h, after w hich a second light fraction o f
8 J cm 2 was delivered using the same irradiation parameters. 
The same irradiation protocol was applied once every week 
for 4 weeks.
To evaluate the clinical response, the sum score, a widely 
used m ethod to m easure the plaque severity, was assessed for 
both lesions at each visit. In this score erythema, induration 
and desquam ation are each scored on  a five-point scale as: 0, 
absent; 1, m inim al (very light pink, hardly any elevation, rare 
scale); 2, m ild (light red /p in k , slight elevation, poorly defined 
scale); 3, m oderate (red, m oderate elevation, defined scales); 
or 4, severe (very red, m arked ridge, heavy scaling). Finally, a 
global sum score (range 0 -1 2 ) was defined as the sum o f  all 
three scores together, reflecting plaque severity.
Biopsy procedure
At the baseline visit, week 1 and 2 weeks after the last treat­
m ent (week 6), 4-m m  punch biopsies from  the treated psori­
atic lesions w ere taken under local anaesthesia w ith  1% 
xylocaine-adrenaline. Biopsies w ere em bedded in Tissue-Tek 
OCT com pound (Miles Scientific, Napierville, IL, U.S.A.) and 
directly frozen into liquid nitrogen. Biopsies were stored at 
-  80 °C until further processing.
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Fluorescence diagnosis
Fluorescence intensity on the skin was recorded at every visit 
before and directly after each irradiation using a digital fluor­
escence imaging system (DyaDerm; Biocam GmbH, Regens­
burg, Germany). The DyaDerm digital imaging system consists 
o f  a flash light [xenon light source w ith  a custom bandpass 
filter (370-440  nm )] and a 12-bit Sony CCD camera com ­
bined in one adjustable arm  coupled to a Pentium IV com pu­
ter equipped w ith  custom -m ade image capturing software 
(Dyaderm Pro v. 1.4; Biocam GmbH). The flash light emits 
seven light pulses per second to the skin w hich are recorded 
by the CCD camera (exposure tim e 100 |i.s) equipped w ith  a 
special Schott GG 455 longpass filter to filter out the excitation 
light. As PpIX fluorescence emission consists o f  light in the 
red spectrum, the red pixels o f  the CCD camera were used to 
generate a fluorescence image. In this way a norm al-coloured 
image and a fluorescence image were processed in real time. 
Because o f  the short exposure time to the excitation light, 
photobleaching o f  PpIX was m inim ized. To correct for differ­
ent lighting environm ents between pictures, a fluorescence 
reference standard (Maccal 8044, 738-00; Multifoil, Utrecht, 
the Netherlands) was included on  every image. Images were 
recorded in 16-bit grey-scale TIFF format.
Analysis of fluorescence images
Sixteen-bit grey-scale TIFF fluorescence images were im ported 
in  NIH ImageJ software (h ttp ://rsb .in fo .n ih .g o v /ij/). Because 
the xenon light source used for excitation has the highest 
intensity in  the centre o f  the illuminated area, shading correc­
tion was perform ed by means o f  the following algorithm:
S =  i/C , w here C =  B/B[mflX; B =  blank image (image from  a 
white hom ogeneous background recorded w ith  the Dyaderm 
system), BimûX =  highest intensity o f B, I =  (uncorrected) 
image, C =  normalized shading image and S =  shading cor­
rected image. Photobleaching in  psoriatic lesions was assessed 
by m easuring the m ean pixel intensity o f  highly fluorescing 
regions w ith in  a psoriatic plaque. Measurements w ere always 
perform ed in the same area w ith in  a plaque.
Immunohistochemistry
Frozen sections (7 lm )  w ere cut from  the skin samples for 
im m unohistochem ical assessment. These were air-dried for 
30 m in  and fixed in cold acetone for 10 m in. After blocking 
for 5 m in  for endogenous peroxidase, using 0-2% sodium 
azide (Dako, Copenhagen, Denmark), sections w ere washed in 
phosphate-buffered saline (PBS; B. Braun, M elsungen, Ger­
many) for 10 m in  before incubation w ith prim ary antibodies. 
The following prim ary antibodies (mouse antihum an) were 
used, diluted in 1% bovine serum  album in (Sigma, St Louis, 
MO, U.S.A.)/PBS: anti-CD4 (clone MT310; 1 : 200), anti-CD8 
(clone DK25; 1 : 200), anti-CD45RO (clone UCHL1;
1 : 100), Ki67 (clone MIB-1; 1 : 200) (all from  Dako) and 
K10 (clone RKSE60; 1 : 100) (Monosan Laboratories, Uden,
the Netherlands). Sections were washed in PBS for 15 min. 
Secondary IgG-labelled polymer, horseradish peroxidase anti­
m ouse EnVision+ (Dako) was added for 30 m in. The sections 
were washed again for 15 m in  in PBS. To visualize the stain­
ing w e used AEC+ High Sensitivity Substrate Chrom ogen for 
10 m in  (Dako). Counterstaining was perform ed w ith Mayer's 
haematoxylin (Sigma). The sections were washed in  tap water, 
dried, and m ounted in glycerol gelatine (Sigma).
Furthermore, haematoxylin and eosin (H&E) staining was 
perform ed on  every biopsy specimen. After dehydration in 
alcohol and Histosafe, the sections were m ounted  in Per­
m ount. W ith these H&E sections w e verified that the biopsies 
under study fulfilled the psoriasis-specific histological criteria.
Immunohistochemical analysis
Analysis o f  digital m icroscopic images was done using IP-lab 
software (Scanalytics Inc., Fairfax, VA, U.S.A.). In order to ana­
lyse Ki67+ cells, digital photographs w ere m ade at X 100 m ag­
nification covering the entire epidermis. A line following the 
basement m em brane was draw n and its length was measured. 
All positive cells above this line w ere counted and divided by 
the length o f  the basement m em brane so the num ber o f  positive 
cells per m illim etre length o f  basement m em brane could be 
calculated.
For quantification o f K10+ cells, digital photographs were 
m ade at X 50 magnification. The surface K10+ (epidermal) 
cells w ere m easured and divided by the total epidermal sur­
face. Thus epidermal differentiation was defined as percentage 
K10+ epidermal surface.
T-cell subsets (CD4, CD8 and CD45RO) w ere analysed by 
counting all positive cells in  the epidermis and dermis sepa­
rately. These num bers w ere divided by the length o f  the stratum 
corneum . In this way T-cell subsets were expressed as the nu m ­
ber o f  positive cells per m illimetre (epi)derm is. All slides were 
encoded to assure that the analysis was perform ed blindly.
Statistics
To compare m ean sum scores, m ean fluorescence intensity 
and expression o f  Ki67, K10, CD4, CD8 and CD45RO 
betw een the two treatm ent regim ens a two-tailed Student's 
t-test was used. One-way analysis o f  variance was used to ana­
lyse differences between tim e points w ith in  each marker. 
W hen significant changes w ere found, Duncan's post hoc test 
was perform ed for analysis betw een tim e points. P <  0 05 was 
regarded as statistically significant. Microsoft Excel 2000 and 
Statistica 6.0 software (Statsoft Inc., h ttp ://w w w .statso ft.com ) 
were used for statistical calculations.
Results 
Clinical efficacy
Although some patients experienced some burning and sting­
ing during the irradiation, generally the treatm ent was well
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tolerated by all patients and no additional analgesics were nee­
ded. These sensations were m ore intense during the second 
light fraction o f 8 J cm -2 .
Psoriatic lesions showed some evident clinical improvem ent 
during the treatm ent period w hich was reflected in a statisti­
cally significant decrease in the clinical plaque severity (sum) 
score (P =  0.009) (Figs 1a and 2). Moreover, starting at 
week 1, the mean sum score o f the ALA-treated lesions was 
significantly lower as compared w ith the placebo-treated 
lesions. Classical psoriatic plaques o f a few centimetres in size 
w ith clinically normal surrounding skin showed the best clin­
ical improvement. This started m ost frequently in the periphery 
o f the plaque. Areas w ithin a plaque that clinically improved 
were usually followed by hyperpigm entation. In two patients 
an increase in the total psoriatic surface area was observed in 
the ALA-treated sites, highly suggestive for Koebnerization.
Fluorescence intensity on the skin
After a 4-h incubation w ith ALA, psoriatic plaques showed 
selectively higher fluorescence compared w ith the surround­
ing (nonlesional) skin (Figs 3 and 4). However, fluores­
cence w ithin m ost plaques was not hom ogeneous, despite 
clinically adequate keratolytic treatm ent 1 week prior to the 
baseline visit. Lesional fluorescence intensity after a 4-h 
incubation w ith ALA was 2-57 times higher compared with 
baseline fluorescence (before ALA application). The first 
light fraction o f 2 J cm-2 caused no statistically significant 
photobleaching (2-4%). During the 2-h dark interval there­
after, fluorescence intensity again increased up to 2-99 times 
baseline fluorescence, indicating new PpIX formation. After 
the second fraction o f 8 J cm -2 , a statistically significant 
decrease in fluorescence intensity (26-69%) was observed.
Fig 1. C linical sum  scores and  im m un o h isto ch em ica l changes d u rin g  frac tiona ted  5 -am ino laevu lin ic  acid (ALA)- o r veh ic le -p h o to d y n am ic  therapy . 
(a) Clinical sum  scores at baseline and  w eeks 1, 2, 3 and  6. The sum  scores o f  th e  ALA-treated sites sign ifican tly  decreased  (P =  0 -009), w hereas 
th e  veh ic le -trea ted  sites d id  n o t sh o w  any  sign ifican t changes d u rin g  trea tm en t (P =  0-239). (b ) K i67 expression  significantly  dec lined  in  the 
ALA-treated sites d u rin g  trea tm en t (P <  0 -001), b u t n o t in  th e  p lacebo-trea ted  sites (P =  0 -275). (C) K10 expression  significantly  increased  in  the 
ALA-treated sites d u rin g  trea tm en t (P =  0-007), b u t n o t in  th e  p lacebo-trea ted  sites (P =  0 -651). ( d - f )  E piderm al and  derm al exp ression  o f  
C D 4+ , C D 8+  and  C D 45R O + cells, respectively. E piderm al C D 4+ cells in  the  veh ic le -trea ted  sites sh o w ed  statistically sign ifican t increases, w h ereas 
C D 4+  cells in  the  ALA-treated sites d id  n o t sh o w  any  statistically sign ificant changes. D erm al C D 45R O + cells sh o w ed  a statistically significant 
decrease d u rin g  ALA trea tm en t. A lthough  the  n u m b e r o f  ep iderm al C D 45R O + cells also sh o w ed  a m arked  decrease, th is w as n o t statistically 
significant. The o pposite  w as observed  w ith  respect to  th e  n u m b e r  o f  C D 8+  cells, w h e re  a sign ifican t ep iderm al decrease in  the  ALA-treated site 
w as seen, vs. a nonsign ifican t d erm al decrease. R esults are sh o w n  as m ean  ±  SEM.
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However, fluorescence was still 2 1 3  times baseline fluores­
cence.
Immunohistochemistry
Epidermal proliferation and differentiation
Epidermal proliferation decreased during PDT as show n by a 
significant reduction in  the num ber o f  epidermal Ki67+ cells
(-60% ; P =  0-001) (Figs 1b and 5). Epidermal K10 expression, 
however, increased significantly, indicating norm alization of 
differentiation (+16%; P =  0-007) (Figs 1cand 5). Thesechan- 
ges w ere in parallel w ith the clinical im provement o f the psori­
atic lesions and w ere absent in the placebo-treated lesions.
T-cell infiltration
CD8+ cells w ere mainly seen in the papillary dermis and to a 
lesser extent in the epidermis (Figs 1e and 5). From baseline 
to week 6 the num ber o f epidermal CD8+ cells showed a 
m arked decrease (-36% ; P =  0-036) in the ALA-treated 
lesions. In  the dermis a decrease was also noted, but this was 
not statistically significant (-31% ; P =  0-232). The num ber of 
CD45RO+ cells, however, decreased in both epidermis 
(-48% ; P =  0-034) and dermis (-43% ; P =0-013) (Figs 1f 
and 5). CD4+ cells in the ALA-treated lesions did not show 
any significant changes in either dermis (-21% ; P =0-429) or 
epidermis (-13% ; P =  0-112) (Fig. 1d). The placebo-treated 
lesions did not show any significant changes in the studied 
T-cell subsets except for a significant increase in  the num ber 
o f  epidermal CD4+ cells (+34% ; P =  0-029).
Fluorescence patterns
Although the studied psoriatic lesions w ere pretreated w ith  a 
keratolytic agent, m ost lesions showed inhom ogenous fluores­
cence, m ostly in  a follicular pattern and different at the differ­
ent days the treatm ent took place (Fig. 4). From the clinical 
appearance o f  the lesions the distribution o f  fluorescence 
w ith in  the plaque was not always predictable. Fluorescence 
values at some sites w ith in  the plaques w ere low er than nor­
m al surrounding skin fluorescence. Epidermal skin barrier also 
appeared to influence PpIX form ation and distribution w ithin 
the plaques as high fluorescence values w ere always seen 
around the sites o f  biopsy.
Fig 3. P h o tob leach ing  o f  p ro to p o rp h y rin  IX 
d u rin g  frac tiona ted  5 -am ino laevu lin ic  acid 
(A L A )-photodynam ic the rap y  (PDT). 
M acroscopic  fluorescence w as m easu red  
d u rin g  frac tiona ted  ALA-PDT at several tim e  
po in ts  u sin g  th e  D yaD erm  im ag ing  system . 
S tatistically sign ifican t changes in  fluorescence 
w e re  seen a t 4  h  incu b a tio n  and  after 
i llu m in a tio n  w ith  th e  second  lig h t dose  o f
8 J cm  2, w h ile  th e  first lig h t dose  d id  n o t 
in d u ce  statistically sign ifican t p h o tob leach ing . 
F luorescence values are  d ep ic ted  in  re lative 
un its  (r.u .)  m ean  + / )  SEM w ith  baseline 
fluorescence set to 1-0. *P <  0-001,
**P <  0-01.
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Fig 4. C linical (a -c ) ,  fluorescence (d - f )  and  
p se u d o co lo u r im ages (g - i )  fro m  th e  sam e 
p a tie n t after 5 -am ino laevu lin ic  acid 
app lication  (4  h ) a t baseline (a, d , g ), w eek  1 
(b , e, h )  and  w eek  2 (c, f, i). The 
d is trib u tio n  o f  fluorescence v aried  largely  at 
th e  d iffe ren t tim e  po in ts  an d  w as generally  in 
a fo llicular pa tte rn . N o te th a t a t th e  sites o f  
b iopsy  fluo rescence w as alw ays presen t.
Fig 5. Im m u n o h isto ch em istry . K i67, keratin
10 (K 10), CD8 and  CD45RO stain ings at 
baseline, w eek  1 an d  w eek  6. K i67 a n d  K10 
are  disp layed  a t X 100 m agn ifica tion ; T-cell 
subsets are  d isp layed  at X 50  m agnification .
Discussion
Four fractionated PDT sessions o f  2 + 8 J cm 2 (2-h dark inter­
val) w ith  10% ALA ointm ent induced clinical im provement in 
psoriatic plaque severity as m easured by a statistically significant 
low er sum score compared w ith  the sites that were treated w ith 
vehicle-PDT. Several authors have described clinical im prove­
m ent o f  psoriasis after m ultiple PDT sessions but an optimal
treatm ent protocol has not yet been established.1 4,7,12 Most 
authors agree that the dose per treatm ent session required for a 
clinical im provement m ust not be too high, as Koebnerization 
and severe pain during irradiation have been reported.8 In our 
study in  two patients an increase in psoriatic activity was 
observed in the ALA-treated sites, but not in the placebo-treated 
sites. In  these sites new psoriatic lesions arose, w hich  is highly 
suggestive for the Koebner phenom enon as nonlesional psoriatic
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skin is also affected by photodynam ic effects. Although various 
factors have been reported to m odulate the Koebner response,13 
in  our patients this was unpredictable. In  this ligh t, it w ould be 
interesting to study the photodynam ic effects of m ethyl- 
aminolaevulinate (MAL)-PDT w hich is no w  licensed in almost 
every European country. As MAL has been reported to accumu­
late m ore selectively than ALA,14 the risk o f Koebnerization 
could theoretically be reduced. To the best of our knowledge, 
the exact differences in PpIX form ation in psoriasis between 
MAL and ALA have not been studied yet. However, w hen  PpIX 
is regarded to accumulate in psoriasis and nonm elanom a skin 
cancer by similar mechanisms, w ith MAL (as Metvix®; Galderma, 
Fort W orth, TX, U.S.A.) one m ight expect less pronounced 
photodynam ic effects in nonlesional skin (e.g. Koebnerization) 
compared w ith lesional skin. It is unknow n, however, how  PpIX 
levels betw een 10% ALA cream and Metvix relate, as Metvix 
contains a relatively high concentration (160 m g g 1) o f  MAL 
compared w ith the 100 mg g)1 ALA that was used in our study, 
although in a study o f Fritsch et ol.14 MAL appeared to be less 
potent than ALA w ith  respect to PpIX form ation in  actinic kera­
tosis. Considering the fact that 1% ALA cream in a study of 
Radakovic-Fijan et ol.7 was able to exert pronounced photo­
dynamic effects in  the treatm ent o f psoriasis, the concentration 
o f  MAL in  Metvix cream m ight be too h igh for this indication.
Koebnerization thus appears to be a significant adverse 
event that is m ost likely to be dependent on  the photo­
dynamic dose, although an exact dose-effect relationship has 
not yet been established. O n the other hand, photodynam ic 
doses that are too low  do not appear to be therapeutically 
effective.1 3,8 In a recent study Radakovic-Fijan et ol.7 reported 
no  significant differences in the clinical response betw een 5 
and 10 J cm 2, whereas 20 J cm 2 appeared to be m ore 
effective. In this study 1% ALA ointm ent was used. As psori­
asis has been reported to accumulate PpIX strongly, low er 
concentrations o f ALA than used for dermato-oncological indi­
cations may be sufficient to exert a beneficial clinical effect. In 
addition, the prim ary goal o f  PDT in psoriasis is not likely to 
be the cytotoxic effect, for which a few higher photodynam ic 
doses are required, but rather the im m unom odulatory effect 
in  w hich exposure to m ultiple low er photodynam ic doses 
over a longer period o f time is thought to be required. Con­
sidering the fact that at the end o f  the second illumination 
macroscopic fluorescence was still 2 1 3  times above baseline 
fluorescence, in our study depletion o f  PpIX cannot be held 
responsible for the mediocre clinical efficacy.
Fractionation o f  the ligh t dose in tw o fractions w ith a 
dark interval in betw een has been reported as a way to 
enhance PpIX form ation as resynthesis o f PpIX is thought to 
take place in the dark period. Moreover, during the dark 
period reoxygenation o f  the tissue may lead to additional 
singlet oxygen and reactive oxygen species form ation.15 
These events may account for the increased PDT-induced 
photodam age. Lowering o f  the fluence rate has also been 
reported to result in  m ore and deeper PDT-induced photo­
damage by a similar m echanism .10 As m ean fluorescence 
directly after the first illumination did not show a statisti­
cally significant decrease, it is likely that i f  the am ount of 
photobleaching is regarded to be related to photodynam ic 
effect, then the first dose o f  2 J cm)2 was too low  to exert 
a significant clinical effect. The second illumination, how ­
ever, did induce statistically significant photobleaching. In 
this light, a twofold illumination scheme o f  5 + 5 J cm 2 
m ight be m ore effective, but the risk o f Koebnerization may 
theoretically be increased. As penetration o f ALA cream is 
one o f  the m ain problem s in the treatm ent o f  dermal p ro ­
cesses, low ering o f  the fluence rate may be m ore useful 
than light fractionation.
Increased epidermal proliferation, abnormal keratinization 
and dermal infiltration o f T-cells and neutrophils are the histo­
logical hallmarks o f  plaque psoriasis, whereas norm alization of 
these parameters is associated w ith clinical improvement. In 
our biopsies norm alization o f epidermal proliferation was 
seen, as reflected by a significant decrease in Ki67 expression, 
w hich is a cell cycle-associated antigen expressed in all parts 
o f  the cell cycle except Gq and early G1, thus representing the 
epidermal proliferative com partm ent.16 Normalization of 
keratinization was also observed, as seen in an increase in 
expression o f  epidermal K10, a marker for terminal differenti­
ation w hich is generally decreased in psoriasis.17
Analysis o f  T-cell infiltration also showed statistically signifi­
cant increases in epidermal CD4+ cells in the vehicle-treated 
sites, whereas CD4+ cells in the ALA-treated sites did not 
show any statistically significant changes. The photodynam ic 
effect m ight be responsible for the stabilization o f  the CD4 
influx into the skin. Dermal and epidermal CD45RO+ cells 
showed a statistically significant decrease during ALA treat­
m ent. W ith respect to the num ber o f  CD8+ cells, a significant 
epidermal decrease in the ALA-treated site was seen, as 
opposed to a nonsignificant dermal decrease.
Thus, the current treatm ent protocol as described in our 
study demonstrated pronounced antipsoriatic effects on  epi­
dermal keratinocytes with respect to proliferation and differen­
tiation. A decrease in the num ber o f  CD45RO+ cells was the 
only statistically significant dermal effect that was observed. 
This is no t surprising w hen the penetration depth o f  the light 
source and ALA cream used are considered. PDT w ith topical 
ALA exerts its m ain effects on  the surface o f  the skin where 
the am ount o f  light energy and photosensitizer concentration 
are the highest. Hence its effects are expected to be found 
mainly in the epidermis.
Heterogeneity o f  fluorescence on  the skin as well as histo­
logically w ithin psoriatic plaques has been described by var­
ious authors.2,7,18 A part o f this seems to be related to the 
am ount o f hyperkeratosis w ithin a psoriatic plaque, as p re­
treatm ent w ith a keratolytic agent improves fluorescence 
hom ogeneity .18 It is no t know n w hat causes the rem aining 
heterogeneity o f  fluorescence after clinically efficient desqua­
m ation, as observed in our patients. These variations in fluor­
escence m ight explain the variable and mostly partial clinical 
response seen after PDT.
The present study reconfirms that PDT has an antipsoriatic 
efficacy and is well tolerated. Because o f the variable clinical
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effect and m ediocre clinical efficacy compared w ith other 
established topical treatments, PDT o f  psoriasis using the cur­
rent protocols w ould not be recom m ended as a first-line treat­
m ent option. However, in  certain patients w ith  lim ited 
chronic plaque psoriasis w here conventional treatments have 
failed, PDT can be an alternative. Perhaps the addition o f top­
ical corticosteroids to PDT m ight enhance clinical efficacy fur­
ther and reduce the risk o f  Koebnerization. M ore studies are 
needed, better to understand PpIX form ation and its photo­
dynamic effects in  psoriasis so that an optim ized treatment 
protocol can be developed.
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Background Psoriasis has been show n to highly accumulate pro toporphyrin  IX 
(PpIX), but a variable distribution w ith in  plaques after fluorescence diagnosis is 
seen. It is unknow n w hat causes this heterogeneity o f  fluorescence in  psoriatic 
skin, despite adequate keratolytic treatm ent. Variations in  fluorescence might 
explain the variable and the m ostly partial clinical response o f  psoriasis seen after 
photodynam ic therapy (PDT).
Objectives This study examines m orphological and im m unohistochem ical differ­
ences in inhom ogeneous PpIX-induced fluorescence in  stable plaque psoriasis. 
Materials and methods Fourteen patients w ith  stable plaque psoriasis w ere included in 
this study. In each patien t one psoriatic plaque was incubated w ith  20% 5-am i- 
nolaevulinic acid (ALA) o in tm ent for 3 h  after keratolytic treatm ent. Fluorescence 
diagnosis w ith  ALA-induced porphyrins (FDAP) was perform ed and subsequently 
high- and low -fluorescent psoriatic skin samples w ere biopsied. Biopsies w ere 
investigated w ith  respect to histological hyperkeratosis (thickness o f  stratum  cor- 
neum ), proliferation (Ki-67 antigen), keratinization (K10, filaggrin) and inflam­
m ation (CD3). Digital images acquired w ith  FDAP w ere analysed using image 
analysis software.
Results Inhom ogeneous fluorescence was seen in 12 o f  the 14 plaques. A signifi­
cantly thicker stratum  corneum  was found in low -fluorescent psoriatic skin 
com pared w ith  highly fluorescent skin. Fluorescence intensity and thickness o f  
the stratum  corneum  proved to be negatively correlated. The variable-fluorescent 
parts o f  the lesional psoriatic skin show ed no differences in  epiderm al prolifer­
ation, keratinization o r inflamm ation.
Conclusions H eterogeneous ALA-induced fluorescence in psoriasis plaques related to 
inhom ogeneous distribution o f  PpIX in the epiderm is may result from  differences 
in penetration  o f  ALA a n d /o r  light w ith in  a plaque caused by differences in  stra­
tum  corneum  thickness. The variable clinical response seen after PDT in psoriasis 
could be explained by this. These findings are consistent w ith  the general 
assum ption that optim al desquam ation p rio r to FDAP or PDT is required for the 
m ost favourable results.
Over recent years, there has been increasing interest in photo­
dynamic therapy (PDT) w ith  topical 5-aminolaevulinic acid 
(ALA) in dermatological practice. Although m ore random ized, 
controlled studies are needed and long-term  follow-up data 
are lacking, PDT has proven to be clinically effective in  super­
ficial skin (pre)malignancies including actinic keratosis, Bowen 
disease and (superficial) basal cell carcinoma. In general, p ro ­
toporphyrin IX (PpIX)-accumulating skin disorders m ay be a 
potential target for PDT. Besides the m ain  oncological indica­
tions for PDT, other (nononcological) indications have also
been studied or are currently under evaluation. As PpIX has 
characteristic fluorescence properties, its preferential accumula­
tion in certain cell types can also be used as a cellular marker. 
In fluorescence diagnosis w ith  ALA-induced porphyrins 
(FDAP), lesional and nonlesional areas are irradiated w ith  blue 
light after incubation o f  the skin w ith  ALA. As PpIX shows red 
fluorescence w hen  excited by blue light, PpIX accumulating 
cells can be visualized.1 Psoriasis has been shown to accumu­
late PpIX selectively and its susceptibility to PDT has been pre­
viously studied by various authors.2 8 In these studies clinical
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efficacy varied widely but results are difficult to compare 
because o f  the different treatm ent parameters that have been 
used.
Heterogeneity o f  fluorescence on the skin as well as histo­
logically w ith in  psoriatic plaques during FDAP have been des­
cribed before by various authors.3,7 10 In a previous study we 
investigated the fluorescence in psoriatic lesions before and 
after fractionated PDT.11 After a 4-h  application o f  topical 
10% ALA, psoriatic plaques showed selectively higher fluores­
cence compared w ith nonlesional skin. However, fluorescence 
w ith in  m ost plaques was not hom ogeneous, despite clinically 
adequate keratolytic treatm ent 1 week prior to the baseline 
visit. The reason for the rem aining heterogeneity o f  fluores­
cence after clinically efficient desquam ation as observed in  our 
patients is unknown. Variable fluorescence seems to be related 
in part to the am ount o f  hyperkeratosis w ith in  a psoriatic 
plaque, as pretreatm ent w ith  a keratolytic agent improves fluor­
escence hom ogeneity .1,10 But an increased metabolic activity 
o f  hyperproliferative parts w ith in  a psoriatic plaque and sub­
sequently an increased synthesis o f  PpIX m ay also influ­
ence fluorescence intensity.3,9 These variations in fluorescence, 
indicating nonuniform  sensitization w ith porphyrins, m ight 
explain the variable and mostly partial clinical response seen 
after PDT o f psoriasis.
In the present study biopsies from  high- and low-fluores­
cent parts w ith in  a psoriatic plaque w ere analysed by 
(im m uno-)histochem istry w ith respect to morphological 
differences (stratum corneum  and epidermal thickness) and 
differences in psoriatic activity as reflected by epidermal 
proliferation and differentiation and inflamm ation markers 
betw een high- and low-fluorescent parts o f the psoriatic 
lesion.
Materials and methods
Patients
This study was approved by the local medical ethics com m it­
tee. Fourteen patients (age range 4 5 -7 0  years; 10 m en, 4 
w om en) w ith stable plaque psoriasis w ere included in this 
study after giving their w ritten  informed consent. All the stud­
ied lesions were located on  the low er extremities. Lesions 
w ere treated w ith  10% salicylic acid in petrolatum  for 1 week 
prior to the baseline visit to rem ove excess scales that could 
potentially interfere w ith  ALA uptake and light penetration. 
Patients w ere not allowed to use any systemic psoriatic treat­
m ents or topical m edication on  these lesions for at least
4 weeks. M edication know n to potentially aggravate psoriatic 
lesions, such as ß-blockers, was also not allowed.
Fluorescence diagnosis
After 3 h  o f  incubation w ith 20% ALA ointm ent fluorescence 
intensity on  the skin was recorded using a digital fluorescence 
imaging system (DyaDerm; Biocam GmbH, Regensburg, Ger­
m any). The DyaDerm digital imaging system consists o f  a
flash light [Xenon light source w ith  a custom  band pass filter 
(370-440  nm )] and a 12-bit Sony CCD camera com bined ii 
one adjustable arm coupled to a Pentium IV computer 
equipped w ith  custom -m ade image-capturing software (Dya- 
derm  Pro v1-4, Biocam GmbH). The flash light emits ligh 
pulses to the skin (rate 7 s)1 ), w hich are recorded by the 
CCD camera (exposure tim e 100 |i.s) equipped w ith  a specia 
Schott GG 455 long-pass filter to filter out the excitation light. 
As PpIX fluorescence emission consists o f light in the red 
spectrum, the red pixels o f  the CCD camera w ere used to gen­
erate a fluorescence image. In this way a normal-coloured 
image and a fluorescence image were processed in real time. 
Because o f  the short exposure tim e to the excitation light, 
photobleaching o f  PpIX was minimalized in  this way. To cor­
rect for different lighting environm ents betw een pictures, a 
fluorescence reference standard (Maccal 8044, 738-00, M ulti­
foil; Utrecht, the Netherlands) was included on  every image 
Images were recorded in 16-bit greyscale TIFF format.
Analysis of fluorescence images
TIFF fluorescence images (16-bit greyscale) were im ported in 
NIH ImageJ software [h t tp ://rsb .in fo .n ih .g o v /ij/  (accessed 23 
February 2006)]. Because the Xenon light source used for 
excitation has the highest intensity in the centre o f  the illu­
m inated area, shading correction was perform ed by means o f 
the following algorithm:
S =  — with C =  —^ ~
C B —m ax
where B =  blank image (image from  a w hite homogeneous 
background recorded w ith  the Dyaderm system), Bimax =  h igh­
est intensity o f  blank image, I =  (uncorrected) image, C =  n or­
malized shading image and S =  shading corrected image.
Biopsy procedure
After FDAP, 4-m m  punch biopsies from  a high-fluorescent 
part and from  a low-fluorescent part o f  the psoriatic lesions 
w ere taken under local anaesthesia w ith  1% xylocain-adren­
alin. In case o f hom ogeneous fluorescence tw o 4-m m  biopsie; 
o f  representative parts w ith in  the plaque w ere taken. Biopsies 
w ere em bedded in Tissue-Tek OCT com pound (Miles Scienti­
fic; Naperville, IL, U.S.A.) and directly frozen in liquid n itro­
gen. Until further processing, biopsies were stored at - 8 0  °C.
Immunohistochemistry
Frozen sections (7 lm )  w ere cut from  the skin samples for 
im m unohistochem ical assessment. These w ere air-dried for 
30 m in  and fixed in cold acetone for 10 m in. Sections were 
washed in phosphate buffered saline (PBS, B. Braun; Melsun­
gen, Germany) for 10 m in before 1-h incubation w ith p ri­
mary antibodies. The prim ary antibodies that w ere used, 
diluted in 1% bovine serum  album in, are depicted in Table 1.
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Table 1 Primary antibodies (mouse antihuman) used for immunohistochemistry
Antibody Marker for Clone Dilution Supplier
Ki-67 Epidermal proliferation MIB-1 1 : 200 DAKOa
Keratin 10 Epidermal differentiation RKSE60 1 :1 0 0 Monosanb
Filaggrin Epidermal differentiation BT576 1 : 6000 Biomedical Technologies Inc.c
CD3 T cells UCTH1 1 :1 0 0 DAKO
aCopenhagen, Denmark; bUden, the Netherlands; cStoughton, MA, U.S.A.
Sections w ere washed in PBS for 15 m in. Secondary IgG- 
labelled polym er, horseradish peroxidase antim ouse EnVision+ 
(DAKO, Copenhagen, Denmark) was added for 30 m in. The 
sections w ere washed again for 15 m in  in PBS. To visualize 
the staining, AEC (3-am ino-9-ethylcarbazol) plus high-sensi- 
tivity substrate chrom ogen for 10 m in  (DAKO) was used. 
Counterstaining was perform ed w ith  Mayer's haematoxylin 
(Sigma; St Louis, MO, U.S.A.). The sections w ere washed in 
tap water, dried and m ounted in glycerol gelatin (Sigma).
Furtherm ore, haematoxylin and eosin staining was per­
form ed on every biopsy specimen. After dehydration in alco­
hol and Histosafe (Adamas Instruments bv; Leersum, the 
Netherlands), these sections were m ounted in Permount 
(Fisher Scientific; Fair Lawn, NJ, U.S.A.). W ith these haema­
toxylin and eosin sections, w e verified that the biopsies under 
study fulfilled the psoriasis-specific histological criteria.
Morphological and immunohistochemical analysis
Analysis o f  digital m icroscopic images was done using Axio- 
Vision Release 4*2 (Carl Zeiss GmbH, Gottingen, Germany). 
Digital photographs o f  the haematoxylin and eosin sections 
w ere m ade at 50 X magnification to examine the m orpholo­
gical characteristics, the thickness o f  the stratum  corneum  
and epidermis. To determine the thickness o f  the stratum 
corneum  the average thickness was calculated as total stra­
tum  corneum  surface including hyperkeratosis per m illi­
m eter length o f stratum  corneum  in different biopsy 
sections. The same procedure was used to assess the epider­
m al thickness.
In order to analyse Ki-67+ cells, digital photographs were 
m ade at 100 X magnification covering the entire epidermis. A 
line following the basement m em brane was draw n and its 
length was measured. All positive cells above this line were 
counted and divided by the length o f  the basement m em brane 
so the num ber o f  positive cells per m illimeter length o f  base­
m ent m em brane could be calculated. For quantification of 
keratin 10 (K10)-positive cells digital photographs were made 
at 50 X magnification. The surface o f K10+ (epidermal) cells 
was measured and divided by the total epidermal surface. 
Thus epidermal differentiation was defined as percentage 
K10+ epidermal surface. Filaggrin expression was assessed by 
m easuring the percentage o f  the length o f  the stratum  cor- 
neum  and stratum  granulosum  that was stained.
CD3+ (T) cells w ere analysed by counting all positive cells 
in  the epidermis and dermis separately. These num bers were 
divided by the length o f  the stratum  corneum . In this way T 
cells w ere expressed as the num ber o f  positive cells per m illi­
m eter (epi)dermis.
Statistics
To compare m ean fluorescence intensity, stratum  corneum  
and epidermal thickness and expression o f  Ki-67, K10, filag- 
grin  and CD3 betw een the tw o regions o f  the lesions a tw o­
tailed Student's t-test was used. P <  0*05 was regarded as 
statistically significant. Microsoft Excel 2000 and Statistica 6*0 
software [Statsoft Inc., h ttp ://w w w .statso ft.com  (accessed 23 
February 2006)] were used for statistical calculations.
Additionally, correlation analysis was perform ed to assess 
the strength o f  the relationship betw een fluorescence intensity 
and m orphological or im m unohistochem ical characteristics. 
The degree o f association was m easured by Pearson's correla­
tion  coefficient (r).
Results
Fluorescence intensity
In accordance w ith our previous results, psoriatic skin showed 
selectively higher fluorescence compared w ith  surrounding 
nonlesional skin after 3-h  incubation w ith  ALA. Despite clinic­
ally adequate keratolytic treatm ent fluorescence was not 
hom ogeneous w ith in  m ost plaques (12 o f 14; 86%, Fig. 1). 
The distribution o f  fluorescence w ith in  the plaque could not 
be predicted by the clinical appearance o f the lesions and was 
seen predom inantly in  a follicular pattern. The intensity of 
high-fluorescence lesional skin was 1 *76 times higher than 
low-fluorescence skin w ith in  plaques (Fig. 2a). Remarkably, 
hom ogeneous fluorescence was seen in two patients (2 o f  14; 
14%).
Thickness of stratum corneum and epidermis
In both high- and low-fluorescent lesional skin hyperkerato­
sis and epidermal hyperplasia w ere seen histologically 
(Fig. 3). The stratum  corneum  proved to be significantly 
thicker in low-fluorescent psoriatic skin (1*64 times thicker,
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Fig 1. Clinical and fluorescence images from one patient after 5-aminolaevulinic acid application. (a) Clinical image with marked low-fluorescent 
lesional skin (1) and high-fluorescent lesional skin (2). (b) Fluorescence image of the same plaque in which heterogeneous fluorescence is seen. 
(c) Pseudo-colour image of (b).
Fig 2. Morphological and immunohistochemical differences in 
psoriatic plaques with heterogeneous fluorescence after 5- 
aminolaevulinic acid application. (a) Normalised fluorescence. The 
intensity of high-fluorescent (HF) skin was significantly higher than in 
low-fluorescent (LF) skin; *P < 0-001. (b) The stratum corneum was 
statistically significantly thicker in low-fluorescent skin compared with 
high-fluorescent skin; *P < 0-05. Error bars denote SEM.
P <  0-05) compared w ith  high-fluorescent skin (Fig. 2b). The 
epidermis was equally broadened throughout the heterogene- 
ic-fluorescent plaque (Table 2).
Immunohistochemistry
Epidermal proliferation Epidermal proliferation was increased in 
both high- and low-fluorescent parts of psoriatic skin as 
show n by an increased num ber o f  epidermal Ki-67+ cells. 
The num ber o f  Ki-67+ cells was not significantly different in 
high- or low-fluorescent lesional skin (HF =  86 positive cells 
per m m  basement m em brane, LF =  69 positive cells per m m  
basement m em brane, P =  0-38) (Table 2, Fig. 3).
Epidermal differentiation The epidermal K10 expression was used 
to assess the extent o f keratinization and appeared to be 
equally decreased throughout the plaque (HF =  58%, LF =  
55%, P =  0-51) (Table 2, Fig. 3). The aggregation o f  kera- 
tinocytes in the psoriatic plaque was reduced as show n by the 
decreased expression o f  filaggrin. In  high- and low-fluorescent 
lesional skin no  statistically significant differences were 
observed (HF =  83%, LF =  79%, P =  0-48) (Table 2, Fig. 3).
T-cell infiltration CD3+ cells w ere seen mainly in the papillary 
dermis and to a lesser extent in the epidermis. In  the high- 
fluorescent affected skin epidermal CD3+ cells were not signi­
ficantly different compared w ith low-fluorescent lesional skin
Fig 3. Morphological and immunohistochemical images of both low- and high-fluorescent psoriatic skin. Haematoxylin and eosin, Ki-67, keratin
10 (K10) and filaggrin stainings of heterogeneous fluorescent lesional skin are displayed at 100 X magnification. CD3 is displayed at 50 X 
magnification. Haematoxylin and eosin sections showed a significantly thicker stratum corneum in low-fluorescent psoriatic skin. 
Immunohistochemically no differences in epidermal proliferation, differentiation and inflammation were found between high- and low-fluorescent 
skin.
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Table 2 Histological results from high- and 
low-fluorescent psoriatic skin (HF and LF) HF lesional 
skin ± SEM
LF lesional 
skin ± SEM P-value
Fluorescence intensity (a.u.) 1-00 ± 0-06 0-57 ± 0-06 <  0-001
Stratum corneum thickness (mm) 0-054 ± 0-009 0-084 ± 0-017 0-036
Epidermal thickness (mm) 0-262 ± 0-090 0-275 ± 0-036 0-688
Ki-67+ nuclei 85-7 ± 18-6 68-9 ± 10-2 0-382
K10 expression (%) 58-2 ± 2-99 55-4 ± 5-15 0-628
Filaggrin (%) 82-6 ± 4-57 78-7 ± 6-41 0-475
Epidermal CD3+ cells 40-2 ± 5-54 42-4 ± 8-94 0-819
Dermal CD3+ cells 296-7 ± 64-8 273-4 ± 44-4 0-686
Values are denoted ± SEM. a.u., arbitrary units
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Fig 4. Correlation between fluorescence intensity and stratum 
corneum thickness, r =  -0-41. Dotted lines indicate 95% confidence 
intervals.
(HF =  40-2 positive cells per m m , LF =  42-4 positive cells 
p er m m , P =  0-82). The num ber o f  dermal CD3+ cells also 
showed no  significant changes betw een both  fluorescent 
groups (HF =  296-7 positive cells per m m , LF =  273-4 posi­
tive cells per m m , P =  0-69) (Table 2, Fig. 3).
Correlation between fluorescence intensity and stratum 
corneum thickness
All corrected fluorescence data (including hom ogeneous-fluor­
escent lesional skin) from  the Dyaderm system w ere com ­
pared w ith  their accompanying stratum corneum  thickness 
values. Correlation analysis revealed a negative correlation 
coefficient o f  r =  -0-41  (Fig. 4). Thus the relation between 
fluorescence intensity and thickness o f  the stratum corneum  
appeared to be weakly correlated.
Discussion
In  the present study application o f 20% ALA ointm ent for 3 h 
under an occlusive dressing induced heterogeneous fluores­
cence w ith in  m ost psoriatic plaques. Fluorescence was meas­
ured after 3 h  o f  ALA application. This tim e point has an 
optimal ratio betw een lesional and normal skin. For higher 
fluorescence values a longer incubation period o f  6 h  in  psori­
asis is needed, but contrast is reduced as surrounding non- 
lesional skin fluorescence is also increasing.9 Each plaque had 
an equal clinical appearance after efficient desquam ation and 
fluorescence distribution was not predictable. Smits et ol.11 
demonstrated macroscopic fluorescence and PpIX content to 
be well correlated. Hence differences in fluorescence intensity 
may therefore be comparable to variations in PpIX accumula­
tion.
This inhom ogeneous fluorescence in FDAP on psoriatic skin 
has been described by several authors, but a reason for the 
variable fluorescence has thus far not been established.3,4,7,8,10 
Differences in the presence o f  hyperkeratosis in  lesional skin 
acting as a mechanical barrier against penetration o f ALA a n d /  
or light m ay be one explanation, but variations in  metabolic 
activity w ith in  psoriatic cells inducing variable synthesis of 
ALA-induced porphyrins could be another.3,7,9
Psoriasis is histologically characterized by epidermal hyper­
proliferation, abnormal keratinization and dermal infiltration 
o f  mainly T cells. Keratinocytes proliferate and m ature rapidly 
so that terminal differentiation, normally occurring in granular 
keratinocytes and then squamous corneocytes, is abnormal. In 
both high- and low-fluorescent lesional skin an equal 
am ount o f  epidermal hyperproliferation was seen as reflected 
by an increase in  Ki-67 expression. No statistically significant 
differences w ere found betw een both groups. Ki-67 is a cell- 
cycle-associated antigen expressed in all parts o f the cell cycle 
except G0 and G 1, representing the epidermal proliferative 
com partm ent.12 Despite fluorescence intensity, an equal dis­
turbance o f keratinization was also observed as a decrease in 
K10 expression, w hich is a m arker for terminal differentiation 
and is generally decreased in psoriasis.13 Another structural 
marker for differentiation is filaggrin. Filaggrin is involved in 
the form ation o f  keratohyalin granules. In normal skin filag- 
grin is present in the stratum corneum  and the stratum gra- 
nulosum  and supports cutaneous hydration. In general, active 
psoriasis is know n for its absent or discontinuous filaggrin 
expression.14,15 In the studied biopsies aggregation of
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keratinocytes was decreased as reflected by a reduced filaggrin 
expression throughout the plaque. The observed reduction in 
filaggrin expression was less decreased than expected in  active 
psoriasis.16 Chronic stable plaque psoriasis as selected for this 
study is a probable explanation for this m inim al reduction in 
filaggrin expression. Analysis o f CD3+ cells showed an 
increase o f  T cells in both epidermis and dermis. Comparing 
high- and low-fluorescent lesional skin significant dissimilari­
ties in T cell counts could not be demonstrated. The CD3 anti­
gen is normally expressed on  the cell surface o f the m ature 
thymocytes and resting or activated peripheral blood lym pho- 
cytes.17 Therefore, according to these study results, differences 
in psoriatic activity— as a possible explanation for the variable 
m etabolic conversion o f  ALA to PpIX reflected by heterogene­
ous fluorescence as seen in fluorescence diagnosis— could not 
be demonstrated, assuming penetration o f  ALA a n d /o r light to 
be a constant factor. To ascertain this conclusion, m ore studies 
are needed to examine the exact PpIX m etabolism  by m easur­
ing the effects o f  enzyme activity involved in the haem syn­
thesis in relation to unpredictable fluorescence intensity in 
FDAP.
Thickness o f  the stratum  corneum  and epidermis were 
investigated to examine to w hat extent the mechanical barrier 
function o f  the stratum  corneum  and the num ber o f m etaboli- 
cally active cells could be responsible for differences in  fluor­
escence intensity w ith in  psoriatic plaques. Epidermal thickness 
is a param eter for clinical induration and the num ber o f  m eta- 
bolically active cells.11 No significant differences in epidermal 
thickness w ere found betw een high- and low-fluorescent 
lesional skin. The stratum  corneum  proved to be significantly 
thicker in low-fluorescent lesional skin suggesting a 
decreased penetration o f  ALA a n d /o r  light compared w ith 
high-fluorescent lesions, w hich w ere found to have a signifi­
cantly thinner stratum  corneum . No differences w ere seen in 
the presence o f  parakeratosis. Parakeratosis is also a histologi­
cal characteristic o f  psoriasis and results from  incom plete 
keratinization resulting in the retention o f  nuclei in the stra­
tum  corneum .18 Hom ogeneous fluorescence w ith  a high 
intensity was observed in two plaques. Biopsies obtained from  
these hom ogeneous high-fluorescent lesions verified an 
equally thickened stratum  corneum  comparable to the high- 
fluorescent samples from  heterogeneously fluorescent lesional 
skin samples. Also, correlation analysis showed a weak negat­
ive correlation betw een the fluorescence intensity o f  the psori­
atic skin and thickness o f  the stratum  corneum.
The stratum  corneum  is the principle barrier to percutane­
ous penetration o f  exogenous substances. Psoriasis is know n 
for its functional and structural defects o f  the stratum  corneum  
resulting in an abnormal permeability barrier. Transepidermal 
water loss levels are increased in  desquamating dermatoses 
such as psoriasis as aggregation betw een keratinocytes is 
decreased.19,20 These study results suggest that not only a 
decreased aggregation o f  keratinocytes in stable plaque psori­
asis, established by a reduction o f filaggrin expression in the 
samples o f  both low - and high-fluorescence lesional skin, but 
in particular the mechanical barrier form ed by the stratum
corneum  is responsible for diffusion rate o f ALA a n d /o r  pen­
etration o f  light.
In  an earlier study by our group heterogeneous fluorescence 
intensity in the psoriatic skin w ith  a variable clinical response on 
PDT was dem onstrated.8 M ore studies are needed to investigate 
w hether heterogeneous fluorescence in  FDAP is related to inho- 
m ogeneous clinical im provement o f  plaque psoriasis after PDT.
In conclusion, the psoriatic activity w ith in  one plaque was 
hom ogeneous, not explaining the heterogeneity o f fluores­
cence intensity seen w ith in  plaque psoriasis. Thus, it appears 
plausible that it is no t the m etabolic activity o f psoriasis but 
mainly the mechanical barrier form ed by the stratum corneum  
that is responsible for differences in fluorescence intensity 
because o f  variable penetration o f  ALA a n d /o r light. Pretreat­
m ent aimed at the removal o f hyperkeratosis seems to be o f 
the utmost importance and is therefore strongly recom mended 
for the most favourable results in FDAP and PDT.
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The effects of keratolytic pretreatment prior to fluorescence diagnosis 
and photodynamic therapy with aminolevulinic acid-induced 
porphyrins in psoriasis
MARLOES M. KLEINPENNING, JOSINE H. KANIS, TIM SMITS, PIET E. J. VAN ERP, 
PETER VAN DE KERKHOF & RIANNE M. J. P. GERRITSEN
Department o f  Dermatology, Radboud University Nijmegen M edical Centre, Nijmegen, The Netherlands
A b strac t
Background: Psoriasis lesions accumulate protoporphyrin IX (PpIX) with a variable distribution within plaques due to 
variations in hyperkeratosis causing differences in penetration of cream or light. Objectives: To study the effects o f different 
kerstolytic pretreatments in PpIX-induced fluorescence diagnosis (FDAP) and during photodynamic therapy (PDT). 
Methods: Two psoriasis plaques of 10 patients were treated with either topical retinoic acid or with a hydrocolloid dressing. 
Tlie hydrocolloid dressing gave tlie best results. Subsequently, two different contralateral plaques of eight patients were 
pretreated with e hydrocolloid dressing or the ytandard pretreatm ent, salicylic acid in petroletum, during the 6 weeks of 
PDT. Biopsies weee invesrigaied with respect to steatum corneum thickness, proliferation, differentiation and inflammaticn. 
Results: Ieritetiyn and point bleedings were noticed after eetinoic acid. A hydtycollold dressing induced the best cliwical 
improvement. Therefore, it was used ai alternative preteeatmens for csoriasts prior to PDT. We oUserved significant clinical 
and immunohistochemical improvement oC psoetasts in the salicylic a d d  as well as the hydrocolloid dreesing pretreated 
plaques. Conclusions: Salicylic acid in petrolatum and a hydrocolloid dtessing frio r to FDAP and P D T  induce improvement o t 
hyperkeratosis. Thus, a hydoocolloiC dressinr is a good alturnative to the current keratolytic pretreatm ent regime.
K ey  w o rd s: /Aminolevutinic acid, fliumscrnsr dirgnosis, ketdtoiysis, phorodynamir therapy, psoriasis, seratum roeneum
In  to ad  n o tio n
Exogenous rs s lic r tiy n  e f  5-aminolevulinic acid 
(ALA) leads to accum ulatien e f seotosoeshyein IX 
tPsIX ), an e ndo renous shotosensitizee, seefeeentially 
in lesional skin. E n d u s e  P sIX  has characterisnc 
fluorescence seoseeties, its senfeeential accum ula­
tion in ceetain cell tyses cant be used as a cellulae 
maekee. In  fluoecscence diagnosis w ith ALA-inCuceC 
soeshyeins (FD A P), letlondl and non-lesional skin 
aee ieeaeiateg with b ,ue light aftar incubation witn 
d-ALA. P s IX  accvm vletirtr cells (tan be visualized, 
as P sIX  shBws red  fluoeescence w hen excited by blue 
light ( i) .  In  reneeal, all P s IX  accum ulating skin 
gisoegees may be a so ten tia l taere t foe fluoeescence 
diagnosis. Besides the: m ain oncological indications,
othee non-oncoiorical ineications have ak o  been 
s tu e ie e  oe aee cueeently  u n eee  evaluariort (2). 
Psoeiasis lesions accu m u la te  Ps>IX setecti^teiJ^ 
a f tn  a s s lic a tio n  o f Ö-Al a  and  its su scestib ility  
ao s h o to ey n a m ie  teea ty ten t has been  seeviouely 
s tu e ie e  by vaeious ^sutirdes (3 -9 ). R’Siis c linical 
f e c e s  o f sh o to g y n am ic  thiseapjr (P D 'S) in ssoe i- 
asis vaeieci laere ly  in  these  stuciies. Howevee, 
eesults aee d ifficu lt to  com saee  because  o f the 
giffeeent teeatment se(iceeu(es that have been used.
A seeviour study fiem ohsteatee clinical and histo- 
rceg^cal imse(lvement of ssoeiasis aftee six well tolee- 
ated P D R  sessions wriüi a weekly inteeval (9). Aftee 
tosical asslication o f 5-ALA on ssoriatic skin, fluo­
eescence eisteibution and intensity v u ied  consieee- 
ably am on° eiffeeen6 ]plaques in nhe saytle sa tien t as
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am ong different patients. This heterogeneous fluo­
rescence on psoriatic skin am ong plaques has been 
described by various authors (5 ,6,8-12). This inho- 
m ogenous fluorescence pattern, indicating a no n ­
uniform  distribution o f porphyrins, may explain the 
variable and mostly partial clinical response seen after 
P D T  in psoriasis. D istribution of PpIX  is determ ined 
by diffusion o f 5-ALA through a plaque and the rate 
o f synthesis o f PpIX  within the plaque. In  another 
previous study, differences in the presence o f hyper­
keratosis and variations in m etabolic activity as pos­
sible explanations for heterogeneous fluorescence in 
psoriasis were therefore exam ined (12). According 
to these study results, inhom ogenous distribution of 
PpIX  may result from differences in the am ount of 
hyperkeratosis. Variations in stratum  corneum  thick­
ness may lead to a variable penetration o f ALA and/or 
light. These variations in the mechanical barrier of 
the skin might explain the variable and mostly partial 
clinical responses seen after P D T  in psoriasis.
In  the present study, different keratolytic pretreat­
m ents supplem entary to the standard keratolytic pre­
treatm ent prior to FD A P and P D T  were clinically 
and immunohistochemically analyzed. T he effects 
o f topical retinoic acid and hydrocolloid occlusive 
dressing were evaluated with respect to fluorescence 
pattern  and intensity, proliferation (Ki-67 antigen), 
differentiation (keratin 10 (K10) and filaggrin) and 
inflammation (CD 3). This pilot study resulted in an 
additive study on hydrocolloid dressing as an adden­
dum  to salicylic acid in petrolatum  prior to PD T . 
Subsequently, the clinical and imm unohistochem ical 
effects o f these two different keratolytic pretreatm ent 
regimes, 10% salicylic acid in petrolatum  and a hydro­
colloid occlusive dressing, on P D T  in psoriasis were 
evaluated in the same m anner as described above.
Materials and methods
Patients
Both studies were approved by the local medical ethics 
committee. Patients were not allowed to use any sys­
temic psoriatic treatm ents for at least 6 m onths and no 
topical m edication on the studied lesions for at least 
2 weeks. M edication known to potentially aggravate 
psoriasis, such as ß-blockers, was also no t allowed.
After giving their written informed consent, 
10 patients with stable p laque psoriasis were included 
in the pilot study on keratolytic pretreatm ent prior 
to FD A P (age: 45-70 years; eight m en, two women). 
T he  studied lesions were located on the extremities 
(eight) or on the thorax (two). At baseline, two con­
tralateral and clinically identical psoriatic plaques
were selected. D uring  the first week, both  plaques 
were treated once daily with 10% salicylic acid in 
petrolatum . Subsequently, one plaque was treated 
with topical retinoic acid (tretinoin 0.05%  in a cream 
base) once daily and a hydrocolloid occlusive dressing 
(D uoderm ; C onvaTec, W oerden, T he N etherlands) 
was applied for the same period o f 1 week on the other 
lesion. FD A P was perform ed on bo th  treated plaques 
at baseline and after 2 weeks o f keratolytic treatm ent.
For the next study, the effects o f keratolytic pre­
treatm ent on P D T , seven patients with stable plaque 
psoriasis (age: 54-75 years; five m en, two women) 
were included after giving their w ritten informed 
consent. At baseline, two clinically identical pso­
riatic plaques were selected in each patient, which 
were all located on the extremities. O ne plaque was 
treated with 10% salicylic acid in petrolatum  once 
daily for 1 week and a hydrocolloid occlusive dress­
ing was applied for 1 week on the other lesion. After
1 week o f keratolytic pretreatm ent, P D T  was per­
formed on these plaques once weekly for 6 consecu­
tive weeks. Between two P D T  sessions, keratolytic 
pretreatm ent with bo th  10% salicylic acid in pet­
rolatum  and a hydrocolloid occlusive dressing was 
continued. T o  evaluate the effects o f keratolytic pre­
treatm ent alone on psoriatic plaques, per patient two 
clinically identical plaques were selected and treated 
like the above-m entioned plaques, bu t no t illumi­
nated. These control plaques were located on the 
extremities (six) and thorax (one).
Fluorescence diagnosis and analysis o f fluorescence 
images
Fluorescence diagnosis and analysis o f fluorescence 
images were done as previously described (12).
Photodynamic therapy
T o  enhance ALA penetration, 10% ALA ointm ent 
(M edac G m bH , W edel, Germ any) was applied under 
an occlusive dressing (Tegaderm ; 3M  Pharm aceuti­
cals, Zoeterwoude, T he  N etherlands). T he  occlusive 
dressing was covered by alum inium  foil to avoid 
prem ature photobleaching effects. After 6 hours the 
ointm ent and foils were removed and the skin sur­
face was cleaned using 80% denaturated alcohol v/v. 
Thereafter, a light fraction o f 10 J/cm2 was delivered 
to both lesions (W aldm ann P D T  1200 L; W aldm ann 
M edische Techniek BV, Tiel, T he  N etherlands), 
600-750 nm , 40 m W /cm 2). After each illum ina­
tion , except after the last one, one plaque again 
was covered with a hydrocolloid occlusive dressing.
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W ithin a few days keratolytic pretreatm ent with sal­
icylic acid in petrolatum  was continued on the other 
plaque, if burning sensations subsided and if scaling 
was apparent.
Sum  score
T o  evaluate the clinical response, the sum  score, a 
widely used m ethod to measure plaque severity, was 
assessed in bo th  studies for all lesions at each visit, 
including the final control visit 1 week after the last 
P D T  treatm ent. In  this score, erythema, induration 
and desquam ation are each scored on a five-point 
scale as: 0, absent; 1, m inim al (very light pink, hardly 
any elevation, rare scale); 2, m ild (light red/pink, 
slight elevation, poorly defined scale); 3, m oderate 
(red, m oderate elevation, defined scales); or 4, severe 
(very red, m arked ridge, heavy scaling). Finally, a 
global sum score (range 0-12) was defined as the sum 
o f all three scores together, reflecting plaque severity.
Biopsy procedure
In  the pilot study at baseline and after 2 weeks of 
supplem entary keratolytic treatm ent, FD A P was 
perform ed and 4-m m  punch biopsies from a high 
fluorescent part and from a low fluorescent part of 
both treated psoriatic lesions were taken under local 
anaesthesia with 1% xylocaine-adrenaline. In  case 
o f hom ogenous fluorescence, one 4-m m  biopsy o f a 
representing part within the plaque was taken.
After 1 week o f keratolytic p retreatm ent with a 
hydrocolloid dressing and  salicylic acid in petro la­
tum , 4-m m  punch  biopsies were taken o f bo th  p la­
ques, which would be treated  w ith P D T . O ne week 
after the last P D T  treatm ent, biopsies were taken 
once more.
All biopsies were em bedded in Tissue-Tek com ­
pound  (Miles Scientific, Naperville, IL , USA) and 
directly frozen into liquid nitrogen. Until further 
processing, biopsies were stored at -80°C .
Immunohistochemistry
Im m unohistochem istry and morphological analysis 
were done as previously described (12).
Statistics
T o  com pare mean sum  score, fluorescence intensity, 
stratum  corneum  and epiderm al thickness and 
expression o f Ki-67, K10, filaggrin and CD3 between
the two regions o f the lesions, a two-tailed Student’s 
t-test was used. A one-way analysis o f variance 
(ANOVA) for repeated m easures was used to analyze 
the difference betw een tim e points w ithin the m ean 
sum  score. W hen significant changes were found, 
a N ewm an-Keuls post hoc test was perform ed for 
analysis betw een tim e points. A p-value < 0.05 
was regarded as statistically significant. M icrosoft 
Excel 2002 and  G raph  Pad Prism  4.0 (G raphPad 
Software, www .graphpad.com ) were used for statis­
tical calculations.
Results
Clinical efficacy
In  the pilot study, pretreatm ent with a hydrocolloid 
dressing and topical tretinoin resulted in a statistically 
significant decrease in the clinical severity score in 
bo th  groups (respectively, p  = 0.001 vs p  = 0.02) 
(Figure 1). In  contrast with topical tretinoin (5/10), 
almost all patients treated with a hydrocolloid dress­
ing showed clinical im provem ent of the treated pso­
riatic plaque (8/10). After 2 weeks, plaques treated 
with a hydrocolloid dressing dem onstrated mainly a 
significant reduction in desquam ation (p < 0.01), but 
also erythema (p < 0.05) and induration (p < 0.05) 
reduced. Topical tretinoin resulted in a significantly 
decreased sum  score after 2 weeks (p < 0.05), bu t 
taking erythem a, induration  and  desquam ation 
separately no  significant changes were seen. After
2 weeks, the sum  score o f psoriasis plaques treated 
with a hydrocolloid dressing was significantly lower
■  Topical retinoic acid □ Hydrocolloid dressing
Baseline After 2 weeks
Figure 1. SUM  score of the pilot study. The clinical SUM scores at 
baseline and after 2 weeks of keratolytic treatment. The clinical 
efficacy improved statistically significantly after application of both 
topical retinoic acid (*p < 0.05) and a hydrocolloid dressing 
(**p < 0.01).
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Baseline Visit 1 Visit 2 Visit 3 Visit 4 Visit 5 Visit 6 Final visit
Figure2. SUM  score during PDT. The clinical SUM scores before, during and after PDT. The clinical efficacy improved statistically 
significantly despite an increase in erythema, induration and desquamation at the last visit after the last PD T session and cessation of the 
keratolytic treatments.
*p < 0.001.
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com pared with the sum  score o f tretinoin-treated  
lesions (p = 0.05). Side effects were pain and point 
bleedings after pretreatm ent w ith topical tretinoin 
and offensive odour w ithout the signs o f infection 
and skin erosions after rem oving the occlusive hydro­
colloid dressing.
Before starting P D T , bu t after 1  week o f kerato- 
lytic pretreatm ent, plaques treated with a hydrocol­
loid dressing showed 24%  clinical improvem ent, 
while plaques treated with salicylic acid in petrolatum  
dem onstrated a reduction o f 11% of the baseline sum 
score. All plaques pretreated with salicylic acid in 
petrolatum  or a hydrocolloid dressing, bu t also the 
control lesions, showed a decrease in the clinical 
severity score. Subsequent P D T  resulted in a final 
reduction o f the sum  score by 37% in the hydrocol­
loid group (p < 0.001) and 43% in the salicylic acid 
in petrolatum  group (p < 0.001) (Figure 2). So, in 
the hydrocolloid group and in the salicylic acid in 
petrolatum  group, a 13% and 32% reduction, respec­
tively, was due to consecutive P D T ; however, w ithout 
a statistically significant difference between both 
groups. T he control groups showed a final reduction 
o f the sum  score o f 47% in the hydrocolloid-treated 
plaques (p < 0.001) versus 25% in the salicylic acid in 
petrolatum -treated plaques (p < 0.05). D uring PD T , 
all psoriasis severity parameters (erythema, indura­
tion, scaling) showed a reduction in intensity. At the 
final visit, 1 week after the last P D T  treatm ent, in all 
groups a deterioration o f the sum  score was observed 
(Table I). Only the hydrocolloid group followed 
by P D T  showed a statistically significant increase 
between the last P D T  treatm ent and the final visit, 
which was due to an increase in scaling (p < 0.001) 
and induration (p < 0.01).
Table I. Clinical improvement during and after PDT.
Clinical improvement (%)
Weeks 0-1 Weeks 0-6 Weeks 0-7
Hydrocolloid and PD T 24.3 74.6 37.0
Salicylic acid and PDT 11.4 63.1 43.4
Control hydrocolloid 10.8 65.9 47.0
Control salicylic acid 9.8 38.5 24.9
Although all patients experienced some burning 
and stinging during irradiation, irradiation of ALA- 
treated psoriasis plaques after pretreatm ent with sal­
icylic acid or hydrocolloid dressing was well tolerated 
by all included psoriasis patients. T he  severity o f dis­
com fort was assessed at every visit (range 0-10 ; 0, no 
discom fort and 10, very severe discomfort). T he  value 
o f discom fort did no t differ between two treatm ent 
regimens, with a m ean value of 6.5 in bo th  studied 
groups. O ne patient discontinued treatm ent after 
three illuminations because o f marked pain in the 
days after P D T  treatm ent.
Fluorescence intensity on the skin
After 2 weeks of keratolytic pretreatm ent and 3 hours’ 
incubation with ALA, psoriatic plaques showed 
selectively, not statistically significant, higher fluores­
cence com pared with the surrounding (non-lesional) 
skin. However, fluorescence within most plaques was 
no t hom ogenous, except in four psoriasis plaques. 
T hree psoriasis plaques treated with topical tretinoin 
showed hom ogenous high fluorescence and one
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plaque treated with a hydrocolloid dressing dem on­
strated a hom ogenous low fluorescent pattern.
Thickness o f stratum corneum and epidermis
After using the hydrocolloid dressing as well as topical 
tretinoin, a thicker stratum  corneum  (p £ 0.05) was 
noticed in low fluorescent psoriatic skin, confirming 
the results of our previous study. T h e  differences 
between these pretreatm ent options were not statis­
tically significantly different for both  low and high 
fluorescent skin. N o  decrease in stratum  corneum  
thickness was noticed after using a hydrocolloid 
dressing or topical retinoic acid as an addendum  for 
salicylic acid in petrolatum . Also in accordance to our 
previous results, there were no  statistically significant 
differences in epiderm al thickness between high 
and low fluorescent skin between both studied pre­
treatm ents, except that the epidermis was thinner in 
low fluorescent skin of hydrocolloid-applied lesional 
skin (p = 0.01) com pared with tretinoin-treated pso­
riatic skin.
U sing the hydrocolloid dressing and salicylic acid 
as a keratolytic agent during P D T , stratum  corneum  
thickness increased, bu t no t statistically significantly. 
Epiderm al thickness decreased significantly in the 
hydrocolloid with PD T -treated  plaques (p < 0.05), 
bu t no  significant epiderm al changes were seen after 
salicylic acid in petrolatum  in com bination with PD T .
Immunohistochemistry
Epidermal proliferation. Ki67 is a nuclear antigen 
present in proliferating cells, bu t absent in resting 
cells, representing the extent of epidermal prolifera­
tion. Epiderm al proliferation was decreased in pla­
ques treated with bo th  hydrocolloid and tretinoin 
(p < 0.05), w ithout statistically significant differences 
between both studied groups. An additional signifi­
cant decrease in Ki67 was seen after P D T  (p < 0.01) 
with no  significant changes between pretreatm ent 
with salicylic acid in petrolatum  and a hydrocolloid 
dressing.
Epidermal differentiation. K10 is a m arker for ter­
m inal epidermal cell differentiation. T he  epidermal 
K10 expression was used to assess the extent of 
keratinization and appeared to be slightly increased, 
bu t n o t statistically significant, throughout the plaque 
in both keratolytic pretreatm ents. Also, no  significant 
changes were dem onstrated after treatm ent with P D T  
in K10 expression.
Filaggrin is a protein produced by differentiating 
cells, subserving m ajor functions in m aturing the 
epidermis, such as keratin filaments and m aintaining 
a norm al hydrating state o f the stratum  corneum. 
D espite the chosen pretreatm ent, the overall filaggrin 
expression showed a discontinuous pattern  in stratum  
corneum  and stratum  granulosum , as expected in 
psoriasis. However, a strong reduction in filaggrin 
expression in low fluorescent lesional skin after tre­
tinoin application was seen (p < 0.01). After P D T  the 
aggregation of keratinocytes in psoriasis was improved 
in bo th  stratum  corneum  and stratum  granulosum, 
as seen by a com parable increase in filaggrin expres­
sion after occlusion with a hydrocolloid dressing 
(p < 0.01) and after using salicylic acid in petrolatum  
(p < 0.05 vs p  < 0.01).
T-cell infiltration. CD3 is an antigen normally 
expressed on the cell surface o f m ature T  cells, 
dem onstrating the extent o f epiderm al and dermal 
inflammation. CD3 positive cells were mainly seen 
in the papillary dermis and to a lesser extent in the 
epidermis. After using a hydrocolloid dressing and 
topical tretinoin, CD3 expression increased in the 
epidermis (p < 0.05), while the am ount o f C D3 pos­
itive cells in the dermis showed no significant changes. 
A statistically significant decrease in CD3 positive 
cells was seen after P D T  in bo th  dermis and epider­
mis, despite keratolytic pretreatm ent (p < 0.05) and 
once m ore w ithout significant differences between 
bo th  studied groups.
Discussion and conclusions
A variable distribution o f PpIX  within psoriasis pla­
ques after fluorescence diagnosis is seen. Variations in 
fluorescence m ight explain the variable and mostly 
partial clinical response seen in psoriasis after PD T . 
This heterogeneity o f fluorescence may result from 
differences in penetration of ALA ointm ent and/or 
light caused by variations in stratum  corneum  thick­
ness (12). Pretreatm ent aim ed at the removal of 
hyperkeratosis seems to be o f utm ost importance 
and is therefore strongly recom m ended for the most 
favourable results in FD A P and P D T  on psoriasis and 
other dermatoses. In  the present study, different 
keratolytic pretreatm ent options prior to FD A P and 
P D T  were studied.
B oth retinoic acid and a hydrocolloid dressing 
induced a clinical im provem ent o f the psoriasis 
plaques, bu t the hydrocolloid dressing decreased 
scaling, erythema and induration best after 2 weeks 
o f pretreatm ent. Besides the clinical results, the
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histological effects on psoriatic skin after keratolytic 
pretreatm ents were also examined. O ur aim was to 
use these different keratolytic pretreatm ents prior to 
FD A P and P D T  in psoriasis in order to reduce the 
am ount o f hyperkeratosis and optimize FD A P and 
P D T  results. However, in daily practice, the main 
use o f these techniques is in non-m elanom a skin 
cancer, including actinic keratosis, Bowen’s disease 
and (superficial) basal cell carcinoma. Preferably no 
changes in the histopathology o f these dermatoses 
are detected and therefore different im m unohisto- 
chemical analyses were performed.
Salicylic acid in petro la tum  reduces the am ount 
o f hyperkeratosis with an increase in fluorescence 
intensity. As previously reported , fluorescence in ten­
sity o f the psoriatic skin is negatively correlated to 
stra tum  corneum  thickness (12). Topical retinoic 
acid as well as hydrocolloid dressing dem onstrated 
no  added value to a further decrease in stratum  
corneum  thickness or keratinization (K10). Only 
an im provem ent in epiderm al proliferation (Ki67) 
was seen. A nother structural m arker for differentia­
tion is filaggrin. Filaggrin has a m ajor function in 
aggregating keratin filaments and  m aintaining a 
norm al hydrating state o f the stra tum  corneum . In 
general, active psoriasis is known for its absent or 
discontinuous filaggrin expression (9 ,13-17). The 
hydrocolloid dressing showed no  change in the dis­
continuous expression o f  filaggrin throughout the 
psoriasis plaque. However, a statistically significant 
reduction  in filaggrin was only seen in low fluores­
cent lesional skin after the application o f tretinoin 
cream , indicating histological irritation and damage 
o f the stra tum  corneum  besides the known clinical 
side effects o f pain and  p oint bleedings o f the treated 
skin. O n the o ther hand , epiderm al inflam m ation 
was increased with bo th  hydrocolloid dressing and 
topical tretinoin  treatm ent, while derm al infiltration 
did no t alter.
T he  m ost prom inent clinical improvem ent of 
psoriasis was seen after occlusion with a hydrocolloid 
dressing. In  contrast to application o f retinoic acid, 
all clinical param eters -  erythema, induration and 
desquam ation -  decreased. These results have been 
confirm ed by previous studies dem onstrating that 
occlusion by prolonged application of a hydrocol­
loid dressing is effective in the treatm ent o f psoriasis 
(13,18,19). In this study, there was no  change in 
filaggrin expression after 1 week o f pretreatm ent 
with a hydrocolloid dressing, bu t G erritsen et al. 
showed a similar clinical improvement o f psoriasis 
after 3 weeks o f occlusion with a hydrocolloid dress­
ing (20). O ther studies also showed a restored gran­
ular cell layer and increasing filaggrin expression 
after a longer occlusion period with a hydrocolloid
dressing. However, immunological param eters such 
as the num ber o f T  cells rem ained unaffected during 
hydrocolloid treatm ent (13,18-20).
C urrently , p rio r to FD A P and P D T , salicylic 
acid in petro la tum  is used as the keratolytic p re­
treatm ent o f choice. T he  clinical and im m unohis- 
tochem ical results o f ou r pilo t study showed an 
opportunity  for a hydrocolloid dressing as an adden­
dum  to the present keratolytic p re treatm ent regime. 
Because o f th e  clinical and histological outcom e and 
the potential to increase fluorescence intensity 
with the least com plications, the hydrocolloid dress­
ing was chosen to be a potential replacem ent for 
salicylic acid p rio r to P D T . Because o f the minim al 
histological changes and com fort for the patient 
(once-weekly application o f the hydrocolloid dress­
ing versus once-daily application o f salicylic acid 
in petro la tum ), use o f the hydrocolloid dressing as 
a p re treatm ent could also be recom m ended prior 
to FD A P.
Several authors have described clinical improve­
m ent o f psoriasis after m ultiple P D T  sessions, but 
an optimal treatm ent protocol has no t yet been estab­
lished (4-6,8,21,22). In the present study, six P D T  
treatm ents with a weekly interval induced significant 
clinical as well as histological im provem ent of 
psoriasis. T hese results are comparable with previous 
conclusions (9). D uring  P D T , no  significant clini­
cal and imm unohistochem ical differences were seen 
between salicylic acid in petrolatum  as a standard 
keratolyticum prior to P D T  and FD A P and a hydro­
colloid dressing as an alternative p retreatm ent option. 
As expected by previous studies, the overall sum 
score, epidermal proliferation, differentiation and 
inflammation improved as a result of P D T  and not 
as a result o f the pretreatm ent of choice (9). Both 
salicylic acid in petrolatum  and a hydrocolloid dress­
ing induce comparable clinical and im m unohisto- 
chemical results. In  certain cases, a hydrocolloid 
dressing might be preferred above salicylic acid in 
petrolatum ; for instance, ifthe  target lesion is difficult 
to reach and when compliance to apply ointments 
might be a problem . As all skin diseases, superficial 
variants o f non-m elanom a skin cancer as well as non- 
oncological indications such as psoriasis, treated 
with FD A P or P D T  require an optimal keratolytic 
pretreatm ent for the m ost favourable results, a hydro­
colloid dressing is a good alternative.
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Clinical and histological effects of blue light on normal skin
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Introduction: Phototherapy w ith  visible light is gaining interest in dermatological practice. 
Theoretically, blue light could induce biological effects comparable to ultraviolet A (UVA) 
radiation.
Objectives: To study the effects o f  blue light on norm al skin in terms o f  photodamage, skin 
ageing and melanogenesis.
M ethods: Eight healthy volunteers were included and irradiation w ith visible blue light was 
given on five consecutive days. Skin biopsies were analysed w ith respect to photodam age 
(p53, vacuolization, sunburn cells), skin ageing (elastosis, MMP-1) and melanogenesis 
(Melan-A).
R esults: No inflammatory cells and sunburn cells were visible before or after irradiation. 
A significant increase in the perinuclear vacuolization o f  keratinocytes was demonstrated 
during treatm ent (P = 0.02) w ith  a tendency towards significance after cessation of 
treatment (P = 0.09). No significant change in p53 expression was seen. Signs o f  elastosis 
and changes in MMP-1 expression were absent. Minimal clinical hyperpigm entation o f  the 
irradiated skin was confirmed histologically w ith  a significant increase in Melan-A-positive 
cells (P = 0.03).
C onclusions: Visible blue light, as given in the present study, does n ot cause deoxyribonucleic 
acid damage or early photo-ageing. The biological effects o f blue light on norm al skin are 
transient melanogenesis and inexplicable vacuolization w ithout resulting apoptosis. In 
conclusion, the (short-term ) use o f  visible blue light in dermatological practice is safe.
T he absorption o f  visible light or ultraviolet (UV) radiation by chrom ophores in the skin is the main factor that is responsible for exerting biological effects o f light on the skin. 
Endogenous chrom ophores can be target molecules. They can 
cause direct damage or induce indirect damage to adjacent 
molecules. The interaction o f UV w ith  chrom ophores can lead 
to a m ultitude o f effects, e.g. the induction o f  oxidative stress, 
activation o f  transcription factors, damage to the cell m em brane 
and deoxyribonucleic acid (DNA) damage, initiating im m uno­
suppression. UVB is responsible for 80% o f  the carcinogenic 
effects o f  sunlight. UVA contributes only the rem aining 20% (1). 
In case o f  UVB, the most important light-absorbing molecules 
are DNA, urocanic acid and melanin. Direct damage caused by 
UVB absorption is not the only mechanism  to induce 
modifications o f  cellular DNA. A second indirect mechanism  to 
induce DNA damage requires singlet oxygen, resulting from 
photoexcitation o f  photosensitizers after irradiation w ith  UVA or 
visible light (2). The combination o f  psoralens and UVA induces
mainly indirect DNA damage by induction o f  singlet oxygen. 
Normally, genomic stability is maintained by DNA repair 
mechanisms and apoptosis (3).
Phototherapy using UV radiation has been part o fth e  treatment 
in dermatology for many years, being used for a variety o f  skin 
disorders. Therefore, studies in photodermatology have been 
focused mainly on carcinogenesis and skin ageing in the UV 
radiation spectrum. UV radiation is able to induce mutagenic 
photoproducts or lesions in DNA and is believed to play an 
important role in initiating skin cancer. Melanin, epidermal 
thickness and the stratum corneum  act as filters by absorbing and 
scattering UVB, UVA, as well as visible and IR radiation (4). All 
cells contain several DNA repair systems (i.e. nucleotide excision 
repair) in order to restore DNA damage after growth arrest to 
protect the cell from the effects ofDNA damage. p53 regulates the 
cell cycle and functions as a tum our suppressor gene (guardian o f 
the genome). It induces growth arrest by holding the cell cycle, 
activates DNA repair mechanisms and induces apoptosis (5). In
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addition to photocarcinogenesis, chronic repeated exposure to UV 
irradiation leads to photo-ageing. Photo-aged skin is characterized 
clinically by fine and coarse wrinkling, roughness, dryness, laxity, 
teleangiectasia, loss o f  tensile strength and pigmentary changes. 
Several processes are involved in the pathogenesis o f  photo-ageing. 
The most prom inent feature o f  photo-ageing is elastosis. Another 
important feature is the activation o f  matrix metalloproteinases 
(MMPs) (6, 7).
Over the last few years, phototherapy w ith visible light has 
been gaining interest in dermatological practice. Nevertheless, the 
effects o f  visible light on  the skin are only partly known. In  a 
previous study o fo u r  group, the effects ofh igh-dose red light on 
normal skin were studied. Five consecutive irradiations w ith 
1 3 0 J/cm 2 induced a significant increase in vacuolization, but 
did not result in apoptosis, photo-dam age or early induction o f 
skin ageing (8). Theoretically, blue light could induce biological 
effects comparable to UVA radiation, because wavelengths o f blue 
light are closely related to the UVA spectrum. It is established that 
UVA has effects on  photo-ageing and, in com bination w ith 
psoralens, carcinogenic side-effects in the long term. Several 
studies have shown that near-UVA irradiation results in  UVA-like 
effects (2, 9, 10). In the present study, the effects o f visible blue 
light w ith a range o f  390-460  nm , w ith  a peak emission o f 
420 nm , on normal skin o f  healthy volunteers w ithout the 
administration o f  an exogeneous photosensitizer are investigated 
w ith respect to melanogenesis (Melan-A), skin ageing (elastosis, 
MMP) and photodamage (p53, vacuolization, sunburn cells).
Methods
Subjects
This study was approved by the local medical ethics committee. 
Eight healthy volunteers (six female, two male) w ith  skin type 
I-III and an average age o f  20.9 years (1 9 -2 4  years) were 
included in this study after w ritten informed consent was given. 
To avoid age-related changes in  the photobiological response o f 
the skin, only non-sm oking volunteers below the age o f4 0  years, 
w ithout a history o f  skin diseases or prolonged sun or UV 
exposure, and w ithout clinical visible photo-dam aged skin were 
included.
Study design
Irradiation was given on  five consecutive days w ith a W aldmann 
450 L photodynam ic therapy (PDT) lamp (Herbert W aldmann 
GmbH & Co., Villingen-Schwenningen, Germany), w ith  an 
emission spectrum  between 380 and 480 nm  and a peak 
emission at 420 nm . Each day, 20 J /cm 2 was given on the sun- 
protected area o f  225 (15 X 15) cm2 on  the buttocks to a 
cumulative dose o f  100 J /cm 2. The surrounding skin was 
covered w ith  light-opaque sheets.
The rationale for using 20 J /c m 2 w ith  a cumulative dosage o f 
100 J /c m 2 was based on different studies using blue light on 
actinic keratoses and acne. In this setting, the results could be 
compared w ith previous results (8, 11, 12).
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Biopsies
In total, six 3 m m  punch biopsies were taken under local 
anaesthesia w ith  1% xylocain-adrenalin. The first biopsy 
(control) was taken outside the irradiated area o f 225 cm2. The 
second biopsy was taken 3 h  after the first irradiation (day 1), 
while the other biopsies were chronologically taken from  the 
irradiated square on the buttocks immediately before the 
irradiation on  days 2, 3, 5 and on day 14. All tissues were 
em bedded in paraffin after a 3-h fixation in formalin.
Histology
The following m onoclonal antibodies were used on the paraffin 
sections: m onoclonal m urine antihum an (clone DO-7, wild type 
and m utant) p53 protein (1 : 200) (DAKO, Glostrup, Denmark), 
m onoclonal m urine antihum an Melan-A (1 :5 0 )  (MART-1, 
Oncogene, San Diego, CA, USA) and m onoclonal m urine 
antihum an MMP-1 (1 : 25) (Abcam, Cambridge, UK).
Haematoxylin and eosin staining was perform ed on  the 
paraffin-embedded sections to assess epidermal histological 
changes and to evaluate vacuolization and sunburn cells 
(keratinocytic apoptosis). Von Giesen staining was perform ed to 
assess the changes in the elastin and collagen m orphology o f  the 
dermis after irradiation. The staining used in this procedure 
included Resorcin-Fuchsin (Chroma-Gesellschaft, Munster, 
Germany), W eigert’s ferric haematoxylin, acidic alcohol and 
Pikrofuchsine (Chroma-Gesellschaft).
From the skin samples sections (6 mm) were cut for 
imm unohistochem ical assessment. The slides were dewaxed 
w ith Histosafe (Adamas, Amerongen, the Netherlands), 
followed by rehydration in  decreasing concentrations o f  alcohol 
(100-50% ) and demineralized water. The slides were pretreated 
in a 10 mM citrate buffer solution (pH 6), heated for 10 m in  at 
450 W  in a microwave and left to cool for 45 min. The sections 
were then air dried and washed in phosphate-buffered saline 
(PBS),(B. Braun, Melsungen, Germany) for 15 m in before 
incubation w ith  prim ary antibodies for 1 h. For the elastin 
staining, this step was substituted by tryptinization with 
trypsine-CaCl2 solution for 5 min. After this initial step, all 
sections were incubated for 15 m in w ith  20% norm al horse 
serum  (Vector Laboratories Inc., Burlingame, CA, USA), diluted 
in PBS, followed by a 1-h incubation w ith  the prim ary antibodies 
diluted in 1% bovine serum  album in (Sigma, St Louis, MO, USA) 
in PBS at room  temperature. All the slides w ere washed in PBS for
15 min, before incubation w ith the second antibody, horse 
antim ouse biotinylated IgG (ABC kit-mouse, Vector Laboratories 
Inc.) for 30 m in. Subsequently, all slides were washed again in 
PBS and incubated w ith avidin b iotin complex solution (ABC kit- 
mouse, Vector Laboratories Inc.) for 30 m in  and labelled w ith a 
m etal-enhanced diam inobenzidine (DAB) substrate (Pierce, 
Rockford, IL, USA) at 37 °C. The slides were counterstained 
w ith Mayer’s haematoxylin (Sigma), and after dehydration in 
100% ethanol and Histosafe, m ounted in Permount (Fisher 
Scientific, Fair Lawn, NJ, USA). The sections were w ashed in tap 
water, dried and m ounted in glycerol gelatin (Sigma).
Evaluation of innovations for phototherapy for psoriasis
Assessment
Photodamage was assessed by counting the num ber o f  p53- 
positive cells, as well as the num ber o f  sunburn cells and cells 
w ith  perinuclear vacuolization all three per 1000 epidermal cells. 
Sunburn cells are epidermal cells w ith pyknotic nuclei and a 
strong an eosinophilic cytoplasm. Perinuclear vacuolization is 
defined as epidermal cells w ith  large cytoplasmic vacuoles 
around pyknotic nuclei, w ithout eosinophilic cytoplasm. 
M elanin-containing cells were scored by counting the num ber 
o f  Melan-A-positive cells per 1000 epidermal cells. The elastin 
content was described qualitively, as elastosis is characterized by 
changes in  candelabra-like structures and the density ofcollagen 
and elastin fibrils in the dermis.
Statistical analysis
For statistical analysis, one-way analysis o f variance (repeated 
measures) and a post hoc Duncan’s test were performed. A P-value 
<  0.05 was considered statistically significant. Data were 
analysed using Microsoft Excel 2007 and Statistica 7.0 software.
Results
Clinical findings
Treatment was well tolerated by all volunteers. None o f them 
experienced discomfort or local effects, such as erythema or 
burning. Only one volunteer showed slight pigm entation on  the 
irradiated skin o f  the buttocks after five treatments.
Histological findings
Apoptosis
No inflammatory cells and sunburn cells were visible before or 
after irradiation. There was a statistically significant increase in 
perinuclear vacuolization o f  keratinocytes after 48 (day 3, 
P = 0 .0 2 ) and 96 h  (day 5, P = 0 .0 2 )  (Fig. 1). This increase in 
vacuolization decreased after cessation o f  the irradiations, but 
there was still a strong tendency towards a significant increase in 
vacuolization o f  keratinocytes on day 14 (P = 0.09). No 
significant change in p53 expression was seen over the whole 
treatm ent period. However, after 24 h, a tem porary statistically 
significant decrease in p53 expression was detected (P <  0.01) 
(Fig. 2).
Photo-ageing
Elastin fibres showed regular-shaped candelabra-like structures 
and no  disorganization o f elastin or collagen fibres during and 
after the irradiation period. Dermal MMP-1 expression was 
visible in  five slides, but no  significant changes were seen as 
compared w ith  the unirradiated control skin o f  each subject.
Vacuolizatiork/IQOG keratinocytes
500 
450 
400 
350 
300 
250 
200 
150 
100 
50 
0
0 3 24 4S 96 312
Time (hours)
Fig. 1. N u m b e r o f  ep id erm al cells w ith  large v acuoles a ro u n d  p yknotic  
n uc le i, w ith o u t an eosinoph ilic  cy toplasm  p e r  1 000  keratinocytes.
*P <  0.05.
p53 expression/IOOO keratinocytes
35 ------------------------------------------------------------------------
0 ------------------ 1------------------ T-------------------T------------------ T------------------ T------------
0 3 24 48 %  312
Tim* (hours)
Fig. 2 . N u m b e r o fp 5 3 -p o s itiv e  cells p e r  1000  keratinocytes.
**P <  0.01 .
Melanogenesis
Minimal hyperpigm entation o f the irradiated skin was seen in 
one volunteer. This was confirmed histologically, as a significant 
increase in Melan-A-positive cells was seen (P = 0.03) on  day 5. 
The clinical hyperpigm entation and histological Melan-A 
expression decreased after cessation o f  the irradiations (Fig. 3).
Discussion
PDT, using exogenously applied photosensitizers, has been 
proven to be clinically effective in superficial skin 
(pre)malignancies including actinic keratosis, Bowen’s disease 
and superficial basal cell carcinoma. Topical application of 
aminolevulinic acid (ALA) induces the accum ulation of 
protoporphyrin IX (PpIX). PpIX has a m axim um  absorption
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Melan-Ä/1000 keratinocytes
60 ----------------------------------------------------------------------------
1 0  ■
0 -----------------------------------------T------------------- T----------------------------------------- .--------------------1
G 3 24 48 96 336
Tim» [hours)
Fig. 3 . N u m b e ro fM e la n -A -p o s itiv e c e H sp e r l0 0 0 k e ra tin o c y te s .
*P <  0.05.
peak at 4 0 8 n m  (Soret band), and as a result, blue light is m ore 
effective than red light in activating PpIX. The visible spectra of 
porphyrins also show weaker absorption peaks at longer 
wavelengths (Q-bands). For optimal activation o f  PpIX, not only 
the maximal absorption spectrum  ofPpIX but also the absorption 
characteristics o f the skin have to be considered. Therefore, red 
light is generally preferred in PDT because o f deeper light 
penetration into the skin (13). The application o f  a standard 
preparation containing m ethyl-aminolevulinate (Metvix®, 
Galderma, France), followed by red light irradiation, has now  
been approved for clinical use in  European countries. However, 
ALA solution (Levulan Kerastick, Dusa Pharmaceuticals Inc., 
W ilm ington, MA, USA) plus blue light exposure has been 
approved for the treatm ent o f  actinic keratosis in  the USA. On 
the other hand, irradiation o f  Propionibacterium  acnes colonies 
w ith visible blue light, w ith  or w ithout the exogenous 
application o f ALA, leads to photoexcitation o f  bacterial 
porphyrins, singlet oxygen production and eventually bacterial 
destruction and anti-inflam matory effects on keratinocytes (14, 
l 5 ) .  Also, in  w ound healing, visible light is used to kill bacteria 
in infected wounds (16). The present study demonstrates that 
irradiation w ith short wave visible light used in PDT for the 
treatm ent o f actinic keratosis and acne does n o t cause epidermal 
and dermal DNA damage, inflamm ation or early signs o fp h o to - 
ageing. However, irradiation w ith blue light results in an 
increased pigm entation and epidermal perinuclear vacuoliza­
tion. Melanogenesis decreased immediately after cessation of 
irradiation w ith short wave visible light and perinuclear 
vacuolization did n o t result in apoptosis.
UV irradiation can result in cellular DNA damage by direct 
excitation o f  DNA (type I) and indirect mechanisms involving 
the excitation o f  photosensitizers (type II), resulting in  singlet 
oxygen form ation. Shorter wavelengths contain m ore energy 
(Planck’s equation). UVB has shorter wavelengths than UVA. 
Therefore, UVB has enough energy to excite DNA molecules 
directly, whereas UVA needs photosensitizers to induce damaging 
effects on  DNA by producing singlet oxygen. Long-wave visible 
light is considered to have no  significant photobiological effects
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on the skin (8). On the other hand, blue light has near UVA 
wavelengths and could therefore induce photobiological effects 
on  the skin comparable w ith  UVA. Recently, Liebmann and 
colleagues demonstrated that blue light may be effective in 
treating hyperproliferative skin conditions, because blue light 
reduces proliferation. This reduction in proliferation is 
attributable to induction o f  differentiation in  skin cells by 
generation o f  nitric  oxide, although they found that irradiation 
w ith  blue light at 4 1 2-416  nm  exerts toxic effects at high or very 
high fluences. However, it is difficult to compare their in vitro 
results w ith our in vivo outcomes, using different fluences (17). 
Other studies have shown that near UVAvisible light can result in 
p53 induction and imm ediate pigm ent darkening, but less 
pronounced than after irradiation w ith  UVA (10, 18, 19). 
Therefore, we hypothesized that blue light, in the model used, 
induces n o  change, or at most a m inor increase, in p53 
expression. Normally, p53 is upregulated in case o f  UV-induced 
DNA damage in order to repair UV-induced DNA damage, but 
chronic sun exposure results in  loss or m utation o f  p53, 
facilitating carcinogenesis (20). Therefore, an increase in p53 
levels may reflect direct DNA damage or the ability o f  the cell to 
detect DNA damage, or both. In our study, an antibody against 
w ild type and m utant p53 was used. Therefore, no  
differentiation as a function o f the m easured p53 expression 
could be demonstrated. Our study demonstrated, overall, no  
change in p53 expression during and after irradiation w ith 
visible blue light. Remarkably, a temporary decrease in p53 
expression was noted after 24 h, w hich could be explained 
theoretically by the M DM2-p53 interaction. MDM2 is the 
principal cellular antagonist o f  p53, acting to lim it the p53 
growth-suppressive function in unstressed cells. MDM2 has 
been reported to be suppressed by higher dose UV irradiation, 
while a lower dosage o f UV irradiation resulted in  induction o f 
MDM2 (2 1 -2 3 ). It is possible that a low  dosage o f  near UVA 
irradiation stimulated a temporary induction ofMDM 2.
In general, an increase in p53 expression initiates form ation o f 
sunburn cells. Sunburn cells may be regarded as examples o f 
apoptosis (24). In our study, a statistically significant increase in 
vacuolization was demonstrated, whereas p53 expression overall 
did not change and no  sunburn cells were detected. Thus, 
perinuclear vacuolization in  our study was probably not an 
apoptotic effect. Perinuclear vacuolization is a phenom enon well 
k now n to dermatopathologists as an artefact in cryo-embedded 
sections. However, we demonstrated vacuolization in paraffin- 
em bedded sections and vacuolization norm alized after cessation 
o f  the irradiation w ith blue light in  contrast w ith  the results after 
illum ination w ith  long-wave visible light (8). As the increase o f 
vacuolization norm alized after cessation o f the irradiation w ith 
blue light, a possible explanation for the increase in vacuolization 
could be a direct (heat-induced) effect o f irradiation w ith  visible 
light. The significance o f  this phenom enon is still unclear, 
because apoptosis as a result o f  UV-induced DNA damage w ith 
additional p53-expression and sunburn cell form ation could not 
be demonstrated.
The m ost prom inent histological feature o f  skin ageing is 
elastosis. In the papillary dermis o f  norm al skin, elastin and
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fibrillin form candelabra-like structures and project perpendicular 
to the basal lamina o f the dermo-epiderm al junction (25). For 
elastosis, changes in candelabra-like structures and the density o f 
the collagen and elastin fibrils in  the dermis w ere analyzed. MMP-
1  is a major dermal protease involved in the degradation o f 
extracellular matrices including collagen, elastin, proteoglycans 
and fibronectin. Multiple exposures o f  the skin to UV radiation 
result in elevated levels o f  MMP-1 (26, 27). No signs o f  skin 
ageing were demonstrated during the whole study period 
indicating n o  extrinsic photo-dam age o f  the skin o f  the 
volunteers before participation into our study and n o  additional 
acute effect o f  visible blue light on  skin ageing. As only the short­
term  effects o f visible light were tested, n o  conclusions can be 
draw n regarding the long-term  effects o fth e  photo-ageing effects 
o f  visible light on the skin.
Production o f  m elanin in hum an skin is stimulated by DNA 
damage caused by UV irradiation. Melanin has photoprotective 
features, as it limits the extent ofUV penetration through the skin 
and scavenges reactive oxygen radicals, leading to oxidative DNA 
damage. Some previous studies have show n that not only UVB 
but also UVA and near UVA light can induce imm ediate pigm ent 
darkening and m elanogenesis (28, 29). Our study confirms these 
previous results by demonstrating minimal clinically visible 
hyperpigm entation o f  the skin irradiated w ith  visible blue light. 
Our clinical finding was confirmed histologically, as a statistically 
significant increase in Melan-A was demonstrated after the 
last illumination w ith  blue light. Hyperpigm entation, both 
macroscopically and microscopically, decreased after cessation 
o f  the irradiations.
Theoretically, blue light could induce biological effects 
comparable to UVA radiation, because wavelengths o f blue light 
are closely related to the UVA spectrum. Several studies have 
show n that near UVA irradiation results in UVA-like effects (2, 9, 
10). The increase in  pigm entation after irradiation w ith  blue 
light is an expected UVA-like effect. However, the present study 
shows that visible blue light does n ot cause DNA damage or early 
photo-ageing. The biological effects o f  blue light that we 
observed are transient melanogenesis and inexplicable 
vacuolization w ithout resulting apoptosis. In  conclusion, the 
(short-term ) use o f visible blue light in dermatological practice, 
as used in  this study, is safe.
Acknowledgments
The authors w ould like to thank Hester Boomkens for her 
assistance w ith  this project.
References
1. Anderson RR, Parrish JA. The optics of human skin. J Invest 
Dermatol 1981; 77: 13-19.
2. Kielbassa C, Roza L, Epe B. Wavelength dependence of oxidative 
DNA damage induced by UV and visible light. Carcinogenesis 1997; 
18: 811-816.
3. Bethea D, Fullmer B, Syed S, et al. Psoralen photobiology and 
photochemotherapy: 50 years of science and medicine. J Dermatol 
Sci 1999; 19: 78-88.
4. Halliday GM. Inflammation, gene mutation and photoimmuno­
suppression in response to UVR-induced oxidative damage con­
tributes tophotocarcinogenesis. MutatRes 2005; 571: 107-120.
5. Duthie MS, Kimber I, Norval M. The effects of ultraviolet 
radiation on the human immune system. Br J Dermatol 1999; 
140: 995-1009.
6. Ohnishi Y, Tajima S, Akiyama M, et al. Expression of elastin- 
related proteins and matrix metalloproteinases in actinic elasto- 
sis of sun-damaged skin. Arch Dermatol Res 2000; 292: 27-31.
7. Berneburg M, Plettenberg H, Krutmann J. Photoaging ofhum an 
skin. Photodermatol Photoimmunol Photomed 2000; 16: 239-244.
8. Tjioe M, Smits T, Blokx WA, et al. High-dose long wave visible light 
induces perinuclear vacuolization in vivo but does not result 
in early photoageing and apoptosis. Exp Dermatol 2003; 12: 
610-614.
9. Cadet J, Berger M, Douki T, et al. Effects of UV and visible 
radiation on DNA-final base damage. Biol Chem 1997; 378: 
1275-1286.
10. Edstrom DW, Porwit A, Ros AM. Effects on human skin of 
repetitive ultraviolet-A1 (UVA1) irradiation and visible light. 
Photodermatol Photoimmunol Photomed 2001; 17: 66-70.
11. Smits T, Moor AC. New aspects in photodynamic therapy of 
actinic keratoses. J Photochem Photobiol B 2009; 96: 156-169.
12. Akaraphanth R, Kanjanawanitchkul W, Gritiyarangsan P. Efficacy 
of ALA-PDT vs blue light in the treatment of acne. Photodermatol 
Photoimmunol Photomed 2007; 23: 186-190.
13. Krutmann J, HonigsmannH, ElmetsC. Dermatological phototherapy and 
photodiagnostic methods; Vol. 1. Heidelberg: Springer-Verlag, 2001.
14. Kjeldstad B, Johnsson A. An action spectrum for blue and near 
ultraviolet inactivation of Propionibacterium acnes; with em­
phasis on a possible porphyrin photosensitization. Photochem 
Photobiol 2001; 4 3 :67-70 .
15. Shnitkind E, Yaping E, Geen S, et al. Anti-inflammatory proper­
ties ofnarrow-bandbluelight. J Drugs Dermatol 2006; 5: 605-610.
16. Lipovsky A, Nitzan Y, Lubart R. A possible mechanism for 
visible light-induced wound healing. Lasers Surg Med 2008; 40: 
509-514.
17. Liebmann J, Born M, Kolb-Bachofen V. Blue-light irradiation 
regulates proliferation and differentiation in human skin cells. 
J Invest Dermatol 2009 [Epub ahead of print].
18. Burren R, Scaletta C, Frenk E, et al. Sunlight and carcinogenesis: 
expression of p53 and pyrimidine dimers in human skin 
following UVA I, UVA 1 1  II and solar simulating radiations. Int 
J Cancer 1998; 76: 201-206.
19. May P, May E. Twenty years of p53 research: structural and 
functional aspects of the p53 protein. Oncogene 1999; 18: 
7621-7636.
20. Mellon I, Spivak G, Hanawalt PC. Selective removal o f transcrip­
tion-blocking DNA damage from the transcribed strand of the 
mammalianDHFRgene. Cell 1987; 51: 241-249.
21. Brash DE, Wikonkal NM, Remenyik E, et al. The DNA damage 
signal for Mdm2 regulation, Trp53 induction, and sunburn cell 
formation in vivo originates from actively transcribed genes. 
J Invest Dermatol 2001; 117: 1234-1240.
22. Ljungman M. Dial 9-1-1 for p53: mechanisms ofp53 activation 
by cellular stress. Neoplasia 2000; 2: 208-225.
23. Moll UM, Petrenko O. The MDM2-p53 interaction. Mol Cancer Res 
2003; 1: 1001-1008.
24. Ziegler A, Jonason AS, Leffell DJ, et al. Sunburn and p53 in the 
onset ofskincancer. Nature 1994; 372: 773-776.
125
C
h
a
p
te
r
 
3
Chapter 3
25. Raghunath M, Bachi T, Meuli M, et aï. Fibrillin and elastin 
expression in skin regenerating from cultured keratinocyte 
autografts: morphogenesis of microfibrils begins at the 
dermoepidermal junction and precedes elastic fiber formation. 
J Invest Dermatol 1996; 106: 1090-1095.
26. Fisher GJ, Wang ZQ, Datta SC, et aï. Pathophysiology of pre­
mature skin aging induced by ultraviolet light. N Engï J Med 1997; 
337: 1419-1428.
27. Pascual-Le TL, Korwin-Zmijowska C, Adolphe M. Effects of 
simulated solar radiation on type I and type III collagens,
collagenase (MMP-1) and stromelysin (MMP-3) gene expres­
sion in hum an dermal fibroblasts cultured in collagen gels. J 
Photochem Photobiol B 1998; 42: 226-232.
28. Pathak MA, Riley FJ, Fitzpatrick TB, et al. Melanin formation in 
human skin induced by long-wave ultra-violet and visible light. 
Nature 1962; 193: 148-150.
29. Porges SB, Kaidbey KH, Grove GL. Quantification of visible 
light-induced melanogenesis in human skin. Photodermatol 1988; 
5: 197-200.
120(0
Evaluation of innovations for phototherapy for psoriasis
The efficacy of high-dose blue light versus red light in 
the treatment of psoriasis: A double blind, randomized 
comparative study
M .M . K leinpenning, M .E. K ooijm ans-O tero , P.E.J. van  Erp, M.J.P. G erritsen  and  P.C.M . van  de K erkhof
Department o f Dermatology, Radboud University Nijmegen Medical Centre, PO  Box 9101, 6500 HB Nijmegen, the Netherlands
Summary
Correspondence
M M . Kleinpenning, M.D. 
M.Kleinpenning@derma.umcn.nl
Abbreviations
LED, light emitting diode; UV, 
ultraviolet; PDT, photodynamic 
therapy; ALA, aminolevulinic acid; 
PpIX, protoporphyrin IX
Key words
Phototherapy, psoriasis, visible 
light, blue light, photobiology
Acknowledgments
The authors would like to 
thank Philips, Eindhoven, the 
Netherlands, fo r  providing the 
L ED ’s based visible light sources 
and sponsoring this study.
Introduction Porphyrin producing bacteria in acne induce endogenous 
protoporphyrin IX (PpIX), which is the target chromophore in treatment of 
acne with visible blue light. PpIX is also present in psoriatic skin without the 
preceding application o f aminolevulinic acid (ALA). Therefore, endogenous 
photosensitizers in psoriasis are a potential target for photodynamic treatment 
with high-dose visible light.
Objectives In the present pilot study treatment with high-dose blue light and 
red light in psoriasis were analyzed with respect to clinical improvement and 
potential side effects.
Methods In 20 patients two stable psoriatic plaques were treated with either 
blue or red light, three times weekly for four consecutive weeks. In order to 
remove scaling, which could potentially interfere with penetration of the light 
into the skin, daily application o f 10% salicylic acid in petrolatum was started 
at the screening visit and continued until end of the study.
Results Clinical improvement was seen after treatment with blue as well as 
after treatment with red light. With respect to scaling and induration, no major 
differences between both light sources were seen. Improvement of erythema, 
however, continued in blue light irradiated plaques throughout the whole 
study period, while after red light no significant improvement was seen after
6 illuminations.
Conclusions The clinical improvement of psoriasis, with respect to erythema, 
in particular after blue light and to a lesser extent after red light indicates that 
visible light treatment could represent a treatment option for psoriasis.
In psoriasis, there remains an unmet medical need for 
the development of new treatments, because in particular 
insufficient efficacy and cumulative toxicity of topical 
therapies, phototherapy and systemic treatments represent 
serious limitations. Over the last few years phototherapy 
with visible light in inflammatory skin disease is gaining 
interest in dermatological practice as a safe alternative 
for ultraviolet (UV)-phototherapy. The absorption of 
visible light or UV radiation by chromophores in the 
skin is the main event in commencing biological effects 
of light on the skin. Endogenous chromophores can be 
target molecules and may cause direct or indirect damage 
to adjacent molecules. An increasing number of studies 
have documented clinical improvement in acne after 
treatment with different laser- and light-based devices. 
Irradiation of Proprionibacterium acnes colonies with 
visible blue light leads to photoexcitation of bacterial 
porphyrins, singlet oxygen production, eventually 
bacterial destruction and anti-inflammatory effects on
keratinocytes.12 Also in wound healing visible light is 
used to kill bacteria in infected wounds.3 
Topical application of aminolevulinic acid (ALA) 
induces the accumulation of protoporphyrin IX (PpIX). 
In general, PpIX accumulating skin disorders can be a 
potential target for photodynamic therapy (PDT). PpIX 
has a maximum absorption peek at 408 nm (Soret band) 
and as a result blue light is more effective than red light 
in activating PpIX. For optimal activation o f PpIX not 
only the maximal absorption spectrum of PpIX but 
also the absorption characteristics of the skin have to 
be considered. Therefore, red light is preferred in PDT 
because o f deeper light penetration in the skin.4 Psoriasis 
has been shown to accumulate PpIX after application of 
ALA and its susceptibility to PDT with red light has been 
previously studied.5-10 PpIX is also present in psoriatic 
skin without the preceding application of its precursor, 
due to endogenous levels o f PpIX.11 Consequently, the 
interaction of blue light and endogenous photosensitizers,
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like PpIX, in psoriasis may represent a new principle 
for photodynamic treatment o f psoriasis without the 
application o f an exogenous photosensitizer. Recently, 
Liebmann et al. demonstrated that blue light may be 
effective in treating hyperproliferative skin conditions, 
because blue light reduces proliferation.12 In the present 
pilot study treatment with high-dose blue and red light 
in psoriasis were analyzed with respect to clinical 
improvement and potential side effects in order to be a 
non-carcinogenic alternative to the current treatments 
with UVB.
Methods
Subjects
The local medical ethics committee approved this study. 
From May 2008 until February 2009 twenty-six patients 
with mild chronic stable psoriasis were invited to participate 
in this study. Finally twenty patients were included in this 
study after given their written informed consent (age: 28­
74 years, mean 55.7 years ± 11.5 SD; 14 men, 6 women). 
The studied lesions were located mainly on the extremities 
(16), on the abdomen (1), back (1) or nates (2). Patients 
were not allowed to use any systemic psoriatic treatment 
for at least 2 months before starting phototherapy with 
visible light. Topical treatment before and during the study 
was restricted to 10% salicylic acid in petrolatum and 
emollients. Other topical treatments were not permitted 
for at least 2 weeks before the study. Medication known to 
potentially aggravate psoriatic lesions, such as ß-blockers, 
was also not allowed (table 1).
Study protocol
At the screening visit, one week prior to baseline, two 
contralateral and clinically identical psoriasis plaques 
were selected. The two target lesions were located on the 
trunk or extremities (exclusion o f plaques localised on 
the extension surface o f elbows and knees, hands, feet, 
groin, scalp and genital areas). The size o f the selected 
plaques was at least 4 cm in diameter. One week before 
baseline these psoriasis plaques were treated with 10% 
salicylic acid in petrolatum once daily in order to remove 
excessive scaling potentially interfering the irradiation 
with visible light. Daily 10% salicylic acid in petrolatum 
was continued until end o f the study. At random one 
psoriasis plaque was illuminated with a red light, while the 
contralateral lesion was treated with a blue light, starting 
at baseline, three times weekly for four consecutive 
weeks. Only the research assistant was informed of the 
assigned treatment. Two blinded observers were involved 
in this study. Previous to every light treatment the two 
plaques to be treated were wetted with water and an 
emollient was applied after irradiation as phototherapy 
may aggravate dryness and desquamation.
In order to evaluate the additional value o f visible light 
to topical keratolytic treatment o f psoriasis, an additional 
pilot study with 10% salicylic acid in petrolatum as 
monotherapy was performed. Seven patients (age: 37-71
Table 1 Inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
Stable plaque psoriasis 
m ore than 5 months
2  symm atrical localised
plaques on trunk or
extremities with a diameter
o f  >4 cm and sum-score >5
Total body surface area of
<10%
W ritten informed consent 
is given
Subject age >18 years 
N o  other skin diseases
Severe scaling (>4)
Target plaques localized on 
extension surface of elbows 
and knees, hands, feet, groin, 
scalp and genital areas 
Topical treatm ent for 
psoriasis >2 weeks before 
start UVB
Systemic treatm ent for 
psoriasis >2 m onths before 
start UVB
M edication potentially 
aggravating psoriasis (beta­
blocker, lithium, prednisone) 
Planned exposure to sun, UVA 
or UVB affecting psoriasis 
during study period
years, mean 55.6 years ± 12.9, 6 men, 1 woman) with 
chronic stable psoriasis were asked to treat one psoriatic 
plaque with salicylic acid in petrolatum once daily for four 
consecutive weeks. In this patient group, no additional 
therapy with visible light was given.
L ight sources
Patients were irradiated on one plaque with LED’s based 
blue light (420nm, ~100mW/cm2, Philips, Eindhoven, 
the Netherlands) and LED’s based red light (630nm, 
~50mW/cm2, Philips, Eindhoven, the Netherlands) on the 
other plaque. Each plaque was irradiated for 20 minutes 
three times weekly for four consecutive weeks.
Assessment
At the screening visit, at baseline and during the two 
weekly control visits a clinical severity score was 
calculated. To evaluate the clinical response, the sum 
score, a widely used method to measure the plaque 
severity, was assessed. In this score erythema, induration 
and desquamation are scored on a five-point scale as: 0, 
absent; 1, minimal (very light pink, hardly any elevation, 
rare scale); 2, mild (light red/pink, slightly elevation, 
poorly defined scale); 3, moderate (red, moderate 
elevation, defined scales); or 4, severe (very red, marked 
ridge, heavy scaling). Finally, a global sum score (range 
0-12) was defined as the sum o f all three scores together, 
reflecting plaque severity. At baseline, psoriasis plaques 
with a total sum score o f less than 5 or with scaling more 
than 4 were excluded.
At each control visit possible adverse events, like 
pigmentation or erythema, were assessed by a comparable 
severity scale (0, no evidence for pigmentation or 
burning; 1, minimal pigmentation or erythema; 2, 
mild pigmentation or marked erythema; 3, moderate 
pigmentation or marked erythema combined with edema;
4, severe pigmentation or blistering).
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Fig 1. Clinical severity score o f psoriasis 
plaques treated w ith blue and red light. 
(A) Total sum score, (B) changes in 
desquamation, (C) changes in  erythema 
and (D) changes in  induration. * = Only the 
results, that were n ot statistically significant, 
are marked. During the whole study period, 
no significant differences were noted 
betw een blue and red light. A ll the others 
differences, no t m arked in this figure, were 
statistically significant (p<0.01).
Statistical analysis
To compare the mean sum score and desquamation, 
erythema and induration separately between the two target 
lesions a two-tailed student’s f-test was used. A one-way 
analysis of variance (ANOVA) for repeated measures 
was used to analyse difference between time points 
within the mean sum score. When significant changes 
were found a two-tailed student’s f-test was performed 
for analysis between time points. A p-value <0.05 was 
regarded statistically significant. Microsoft Excel 2007 
and SPSS 16.0 were used for statistical calculations.
Results
C linical efficacy
Identical sum scores were found at baseline indicating a 
comparable clinical severity between both studied groups 
(sum score o f 7.7; SD ±1.3). Generally, the treatment 
was very well tolerated by all patients. Some patients 
experienced a slight burning during the irradiation with 
blue light. No clearance was seen. The psoriatic lesions 
showed statistically significant clinical improvement 
during the treatment period, which was reflected in a 
significant decrease in the clinical plaque severity (sum) 
score (p<0.01). No significant differences in sum score 
were found between blue (-34%) and red light (-27%) 
(table 2).
Remarkably, the sum score was already significantly 
decreased based on only one week o f pretreatment with 
salicylic acid in petrolatum (p<0.01). Both blue (p<0.05) 
and red light (p<0.05) induced statistically significant 
decreases in the clinical plaque severity score during
Table 2 Percentual im provement betw een different timepoints. 
S = screening and start pretreatm ent o f  10% salicylic acid in 
petrolatum. Thus, S-0 is solely the effect o f  one week salicylic 
acid in petrolatum  prior to  baseline (t=0). * p<0.01, ** p<0.05
Percentual S-0 W eek W eek Week
improvement 0-2 2-4 0-4
Total sum-score Blue 19.5* 21.0* 16.3* 33.9**
Red 22.1* 18.3* 10.2 26.7*
Desquamation Blue 47.8* 16.7 -10.0 8.3
Red 52.1* 0 -18.2 -18.2
Erythem a Blue 3.4 25.0* 23.8* 42.9*
Red 3.4 28.6* 10.0 35.7*
Induration Blue 8.0** 21.7* 22.2* 39.1**
Red 12.0** 28.6* 10* 35.7*
the whole study period. However, the psoriatic lesions 
treated with red light did not show an overall clinical 
improvement (sum score) anymore after 6 treatments 
(p=0.26) (figure 1).
After one week o f pretreatment, desquamation (p<0.01) 
as well as induration (p<0.01) decreased, while erythema 
did not change (p=0.43). The decrease in desquamation 
was maximal after one week o f pretreatment (p<0.01) and 
this effect was maintained by continuing the pretreatment 
during the whole study period. A statistically significant 
improvement o f both induration and erythema were seen 
until the end o f the study period. However, the psoriasis 
lesions treated with red light showed a continuous 
decrease in erythema until the last treatment, although 
not statistically significant anymore (p=0.10) (figure 1).
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Table 3 Percentual improvem ent betw een different tim epoints 
for salicylic acid in  petrolatum as m onotherapy during 4 weeks 
o f treatm ent in  order to evaluate the additional effect o f visible 
light on psoriasis (table 2). SA = 10% salicylic acid in  petrolatum. 
* p<0.01, ** p<0.05
Percentual improvement 0-2 weeks 2-4 weeks 0-4 weeks 
o f SA as m onotherapy
Total sum-score 18.2* 25.9* 39.4*
D esquamation 43.5* 46.2* 69.6*
Erythem a -5 14.3 10
Induration 13.0 25** 31.8**
In order to evaluate the additional value o f visible light 
on the keratolytic pretreatment o f psoriasis, 7 patients 
were invited to treat one psoriasis plaque once daily with 
10% salicylic acid in petrolatum for four consecutive 
weeks (table 3). The clinical severity at baseline was 
not comparable with the psoriatic plaques illuminated 
with high-dose visible light. The sum score at baseline 
was lower with a strong tendency towards significance 
(p=0.07). Therefore, percentual improvement between the 
different time points was calculated. The total sum score
also decreased significantly (-39%, p.0.01) after one
month o f topical keratolytic treatment as monotherapy. 
This clinical improvement was predominantly based on 
significant decreases o f desquamation (p<0.01), but also 
induration improved significantly (p<0.05). Concerning 
the effects on desquamation, salicylic acid in petrolatum 
is superior to treatment with high-dose visible light 
(-8% and +18% versus -70%). No additional effects of 
treatment with visible light on induration was seen (-39% 
and -36% versus -35%). Erythema did not change after 
four weeks o f salicylic acid ointment alone, whereas both 
blue and red light induced a significant improvement of 
erythema beyond the salicylic acid in petrolatum induced 
improvement (-43% and -36% versus -10%) (table 2 
and 3). Concerning the effects on erythema, visible 
light, especially blue light, has a significant value on the 
inflammation o f psoriasis.
Erythem a and hyperpigm entation
No erythema surrounding the studied lesions was 
noticed. Almost all areas treated with blue light showed 
surrounding hyperpigmentation (16/20, 80%). The 
severity o f the hyperpigmentation increased from 
minimal to mild according to the number o f treatments 
(p<0.01). Only one patient demonstrated minimal 
hyperpigmentation o f the surrounding skin after 
illumination with red light (figure 2).
Discussion
Irradiation with high-dose blue as well as with red light, 
three times weekly for four consecutive weeks, induced 
improvement o f psoriasis. This clinical improvement was 
comparable for both light sources, except for erythema.
o
c
<D£tt
CL« 1"
Q.
X
c
«
s
0-
Fig. 2 H yperpigm entation severity score, * p<0.01
The clinical improvement for blue irradiated psoriasis 
plaques continued throughout the whole study period, 
while the sum score in the red irradiated plaques showed 
no statistically significant improvement o f erythema 
anymore after 6 illuminations.
A disturbing factor in this study is the use o f salicylic acid 
in petrolatum on the clinical results. As light does not 
penetrate into the skin with severe scaling, it is inevitable 
to use salicylic acid ointments as pretreatment. Starting one 
week before baseline the selected psoriasis plaques were 
treated with 10% salicylic acid in petrolatum once daily in 
order to remove excessive scaling potentially interfering 
the irradiation with visible light. Daily 10% salicylic acid 
in petrolatum was continued until end of the study. It is 
known that the application o f petrolatum and salicylic 
acid improves psoriasis. Salicylic acid reduces the amount 
of hyperkeratosis in order to enhance the penetration 
of light, whereas petrolatum increases hydration and 
reduces desquamation by normalization o f proliferation 
and differentiation in psoriasis.13 Our study demonstrates 
that salicylic acid in petrolatum is responsible for a major 
decrease o f desquamation, but also induration decreased 
significantly. In conclusion, salicylic acid in petrolatum 
has such a great impact on desquamation, that irradiation 
with blue or red light does not have an added value on 
descaling o f psoriasis. No additional effect of visible 
light on the induration of the psoriasis plaques was seen, 
probably because the amount o f hyperkeratosis influences 
the clinical score o f induration and the treatment period of 
four weeks was too short. On the contrary, no significant 
improvement o f erythema was seen after treatment with 
salicylic acid in petrolatum, whereas treatment with both 
blue and red light resulted in a significant improvement 
of erythema. Blue light was superior in improving 
inflammation, as treatment with red light showed no 
statistically significant improvement o f erythema anymore 
after 6 illuminations. However, it needs to be mentioned 
that the fluence rate o f red light was lower.
LED 
■  Blue 
□  Red
Screening Baseline 2 weeks End (4 weeks)
Time
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The results o f our study are not comparable with previous 
results. In 2002 Maari et al. selected 17 psoriasis plaques 
which were exposed to blue light three times weekly for 
four consecutive weeks. No significant difference was 
seen between the irradiated plaque and the control plaque 
after 12 illuminations.14 The most plausible explanation 
is the much lower irradiation dosage used in this study 
o f Maari. Another possible explanation for the failing 
clinical improvement after irradiation with blue light in 
the study o f Maari could be the fact that no keratolytic 
pretreatment had been given in order to remove excessive 
scaling, acting as a mechanical barrier and therefore 
potentially interfering irradiation with visible light. 
After ALA administration, PpIX accumulation is seen 
preferentially in differentiating cells in the epidermis.1516 
Improvement o f psoriasis plaque severity after ALA-PDT 
has been shown in different studies.7 810 Increased PpIX 
levels have also been demonstrated in psoriasis plaques 
without the administration o f ALA. Endogenous PpIX is 
mainly present in the stratum corneum o f patients with 
psoriasis.11 However, no improvement o f plaque severity 
was seen after treatment with low-dose blue light without 
keratolytic pretreatment in the study o f Maari et al. and 
our study with high-dose visible light demonstrated 
a significant clinical improvement after one week of 
pretreatment with a keratolytic ointment, implicating 
a different localization o f PpIX or another unknown 
photosensitizer to be responsible for the clinical results. 
PpIX has a maximum absorption spectrum in the blue 
visible light spectrum with weaker absorption peeks at 
longer wavelengths (633 nm, spectrum o f red visible 
light). Red light penetrates deeper into the skin and 
is therefore generally preferred as a light source for 
activating PpIX, because not only the maximal absorption 
spectrum o f PpIX but also the absorption characteristics of 
the skin have to be considered for an optimal therapeutic 
efficacy. Red light may also have angiogenesis inhibiting 
qualities by activating other chromophores in the skin, 
like hemoglobin, or anti-inflammatory properties by 
influencing the release o f cytokines from macrophages 
or other cells, but its exact mode o f action spectrum 
is not yet fully understood.1;2;17;18 Our study not only 
demonstrates clinical improvement of psoriasis after 
irradiation with deeper penetrating red light, but in 
particular after treatment with blue light. The clinical 
effects after treatment with blue light persisted throughout 
the study, while the clinical improvement o f the psoriasis 
plaques irradiated with red light discontinued after two 
weeks. Probably, the concentration o f an unknown 
photosensitizer, responsible for the clinical improvement 
o f erythema in psoriasis after irradiation with high-dose 
blue light, is highest in the upper part of the epidermis. 
An exogenous agent penetrating the ruptured skin barrier 
or an endogenous photosensitizer may be responsible 
for the demonstrated clinical improvement o f erythema 
in psoriasis after treatment with high-dose blue light. 
Recently, Liebmann et al. demonstrated that blue light 
may be effective in treating hyperproliferative skin 
conditions, because blue light reduces proliferation. The
reduction in proliferation is attributable to induction of 
differentiation in skin cells by generation o f nitric oxide. 
Furthermore, they found that irradiation with blue light at 
412-416 nm exerts toxic effects only at high or very high 
fluencies as compared to irradiation with UV light.12 
A side effect o f using blue light in the treatment of 
psoriasis is the presence o f evident hyperpigmentation of 
surrounding skin in 80% o f the treated psoriasis plaques. 
In previous studies with visible light, hyperpigmentation 
affected also some acne patients, but this resolved within 
3 months.19 In 2007, Lee et al. showed a significant 
decrease in melanin level after red irradiation in facial 
acne patients, whereas with blue light the melanin level 
increased slightly.20 However, both UVA and UVB are 
also capable o f inducing delayed tanning. It is known 
that skin pigmentation is the result o f melanin synthesis 
induced by the activation o f enzymes in melanocytes in 
the basal layer o f the epidermis in response to factors, 
such as ultraviolet light. A possible explanation for the 
hyperpigmentation seen after treatment with blue light 
could be that in the light spectrum, wavelengths o f blue 
light are near the wavelengths o f ultraviolet light. Previous 
studies have shown that near UVA visible light can result 
in immediate pigment darkening.21;22 In a previous study 
o f our group, minimal hyperpigmentation o f normal 
skin o f healthy volunteers irradiated with blue light 
was seen after 5 irradiations. This clinical finding was 
confirmed histologically, as also a significant increase in 
Melan-A positive cells was demonstrated. Both clinical 
hyperpigmentation and Melan-A expression decreased 
after cessation o f the irradiations with blue light.23 
A shortcoming o f our study is lacking o f follow up data. 
Although it is not known whether the hyperpigmentation 
o f the surrounding skin noticed in our patient group 
resolved within a few months, one can expect this 
to happen. Besides hyperpigmentation no other 
complications were noticed. Because no ultraviolet 
radiation is emitted, the chance o f side effects as effect 
o f ultraviolet radiation, premature aging and skin cancer, 
is considered negligible. The clinical improvement 
o f psoriasis after both blue and red light indicates that 
visible light treatment can be a treatment option for 
psoriasis, whereas the current available treatment options 
for psoriasis have considerable limitations.
In previous acne studies, mixed blue and red led 
phototherapy, probably by combining the antibacterial 
and anti-inflammatory qualities, showed to be a more 
effective treatment than blue light alone. Perhaps that 
the combination o f both red and blue light may also be 
an effective treatment for psoriasis. The next step is to 
optimize the efficacy o f treatment with visible light which 
depends on several factors, like dose and frequency o f the 
treatment. In general, clearance o f psoriasis is reached 
after ±30 treatments o f narrow-band UVB-phototherapy 
with a 3 weekly treatment protocol.24 In our study, 
patients did not reach clearance after a total number of 
12 treatments, probably because the treatment protocol 
o f three times weekly for four consecutive weeks was too 
short. Dose finding studies and comparisons o f various
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treatment schedules with different exposition durations, 
are needed. With a prolonged treatment duration, not 
only erythema will improve, but possibly also induration 
may decrease.
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4.1 Introduction
In this chapter the results of the experiments described in this thesis will be summarized 
and further discussed. The central issue in this thesis was to study the effects of 
fluorescence diagnosis and different forms of photo(dynamic)therapy on healthy and 
diseased skin. Several aims, defined in chapter 1.7, are extensively discussed in the 
chapters 2 and 3.
Diagnostic and therapeutic innovations in photodermatology in psoriasis and (pre) 
malignancies of the skin
I To study fluorescence diagnosis and photodynamic therapy for non-melanoma skin 
cancer
II Optimization of UVB phototherapy and evaluation of innovations in phototherapy for 
psoriasis
In the following sections, the findings of chapters 2 and 3 will be summarized and 
discussed.
4.2 Fluorescence diagnosis and photodynamic therapy for 
non-melanoma skin cancer
The first aim of this thesis was to study diagnostic methods and treatment options for 
non-melanoma skin cancer. Skin cancer is the most common cancer in Western world 
with a continuous increasing incidence. The majority of skin cancer is formed by NMSC. 
More and more NMSC arise in skin areas with field cancerization. Field cancerization 
is characterized by multiple (pre)malignant lesions diffusely spread, in particular, in UV- 
exposed skin. AKs and squamous cell carcinoma in situ (Morbus Bowen or Bowen's 
disease) are generally regarded as cutaneous epithelial premalignancies that are able 
to progress to invasive S C C .12 If potentially invasive AKs are diagnosed and treated at 
an early stage, cure rate will increase, morbidity and mortality will decrease and costs 
of treatment will be minimized. In the first part of chapter 2, FDAP is studied. FDAP 
may provide additional information in demarcation of lesional skin and differentiating 
between non-invasive AKs, potentially invasive AKs and invasive SC C. Unfortunately, 
as shown by the results of this thesis, this procedure still has a low reproducibility due 
to numerous factors influencing fluorescence detection and poor understanding of the 
mechanisms involved in PpIX tumor selectivity. In the second part of chapter 2, PDT 
with moderate to severe field-cancerization is evaluated. PDT, which can be used over 
large surface areas with good clinical outcome, may have significant advantages over 
the standard treatment options. PDT has proven to be an effective treatment option 
for AKs. However, as PDT is not in all cases that successful, the optimum treatment 
regimen for PDT in AKs still has to be determined.
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4.2.1 To evaluate the value of FDAP as a diagnostic tool to discriminate 
between different stages of KIN or proliferative status
In paragraph 2.1 the potential value of FDAP as a non-invasive diagnostic procedure 
to discriminate between different stages of keratinocytic intraepidermal neoplasias 
(KIN) is described. After adequate keratolytic pretreatment, FDAP was performed in 
14 patients with 86 for AK suspicious lesions. Biopsy specimens were taken, on which 
(immuno)histochemistry was performed for histopathologic classification. Other factors, 
influencing macroscopic fluorescence intensity were also evaluated including stratum 
corneum thickness and proliferative activity by assessment of Ki67-antigen expression. 
The fluorescence ratio (lesional:non-lesional skin) showed no statistically significant 
difference between the different levels of keratinocytic intraepidermal neoplasia. 
When the lesions were classified according to the conventional nomenclature, AK and 
Morbus Bowen, we also found no significant differences. However, Bowen's disease 
tended to have higher fluorescence ratios than the low-grade AKs. Three suspicious 
lesions of one patient showed micro-invasion and these were classified as micro- 
invasive S C C  accordingly. The highest fluorescence ratios were found in these micro- 
invasive SC Cs, but the low number of SC C s and the fact that they came from a single 
patient did not allow reliable statistical comparison. Only six lesions, classified as 
verrucous hyperkeratosis, showed a lower fluorescence ratio compared to normal skin, 
all KIN stages and micro-invasive SCC. Analysis of proliferative activity as assessed 
by immunoreactivity of the Ki67-antigen did not reveal any significant differences 
in fluorescence ratios among the different levels of Ki67-expression. Macroscopic 
fluorescence and stratum corneum thickness were negatively correlated. Thus, FDAP 
is not useful in discriminating between the different KIN-stages nor can it be used as a 
marker for proliferative activity.
4.2.2 To investigate the possibility to discriminate between A K s and cutaneous 
S C C  with FDAP
In the previous study, a higher fluorescence intensity was observed in micro-invasive 
SC C s compared with AKs. In paragraph 2.2, the potential applicability of FDAP 
in discriminating AKs from S C C  is further investigated. The lesional:non-lesional 
fluorescence ratio of AKs were compared with the fluorescence ratio of SCC. After 
one week of pretreatment with 10% salicylic acid in petrolatum, FDAP was performed 
in 13 patients with 36 lesions suspicious for AK, Bowen's disease or SCC. Biopsies 
were taken for histological assessment of the diagnosis and measurement of stratum 
corneum thickness. Macroscopic fluorescence between KIN I and II did not show 
statistically significant differences, whereas KIN III demonstrated a significantly higher 
fluorescence ratio compared to KIN I, but not KIN II. When the lesions were classified 
according to the conventional classifying system, the highest fluorescence ratios were
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found in Bowen's disease. These fluorescence ratios tended to be significantly higher 
compared to SC Cs. However, the highest fluorescence ratios of all S C C  were micro- 
invasive SCC. These values showed a significant higher fluorescence compared to the 
moderately and well differentiated SC C s and were comparable with the fluorescence 
intensity of Bowen's disease. The micro-invasive SC C s are clinically less apparent 
compared to other, more invasive, SCCs. Consequently, micro-invasive SC C s 
are more difficult to differentiate from premalignant squamous cutaneous lesions. 
Therefore, FDAP could be a potentially diagnostic tool. As both Bowen's disease and 
micro-invasive S C C  have comparable high fluorescence ratios, FDAP could be used 
to discriminate which premalignant lesions have the tendency to progress into SC C  
or which squamous cutaneous premalignant lesion already progressed into an early 
invasive cancer. No significant differences in stratum corneum thickness between 
the different histological diagnoses was seen. Assessment of the stratum corneum 
thickness in relation to the fluorescence intensity revealed a negative correlation, 
which suggests stratum corneum to have a negative effect on fluorescence intensity 
measured with FDAP. This correlation between the amount of hyperkeratosis and 
fluorescence intensity was less pronounced, whereas pretreatment with salicylic acid 
in petrolatum minimized the amount of hyperkeratosis substantially, indicating that 
there are other factors influencing PpIX accumulation. Thus, FDAP is not useful in 
discriminating SC C s from AKs or in differentiating between the different KIN stages, 
as mentioned in paragraph 2.1. However, there could be a potential applicability 
of FDAP to differentiate premalignant lesions with a tendency to progress into SC C  
and squamous cutaneous lesions already progressing into an early invasive cancer 
from other squamous cutaneous (pre)malignancies. At this very moment, FDAP is 
not sensitive enough to state with certainty that a lesion is AK, Bowen's disease or 
SCC. More research has to be performed to find out whether FDAP has a place as a 
diagnostic tool in NMSC.
4.2.3 To study the clinical efficacy of PDT with topical methyl aminolevulinate 
(MAL-PDT) in field cancerization with respect to the number of A K s and skin 
rejuvenation
As discussed in paragraph 1.5.8, therapies for AKs are not always successful, 
demand patient's utmost compliance and have important side-effects (pain, scarring, 
loss of pigmentation). Since AKs often appear in areas with field cancerization, PDT 
may have significant advantages over the standard treatment options. Both MAL- 
PDT and ALA-PDT are clinically effective in treatment of AKs. In studies of various 
authors, clinical efficacy varied largely. Results are difficult to compare because of 
the different treatment parameters that have been used in these studies.3-7 Adequate 
treatment protocols are essential for good therapeutic results with minimal unwanted 
negative side effects. The optimum treatment regimen for PDT in AKs still has to
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be determined. In paragraph 2.3, clinical efficacy of PDT with topical methyl 
aminolevulinate (MAL-PDT) in field cancerization was evaluated with respect to the 
number of AKs and photodamage. In total, 14 patients with 223 AKs on the face or 
scalp were treated with MAL-PDT. Two treatments with a three monthly interval were 
given. At baseline, before the second treatment and 3 months after the end of therapy, 
the number of AKs were counted and photodamage was assessed. Improvement 
of photodamage was related to the degree of skin changes with respect to skin 
roughness, hyperpigmentation, hypopigmentation, scarring, atrophy, telangiectasia 
and wrinkling. Complete clearance was reached in patients with a moderate degree 
of actinic damage, whereas a severe degree of field cancerization demonstrated only 
partial clearance. The global score for photodamage improved significantly. After the 
follow up period, none of the patients reaching clearance had developed relapsing or 
new AKs. In conclusion, MAL-PDT induces a high clearance rate of AKs, dependent 
on the degree of field cancerization, with a good improvement in photodamage and 
prevention of developing new AKs during the follow-up period. When treating thin 
and few AKs, it seems that one treatment using MAL-PDT is sufficient, although two 
treatment sessions are recommended for more hyperkeratotic lesions.8 Apparently, 
skin areas with severe actinic damage in the face or on the scalp need more MAL-PDT 
sessions to achieve complete clearance. Our results demonstrate that two treatments 
with MAL-PDT give excellent cosmetic results with good clinical results in patients with 
multiple AKs with a maximum of 10 to 12 A K lesions per patient, namely a moderate 
degree of field cancerization. Despite our relatively short follow up period of maximum 
six months, none of the patients reaching clearance had developed relapsing or new 
AKs after three months. Just after six months, the first relapses were seen. Therefore, 
the patient burden in the clearance group was significantly decreased, because these 
patients did not need any treatment for their chronically photodamaged skin for a long 
period of six months. However, more studies are needed for optimizing the treatment 
protocol of MAL-PDT in patients with larger numbers of AKs, i.e. a severe degree of 
field cancerization. In conclusion, the clearance rate seems to be dependent on the 
degree of field cancerization. Thus, more PDT sessions are needed in patients with a 
severe degree of field cancerization.
Discussion and future suggestions for PDT and FDAP in NMSC
Our two studies, described in chapter 2, demonstrate that, at this moment, FDAP is not 
sensitive enough to discriminate SC C s from AKs or to differentiate between the different 
KIN stages. Interpretation of FDAP results in different tissue types is still problematic, as 
a result of numerous factors influencing fluorescence detection and poor understanding 
of the mechanisms involved in PpIX selectivity. The exact cause of different affinities 
for PpIX accumulation in different skin diseases is unknown. Disruptions in stratum 
corneum integrity and/or alterations in the heme biosynthetic pathway are thought to 
be responsible for this.9-11 As penetration of the precursor of PpIX through the stratum
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corneum is a prerequisite for PpIX formation in the skin, stratum corneum thickness 
and integrity can influence macroscopic fluorescence in vivo.12 The results of this 
thesis demonstrate a negative correlation between stratum corneum thickness and 
fluorescence intensity. However, the correlation between the amount of hyperkeratosis 
and fluorescence intensity in S C C  and its precursor lesions was less pronounced. 
Pretreatment with salicylic acid in petrolatum minimized the amount of hyperkeratosis 
substantially, indicating that there are other factors influencing PpIX accumulation. In 
a recent study of de Leeuw et al., FDAP was promoted to be a potential diagnostic 
tool for early, pre-clinical stage NMSC. Large area skin fluorescence detection with 
5-ALA, encapsulated in liposomes for better skin penetration, was used for detection of 
early NMSC. In 61 out of 93 referred patients, focal increases in fluorescence intensity 
were detected. The positive fluorescence appeared to be correlated to 212 benign 
lesions, 71 AKs, 3 BCCs and one SCC. Five AKs were not noted clinically by the 
patient or doctor, but were identified with fluorescence diagnosis and later confirmed 
by histological examination. AKs were not classified according to the KIN-classification 
and information on micro-invasion is not presented by the authors. All other lesions 
were already identified with clinical investigation and dermatoscopy. They concluded 
that FDAP is able to induce a high discrimination between normal and diseased skin, 
whereas 74% (212/285) were benign lesions already clinically diagnosed. They also 
stated that, in contrast with previous studies, the number of tumors assessed in this 
study was higher than the number of tumors determined by clinical diagnosis.13 However, 
25% of the biopsied lesions (71/285) were AKs, of which the diagnosis is usually made 
on the clinical characteristics and in only 5 AKs the diagnosis was missed clinically. It 
remains a point of discussion whether it is essential to discriminate these preclinical 
AKs with fluorescence diagnosis. This is clinically not relevant. In field cancerization 
the whole skin area has to be treated. Consequently, the clinically missed AKs in areas 
with field cancerization will also be treated. A biopsy is only necessary to exclude 
deeper involvement in order to distinguish AK from SCC. It is more likely to consider 
AKs, which are not noted clinically, to be benign and far away from progression into 
SCC. Only in AKs with a tendency to progress into SCC, in cases were demarcation 
of lesional skin is clinically problematic, in dermatological screening of field-cancerized 
skin and to study PpIX accumulation during PDT, FDAP may provide relevant additional 
information. As long as interpretation of these data is still problematic, because of the 
low reproducibility of the procedure, FDAP is not useful in routine patient care as a 
non-invasive technique for detection and demarcation of skin (pre)malignancies. 
Topical application of ALA or MAL leads to formation of PpIX in the skin. Its preferential 
accumulation in certain cell types can be used as a cellular marker, but is also used to 
treat various skin diseases. Despite the problematic interpretation of FDAP in NMSC, 
PDT is an approved treatment option for AKs, Bowen's disease, superficial BCCs and 
small nodular BCCs. In order to optimize the current treatment protocol for PDT in AKs, 
a study (last part chapter 2) was performed on the clinical efficacy of PDT with topical
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methyl aminolevulinate (MAL-PDT) in field cancerization. The standard treatment 
procedure is occlusive treatment with MAL for 3 hours, which results in high and 
selective accumulation of PpIX. Subsequently, dysplastic cells are killed by phototoxic 
damage as a result of illumination with blue or red light. Our results demonstrate that 
the clearance rate seems to be dependent on the degree of field cancerization. More, 
than the standard two, PDT sessions seem to be essential for patients with a severe 
degree of field cancerization. In a recent study of Wiegell et al., the clinical efficacy of 
MAL-PDT for the treatment of AKs in the face and on the scalp was studied using a 
non-established protocol. Two symmetrical areas were treated with a standard red LED 
light after three hours of incubation with MAL cream or with continuous daylight after 
two-and-a-half hour occlusion of MAL. The effective light dose of the standard LED light 
was 37 J/cm2, whereas the patients stayed outdoors on average for four hours with a 
mean effective dose of 30 J/cm2. Interestingly, the clinical efficacy of daylight-PDT was 
comparable with the standard MAL-PDT protocol. Daylight-PDT was also significantly 
less painful.1415 Daylight contains various wavelengths, also outside the red range, 
such as blue light. Illumination with daylight resulted in lower fluorescence intensity 
due to continuous activation of PpIX, probably because of continuous illumination and 
more effective activation of PpIX due to blue light. Since pain is a limiting factor in 
PDT and daylight-PDT can be easily performed, this daylight-PDT protocol may be 
an interesting new concept. However, it is theoretically possible that daylight activates 
PpIX mainly in the superficial layers of the skin, resulting in inadequate treatment of 
deeper lesions, like BCCs and Bowen's disease. Thus, daylight-PDT might be only 
suitable for superficial AKs and mild field cancerization or multiple treatments over a 
longer period of time are needed for increased effectiveness in deeper lesions. Maybe, 
in the future, ALA or MAL could play a role in daily practice as an additive to day cream 
or sunscreens in order to treat and prevent early actinic damage.
4.3 Optimization of UVB phototherapy and evaluation of 
innovations in phototherapy for psoriasis
4.3.1 Optimizing UVB phototherapy in psoriasis
The second aim of this thesis was to improve phototherapy for psoriasis. The first 
part of the second aim was to optimize the currently used UVB phototherapy in 
psoriasis by assessing the effects of different dosage regimens, the predictors of the 
time to clearance and the role of non-adherence on the outcome. Phototherapy is 
an important treatment option in extensive psoriasis and/or when topical application 
of anti-psoriatic agents fail. UVB phototherapy is preferred above PUVA, because its 
efficacy is comparable and systemic administration of psoralens has significant side 
effects. Moreover, PUVA has demonstrated cumulative toxicity and carcinogenicity.
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Differences in time to clearance, predictors of time to clearance and the effects of 
non-adherence to the time of clearance of psoriasis treated with narrow-band UVB 
phototherapy in different dosage regimens were studied in chapter 3. Our aim was 
to optimize the dosage regimen with most optimal therapeutic results and cost- 
effectiveness with minimal unwanted side-effects.
4.3.1.1 To study the time to clearance in patients with psoriasis in a randomized, 
controlled trial, in which patients are treated with narrow-band UVB phototherapy in 
either a high-dose or a low-dose regimen
Over the last few years, several studies have been done in order to find the optimum 
dosage regimen for small spectrum UVB phototherapy in psoriasis. The short-coming 
of most of these studies is the body-half comparison setting, in which the systemic effect 
of UVB treatment is omitted. UVB irradiation affects local and systemic immunity by a 
decrease in LCs, impairment of Th1-immune responses and induction of cis-urocanic 
acid. As described in paragraph 3.1, 109 patients with stable plaque psoriasis were 
randomized to either a high-dose or a low-dose regimen. After randomization, patients 
with mild to moderate psoriasis were irradiated with either 40% or 20% incremental 
dosages, three times weekly. Treatment was stopped when clearance was reached 
or in case of treatment failure (>30 treatments without reaching clearance, persisting 
erythema or worsening of the psoriasis). Clearance was defined as a 90% reduction 
of baseline PASI. The number of patients achieving clearance and the number of 
dropouts were comparable in both irradiation protocols. In total, 77 patients (70.6%) 
achieved clearance: 41 patients (75%) treated according to the high-dose regimen 
and 36 patients (67%) irradiated with the low-dose regimen. The high-dose regimen 
resulted in 20% fewer treatments without significant differences in cumulative UV dose, 
but with more protocol adjustments during the first irradiations because of erythema. In 
the follow-up period, three months after cessation of UVB-phototherapy, no differences 
in relapses could be demonstrated. However, a significant lower PASI was measured 
in the follow-up period in the high-dose regimen, indicating better long-term effects on 
psoriasis. Thus, a high-dose regimen results in 20% fewer treatments with better long­
term effects. Compared to low-dose irradiation regimens, a high-dose regimen results 
in cost-effective benefits and a lower burden of treatment for patients. Based on these 
results, we prefer UVB phototherapy in a high-dosage regimen for psoriasis.
A maximum cumulative dosage is set for PUVA treatment, as it is established that 
PUVA therapy has carcinogenic side-effects. For UVB no maximum dose has been 
established yet, because the role of UVB phototherapy in developing skin cancer is 
less clear. UV wavelengths longer than 313nm are not effective in resolving psoriasis, 
whereas wavelengths shorter than 300nm produce only UV burns without clearing 
psoriasis. As narrow-band UVB excludes short wavelengths of the UVB-spectrum, and 
is closer to UVA, higher doses are needed to induce a photobiological effect. Therefore,
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theoretically, narrow-band UVB phototherapy has an increased risk of developing skin 
cancer compared to broad-band UVB phototherapy. In 2007, Kirke et al. demonstrated 
a limited higher clearance rate after treatment with narrow-band UVB phototherapy 
compared with selective broad-band UVB with an equal number of exposures and 
cumulative dosage to clearance.16 They suggested that phototherapy using a selective 
broad-band source might be a safer option. However, narrow-band UVB phototherapy 
is preferred by Tjioe et al.. They found similar effects on inflammation and photodamage 
after irradiations in narrow- and broad-band UVB phototherapy in healthy volunteers.17 
The carcinogenic risk is negated by the increased efficacy compared with broadband 
UVB phototherapy. Up till now, no significant association between the development 
of NMSC and narrow-band UVB-phototherapy has been demonstrated.18 However, 
sunburn and chronic sun exposure are well-known risk factors for developing NMSC. 
Most protocol adjustments in the present study were made because of erythema after 
four to five irradiations in the high-dose regimen. Consequently, a protocol adjustment 
in the second week with a high-dose regimen is desirable to prevent moderate to 
severe erythema. Minimal perceptible erythema is essential as it indicates an 
adequate treatment dosage, but well-defined and symptomatic erythema are potential 
carcinogenic risk factors. Therefore, intensive personal guidance of the psoriasis 
patient during narrow-band UVB therapy is required to avoid burning and to achieve 
optimal results during and after UVB phototherapy.
4.3.1.2 To assess predictors for the time to clearance of psoriasis with narrow-band 
UVB phototherapy
Independent of the dosage schedule, there is a high individual variability in the number 
of UVB treatment sessions patients need for clearance. The above mentioned study 
demonstrates that patients with mild to moderate psoriasis receiving UVB-phototherapy 
with a high-dose regimen needed significantly fewer irradiation sessions to achieve 
clearance. A lower MED, higher cumulative dosage and more protocol adjustments 
were associated with more irradiation sessions and are thus potential predictors of 
time to clearence. Potential other predictors of time to clearence are itch and habitual 
scratching and life style factors (average alcohol consumption and smoking habits) 
which were assessed by validated questionnaires, described in paragraph 3.2. 
Higher levels of itching and scratching at study entry were significantly associated with 
more irradiation sessions before achieving clearance. Thus, several factors could be 
identified as predictors of the time to clearance. However, the severity of psoriasis, skin 
type or lifestyle variables, like smoking habits and alcohol use, did not influence the 
treatment outcome.
The role of itching and related scratching behavior has frequently been neglected in 
psoriasis, specifically in their role with respect to treatment efficacy of UVB treatment. 
Most patients with psoriasis suffer from relatively persistent itching and scratching.
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UVB phototherapy itself can also elicit itching and scratching as a result of erythema 
and dryness of the skin. We found that the levels of itching and scratching predicted 
the time to clearance, independently of the above mentioned clinical and treatment- 
related factors. High levels of itching and scratching may worsen plaque psoriasis 
(Koebner phenomenon, see paragraph 1.6.2). Thus, the beneficial effects of UVB 
treatment, may be counteracted by severe itch and habitual scratching. Worsening 
of psoriasis during phototherapy results in the need of more irradiations to achieve 
clearance and consequently reduce the cost-effectiveness of high-dose UVB 
phototherapy. Therefore, identification and guidance of patients with a chronic skin 
disease, who are experiencing itching and scratching, may be cost-effective adjuncts 
to UVB phototherapy. However, itching and scratching did not influence the number 
of patients with psoriasis achieving clearance, which suggests that other factors are 
responsible for treatment failure during treatment with UVB phototherapy.
4.3.1.3 To establish whether treatment adherence is a predictor of long-term 
treatment response in patients with psoriasis who had been successfully treated with 
UVB phototherapy
UVB phototherapy for psoriasis is generally offered in an outpatient clinic, which requires 
the patient to travel three times weekly for eight to ten weeks. The tendency of patients 
to adhere to previous treatment recommendations and advice might be a predictor of 
the long-term effectiveness and maintenance of results after successful treatment. Non­
adherence is a common problem in patients with chronic dermatological conditions, 
including psoriasis. The role of non-adherence on the outcome of dermatological 
treatments, including the long-term effectiveness of UVB therapy in psoriasis, is not 
well understood. The consequences of non-adherence on the therapeutic efficacy of 
UVB phototherapy are described in paragraph 3.3. Non-adherence was assessed 
at baseline in patients, randomized for either narrow-band UVB phototherapy with a 
low-dose regimen or to UVB treatment with a high dose protocol. We used the non­
adherence scale of the ISDL (Impact of Skin Disease on Daily Life) questionnaire19 
asking to what extent patients generally followed the treatment instructions given by 
dermatologists. Regarding the level of non-adherence, 8% of the patients indicated 
to be largely non-adherent with recommended treatment and advice and 63% of the 
patients indicated to be sometimes non-adherent, while 29% were largely adherent. A 
higher level of non-adherence was significantly related to a higher PASI score in the 
follow-up period after cessation of UVB treatment. In accordance to these results, non­
adherence with (previous) dermatological treatment is a predictor of long-term efficacy 
after UVB phototherapy. Therefore, short systematic assessment of non-adherence by 
means of a questionnaire prior to the first irradiation and intensive personal guidance 
of the patient during narrow-band UVB therapy are cost-effective adjuncts to UVB 
phototherapy in psoriasis.
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Discussion and future suggestions for UVB phototherapy in psoriasis
In order to optimize adherence of psoriasis patients undergoing UVB phototherapy and 
to improve the cost-effectiveness, home phototherapy for psoriasis was introduced 
in Sweden in the late 1970's to treat patients living far from their local phototherapy 
unit.20 Recently, more studies on the efficacy and safety of home UVB phototherapy 
are published because of increasing interest for this treatment option.21'23 A drawback, 
limiting the use of home UVB phototherapy, is the potential increased risk of erythema, 
resulting in low dose regimens causing undertreatment. This undertreatment may 
result in prolonged treatment periods with increased cumulative doses. Recently, it was 
demonstrated that UVB phototherapy at home resulted in a lower burden of treatment 
and led to greater patients' satisfaction. UVB phototherapy administered at home was 
equally effective and equally safe as (low-dose) UVB phototherapy administered in an 
outpatient setting. However, patients treated at home had a higher mean total number 
of irradiations than patients treated in the outpatient setting. The mean cumulative 
dose and the number of treatments needed of TL-01 ultraviolet B light at the end 
of therapy were slightly higher for patients treated at home. Long-term efficacy was 
not evaluated. The patients treated with home UVB-phototherapy needed 70% more 
irradiations (34 instead of 20 irradiations) to reach clearance with a higher cumulative 
dosage compared to our outpatient group irradiated with a high-dose UVB regime. 
Their objects treated with outpatient UVB-phototherapy demonstrated comparable 
results (number of treatments needed to reach clearance, cumulative dosage) with 
our low-dose irradiated group. Comparing our study with these recent results, it can be 
concluded that UVB phototherapy with erythematogenic dose regimen is more effective 
than home UVB therapy. In our opinion, for the best short- and long-term results, UVB 
phototherapy should preferentially be administered in an out-patient setting with a 
high-dose regimen under support of experienced personnel to achieve optimal results 
and to avoid burning. When home UVB-phototherapy is considered, non-adherence 
should be assessed before starting treatment.
As described in chapter 3, high-dose UVB phototherapy is superior to low-dose UVB 
treatment regarding clinical results and cost-effectiveness, especially in combination 
with professional guidance of non-adherent patients and patients suffering from chronic 
itch and habitual scratching behavior. Further studies on decreasing the risk of erythema 
in the second week of high-dose UVB therapy and the effects of psychological support 
during phototherapy on time to clearance should be performed.
4.3.2 Evaluation of innovations in phototherapy for psoriasis
The final part of the second aim was to study several innovative treatment options for 
psoriasis, based on phototherapy with visible light, with and without the administration 
of photosensitizers. There is a permanent need for new treatment modalities in the 
treatment of psoriasis as topical therapies are not always successful and demand
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patient's utmost compliance, and many systemic and photo(chemo)therapies are 
limited by cumulative toxicity and carcinogenicity in the long run. Psoriasis has been 
shown to highly accumulate PpIX selectively and its susceptibility to PDT has been 
previously studied by various authors.24’28 In these studies clinical efficacy varied largely, 
but results are difficult to compare because of the different treatment parameters that 
have been used. Considering the discomfort of this treatment and variable clinical 
efficacy, several authors therefore concluded PDT to be unsuitable for the treatment 
of psoriasis.27;29;30
4.3.2.1 To study the clinical effectiveness and immunohistochemical changes of ALA- 
PDT in patients with psoriasis
Previous studies on PDT in psoriasis have mainly focused on clinical efficacy. 
However, knowledge on the histological effects of PDT in psoriasis is crucial, to better 
understand the mechanism responsible for the clinical improvement of psoriasis. The 
aim of paragraph 3.4 was to evaluate the clinical and histological effects of PDT in 
psoriasis with respect to the histological hallmarks of psoriatic plaques, epidermal 
hyperproliferation, abnormal keratinization and inflammation. Eight patients with stable 
plaque psoriasis and symmetrical involvement were included. After clinical adequate 
keratolytic pretreatment with 10% salicylic in petrolatum, the psoriasis plaques, all 
located on the lower extremities, were treated with four fractionated PDT sessions 
with 10% ALA ointment once weekly. Psoriasis severity was clinically assessed by 
using the SUM score. This treatment resulted in a significant clinical improvement 
of chronic psoriasis plaques compared with the sites treated with vehiculum-PDT. 
Generally, treatments were well tolerated by all patients. Some patients complained 
of pain, but this was no reason for discontinuation of treatment. Two patients in our 
study demonstrated an increase in psoriatic activity, but not in the placebo-treated 
plaques. This observation is highly suggestive for the Koebner phenomenon. To study 
the histological effects, biopsies were taken at baseline, after one week and at week 6 
(two weeks after the last treatment session). Histologically, normalization of epidermal 
proliferation (60% decrease of Ki67-expression), normalization of differentiation (16% 
increase of K10-expression) and a decrease in T cell infiltration were seen. Already 
one week after the first PDT session not only clinical improvement, but also statistically 
significant improvements of differentiation and proliferation were seen and these 
observations were even more pronounced at week 6. Significant improvement of 
epidermal CD8+ and dermal CD45RO+ cells were not seen until week 6, while the 
amount of CD4+ cells did not change.
To study PpIX in the treated areas, fluorescence intensity on the skin was assessed. 
Despite adequate keratolytic pretreatment, most treated psoriasis plaques showed 
inhomogeneous fluorescence. The fluorescence intensity varied within plaques and 
within patients. Consequently, an inhomogeneous photodynamic dose is delivered
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over the epidermal surface. These variations in fluorescence could be the explanation 
for the variable and mostly partial clinical response seen after PDT. Histologically, after 
one treatment improvement of histological hallmarks of psoriasis in the epidermis were 
seen, whereas anti-psoriatic effects in the dermis were not seen until week 6. PDT has 
its main effects in the epidermis. However, the clinical efficacy of PDT in psoriasis is 
dependent on deliverance of an adequate photodynamic dose in both epidermis and 
dermis. It is possible that due to an impaired distribution of the photodynamic effect in 
the deeper layers of the skin multiple PDT sessions with a low photodynamic dose are 
needed to induce significant dermal effects in psoriasis. An impaired photodynamic 
effect could be the result of impaired penetration of the photosensitizer as well as of the 
light. The present study confirms that PDT is able to improve psoriasis both clinically and 
histologically. Because of its partial response compared to the established treatment 
options for psoriasis, the time-consuming treatment procedure and its potential 
unfavorable adverse event profile (risk of Koebnerization and pain during treatment), 
PDT will not be a first-line treatment option for psoriasis. PDT could be considered in 
case of limited psoriasis (in cosmetic sensitive areas), when conventional treatments 
have failed.
4.3.2.2 To study the morphological and immunohistochemical differences in 
inhomogeneous PpIX-induced fluorescence in stable plaque psoriasis
The heterogeneous fluorescence in psoriasis, observed in the previous study, was 
further studied in paragraph 3.5, as it is unknown what causes this variable distribution of 
fluorescence between plaques and patients, despite adequate keratolytic pretreatment. 
Variable fluorescence seems to be related in part to the amount of hyperkeratosis within 
a plaque, as pretreatment with a keratolytic agent improves fluorescence homogeneity. 
Theoretically, hyperkeratosis induces a limited penetration of ALA ointment and light. 
Also an increased metabolic activity of hyperproliferative parts within a psoriasis plaque 
and subsequently an increased synthesis of PpIX may influence fluorescence intensity. 
After clinical adequate desquamation, the clinical appearance of the studied stable 
psoriatic plaques of fourteen patients was equal. However, fluorescence distribution 
following incubation with 20% ALA ointment for three hours was not predictable. 
Biopsies were taken from high- and low-fluorescent parts within psoriasis plaques 
and analyzed with respect to morphological differences and differences in psoriatic 
activity. A significantly thicker stratum corneum was found in low-fluorescent psoriatic 
skin, thereby proving that fluorescence intensity and stratum corneum thickness 
are negatively correlated. The variable-fluorescent parts of lesional psoriatic skin 
showed no significant differences in epidermal proliferation (Ki67), keratinization (K10, 
filaggrin) or inflammation (CD3). According to these results, differences in psoriatic 
activity are not responsible for differences in fluorescence distribution, assuming that 
stratum corneum functions as a mechanical barrier in limiting penetration of ALA and
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light. In psoriasis, stratum corneum structure and function correlates with phenotype 
in psoriasis.31 Disturbances in stratum corneum integrity could be responsible for 
the increased PpIX-fluorescence in psoriatic skin after application of ALA. However, 
hyperkeratosis is frequently seen in psoriasis and according to the present study, 
there is a negative correlation between stratum corneum thickness and fluorescence 
intensity. Pretreatment aimed at the removal of hyperkeratosis seems to be of utmost 
importance and is therefore strongly recommended for the most favorable results in 
FDAP and PDT. Consequently, a homogeneous photodynamic dose is delivered over 
the entire epidermal surface, minimizing the chance of Koebnerization and suboptimal 
PDT as a result of insufficient fluence.
4.3.2.3 To study the effects of different keratolytic pretreatments in PpIX-induced 
fluorescence diagnosis (FDAP) and during photodynamic therapy (PDT)
Inhomogeneous distribution of PpIX may result from variations in the amount of 
hyperkeratosis, leading to a variable penetration of ALA and light. Apparently, 
pretreatment of the psoriasis plaques with 10% salicylic acid in petrolatum was 
not sufficient to remove all hyperkeratosis. In paragraph 3.6, different keratolytic 
pretreatment supplementary to the standard keratolytic pretreatment, 10% salicylic 
acid in petrolatum, prior to FDAP and PDT were clinically and immunohistochemically 
analyzed. Both topical retinoic acid and a hydrocolloid dressing induced a clinical 
improvement of psoriasis, but the hydrocolloid dressing decreased scaling, erythema 
and induration best after 2 weeks of pretreatment. Our aim was to use these keratolytic 
agents to reduce the amount of hyperkeratosis in order to optimize FDAP and PDT 
results. As in daily practice FDAP and PDT are used in non-melanoma skin cancer, 
no significant changes in histopathology were required. Both topical retinoic acid and 
the hydrocolloid dressing demonstrated no added value to a more homogeneous 
fluorescence pattern or a further decrease in stratum corneum thickness or keratinization. 
A hydrocolloid dressing induced the best clinical improvement. Application of tretinoin 
cream induced clinical side effects, pain and point bleedings of the treated skin, 
and a significant reduction in filaggrin, indicating irritation caused by damage to the 
stratum corneum. According to these results, a hydrocolloid dressing was used as an 
alternative pretreatment to 10% salicylic acid in petrolatum. Subsequently, these two 
different keratolytic pretreatment regimes were evaluated in combination with PDT of 
psoriasis. Six PDT treatments with a weekly interval were administered to all pretreated 
plaques of 10 included patients with stable plaque psoriasis. No significant clinical and 
immunohistochemical differences were seen between salicylic acid in petrolatum, as 
the standard keratolyticum prior to FDAP and PDT, and a hydrocolloid dressing, as an 
alternative pretreatment option. As expected by our previous studies (paragraph 3.4), 
the clinical appearance and immunohistochemical hallmarks of psoriasis improved 
as a result of PDT, but not as a result of the pretreatment of choice. In conclusion,
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the clinical and histological effects of a hydrocolloid dressing were comparable with 
the results of salicylic acid in petrolatum. According to these results, a hydrocolloid 
dressing is a good alternative keratolytic pretreatment option and might be preferred 
above salicylic acid in petrolatum, for instance if the target lesion is difficult to reach 
and when compliance to apply ointment might be a problem.
Discussion and future suggestions for PDT in psoriasis
In chapter 3 a search for the optimal PDT treatment protocol was done. PDT has 
shown to improve psoriasis both clinically and histologically, but currently it is still 
not suitable as a standard treatment option for psoriasis because of the variable and 
partial clinical responses. These variable and partial clinical responses after PDT could 
be explained by differences in hyperkeratosis within and between psoriasis plaques. 
Pretreatment aimed at the removal of hyperkeratosis seems to be of utmost importance 
and is therefore strongly recommended for the most favorable results in FDAP and 
PDT. Pretreatment of hyperkeratosis can be achieved with keratolytics, but also with 
curettage/debulking, tape stripping, microdermabrasion or laser ablation.32‘35 These 
pretreatments enhance PpIX fluorescence by facilitating penetration of its precursor 
into the skin, but consequently its selectivity could be decreased as the uptake of 
ALA in normal skin is also increased. Both 10% salicylic acid in petrolatum and a 
hydrocolloid dressing induce improvement of fluorescence intensity of the lesional 
skin, but are not sufficient to remove all hyperkeratosis. Further development of more 
adequate keratolytic pretreatment options are necessary to optimize the results of PDT 
and FDAP
Future studies on optimizing the treatment protocol for PDT in psoriasis should not 
only aim at minimizing the amount of hyperkeratosis. Selective PpIX accumulation in 
lesional skin is influenced by a multistep process of the photosensitizer: penetration 
through the epidermis, cellular uptake and metabolic conversion into porphyrins. More 
studies are necessary to optimize the intrinsic factors of the skin, but also extrinsic 
factors of the drug used influencing the PpIX accumulating factors. The penetration of 
hydrophilic ALA is limited, because the stratum corneum contains lipophilic elements. 
ALA esters with an increased lipophilic nature may thus enhance their penetration 
into the skin. Penetration enhancers increase PpIX fluorescence and improve the 
clinical outcome in PDT.11 3637 Several studies have been performed on the use of 
iron-chelating additives, preventing breakdown of PpIX by inhibition of ferrochelatase, 
or iontophoresis to increase the penetration of ALA.38‘41 As PpIX production is also 
dominated by temperature-dependent processes, elevating skin temperature during 
ALA application may also improve treatment results.42 43 Thus, simple pretreatments or 
additions to the regular practice of PDT, aimed to optimize intralesional PpIX content, 
improve the clinical outcome. Dosimetry should also be taken into account, because 
PDT has its main effects in the epidermis. The target for photodynamic effects in 
psoriasis is not solely localized in the epidermis, but also in the dermis. Photodynamic
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doses that are too low do not appear to be therapeutically effective. On the other hand, 
psoriasis is highly susceptible for Koebnerization. The Koebner phenomenon is most 
likely a dose-dependent side effect of PDT, although an exact dose-effect relationship 
has not yet been established.44‘47 In conclusion, an optimal treatment protocol still has 
to be established for PDT in psoriasis.
4.3.2.4 To study the clinical and histological effects of blue light on normal skin
The absorption of visible light or UV radiation by chromophores in the skin is the main 
event in commencing biological effects of light on the skin. In PDT, irradiation with 
visible light induces activation of PpIX and subsequent formation of oxygen radicals 
results in selective tissue destruction. PpIX has a maximum absorption peak at 408nm 
and as a result blue light is more effective than red light in activating PpIX. The visible 
spectra of porphyrins also show weaker absorption peaks at longer wavelengths. For 
optimal activation of PpIX, not only the maximal absorption spectrum of PpIX, but also 
the absorption characteristics of the skin have to be considered. Therefore, red light 
is generally preferred in PDT because of deeper light penetration into the skin. The 
application of a standard preparation containing MAL, followed by red light irradiation 
has now been approved for AKs, Bowen's disease, superficial and small nodular BCCs 
in European countries. However, ALA solution plus blue light exposure has been 
approved for the treatment of AKs in the USA.
Irradiation of Propionibacterium acnes colonies with visible blue light, with or without the 
exogenous application of ALA, leads to photoexcitation of bacterial porphyrins, singlet 
oxygen production, eventually bacterial destruction and anti-inflammatory effects on 
keratinocytes.4849 Nevertheless, the effects of visible light on the skin are only partly 
known. For the photodynamic effect, it is essential to increase the amount of locally 
available chromophores by applying 5-ALA or MAL. However, chromophores, such as 
DNA and bilirubin are naturally available in the skin. It is feasible that irradiation of these 
endogenous chromophores could induce oxidation of surrounding molecules and lead 
to adverse photobiological reactions, like photo-ageing and photocarcinogenesis.5051 
Multiple irradiations of high-dose red light on normal skin induces a significant 
increase in vacuolization, without signs of apoptosis, photo-damage or skin ageing.52 
Theoretically, blue light could induce biological effects comparable to UVA radiation, 
because wavelengths of blue light are closely related to the UVA spectrum. It is 
established that UVA has effects on photo-ageing and, in combination with psoralens, 
carcinogenic side-effects on the long-term. Several studies have shown that near UVA 
irradiation results in UVA-like effects. In paragraph 3.7 the clinical and histological 
effects of blue light on normal skin were studied. Eight healthy volunteers were 
included and irradiation with visible blue light to a cumulative dose of 100 J/cm2 was 
given on five consecutive days. This study demonstrated a significant increase in 
perinuclear vacuolization with normalization after cessation of the irradiations, without
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signs of apoptosis, like the presence of sunburn cells or changes in p53-expression. 
No signs of photo-ageing were demonstrated. As only the short-term effects of visible 
light were tested, no conclusions can be drawn regarding the long-term effects of the 
photo-ageing effects of visible light on the skin. Clinically, mild hyperpigmentation was 
noticed and this was histologically confirmed by a significant increase of Melan-A. Both 
clinical and histological hyperpigmentation decreased after cessation of treatment. 
According to these results, the biological effects of blue light on normal skin are 
transient melanogenesis and inexplicable vacuolization without resulting apoptosis. 
Thus, (short-term) use of visible blue light in dermatological practice is safe for patients 
and personnel of the phototherapy department.
4.3.2.5 To study the effects of blue and red light in stable plaque psoriasis
Psoriasis has shown to accumulate PpIX after application of ALA. PpIX is also 
present in psoriatic skin without the preceding application of its precursor. PpIX has 
a maximum absorption peak at 408nm and as a result blue light is more effective 
than red light in activating PpIX. On the other hand, multiple exposures to blue light 
without the administration of ALA, the precursor of PpIX, have been reported to induce 
anti-inflammatory effects. Recently, Liebmann et al. demonstrated that blue light may 
be effective in treating hyperproliferative skin conditions, because blue light reduces 
proliferation.53 Consequently, the interaction of high-dose visible light and potential 
endogenous photosensitizers, like PpIX, in psoriasis may represent a new principle 
for photodynamic treatment of psoriasis. In paragraph 3.8 treatments with high-dose 
blue light and red light in psoriasis were analyzed with respect to clinical improvement 
and potential side effects. In 20 patients two stable psoriatic plaques were treated 
with either blue or red light, three times weekly for four consecutive weeks. One week 
before baseline until the end of the study, psoriasis plaques were treated with 10% 
salicylic acid in petrolatum once daily. A significant decrease in desquamation was 
demonstrated one week after pretreatment and this effect was maintained by continuing 
the pretreatment during the whole study period. Also induration decreased significantly 
after one week of pretreatment, whereas erythema did not change. Both treatment 
with red and blue light induced a decrease in erythema and induration. Blue light was 
superior in improving inflammation, as treatment with red light showed no statistically 
significant improvement of erythema anymore after 6 illuminations. However, it needs 
to be mentioned that the fluence rate of red light was lower. Treatment was very well 
tolerated by all patients. Besides hyperpigmentation no other complications were 
noticed.
To evaluate the additional value of visible light on the keratolytic pretreatment of 
psoriasis, 7 patients were invited to treat one psoriasis plaque once daily with 10% 
salicylic acid in petrolatum as a monotherapy for four consecutive weeks. This additional 
pilot study demonstrates that salicylic acid in petrolatum is responsible for the major
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decrease of desquamation, but also induration decreased significantly. In conclusion, 
treatments with salicylic acid in petrolatum has such a great impact on desquamation, 
that irradiation with blue or red light does not have an added value on descaling of 
psoriasis. Also no additional effect of visible light on induration of the psoriasis plaques 
was seen, probably because the amount of hyperkeratosis influences the clinical score 
of induration. Erythema did not change after four weeks of salicylic acid ointment 
alone, whereas both blue and red light induced a significant improvement of erythema. 
Improvement of erythema in blue irradiated psoriasis plaques continued throughout 
the whole study period, while after treatment with red light no statistically significant 
improvement was seen after 6 illuminations. The clinical improvement of psoriasis, with 
respect to erythema, in particular after blue light and to a lesser extent after red light 
indicates that visible light treatment could represent an alternative treatment option for 
psoriasis.
Discussion and future suggestions for phototherapy with visible light
Photodamage is characterized by an increase in p53-expression, the presence of 
sunburn cells and cells with perinuclear vacuolization. The perinuclear vacuolization 
in our study was probably not an apoptotic effect, because the p53-expression did 
not change and sunburn cells were absent. As described in chapter 3, irradiation 
with visible light appears to be safe, but it is unknown what causes the perinuclear 
vacuolization. Long-term studies could provide more information on the significance 
of this phenomenon. The presented study on blue light, but also the previous study of 
Tjioe et al. on red light, were done with a broad-band light source, emitting wavelengths 
ranging from 380-480nm, respectively 560-700nm.52 Nowadays, different light sources 
with different illumination parameters are used, for example small-band light sources. 
Differences in light sources changes light dosimetry. Thus, new and long-term studies 
with the use of current light sources are needed.
A short-coming of the study on the effects of blue and red light in psoriasis is the lower 
fluency of red light. Both blue and red light induced an improvement on erythema in 
psoriasis. As mentioned before, the decrease in inflammation continued throughout 
the study for the psoriasis lesions treated with blue light. Possibly, red light could 
demonstrate comparable results with an equal fluency. Perhaps that the combination 
of both red and blue light could also be an effective treatment for psoriasis. Therefore, 
in the future more studies are needed on dose finding, frequency of treatment and 
comparing various treatment schedules with different exposition durations. With a 
prolonged treatment duration, like in UVB phototherapy for psoriasis, not only erythema 
will improve, but possibly also induration will decrease. Also, the exact mechanism 
responsible for the improvement of psoriasis after irradiations with high-dose visible 
light are still not known and needs further investigation.
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4.4 General conclusions
- FDAP is not useful in discriminating between the different KIN-stages nor can it be 
used as a marker for proliferative activity.
- At present, FDAP is not sensitive enough to state with certainty that a lesion is AK, 
Bowen's disease or SCC.
- MAL-PDT induces a high clearance rate of AKs with a marked improvement in 
photodamage and prevention of developing new AKs.
- The efficacy of MAL-PDT in AKs is dependent on the degree of field 
cancerization.
- More than two PDT sessions are needed in patients with a severe degree of field 
cancerization.
- UVB-phototherapy in a high-dose regimen results in 20% fewer treatments with 
better long-term effects with cost-effective benefits and a lower burden of treatment 
for patients.
- The beneficial effects of UVB treatment may be counteracted by severe itch and 
habitual scratching.
- Identification and guidance of patients with a chronic skin disease, who are 
experiencing itching and scratching, could be a cost-effective adjunct to UVB 
phototherapy.
- A higher level of non-adherence is related to a higher PASI score in the follow-up 
period after cessation of UVB treatment.
- Non-adherence with (previous) dermatological treatment is a predictor of long-term 
efficacy after UVB phototherapy.
- Assessment of barriers and/or facilitators for adherence and identification of 
patients might be cost-effective adjuncts to UVB phototherapy.
- Fractionated PDT is able to clinically and histologically improve psoriasis.
- Fractionated PDT in psoriasis is able to normalize proliferation and differentiation in 
the epidermis and to reduce relevant T cell subsets predominantly in the epidermis, 
but also in the dermis.
- Differences in stratum corneum thickness, but not differences in psoriatic activity, 
are responsible for heterogeneous fluorescence within and between psoriasis 
plaques.
- These variations in fluorescence may explain the variable and mostly partial clinical 
response seen after PDT in psoriasis.
- Stratum corneum thickness is negatively correlated with fluorescence intensity, 
indicating that the skin barrier limits penetration of ointments and/or light.
- Pretreatment aimed at the removal of hyperkeratosis is essential for most optimal 
results in FDAP and PDT.
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- A hydrocolloid dressing is a good alternative pretreatment option to the current 
keratolytic pretreatment, salicylic acid in petrolatum.
- Blue light does not induce photodamage or photo-ageing and may be used as a 
safe treatment option in dermatological practice.
- The biological effects of blue light on normal skin are transient melanogenesis and 
inexplicable vacuolization without resulting apoptosis.
- The (short-term) use of visible blue light in dermatological practice is safe.
- Both treatment with red and blue light induces a decrease in erythema within 
psoriasis plaques.
- Salicylic acid in petrolatum as a monotherapy significantly decreases the amount 
of desquamation and induration in psoriasis.
- Treatment with visible light, in particular blue light and to a lesser extent red light, 
could represent an alternative treatment option for psoriasis.
4.5 Future perspectives
Nowadays, PDT is an approved treatment option for AKs, Bowen's disease, superficial 
BCCs and small nodular BCCs. Despite excellent clinical results observed with PDT 
in NMSC, there is still a significant number of recurrent lesions within three years after 
PDT.54 At this moment, FDAP is not sensitive enough as a non-invasive technique 
for detection and demarcation of skin (pre)malignancies. However, FDAP is still an 
interesting tool to study PpIX accumulation in vivo. Therefore, FDAP may be helpful in 
optimizing PDT and the exploration of new indications for PDT 
PDT is time consuming and often painful for the patient. As mentioned in the general 
discussion, daylight-PDT would make the treatment independent of the clinic and 
less painful due to the continuous activation of small amounts of porphyrins during its 
formation. Maybe, in the future, ALA or MAL could play a role in daily practice as an 
additive to day cream or sunscreens in order to treat and prevent early actinic damage. 
Since our studies confirmed that PDT is able to improve psoriasis, future possibilities 
for daily practice would be ALA or MAL containing ointments in the topical treatment 
of psoriasis.
UVB phototherapy is an important treatment option in extensive psoriasis and/or 
when topical application of anti-psoriatic agents fail. In order to optimize adherence of 
psoriasis patients undergoing UVB phototherapy and to improve the cost-effectiveness, 
home phototherapy for psoriasis is of upcoming interest. A major drawback of home 
UVB phototherapy is the potential increased risk of erythema, resulting in low dose 
regimens causing undertreatment. Whereas more research is still necessary to optimize 
the current UVB dosage schedule, there are recent studies on the use of visible light in 
psoriasis. Both PDT as high-dose visible light are safe treatments and able to induce 
improvement of psoriasis. Maybe, in the future, it may be possible to treat psoriasis
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in a home setting with high-dose visible light whether or not in combination with ALA 
or MAL containing anti-psoriatic ointments. This kind of home phototherapy would 
decrease the risk of undertreatment and actinic damage. Also clothing (e.g. pyjamas) 
or other applications containing high dose visible (LED) light may be easily used in 
daily practice to treat psoriasis.
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5.1 Introductie
Het centrale thema in dit proefschrift is onderzoek naar diagnostische en therapeutische 
innovaties binnen de fotodermatologie. Licht bestaat uit verschillende golflengtes 
en heeft verschillende invloeden op de huid. Het fotobiologische effect van licht 
is afhankelijk van de golflengte. Licht is een causale factor van (voorstadia van) 
huidkanker, maar licht kan ook gebruikt worden als diagnostisch hulpmiddel of als 
behandeling bij inflammatoire dermatosen of verschillende vormen van non-melanoma 
huidkanker (NMSC).
Er werden twee doelstellingen geformuleerd, waarbij een verdeling werd gemaakt 
tussen de effecten van licht op actinische keratosen (AKs) en plaveiselcelcarcinomen 
(PCCs) en de effecten van licht op psoriasis.
I: Het optimaliseren van fluorescentiediagnostiek en fotodynamische therapie bij non­
melanoma huidkanker (hoofdstuk 2)
II: Het verbeteren van UVB-lichttherapie bij psoriasis en het evalueren van 
vernieuwingen binnen de fotodermatologie voor psoriasis (hoofdstuk 3)
Hiervoor werd in de algemene introductie, hoo fdstuk 1, een overzicht gegeven van 
de onderwerpen, die relevant zijn als achtergrondinformatie voor dit proefschrift. 
De verschillende effecten van zowel zichtbaar als ultraviolet licht op de huid, maar 
ook de relevante aspecten van AKs en psoriasis werden uitvoerig besproken. De 
doelstellingen werden in hoo fdstuk 2 en hoo fds tuk  3 aan de hand van originele 
artikelen beantwoord.
5.2 Het optimaliseren van fluorescentiediagnostiek en 
fotodynamische therapie bij non-melanoma huidkanker
In hoo fds tuk  2 werden zowel diagnostische methoden als behandelmogelijkheden 
voor NMSC bestudeerd. Huidkanker is de meest voorkomende vorm van kanker in 
de Westerse wereld met een voortdurend groeiende incidentie. De meeste patiënten 
met huidkanker hebben NMSC. Meer en meer NMSC ontstaan in gebieden met 'field 
cancerization'. Field cancerization wordt gekenmerkt door huidgebieden met multipele 
(pre)maligne huidlaesies, die diffuus verspreid zijn, met name op de zonblootgestelde 
huid. AK en Morbus Bowen worden gezien als voorstadia van PCC, dat kan 
metastaseren. Naast spontane regressie toont een aanzienlijk deel van de AKs ook 
progressie naar PCC. Omdat voorafgaand aan deze progressie niet duidelijk is welke AK 
de potentie heeft om maligne te worden, is het essentieel om alle AKs te diagnosticeren 
en behandelen. Hierdoor zal de kans op genezing toenemen en de kosten van de
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behandeling afnemen. Ook morbiditeit en mortaliteit zullen geminimaliseerd worden. 
In het eerste deel van hoofdstuk 2 werd fluorescentiediagnostiek (FDAP) onderzocht. 
Het laatste deel van dit hoofdstuk beschreef het onderzoek naar de effecten van 
fotodynamische therapie (PDT) bij AKs in het gelaat of op de scalp.
5.2.1 Het evalueren van de waarde van fluo rescen tied iagnostiek  als 
d iagnosticum  om  te  kunnen d iscrim ineren  tussen ve rsch illende  KIN-stadia o f 
p ro life ra tie -sta tus
FDAP kan van toegevoegde waarde zijn in het afgrenzen van aangedane huid en 
bij het differentiëren tussen AKs en invasieve PCCs. Deze diagnostische methode 
is nog steeds niet reproduceerbaar door verschillende factoren, die de detectie 
van de fluorescentie beïnvloeden, en door de beperkte kennis over de selectiviteit 
van protoporfyrine IX (PpIX). In eerste instantie werd FDAP toegepast op AKs. De 
potentiële waarde van FDAP als non-invasieve diagnostische procedure om te 
differentiëren tussen de verschillende stadia van keratinocytische intra-epidermale 
neoplasieën (KIN) werd beschreven in paragraaf 2.1. KIN III laesies neigden naar 
een hogere lesionale:non-laesionale fluorescentieratio vergeleken met KIN I en KIN II 
laesies, maar er werden geen significante verschillen geconstateerd in fluorescentie- 
ratio tussen de verschillende KIN-stadia. Geconcludeerd werd dat FDAP niet kan 
differentiëren tussen de verschillende KIN-gradaties. Tevens werd gekeken naar 
andere factoren, die de macroscopische fluorescentie zouden kunnen beïnvloeden, 
zoals de dikte van het stratum corneum en de proliferatiegraad (expressie van Ki67- 
antigeen). Macroscopische fluorescentie bleek onafhankelijk van de proliferatiegraad, 
maar is daarentegen negatief gecorreleerd met de dikte van het stratum corneum. 
Per toeval werden bij 1 patiënt 3 beginnende, micro-invasieve, plaveiselcelcarcinomen 
gebiopteerd, welke de hoogste fluorescentie-ratios toonden. Hierop werd een 
vervolgonderzoek (paragraaf 2.2) ingezet om te onderzoeken of FDAP gebruikt kan 
worden om AKs te onderscheiden van invasief PCC.
5.2.2 Het bestuderen van de m oge lijkhe id  om  m iddels fluo rescen tied iagnostiek  
te  d iscrim ineren  tussen actin ische  keratose en p lave ise lce lcarc inoom
In paragraaf 2.2 werd de fluorescentie-ratio van AKs vergeleken met de 
macroscopische fluorescentie van PCCs. KIN III laesies hadden in dit onderzoek een 
significant hogere fluorescentie-ratio vergeleken met de laaggradige AKs, terwijl de 
macroscopische fluorescentie opnieuw vergelijkbaar laag was tussen KIN I en KIN II 
laesies. De fluorescentie-intensiteit van KIN III laesies was hoger dan de fluorescentie- 
ratios van PCCs. Opnieuw werd geconcludeerd dat FDAP niet gebruikt kan worden 
om te differentiëren tussen de verschillende KIN-gradaties, maar dat FDAP ook niet 
in staat is om PCCs te onderscheiden van AKs. Ook in deze studie werd gekeken
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naar de invloed van het stratum corneum op de fluorescentie-intensiteit. Tussen de 
verschillende histologische diagnoses werden geen verschillen in stratum corneum 
dikte gezien. Opnieuw werd een negatieve correlatie tussen stratum corneum dikte en 
fluorescentie aangetoond, maar ondanks klinisch adequate ontschilfering voorafgaand 
aan FDAP, was deze correlatie minder sterk dan bij onze eerdere onderzoeken. Dit 
suggereert dat er, naast de hoeveelheid hyperkeratose, ook andere factoren van 
invloed zijn op de PpIX-accumulatie. Echter, bij nadere analyse bleek dat de hoogste 
macroscopische fluorescentie-waardes van PCCs afkomstig waren van micro- 
invasieve plaveiselcelcarcinomen (mi-PCCs), vergelijkbaar met de resultaten van ons 
eerdere onderzoek (paragraaf 2.1). De mi-PCCs hadden een fluorescentie-intensiteit 
overeenkomstig met KIN III laesies. Klinisch zijn mi-PCCs moeilijker te onderscheiden 
van AKs dan andere, meer invasieve PCCs. In combinatie met het klinische beeld 
kan FDAP mogelijk AKs met maligne potentie en mi-PCCs onderscheiden van 
overige verdachte laesies. Op dit moment is FDAP niet sensitief genoeg om te dienen 
als alternatief voor histopathologisch onderzoek. Op basis van macroscopische 
fluorescentie is niet met zekerheid te stellen of er sprake is van AK, Morbus Bowen of 
PCC. Meer onderzoek is nodig om te achterhalen of FDAP van aanvullende waarde 
kan zijn als non-invasief diagnostisch hulpmiddel bij NMSC.
5.2.3 Het bestuderen van de k lin ische  e ffe c tiv ite it van fo todynam ische  
therap ie  met top ica le  m ethylam ino levu linaat (MAL-PDT) in fie ld  cancerization, 
w aarb ij het aantal ac tin ische  keratosen en de mate van actin ische  schade 
werden geb ru ik t als u itkom stm aten
De standaardbehandelingen voor AKs zijn niet altijd even effectief, hebben aanzienlijke 
bijwerkingen (pijn, verlittekening, verlies van pigmentatie) en vereisen een goede 
coöperatie van de patiënt. PDT bij AKs geeft goede klinische resultaten en heeft 
voordelen ten opzichte van de standaardbehandelingen, met name wanneer er sprake 
is van uitgebreide actinische schade, zogenaamde field cancerization. De behandeling 
van AKs met MAL-PDT is inmiddels een geregistreerde behandeling, maar het huidige 
behandelprotocol is niet altijd even effectief. In paragraaf 2.3 werd MAL-PDT toegepast 
op field cancerization op de scalp en in het gelaat. Patiënten met milde actinische 
beschadigingen bereikten volledige genezing met maximaal 2 PDT-behandelingen. 
Een meer ernstige graad van field cancerization gaf een gedeeltelijke, maar statistisch 
significante verbetering. De globale score voor actinische schade, gerelateerd aan 
veranderingen in huidoppervlak, hyperpigmentatie, hypopigmentatie, verlittekening, 
atrofie, teleangiëctasieën en rimpelvorming, verbeterde significant. In de follow-up 
periode werden de eerste recidieven pas na 6 maanden gezien bij de patiënten met 
complete genezing. Vier patiënten hebben het onderzoek vroegtijdig verlaten, omdat 
zij vanwege de pijn tijdens de belichtingen een andere behandeling hebben gekozen. 
Hun pijnscore en aantal AKs per behandelveld waren vergelijkbaar met de patiënten,
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die het onderzoek wel hebben volbracht. Uit deze resultaten kon geconcludeerd worden 
dat MAL-PDT een effectieve behandeling is voor AKs met een preventieve werking 
tegen nieuwe AKs gepaard gaande met een verbetering van cosmetiek. Echter, het 
effect is afhankelijk van de ernst van field cancerization. Patiënten met een milde 
uitgebreidheid van AKs (maximaal 10 tot 12 AKs per behandelveld) hebben voldoende 
aan maximaal 2 belichtingen. Voor de patiënten met ernstige actinische schade, meer 
dan 19 AKs per behandelveld, zijn waarschijnlijk meerdere behandelsessies met MAL- 
PDT noodzakelijk voor een goed therapeutisch effect. Er is meer onderzoek nodig om 
het protocol voor PDT bij ernstige actinische schade te optimaliseren, maar ook om 
pijn tijdens PDT te beperken.
5.3 Het optimaliseren van UVB-lichttherapie en het evalueren 
van vernieuwende vormen van lichttherapie voor psoriasis
5.3.1 Het optimaliseren van UVB-lichttherapie bij psoriasis
Het tweede doel van dit proefschrift was het verbeteren van de standaard lichttherapie 
bij psoriasis en het evalueren van vernieuwingen in lichttherapie voor psoriasis. In 
het eerste deel van hoofdstuk 3 werd de huidige UVB-lichttherapie bij psoriasis 
geoptimaliseerd door de effecten van 2 verschillende belichtingsschema's te 
onderzoeken. Gelijktijdig met dit vergelijkend onderzoek werd ook gekeken naar 
psychosociale factoren, die van invloed kunnen zijn op het klinische effect van de 
lichttherapie, en naar de rol van compliance op het behandelresultaat.
Lichttherapie is een belangrijke behandeloptie bij uitgebreide psoriasis en/of wanneer 
topicale therapieën onvoldoende werkzaam zijn. UVB-lichttherapie heeft de voorkeur 
boven PUVA-lichttherapie, omdat de effectiviteit vergelijkbaar is en het toedienen van 
psoralenen vaak gepaard gaat met bijwerkingen. Het gebruik van PUVA-lichttherapie 
wordt beperkt door cumulatieve toxiciteit en carcinogene bijwerkingen op termijn. 
Verschillen in behandelduur tussen verschillende belichtingsschema's, psychosociale 
factoren van invloed op het effect van de behandeling en de rol van non-compliance 
van de patiënt op het uiteindelijke behandelresultaat werden bestudeerd. Het doel 
was om het protocol van UVB-lichttherapie bij psoriasis te optimaliseren, waardoor 
de klinische resultaten verbeteren en de kosten-effectiviteit toeneemt met minimale 
bijwerkingen.
5.3.1.1 Het bestuderen van verschillen in behandelduur bij patiënten met psoriasis, 
die behandeld worden met UVB-lichttherapie in een hoog of laag gedoseerd 
belichtingsschema, in een dubbelblind, gerandomiseerd onderzoek
De afgelopen jaren zijn meerdere onderzoeken verricht naar het optimale 
belichtingsschema voor smal spectrum UVB-lichttherapie bij psoriasis. De meeste
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onderzoeken bestudeerden verschillende belichtingschema's in een links-rechts 
vergelijking binnen een en dezelfde patiënt. De onderzoekers hebben hierbij geen 
rekening gehouden met de systemische effecten van UVB-lichttherapie. UVB- 
belichting beïnvloedt zowel de lokale als de systemische immuniteit door afname van 
Langerhanscellen, afremming van Th1-reacties en het induceren van cis-urocaanzuur. 
In paragraaf 3.1 werden 109 patiënten met stabiele psoriasis vulgaris willekeurig 
verdeeld over twee verschillende belichtingsschema's. De helft van de patiënten werd 
behandeld met een hoog gedoseerd belichtingsschema, terwijl de andere patiënten 
een laag gedoseerd belichtingsschema kregen toegewezen. Patiënten werden 3 keer 
per week belicht met een stijgingspercentage van 40% (hoog gedoseerd schema) 
of 20% (laag gedoseerd schema). De therapie werd gestopt als er sprake was van 
clearance, wanneer er, ten opzichte van de start van het onderzoek, minder dan 
10% van de psoriasis plaques resteerde. Er werd ook gestopt wanneer er na 30 
belichtingen nog geen 90% verbetering werd geconstateerd, de psoriasis toenam 
ondanks de lichttherapie of in geval van persisterende roodheid en verbrandingen 
als gevolg van de lichttherapie. Uiteindelijk was het aantal patiënten, dat een 
verbetering van 90% behaalde, en het aantal patiënten, dat uitviel, vergelijkbaar in 
beide belichtingsschema's. Het hoog gedoseerde schema gaf sneller clearance met 
20% minder belichtingen zonder verschil in cumulatieve UV-dosis, maar wel met meer 
protocolaanpassingen als gevolg van erytheem. In de follow-up periode werden geen 
verschillen gezien in het terugkeren van psoriasis plaques. Wel werd in het vervolg­
traject een minder ernstige psoriasis gezien bij patiënten, die het hoog gedoseerde 
schema hadden gevolgd. Hieruit kan geconcludeerd worden dat het hoog gedoseerde 
schema niet alleen leidt tot significant minder belichtingen, maar ook betere lange 
termijn resultaten geeft.
5.3.1.2 Het aantonen van psychosociale factoren, die van invloed zijn op het effect 
van de behandeling met smal spectrum UVB-lichttherapie bij psoriasis
Onafhankelijk van het belichtingsschema is er een grote individuele verscheidenheid 
in het aantal belichtingen, dat een patiënt nodig heeft om 90% verbetering van 
psoriasis te bereiken. In paragraaf 3.1 werd aangetoond dat patiënten, die behandeld 
werden met een hoog gedoseerd UVB-belichtingsschema, significant minder 
belichtingen nodig hadden. Een lagere startdosis, hogere cumulatieve doseringen en 
meer protocolaanpassingen werden in eerdere onderzoeken geassocieerd met meer 
benodigde belichtingen.
Potentieel andere voorspellende factoren voor de behandelduur, jeuk met habitueel 
krabben en leefstijlfactoren (alcoholconsumptie, rookgewoontes), werden via 
vragenlijsten onderzocht in een additionele studie, beschreven in paragraaf 3.2. 
Geconcludeerd werd dat er meerdere factoren van invloed zijn op de behandelduur. 
Meer jeuk gevolgd door habitueel krabben bleek significant geassocieerd te zijn
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met meer belichtingen. Niettemin is gebleken dat jeuk met habitueel krabben niet 
verantwoordelijk is voor het aantal patiënten, dat uiteindelijk clearance middels 
lichttherapie bereikt. Dit suggereert dat er andere factoren verantwoordelijk zijn voor 
het vroegtijdig afbreken van lichttherapie bij psoriasis. Echter, de ernst van psoriasis, 
huidtype of leefstijlvariabelen, roken en alcoholgebruik hadden geen invloed op het 
behandelresultaat.
De rol van jeuk en het hieraan gerelateerde habituele krabben worden regelmatig 
verwaarloosd bij psoriasis, met name bij UVB-lichttherapie. Veel patiënten met 
psoriasis hebben last van jeuk. Tevens kan lichttherapie ook jeuk geven als gevolg 
van erytheem en droge huid. In ons eerdere onderzoek werd de voorkeur gegeven 
aan hoog gedoseerd belichten met UVB-lichttherapie. De gunstige effecten van dit 
hoog gedoseerd belichten, minder belichtingen met betere lange termijn effecten, 
kunnen belemmerd worden door een verhoogd risico op erytheem met jeuk als gevolg. 
Door krabben kan het Koebner-fenomeen opgewekt worden, waardoor psoriasis 
kan verslechteren. Verslechtering van psoriasis leidt weer tot een verlenging van 
de lichttherapie met een afgenomen kosten-effectiviteit tot gevolg. Omdat jeuk en 
krabben voorspellende factoren zijn voor de tijd, die nodig is om clearance te bereiken 
met UVB-lichttherapie, is het belangrijk om patiënten met een chronische jeukende 
huidaandoening vroegtijdig te herkennen en goed te begeleiden.
5.3.1.3 Het vaststellen of compliance aan een behandeling een voorspellende factor 
is voor het lange termijn effect bij patiënten met psoriasis, die succesvol behandeld zijn 
met UVB-lichttherapie
UVB-lichttherapie wordt meestal in een poliklinische setting aangeboden. Hiervoor 
moet een patiënt gemiddeld 3 keer per week gedurende 8 tot 10 weken naar het 
ziekenhuis reizen. De mate, waarin patiënten zich houden aan de voorschriften van 
eerder gegeven behandelingen en adviezen, kan een voorspellende factor zijn voor 
de lange termijn effecten en behoud van resultaat na een succesvolle behandeling. 
Zich onttrekken aan de voorschriften en adviezen is een veelvoorkomend probleem 
bij patiënten met chronische huidaandoeningen, zoals psoriasis. Wat de invloed is van 
deze non-adherentie op het effect van dermatologische behandelingen, zoals UVB- 
lichttherapie bij psoriasis, was nog onduidelijk. In paragraaf 3.3 werden de gevolgen 
van het zich onttrekken aan de behandeladviezen bij UVB-lichttherapie beschreven. 
Non-adherentie werd aan het begin van de lichttherapie geanalyseerd aan de hand 
van vragenlijsten. Er werd gebruik gemaakt van een ISDL-schaal (Impact of Skin 
Disease on Daily Life). In deze vragenlijsten werd gevraagd in welke mate patiënten 
de instructies en adviezen van hun dermatoloog over een behandeling volgden of in 
het verleden zijn nagekomen. Van alle patiënten bleek 8% meestal non-adherent te 
zijn en 63% soms niet adherent, terwijl 29% meestal wel de adviezen en instructies 
van hun behandeld arts opvolgden. Naarmate non-adherentie meer aanwezig was bij
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een patiënt werd dit gecorreleerd aan een ernstigere psoriasis in de follow-up periode 
na een succesvolle UVB-lichtkuur. Hieruit werd geconcludeerd dat non-adherentie 
aan (eerdere) dermatologische behandelingen een voorspellende factor is voor het 
lange termijn effect van UVB-lichttherapie. Het vroegtijdig vaststellen van de mate van 
adherentie bij patiënten met psoriasis, die UVB-lichttherapie voorgeschreven hebben 
gekregen, is hierdoor een kosteneffectieve toevoeging. Door een korte vragenlijst in 
te vullen voorafgaand aan de eerste belichting en intensieve persoonlijke begeleiding 
tijdens UVB-lichttherapie kan non-adherentie vroegtijdig opgespoord worden met als 
resultaat betere lange termijn effecten.
5.3.2 Het evalueren van vernieuwende vormen van lichttherapie voor 
psoriasis
In het laatste deel van hoofdstuk 3 werden verschillende vormen van lichttherapie met 
zichtbaar licht, met en zonder het toedienen van fotosensitizers, op de gezonde huid 
en bij psoriasis onderzocht. Er is een permanente vraag naar nieuwe behandelingen 
voor psoriasis, omdat topicale therapieën vaak onvoldoende effectief zijn en veel 
inzet van patiënten vragen. Daarnaast worden vele systemische en lichttherapieën 
op termijn beperkt door cumulatieve toxiciteit en carcinogene werking. Verschillende 
onderzoeken zijn gedaan naar de mogelijkheden om psoriasis met PDT te behandelen, 
omdat psoriasis selectief PpIX kan accumuleren. In deze onderzoeken varieerden de 
klinische resultaten sterk, maar deze resultaten zijn moeilijk onderling te vergelijken, 
omdat er verschillende protocollen werden gebruikt. Gezien de pijn tijdens de 
fotodynamische belichtingen en de wisselende klinische resultaten werd tot nu toe 
gesteld dat PDT niet geschikt is om te gebruiken als behandeling bij psoriasis.
5.3.2.1 Het bestuderen van de klinische en histologische veranderingen tijdens PDT 
bij psoriasis
Eerdere onderzoeken naar PDT bij psoriasis hebben de nadruk gelegd op de klinische 
resultaten. Het is echter belangrijk om de kennis over de histologische effecten van 
PDT op psoriasis te vergroten om hiermee de klinische veranderingen in psoriasis na 
PDT beter te kunnen begrijpen. Het doel van het onderzoek beschreven in paragraaf 
3.4 was om naast de klinische resultaten ook de veranderingen in de histologische 
kenmerken van psoriasis, epidermale proliferatie, abnormale keratinisatie en 
inflammatie, als gevolg van PDT te evalueren. Na een keratolytische voorbehandeling 
werden unilaterale psoriasis plaques behandeld met 10% ALA gedurende 4 uur 
gevolgd door twee gefractioneerde PDT-belichtingen, eenmaal per week gedurende
4 weken. Contralaterale plaques werden behandeld met placebo-PDT in hetzelfde 
belichtingsschema. Deze PDT-behandeling resulteerde in een significante verbetering 
van psoriasis vergeleken met de placebo-behandelde plaques. De behandelingen
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werden goed verdragen door de patiënten. Enkele patiënten vermeldden pijn tijdens 
de belichting, maar de pijn was geen reden om de belichtingen te onderbreken of 
te stoppen. Twee patiënten lieten een klinische verslechtering zien in de plaques 
behandeld met ALA-PDT en niet in de placebo-behandelde plekken. Een mogelijke 
verklaring voor deze toename van psoriasis is het Koebner-fenomeen als gevolg 
van PDT. Histologisch normaliseerden epidermale proliferatie (60% afname van 
Ki67-expressie) en differentiatie (16% toename van K10-expressie) en werd er een 
afname van het T-cel infiltraat gezien. Niet alleen verbeterden de klinische aspecten 
van de behandelde psoriasis plaques binnen 1 week, maar ook differentiatie en 
proliferatie lieten vanaf het begin significante verbeteringen zien. Deze histologische 
verbeteringen namen verder toe gaandeweg het onderzoek. Significante verbeteringen 
van het inflammatoire infiltraat werden gezien vanaf week 6. Epidermale CD8+ cellen 
en dermale CD45RO+ cellen namen significant af vanaf week 6, terwijl CD4+ cellen 
niet veranderden.
De hoeveelheid PpIX in de behandelde plaques werd bestudeerd middels FDAP 
Ondanks adequate ontschilfering lieten de meeste psoriasis plekken een onregelmatige 
distributie van fluorescentie zien. Deze variaties in fluorescentie-distributie werden 
tussen de psoriasis plaques gezien, maar ook binnen een en dezelfde psoriasisplek. 
Deze niet gelijkmatige verdeling van fluorescentie geeft een variabele fotodynamische 
dosis verspreid over het epidermale oppervlak. Een variabel fotodynamisch effect kan 
het gevolg zijn van een verminderde penetratie van zowel de fotosensitizer als het licht 
in de huid. Dit kan een verklaring zijn voor de wisselende therapeutische resultaten van 
PDT bij psoriasis. Geconcludeerd werd dat PDT psoriasis zowel klinisch als histologisch 
kan verbeteren, maar dat PDT geen eerste keus behandeling voor psoriasis zal 
worden door de wisselende resultaten, het tijdrovende aspect van de behandeling en 
risico op het Koebner-fenomeen. PDT kan overwogen worden bij beperkte psoriasis in 
cosmetisch essentiële gebieden, waar de conventionele behandelingen onvoldoende 
resultaat hebben gegeven.
5.3.2.2 Het onderzoeken van de morfologische en immunohistochemische verschillen 
in psoriasis plaques met heterogene PpIX-geïnduceerde fluorescentie
De heterogene fluorescentie-distributie, die werd beschreven in de vorige paragraaf, 
werd verder onderzocht in paragraaf 3.5. Het is onbekend waardoor deze verschillen 
in fluorescentie-intensiteit binnen dezelfde plaques en tussen verschillende psoriasis 
plaques worden veroorzaakt. Variaties in fluorescentie lijken voor een deel verklaard 
te kunnen worden door de mate van hyperkeratose, aangezien door keratolytische 
voorbehandelingen een meer homogene fluorescentie ontstaat. In theorie beperkt de 
hoeveelheid hyperkeratose de penetratie van licht en topicale middelen in de huid. 
Echter, de fluorescentie-intensiteit kan ook beïnvloed worden door de metabole activiteit 
van proliferatieve delen in een psoriasis plaque, waardoor de PpIX-synthese toeneemt.
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Om de vraag te kunnen beantwoorden of de heterogene fluorescentie gerelateerd zou 
kunnen zijn aan de activiteit van de psoriasis of door beperkingen in het doordringen 
van de fotosensitizer of het licht in de huid, werd FDAP verricht op psoriasis plaques 
na keratolytische voorbehandeling. Ondanks klinische adequate ontschilfering 
bleef de fluorescentie-distributie na 3 uur incubatie met 20% ALA onvoorspelbaar. 
Biopten werden afgenomen van hoog- en laagfluorescente delen in een psoriasis 
plaque. Een significant dikker stratum corneum werd gezien in de laagfluorescente 
psoriasishuid. Er werd geconcludeerd dat fluorescentie-intensiteit en stratum corneum 
dikte negatief gecorreleerd zijn. Er werden geen verschillen gezien in epidermale 
proliferatie (Ki-67), differentiatie (K10 en filaggrine) of inflammatie (CD3) tussen de 
hoog- en laagfluorescente psoriasishuid. Uit deze resultaten blijkt dat de verschillen in 
psoriasisactiviteit niet verantwoordelijk zijn voor de verschillen in fluorescentie, maar 
dat het stratum corneum functioneert als een mechanische barrière voor ALA en licht. 
Blijkbaar was een week voorbehandeling met 10% salicylzuur in vaseline eenmaal 
daags gedurende een week onvoldoende om alle hyperkeratosen te verwijderen. Het 
verwijderen van hyperkeratosen voorafgaand aan de behandeling is belangrijk om PDT 
en FDAP bij psoriasis en andere huidaandoeningen te optimaliseren. Op deze manier 
wordt de fotodynamische dosis egaal verdeeld, waardoor de kans op een suboptimale 
behandeling door een te lage dosis en het risico op het Koebner-fenomeen verkleind 
worden.
5.3.2.3 Het bestuderen van verschillende keratolytische voorbehandelingen 
voorafgaand aan fluorescentie-diagnostiek en fotodynamische therapie
De heterogene accumulatie van PpIX is mogelijk het resultaat van verschillen in de 
hoeveelheid hyperkeratose, waardoor ALA en licht ongelijkmatig de huid kunnen 
binnenkomen. Blijkbaar was een week voorbehandelen met 10% salicylzuur in 
vaseline eenmaal daags onvoldoende om alle hyperkeratosen te verwijderen. In 
paragraaf 3.6 werden verschillende keratolytische voorbehandelingen als aanvulling 
op de reguliere voorbehandeling, 10% salicylzuur in vaseline, onderzocht. De 
klinische aspecten, met name de hoeveelheid hyperkeratose, van de bestudeerde 
psoriasis plaques verbeterden door gebruik van tretinoïne-crème en een hydrocolloïd 
verband. Echter, het aanbrengen van een hydrocolloïd verband gedurende een week 
gaf de beste klinische afname van schilfering, erytheem en induratie na 2 weken 
voorbehandelen. Ons doel was om de hoeveelheid hyperkeratosen voorafgaand aan 
FDAP en PDT met deze 2 alternatieve keratolytica te minimaliseren. Beide keratolytica 
hadden geen additionele werking op het homogeniseren van de fluorescentie of op 
afname in dikte van het stratum corneum ten opzichte van salicylzuur in vaseline. Het 
aanbrengen van tretinoïne-crème gedurende een week eenmaal daags resulteerde 
in lokale huidirritatie en puntbloedingen. Histologisch werd een significante afname 
van filaggrine-expressie gezien, wat duidt op irritatie als gevolg van beschadiging van
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het stratum corneum. Omdat in de dagelijkse praktijk FDAP en PDT vooral gebruikt 
worden bij NMSC is het wenselijk dat er geen significante histologische veranderingen 
optreden. Er werd besloten aan de hand van deze resultaten om het hydrocolloïd 
verband te gebruiken als alternatief voor 10% salicylzuur in vaseline in een aanvullende 
studie, waarbij psoriasis na keratolytische voorbehandeling behandeld werd met 
PDT. Er werden geen klinische en immunohistochemische verschillen gezien tussen 
de psoriasis plaques voorbehandeld met een hydrocolloïd verband of het standaard 
keratolyticum, salicylzuur in vaseline, na 6 PDT-behandelingen met een interval van 
een week. Zoals verwacht, op basis van ons eerdere onderzoek (paragraaf 3.4), 
verbeterden de psoriasisplekken door de behandeling met PDT, maar niet door de 
keuze van het keratolyticum. Er werd geconcludeerd dat de klinische en histologische 
effecten van een hydrocolloid verband vergelijkbaar zijn met die van salicylzuur in 
vaseline. Een hydrocolloïd verband is dus een goed alternatief voor de standaard 
keratolytische voorbehandeling, 10% salicylzuur in vaseline, met name wanneer de 
plek, die behandeld dient te worden, moeilijk bereikbaar is voor de patiënt of wanneer 
het dagelijks aanbrengen van een crème of zalf problematisch is.
5.3.2.4 Het bestuderen van de klinische en histologische effecten van blauw licht op 
normale huid
De absorptie van zichtbaar of UV-licht door chromoforen in de huid is van belang voor 
het genereren van biologische effecten in de huid. Bij PDT wordt PpIX geactiveerd 
door zichtbaar licht, waardoor zuurstofradicalen worden gevormd met als resultaat 
gerichte weefseldestructie. PpIX heeft een maximale absorptie-piek op 408 nanometer. 
Hierdoor is blauw licht beter in staat om PpIX om te zetten dan rood licht. Porfyrines 
hebben ook nog kleinere absorptie-pieken voor hogere golflengtes. Voor optimale 
activatie van PpIX is niet alleen maximale activatie van PpIX essentieel, maar is ook 
het absorptie-spectrum van de huid van belang. Rood licht kan PpIX ook activeren 
en heeft een hogere golflengte, waardoor rood licht dieper in de huid kan komen dan 
blauw licht. In Europa is op dit moment PDT, waarbij MAL wordt gebruikt in combinatie 
met rood licht, een geregistreerde behandeling voor AKs, Morbus Bowen, superficiële 
en laagrisico nodulaire basaalcelcarcinomen (BCCs). Echter, in Amerika is een ALA- 
oplossing in combinatie met blauw licht geregistreerd als behandeling voor AKs. 
Belichting van Propionibacterium acnes in acne met zichtbaar blauw licht resulteert, 
zowel met als zonder het aanbrengen van ALA, in activatie van bacteriële porfyrines, 
aanmaak van zuurstofradicalen en anti-inflammatoire effecten op keratinocyten. 
Desondanks zijn de effecten van zichtbaar licht op de huid slechts gedeeltelijk bekend. 
Voor een fotodynamisch effect is het essentieel om de hoeveelheid lokaal beschikbare 
chromoforen op te hogen door MAL of ALA op de huid aan te brengen. Chromoforen, 
zoals DNA en bilirubine, zijn van nature al aanwezig in de huid. Het is aannemelijk dat 
belichting van deze endogene chromoforen kan resulteren in oxidatie van omliggende
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moleculen met hierdoor schadelijke fotobiologische reacties, zoals zonneschade 
en carcinogene bijwerkingen. In eerder onderzoek werd aangetoond dat multipele 
belichtingen met hoog-gedoseerd rood licht resulteerden in een significante toename 
van vacuolisatie zonder tekenen van celdood, zonneschade of huidveroudering. In 
theorie kan blauw licht biologische effecten opwekken, die vergelijkbaar zijn UVA 
straling, aangezien de golflengte van blauw licht dichtbij het UVA-spectrum gelegen is. 
Het is aangetoond dat UVA invloed heeft op de huidveroudering en, in combinatie met 
psoralenen, op de lange termijn carcinogene bijwerkingen heeft. Enkele onderzoeken 
hebben aangetoond dat golflengtes gelegen naast het UVA-spectrum dezelfde effecten 
als UVA kunnen hebben. In paragraaf 3.7 werden de klinische en histologische 
effecten van blauw licht op normale huid bestudeerd. Acht gezonde vrijwilligers werden
5 achtereenvolgende dagen belicht met zichtbaar licht tot een cumulatieve dosis van 
100 J/cm2. Een significante toename van perinucleaire vacuolisatie werd gezien. De 
perinucleaire vacuolisatie normaliseerde na het staken van de belichtingen. Er was 
geen sprake van apoptose, zoals de aanwezigheid van zonbeschadigde cellen met 
eosinofiel cytoplasma of veranderingen in p53-expressie. Ook werden geen tekenen 
van huidveroudering gezien. Omdat alleen de korte termijn effecten van zichtbaar licht 
werden onderzocht, konden geen conclusies getrokken worden over de lange termijn 
effecten van blauw licht op de huid. Klinisch werd milde hyperpigmentatie gezien, welke 
histologisch werd bevestigd door een significante toename van Melan-A. Zowel de 
klinische als de histologische hyperpigmentatie normaliseerden na het staken van de 
belichtingen. Geconcludeerd werd dat de effecten van blauw licht op de huid bestaan 
uit transiënte melanogenese en onverklaarbare vacuolisatie zonder apoptose. Dus, 
(kortdurend) gebruik van zichtbaar blauw licht voor dermatologische aandoeningen 
lijkt veilig voor patiënten en dermatologisch personeel.
5.3.2.5 Het onderzoeken van de effecten van blauw en rood licht bij psoriasis
Psoriasis accumuleert PpIX na het aanbrengen van ALA op de huid. PpIX is ook 
endogeen aanwezig in psoriasis plaques zonder het aanbrengen PpIX-precursors. 
Zoals eerder beschreven, wordt PpIX maximaal geactiveerd door blauw licht. Recent 
is aangetoond dat blauw licht anti-inflammatoire effecten heeft op de huid, waardoor 
blauw licht effectief zou kunnen zijn in het behandelen van hyperproliferatieve 
huidaandoeningen, zoals psoriasis. Wij veronderstelden dat PDT therapie door de 
interactie van hoog gedoseerd zichtbaar licht met endogene chromoforen een nieuwe 
behandelmogelijkheid voor psoriasis zijn kunnen zijn. In paragraaf 3.8 werden 
behandelingen met hoog gedoseerd blauw en rood licht bij psoriasis geanalyseerd. 
Een week voorafgaand aan de belichtingen tot aan het einde van het onderzoek werd 
voorbehandeld met 10% salicylzuur in vaseline. Hierdoor namen de hoeveelheid 
schilfering en induratie al af voor het starten van de behandeling met zichtbaar licht. 
De belichtingen, die 3 keer per week gedurende 4 weken plaatsvonden, resulteerden
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in afname van erytheem en verdere verbetering van induratie. De roodheid van de 
psoriasis plaques door blauw licht nam af gedurende de gehele onderzoeksperiode. 
Aangezien rood licht alleen gedurende de eerste 6 behandelingen afname van 
erytheem liet zien, bleek blauw licht superieur in het verbeteren van de inflammatoire 
component. Rood licht had echter een lagere lichtintensiteit dan blauw licht, wat een 
verklaring kan zijn voor de tijdelijke verbetering ten opzichte van het hoger gedoseerde 
blauwe licht. De belichtingen werden door alle patiënten goed verdragen. Behoudens 
hyperpigmentatie werden geen bijwerkingen geconstateerd.
Om het additionele effect van de keratolytische voorbehandeling nader te onderzoeken, 
kregen 7 patiënten met psoriasis 10% salicylzuur in vaseline als monotherapie gedurende 
4 weken. Hiermee werd aangetoond dat salicylzuur in vaseline verantwoordelijk is voor 
de grootste afname van schilfering en daarmee ook van induratie. We concludeerden 
dat de afname van erytheem het gevolg is van de belichtingen met zichtbaar licht en 
dat zichtbaar licht geen invloed heeft op de hoeveelheid schilfering en induratie. De 
klinische verbetering, met name van de inflammatoire component, voornamelijk na 
belichtingen met blauw licht en in mindere mate na behandeling met rood licht, gaf 
aan dat behandeling met zichtbaar licht een alternatief kan zijn als behandeling bij 
psoriasis.
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X-rays
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V is ib le  ligh t
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F igure 1: The light spectrum is classified in different forms of light according to wavelength. The 
visible spectrum is visible to the human eye, which responds to wavelengths from 400nm to 
760nm.
F igure 3: Penetration depth of visible light in the skin.
F igure 7: Clinical appearance (A) and histopathology (B) of AK.
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Figure 8: Clinical appearance (A) and histopathology (B) of SCC.
Figure 9: Clinical appearance (A) and histopathology (B) of psoriasis.
185
Colour illustrations
Chapter 2.1
Figure 3: Images acquired with fluorescence diagnosis imaging system.
Color (A), fluorescence (B), and pseudocolor (C) images from two lesions classified as Bowen’s 
disease. Note that fluorescence corresponds well with clinical picture. Color (D), fluorescence (E), 
and pseudocolor (F) images from verrucous hyperkeratosis with no atypia. Lesional fluorescence 
is lower than surrounding normal-appearing skin fluorescence.
Chapter 2.3
____
Figure 1: Patient at baseline (A), before the second treatment (B) and after 3 months of follow-up (C).
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After 4  tre a tm e n ts
Untreated plaque
Chapter 3.4
F igure  2: Clinical improvement in 
5-aminolaevulinic acid-photodynamic 
therapy-treated psoriatic plaques. After 
four treatments most psoriatic plaques 
clinically improved as reflected by a 
reduction in the plaque severity (sum) 
score. This was not seen in the placebo 
and untreated lesions. Note the partial 
response and the postinflammatory 
hyperpigmentation.
(6)
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F igure  4: Clinical (a-c), fluorescence (d-f) and pseudocolour images (g-i) from the same patient 
after 5-aminolaevulinic acid application (4 h) at baseline (a, d, g), week 1 (b, e, h) and week 2 (c, 
f, i). The distribution of fluorescence varied largely at the (d ifferent tim e [3 oints and was generally 
in a follicular pattern. Note that at the sites of biopsy fluorescence was always present.
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Ki67
K10
CD8
CD45RO
Baseline Week 1 Week 6
F igure  5: Immunohistochemistry. Ki67, keratin 10 (K10), CD8 and CD45RO stainings at baseline, 
week 1 and week 6. Ki67 and K10 are displayed at x100 magnification; T-cell subsets are 
displayed at x50 magnification.
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Figure 1: Clinical and fluorescence images from one patient after 5-aminolaevulinic acid 
application. (a) Clinical image with marked low-fluorescent lesional skin (1) and high-fluorescent 
lesionalsfin (2). (b) F luorescence image of the same plaque i f  which heterogeneous fluorescence 
is seen. (c) Pseudo-colour image of (b).
F igure  3: Morphological and immunohistochemical images of both low- and high-fluorescent 
psoriatic skin. Haematoxylin and eosin, Ki-67, keratin 10 (K10) and filfggrin stainings of 
heterogeneous fluorescent lesional skin gne displayed at 100x magnification. CD3 is displayed 
at 50x magnification. Haematoxylin and eosin sections showed a significantly thicker stratum 
corneum in low-fluorescent psnriatic skin. Immunohistochemically no differences ia epidermal 
proliferation, differentiation andinflammation were found between high- and low-fluorescent
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